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In this study, indomethacin-loaded self-nanoemulsifying drug delivery systems 
(SNEDDS) were developed in liquid, solid and carrier-mediated formulations in order to 
improve the solubility of this model poorly water soluble drug.  
Liquid SNEDDS based on Capryol™ 90 (oil phase), Cremophor® RH 40 
(surfactant) and Transcutol® HP (co-surfactant) were thermodynamically stable and 
produced clear nanoemulsions upon dilution. Optimized liquid formulations were 
transformed into solid SNEDDS by adsorption onto the inert carriers Syloid® XDP 3150, 
Neusilin® US2 and Florite® PS-200. Ratios of adsorbent: liquid SNEDDS of 1:1.5 and 1:2 
resulted in solid SNEDDS formulations that exhibited fair to passable powder flow 
properties. Carrier-based solid SNEDDS formulations were developed using the solid 
self-emulsifying carriers Gelucire® 44/14 and Gelucire® 48/16 and prepared by hot melt 
extrusion. 
The absorbent-based solid SNEDDS maintained the self-nanoemulsification 
properties of the original liquid SNEDDS formulations, with solid state analysis 
suggesting that the drug had remained in a dissolved state within these formulations. 
Similarly, physical characterization of the carrier-based solid SNEDDS formulations 
indicated that the drug was molecularly dispersed within the system and that the self-
nanoemulsifying properties of the carrier were unchanged.  The only exception was 
those formulations prepared at the highest drug: carrier ratio (3: 10).  For both 
absorbent-based and carrier-based solid SNEDDS, the in vitro dissolution efficiency was 
significantly higher than that obtained for the pure drug.  However, incorporation of 
adsorbents into Gelucire®-based solid SNEDDS formulations resulted in reduced 
dissolution of the drug. Gelucire®48/16-based solid SNEDDS prepared at 50oC were 
more physically stable to storage at 30oC/75% RH for 6 months than formulations 
processed at 40oC, suggesting that complete melting of the carrier during manufacture is 
essential for production of physically stable formulations. 
Overall, a range of liquid, solid and carrier-based SNEDDS formulations were 
successfully developed and offer useful alternatives to improving the solubility of poorly 








The oral route is the most commonly used method for administration of drugs, 
with nearly 80% of the marketed dosage forms being delivered orally. This route of drug 
administration is the most convenient and non-invasive, leading to better patient 
compliance. Aqueous solubility of drugs is one of the most important factors that 
determine their dissolution performance and hence oral absorption and bioavailability. 
About 70% of new drug substances are poorly water soluble and exhibit slow dissolution 
rates and often incomplete oral bioavailability. Therefore, different formulation strategies 
have been investigated for enhancing the solubility of poorly soluble drugs with the aim 
of improving oral bioavailability. 
This study investigated the utility of self-nanoemulsifying drug delivery systems 
(SNEDDS) as a lipid-based formulation approach to improve solubility and in vitro 
dissolution performance of the poorly soluble model drug, indomethacin. For this 
purpose, different drug-loaded SNEDDS were prepared in liquid, solid and carrier-based 
formulations. Liquid indomethacin-loaded SNEDDS formulations prepared with Capryol™ 
90 (oil phase), Cremophor® RH 40 (surfactant) and Transcutol® HP (co-surfactant) 
showed maximum self-nanoemulsification efficiency and the smallest droplet size 
compared to other liquid SNEDDS formulations tested.  Solid SNEDDS of indomethacin 
were produced by either adsorbing the optimum liquid SNEDDS on to different 
adsorbents like Syloid® XDP 3150, Neusilin® US2 and Florite® PS-200 or by directly 
dissolving the drug in semisolid or solid self-emulsifying carriers such as Gelucire®44/14 
and Gelucire®48/16, adopting the hot melt extrusion (HME) technique for manufacture. 
All solid SNEDDS produced demonstrated self-nanoemulsification properties after 
dilution with aqueous media and showed significantly higher in vitro dissolution 
performance compared to the pure drug. Physicochemical characterization of these solid 
formulations proved that the drug remained in a solubilized state within the formulations. 
The results of this study enhance and add to the knowledge in the literature on 
the improvement of solubility of poorly soluble drugs and the development of industrially-
feasible lipid-based oral formulations. Adoption of the novel adsorbents used in this 
study, such as Florite® PS-200 and Neusilin®US2, to solidify liquid SNEDDS of 
indomethacin could be applicable on an industrial level to produce homogenous powder 
formulations, especially when liquid SNEDDS are sprayed on to the adsorbent and 
mixed with high shear mixers. These powder formulations could be further extended on 
the industrial scale to formulate self-emulsifying tablets that will contribute to increasing 
the currently limited number of commercially available solid SNEDDS dosage forms. 
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Successful development of solid SNEDDS of indomethacin by direct dissolving of the 
drug in solid self-emulsifying carriers may increase the possibility of using these types of 
carriers for direct production of highly stable solid SNEDDS formulations. Utilization of 
hot melt extrusion technology instead of traditional melting methods for processing solid 
self-emulsifying carriers and developing stable solid SNEDDS formulations will certainly 
ease the scaling up of this continuous process to the industrial level.  
Overall, a range of liquid, solid and carrier-based SNEDDS formulations were 
successfully developed and provide alternative methods of improving the solubility of 
poorly water-soluble drugs. These formulations are potentially scalable, offering 
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 Oral route of drug administration 1.1.
The oral route of drug administration is the most commonly employed method, 
administering nearly 80% of the commercially available dosage forms (Morishita and 
Peppas, 2012). Oral drug administration offers the most convenient and non-invasive 
way of drug delivery that results in better patient compliance. Also, it is the most cost-
effective to pharmaceutical industry with a wide range of dosage form designs and the 
least sterility limitations (Krishnaiah, 2010).  However, the bioavailability of drugs 
administered orally depends on many factors that are related to the aqueous solubility of 
the drug in gastro-intestinal (GI) fluids, drug intestinal permeability, drug stability in the GI 
environment, and drug metabolism in the liver (Kalepu et al., 2013, Krishnaiah, 2010, 
Porter et al., 2008).  Aqueous solubility and intestinal permeability of the drug are 
considered as the key factors that affect oral absorption and bioavailability (Beig et al., 
2012, Krishnaiah, 2010, Vieth et al., 2004).  
With significant increase in the number of pharmacologically active compounds 
discovered, it was reported that nearly 70% of new drug candidates exhibit poor aqueous 
solubility (Ku and Dulin, 2012). Formulation of these compounds into oral dosage forms 
with improved bioavailability represents a challenge in the area of pharmaceutical 
research (Buckley et al., 2012, Dahan and Hoffman, 2008, Lipinski et al., 2001).       
Aqueous solubility is the primary factor that determines the bioavailability of orally 
administered drugs by affecting their dissolution properties (Kawabata et al., 2011). 
Poorly water soluble drugs, with aqueous solubility less than 100 µg/ml and administered 
in doses more than 100 mg, exhibit a slow dissolution rate and often incomplete 
bioavailability. For these drugs, the dose/solubility ratio or the volume of gastrointestinal 
fluids required to dissolve the administered dose may exceed the available volume of 
fluids and this lead to incomplete bioavailability of oral dosage forms (Horter and 
Dressman, 2001). Attempts to improve oral efficacy of such drugs by increasing the dose 
may result in gastrointestinal toxicity and therefore reduced patient compliance. In 
addition, poor powder properties, and high cost of manufacturing may arise during drug 
product development (Kawabata et al., 2011). Therefore, different approaches to 
improve aqueous solubility of poorly soluble drugs have been investigated. For example, 
modification of the chemical structure or design of prodrugs during the early optimization 
phase of poorly soluble drugs has been studied as possible options to enhance the 
aqueous solubility.  Also, other approaches that focused on improving the dissolution of 
poorly soluble drugs have been considered as alternative methods of increasing the 
solubility of poorly soluble drugs (Kawabata et al., 2011).  The following section 
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describes different formulation approaches that are based on the biopharmaceutical 
characteristics of drug substances.  
 Biopharmaceutics classification system and different formulation 1.2.
approaches 
Application of the biopharmaceutics classification system (BCS) helps to 
understand the physicochemical and biopharmaceutical properties of drugs in order to 
improve developing pharmaceutical drug products (Kawabata et al., 2011). According to 
BCS, drugs are grouped into four classes (I – IV) - depending on their aqueous solubility 
and intestinal permeability (Figure 1.1).  
 
Figure  1.1  Biopharmaceutics classification system (BCS) (Pouton, 2006) 
   
According to FDA (2000), a drug substance is said to be “highly soluble” when 
the maximum dose is soluble in an amount of 250 ml or less of aqueous medium over 
the pH range of 1 – 7.5 at 37oC. Also, FDA considers the drug to be “highly permeable” 
when 90% or more of the administered dose is absorbed in humans. 
Generally, oral absorption of class I drugs (high solubility and high permeability) 
has no rate-limiting step and, therefore, well-designed conventional solid dosage forms 
will ensure rapid dissolution in gastrointestinal tract (Pouton, 2006).  On the other hand, 
oral bioavailability of BCS class II drugs (low solubility and high permeability) is thought 
to be dissolution rate limited and enhancement of the dissolution rate of the drug will 
maximize its oral absorption (Kawabata et al., 2011, Pouton, 2006).  Considering class III 
drugs (high solubility and low permeability), their oral absorption is limited by membrane 
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permeability. Improved efficacy of such drugs can be achieved upon administration of a 
high dose (Desai et al., 2012) or upon addition of permeation enhancers, such as fatty 
acids, bile salts or surfactants, to the drug product (Kawabata et al., 2011). Finally, the 
bioavailability of class IV drugs is limited by both low solubility and low intestinal 
permeability. Strategies to enhance aqueous solubility of class II drugs can be applied 
for class IV drugs, even though low permeability remains as a barrier to overcome  
(Kawabata et al., 2011, Pouton, 2006).   
A schematic presentation of different formulation approaches based on the BCS 
is depicted in Figure 1.2. As can be seen, the solubility, dissolution rate and thus 
bioavailability of BCS class II drugs can be improved by different formulation methods 
which can be utilized during both preformulation studies and formulation product 
development (Kawabata et al., 2011). The formulation methods that can be utilized 
during the preformulation studies include crystal modifications to utilize the metastable 
crystalline form of the drug (Blagden et al., 2007), formation of salts of ionizable drugs 
(Elder et al., 2013, Guzman et al., 2007), and co-crystal formation (Elder et al., 2013, 
Jung et al., 2010). On the other hand, particle size reduction (Horter and Dressman, 
2001, Krishnaiah, 2010, Merisko-Liversidge et al., 2003), pH modification (Riis et al., 
2007), amorphization (Kawabata et al., 2011), complexation with cyclodextrins (Brewster 
and Loftsson, 2007, Hassan et al., 2007) and lipid formulations (Dahan and Hoffman, 
2008, Kossena et al., 2007, Pouton, 2006) can be employed during the formulation 
design phase.      
 




Figure  1.2 Different formulation approaches based on BCS (Kawabata et al., 2011) 
 
All formulation methods assigned for BCS class II drugs aim to enhance their 
dissolution rate which will then reflect on enhanced oral bioavailability of this class of 
drugs. Therefore, modification of the factors that affect the dissolution rate will improve 
the dissolution and hence, the bioavailability. The relation between these factors 
affecting dissolution rate was described by the Noyes-Whitney equation (Sun et al., 





(𝐶𝑠 − 𝐶𝑥)   (Equation 1.1) 
where dC/dt is the dissolution rate, D is the diffusion coefficient, A is the surface area, V 
is the volume of the dissolution medium, Cs is the saturation solubility, Cx is the drug 
concentration of bulk solution, and h is the hydrodynamic boundary layer thickness.  
From this equation, it can be noticed that reduction of particle size, for instance, will 
cause an increase in the dissolution rate of drugs due to increased total surface area of 
drug particles (Horter and Dressman, 2001) and decreased diffusion layer thickness 
(Mosharraf and Nyström, 1995). 
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Considering the various technologies available for poorly soluble drugs, lipid 
formulation approaches appear promising for marked enhancement of solubility, 
dissolution properties and oral bioavailability.  The following section will be focused on 
description of different lipid-based formulations and their role in improvement of solubility 
and dissolution properties. 
 Lipid formulations 1.3.
Utilization of lipid formulations to enhance gastrointestinal absorption of poorly 
water soluble drugs has gained much popularity in the area of pharmaceutical research 
(Pouton, 2006). Enhanced absorption of lipophilic drugs from lipid-based formulations 
can be attributed to several different factors.   
The presence of lipids in the GI tract promotes biliary secretions, including 
phospholipids, bile salts and cholesterol. These products, together with gastric 
movement, form emulsions that enhance the solubilization of poorly soluble drugs 
(Kossena et al., 2007). Also, lipids present in these formulations may undergo enzymatic 
degradation in the GIT. Subsequent interaction of the formed hydrolytic products with 
biliary secretions will lead to the formation of micellar structures that prevent drug 
precipitation (Dahan and Hoffman, 2008). In addition, surfactants incorporated into these 
delivery systems may contribute to solubilization of the lipophilic drug (Dahan and 
Hoffman, 2008). 
The ability of lipids to prolong gastric residence time may contribute to increased 
dissolution of the drug at the absorptive site and subsequently improvement of 
absorption (Dahan and Hoffman, 2008). However, enhancement of intestinal 
permeability by lipids (Constantinides and Wasan, 2007) is not considered as a 
mechanism for the enhancement of oral absorption of poorly water soluble (class II) 
drugs for which permeability is not a rate-limiting step (Dahan and Hoffman, 2008), but 
may be important for class III and IV drugs. 
Lipid-based formulations consist of a drug dissolved in a mixture of different 
excipients with a wide variety of physicochemical properties, including triglycerides, 
mono and diglycerides, lipophilic or hydrophilic surfactants and cosolvents (Pouton, 
2006). In order to identify the most appropriate formulations for specific drugs, based on 
their physicochemical properties, and to help identification of their performance 
characteristics, the lipid formulation classification system (LFCS) was introduced in the 
year 2000 (Pouton, 2000) and then updated in the year 2006 (Pouton, 2006).  
According to Pouton (2000), three main types of lipid formulation systems were 
identified: Types I, II, and III, with Type III being sub-divided into IIIA and IIIB. Type I 
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systems comprise simple and biocompatible formulations containing the drug dissolved 
in triglycerides and/or mixed glycerides. Type II systems include a lipophilic surfactant 
(HLB < 12) to improve the solvent capacity of the formulation. This type of  formulation is 
characterized by efficient self-emulsification and by the absence of water soluble 
components (Pouton, 2000). Type III systems incorporate hydrophilic surfactants (HLB > 
12) and/or water-soluble co-solvents (Type IIIA) with oils. Type IIIB is characterized by 
containing greater proportions of water-soluble components which may reach up to 50% 
of the formulation (Pouton, 2000).  
The LFCS (Table 1.1) was updated in 2006 (Pouton, 2006) and included an 
additional category (Type IV) of lipid formulations comprising hydrophilic surfactants and 
co-solvents with no oils. According to Pouton (2006), mixing a surfactant with a co-
solvent increases solvent capacity on dilution, facilitates dispersion of the surfactant and 
reduces variability and irritancy caused by high concentrations of surfactant. Although 
Type IV formulations can be useful for hydrophobic drugs, the safety of these systems 
has to be evaluated especially for chronic use (Pouton, 2006).  
General properties, advantages and disadvantages of each type of lipid 
formulation (Pouton, 2006) are shown in Table 1.2. 
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Table  1.1 The proposed lipid formulation classification system (LFCS) showing 




Excipients in formulation 
Content of formulation (% w/w) 
Type I Type II Type IIIA Type IIIB Type IV 
Oils: triglyceride or mixed 
mono and diglycerides 
100 40 – 80  40 – 80  < 20 - 
Water insoluble surfactant  
(HLB < 12) 
- 20 – 60  - - 0-20 
Water soluble surfactant  
(HLB > 12) 
- - 20 – 40  20 – 50  30 – 80  
Hydrophilic cosolvents (e.g., 
PEG, propylene glycol, 
Transcutol) 
- - 0 – 40  20 – 50  0 – 50  
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Table  1.2 Characteristic features, advantages and disadvantages of the 
various types of lipid formulations (Pouton, 2006). 
 
1.3.1. Selection of a suitable lipid-based formulation 
Improvement of low GI absorption of poorly soluble drugs requires a careful 
consideration of the physicochemical properties of the drug candidate in addition to the 
interaction of the formulation with the GIT (Hauss, 2007).   
1.3.1.1. Physicochemical considerations 
Selection of the most suitable lipid-based formulation for specific drugs is largely 
determined by their physicochemical properties. For example, some poorly water soluble 
drugs that have poor solubility in glycerides as well as mixed micelles of bile salts and 
lecithin are not capable of being formulated in Type I, Type II or Type IIIA systems 







Characteristics Advantages Disadvantages 
Type I Non-dispersing; requires 
digestion 
GRAS1 status, simple; 
excellent capsule compatibility 
Formulation has poor 
solvent capacity unless 
drug is highly lipophilic 
Type II SEDDS2 without water 
soluble component  
Unlikely to lose solvent 
capacity on dispersion 
Turbid o/w dispersion 
(particle size 0.25 to 2 µm) 
Type IIIA SEDDS/SMEDDS3 with 
water soluble 
components 
Clear or almost clear 
dispersion; drug absorption 
without digestion 
Possible loss of solvent 
capacity on dispersion; 
less easily digested 
Type IIIB SMEDDS with water 
soluble component 
Clear dispersion; drug 
absorption without digestion 
Likely loss of solvent 
capacity on dispersion 
Type IV Oil-free formulation based 
on surfactant and co-
solvents 
Good solvent capacity for 
many drugs; disperses to 
micellar solution 
Loss of solvent capacity 
on dispersion; may not be 
digestable 
1 Generally Regarded As Safe 
2 Self-Emulsifying Drug Delivery Systems 
3 Self-Micro Emulsifying Drug Delivery Systems 
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P value approximately 2) are unlikely to have improved absorption from lipid formulations 
(Pouton and Porter, 2008, Pouton, 2000). In addition, the bioavailability of lipophilic 
drugs (high log P values > 5) may be greater from lipid formulations due to incorporation 
into mixed micelles (Pouton and Porter, 2008) and enhancement of their dissolution in 
the gut lumen for more efficient absorption (Pouton, 2000). 
Chemical and physical stability of the drug must be essentially considered before 
selection of a suitable lipid formulation (Hauss, 2007).    
1.3.1.2. Biopharmaceutical considerations 
Close consideration of the biopharmaceutical properties of the drug is important 
for selection of the most suitable lipid formulation for oral use. Physiological factors that 
may affect the rate of drug absorption from the GIT and its transport to the systemic 
circulation require essential determination in order to formulate the optimum lipid-based 
formulation (O'Driscoll and Griffin, 2008).   
The solvent capacity of the lipid or its ability to solubilize the entire dose of the 
drug to allow its GI absorption is a prime consideration for lipid formulations (Pouton, 
2000). The lipid excipient should solubilize the drug and maintain it in a solubilized state 
until GI absorption takes place (Hauss, 2007, Pouton, 2006). Lipid systems containing 
hydrophilic excipients, such as Type III formulations, are more prone to drug precipitation 
upon dilution and dispersion (Pouton, 2006). The possibility of precipitation can be 
anticipated by investigating the equilibrium solubility of the drug in different components 
of the formulation after dilution, dynamic dispersion / precipitation performance of the 
formulation, and then assessing the correlation between the two experiments (Pouton, 
2006).  
Inclusion of surfactants and co-solvents into lipid formulations must be assessed 
carefully to avoid drug precipitation on dilution (Pouton and Porter, 2008). It was reported 
that loss of solvent capacity of lipid formulations upon dilution may be more prominent if 
a co-solvent is incorporated rather than those containing non-ionic surfactants (Pouton 
and Porter, 2008). This is due to the fact that the drug solubility in a micellar solution of 
surfactant is directly proportional to the surfactant concentration or the number of 
micelles present, whereas the drug solubility in aqueous solutions of co-solvents will be 
lost upon dilution (Pouton and Porter, 2008).         
Type III and Type IV formulations may lose their solvent capacity on dilution due 
to partitioning of water-soluble surfactant components into the continuous phase. 
Therefore, these types of formulations must be tested for in vitro dispersion to predict 
precipitation which may take place in the intestinal lumen (Pouton and Porter, 2008). 
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In general, the proportion of the components of lipid formulations should be 
monitored closely to avoid the likelihood drug precipitation that may occur with slight 
modifications of the components (Pouton, 2006).     
Moreover, the susceptibility of lipid formulations to digestion in the small intestine 
should be considered for selection of the type of formulation.  Lipids undergo digestion in 
the GIT by the effect of gastric lipases (lipolysis) and subsequently, their digestion 
products may interact with biliary secretion of bile salts, phospholipids and cholesterol 
present in the intestinal lumen to form micellar structures to solubilize drugs (Dai, 2010). 
It has been reported that digestion of lipid components of the formulation may lead to 
loss of solvent capacity, and subsequent reduction of solubility of the drug in the gut 
lumen resulting in precipitation of the drug and reduction of the absorption rate (Pouton, 
2000, Pouton and Porter, 2008).  The presence of surfactants in Types II, III, and IV 
formulations may inhibit the digestion of the oil within these formulations (Pouton, 2000).  
In vitro tests for lipid digestion, using a lipolysis model, may give a prediction of 
the possibility of in vivo precipitation of lipid-based formulations (Dai, 2010, Dahan and 
Hoffman, 2008). In vitro lipolysis test is necessary for evaluation of different types of 
lipid-based formulations including Type IV formulations because surfactants, also, may 
undergo digestion (Pouton and Porter, 2008). Correlation  between the in vitro lipolysis 
assay and the oral bioavailability has been reported for some lipid based formulations of 
drugs such as halofantrine (Porter et al., 2004), dexamethasone and griseofulvin (Dahan 
and Hoffman, 2007).    
1.3.2. Formulation approaches of lipid-based drug delivery systems  
Lipid-based formulations can be developed in different ways to achieve the 
desired formulation objectives. The process of development should start from selection 
of the most appropriate lipid excipients considering their stability, compatibility, fatty acid 
content, HLB value, and digestibility. The selected lipid excipients may affect the 
solubility and dissolution / dispersion properties of the formed system. Formulation 
techniques suitable for the desired dosage form in addition to drug loading are then to 
be identified (Kalepu et al., 2013).  
Different lipid-based formulation approaches have been designed and 
investigated. These include: lipid solutions (Grove et al., 2005, Mu et al., 2013), lipid 
suspensions (Larsen et al., 2008, Mu et al., 2013), liposomes (Chen et al., 2013, Chen 
et al., 2009, Hu et al., 2013), solid lipid nanoparticles (Mehnert and Mäder, 2012, 
Muchow et al., 2008) and self-emulsifying drug delivery systems (SEDDSs) (Porter et 
al., 2008, Pouton and Porter, 2008).   A brief description of these different lipid-based 
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formulation approaches and their benefit in improving the dissolution properties and/or 
bioavailability of many poorly soluble drugs is given below.   
1.3.2.1. Lipid solutions 
Dissolving a poorly soluble drug in lipids is the simplest method to improve 
bioavailability (Mu et al., 2013). Careful selection of the appropriate lipid excipient is 
important for this type of formulation due to the wide variability in physicochemical 
properties and digestibility of lipids which may affect solubilization of the drug (Mu et al., 
2013). For example, the solubility of seocalcitol, a poorly soluble vitamin D analogue 
with log P value 4.8, was significantly increased upon dissolving in medium chain 
triglycerides (5.3 mg/g) and long chain triglycerides (1.7 mg/g) compared to the 
aqueous solubility (20 ng/g) of the drug (Grove et al., 2005).  In addition, oral 
administration of both lipid solutions of seocalcitol in rats resulted in two-fold increase in 
the bioavailability of the drug, compared to only 10 ± 5% bioavailability obtained from a 
reference propylene glycol solution. This enhancement of solubility was attributed to the 
ability of lipid formulations to keep the drug solubilized in the GIT until absorption is 
complete. No significant differences were detected between the medium and long chain 
triglycerides  (Grove et al., 2005).  
  Solubilization of the drug during in vitro digestion was reported to be affected by 
different factors that are related to  type of lipid solutions (Mohsin, 2012), type of drugs 
investigated (Dahan and Hoffman, 2007) and amount of lipid used in the formulation 
(Porter et al., 2004).  
  Formulation of the lipophilic drugs dexamethasone and griseofulvin in different 
lipid solutions comprising either small chain triglyceride (SCT), medium chain 
triglyceride (MCT) or long chain triglyceride (LCT) affected their in vitro performance as 
well as the in vivo bioavailability. The effect of different lipids on the in vitro and in vivo 
performance of dexamethasone formulations was comparable, whereas griseofulvin 
formulations showed better in vivo and in vitro performance from the MCT formulations 
compared to LCT and SCT (Dahan and Hoffman, 2007). The solubilization of the drug 
in the GIT was also affected by the type of the lipid used in the formulation (Mohsin, 
2012). Formulation of fenofibrate lipid solutions in MCT resulted in about 5 – 7 % of the 
drug dissolved in the aqueous phase after in vitro digestion, whilst 21 – 36 % of 
fenofibrate was dissolved following digestion of a LCT (soybean oil) formulation 
(Mohsin, 2012). Furthermore, the amount of the lipid in the formulation may affect the in 
vitro solubilization of the drug as well as its bioavailability. For example, Porter et al. 
(2004) reported that more halofantrine was solubilized in the aqueous phase when 
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formulated in MCT formulations containing high lipid amount (≈25 mg triglyceride / ml 
digestion medium), whereas improved solubilization capacity of the drug was observed 
from the LCT formulations prepared with low lipid content (≈5 mg triglyceride / ml 
digestion medium). The oral bioavailability of halofantrine after oral administration of 
LCT formulations at low lipid content was higher than that obtained from MCT 
formulations, indicating good correlation between in vitro solubilization data and in vivo 
oral bioavailability in dogs (Porter et al., 2004).                
1.3.2.2. Lipid suspensions 
Lipid based suspensions may be useful when solubility in lipids is very limited 
(Mu et al., 2013). A study has shown that the oral bioavailability of danazol from different 
lipid based suspensions did not differ from that obtained when a lipid solution was orally 
administered in rats, indicating that a lipid-based suspension may perform as a lipid 
solution (Larsen et al., 2008). However, formulation of lipid suspensions may be limited 
by their physical stability and the crucial need for sedimentation control (Mu et al., 2013).          
1.3.2.3. Liposomes 
Liposomes are enclosed vesicles composed of one or two phospholipid bilayers 
surrounding a central aqueous cavity. Because of their biphasic property, liposomes 
have the ability to incorporate both hydrophilic and lipophilic drugs (Krishnaiah, 2010). 
These lipid-based formulations have been shown to improve oral absorption of different 
types of drugs such as insulin (Hu et al., 2013, Zhang et al., 2014, Niu et al., 2014), 
fenofibrate (Chen et al., 2009), and cyclosporine A (Chen et al., 2013). Enhancement of 
oral absorption by liposomal formulations has been attributed to possible increase in 
solubility of the drug, protection against digestive degradation, and enhanced 
permeation through the intestine  (Hu et al., 2013). Also, liposomal phospholipids may 
interact with bile salts in the gastrointestinal tract to form mixed micelles that will 
enhance oral absorption of poorly water soluble drugs (Chen et al., 2009). 
Application of liposomes for oral administration is limited by the high susceptibility 
of phospholipids and cholesterol to possible hydrolysis due to the effect of gastric acid, 
pancreatic lipases, and micellization by bile salts (Parmentier et al., 2012). Different 
liposomal modifications such as polymer coating of the vesicles (Chen et al., 2013) and 
interaction of bile salts with phospholipids (Hu et al., 2013, Niu et al., 2014, Chen et al., 
2009) have been investigated to evaluate stability of liposomes. However, accurate 
prediction of the stability of liposomes in human GIT from in vitro stability assays is 
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dependent on the degree of simulation of the physiological conditions in addition to the 
type of the animal model selected for the assays (Parmentier et al., 2012). 
1.3.2.4. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are highly stable matrix systems that utilize non-
toxic solid lipids for drug delivery (Mehnert and Mäder, 2012, Müller et al., 2000). 
Because these systems incorporate solid lipids, they have been used for controlling 
drug release after oral administration (Mehnert and Mäder, 2012, Müller et al., 2008).  
Solid lipid nanoparticles can be produced by different technologies such as high 
pressure homogenization and microemulsion techniques (Muchow et al., 2008). Those 
produced by high pressure homogenization methods may reach an average particle 
size below 500 nm (Mehnert and Mäder, 2012). 
Enhanced oral bioavailability of several drugs such as ferrous sulfate (Zariwala et 
al., 2013), risperidone (Silva et al., 2012), lovastatin (Suresh et al., 2007), and 
nitrendipine (Kumar et al., 2007) has been reported when these drugs were loaded into 
solid lipid nanoparticles. Improved oral absorption from SLN was attributed to 
solubilization of the drug in the micelles that form upon degradation of lipids in the gut 
wall (Muchow et al., 2008).    
Although solid lipid nanoparticles are safe and tolerable, they have a relatively 
low drug loading capacity and potential displacement of the incorporated drug from the 
formed SLN may occur during storage. Expulsion of the drug from SLN may be due to 
possible crystallization of the lipids during storage and subsequent formation of a more 
densely packed crystalline structure that has low drug affinity (Muchow et al., 2008). 
1.3.2.5. Self-emulsifying drug delivery systems 
The following sections of this review will focus on self-emulsifying drug delivery 
systems as a part of the proposed study.  
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 Self-emulsifying drug delivery systems as a tool for improving in 1.4.
vitro dissolution and oral absorption of poorly soluble drugs 
1.4.1. Definition and general properties  
Self-emulsifying drug delivery systems (SEDDS) or self-emulsifying oil 
formulations (SEOF) are isotropic mixtures of natural or synthetic oils with lipophilic or 
hydrophilic surfactant, co-solvents, and the solubilized drug substance (Porter et al., 
2008, Neslihan Gursoy and Benita, 2004, Hauss, 2007). These systems are Type II and 
Type III formulations in the LFCS (Mu et al., 2013) and can rapidly form fine oil in water 
emulsions, microemulsions or nanoemulsions upon dispersion in the gastrointestinal 
fluids under mild agitation produced by the digestive motility of the stomach and the 
intestines (Porter et al., 2008, Neslihan Gursoy and Benita, 2004, Hauss, 2007).  Based 
on the size range of their oil droplets, SEDDS can be classified into self-microemulsifying 
systems (SMEDDS) with oil droplet size from 100 to 250 nm and self-nanoemulsifying 
systems (SNEDDS) with oil droplet size less than 100 nm (Kawabata et al., 2011, Kohli 
et al., 2010).   
Compared to lipid solutions, SEDDS have the potential of increased drug loading 
capacity because of increased solubility of poorly soluble drugs with intermediate 
partition coefficient (2 < log P < 4) in the amphiphilic surfactants, co-surfactants and co-
solvents components of the formulation (Pouton, 2000). In addition, formation of 
submicron droplets will provide a large interfacial surface area for transfer of the drug 
resulting in increased rate and extent of absorption and hence, improved bioavailability 
(Chakraborty et al., 2009). Also, SEDDS may enhance the bioavailability of poorly 
soluble drugs, for which absorption is dissolution rate limited, because these 
formulations maintain the drug in a dissolved state throughout the GI tract (Chakraborty 
et al., 2009, Tang et al., 2008). Moreover, anhydrous SEDDS may provide protection for 
drugs from the enzymatic and chemical hydrolysis within the aqueous environment of 
the GIT (Gupta et al., 2013). 
1.4.2. Selection of suitable drug candidate for SEDDS 
Self-emulsifying drug delivery systems can be used as a formulation approach for 
drugs that have poor water solubility and slow dissolution rates (Kohli et al., 2010). 
Therefore, determination of the drug’s lipophilicity (or its octanol : water log P) and its 
solubility in the selected lipid excipients and in mixtures of these lipids may be the most 
important parameters to determine the feasibility of the SEDDS technology for the drug 
(Mu et al., 2013, Hauss, 2007). Interaction between different formulation components 
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may influence the final properties of a formulated SEDDS or SMEDDS, such as 
dispersion behaviour of the formulation upon dilution and solubility of the drug in the 
excipients mixture, and in this case, a compromise of the formulation characteristics is 
required in order to predict the optimal formulation (Holm et al., 2006). In addition, 
because determination of the aqueous solubility and/or log P do not reflect the in vivo 
behaviour of the SEDDS formulation, each drug compound must be assessed 
individually to predict the usefulness of SEDDS formulation (Kohli et al., 2010) .    
Further to the requirement of low dose of the drug (Kohli et al., 2010), the drug 
compound must exhibit high chemical stability in the selected lipid excipients (Kawabata 
et al., 2011).   
1.4.3. Mechanisms of self-emulsification 
Reiss (1975) has suggested that self-emulsification takes place when the entropy 
change that favours dispersion is greater than the energy required to increase the 
surface area of the dispersion. The free energy of formation of a conventional emulsion 
(G) is a direct function of the interfacial energy required to create a new interface 
between the oil and water phases, and can be represented by the equation: 
   ∆𝐺 = ∑𝑁𝑁𝑟2 𝜎   (Equation 1.2) 
where, G is the free energy associated with emulsification process, N is the number of 
droplets with radius r, and σ is the interfacial energy (Gupta et al., 2013).  
An emulsion is an unstable system because oil and water phases tend to 
separate in order to reduce the high free energy of the system at the interfacial area. 
Addition of emulsifying agents tends to reduce the interfacial energy between the two 
phases due to formation of a mechanical barrier around the emulsion droplets 
preventing coalescence (Gupta et al., 2013). Thus, formation of a stable emulsion with 
negative free energy takes place. In contrast, the free energy required to form the 
emulsion in self-emulsifying formulations is low and therefore, emulsification takes place 
spontaneously (Neslihan Gursoy and Benita, 2004). Therefore, formulation of a stable 
and spontaneous dispersion for oral administration may require the incorporation of a 
surfactant which is able to reduce the interfacial energy between the two phases and 
then lower the free energy of the system to the minimum (Shafiq et al., 2007).    
In addition, dielectric spectroscopy studies have revealed that emulsion formation 
may be related to the formation of a liquid crystalline phase (liquid crystal) between the 
oil/surfactant and the water phases (Craig et al., 1995).  Penetration of water into these 
liquid crystals will lead to continuous solubilization of water within the oil droplets until 
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the formation of dispersed liquid crystal phase, for which the actual amount depends on 
concentration of the surfactant in the binary mixture. Formation of liquid crystal interface 
around the oil droplets upon dispersion in water will lead to stabilization of SEDDS 
formulation and prevention of coalescence (Gupta et al., 2013, Neslihan Gursoy and 
Benita, 2004).    
1.4.4. Improvement of oral absorption by SEDDS 
Different studies have shown that the bioavailability of poorly water soluble drugs 
can be improved upon oral administration of different SEDDS formulations (Seo et al., 
2013, Holm et al., 2012, Wang et al., 2010, Atef and Belmonte, 2008). A study 
conducted in dogs compared the oral bioavailability of a lipophilic model drug after 
administration of SEDDS, polyethylene glycol (PEG) 400 solution, capsule and tablet 
dosage forms. The results showed higher values of maximum plasma concentration 
(Cmax) and area under the curve (AUC) from the SEDDS formulation compared to other 
dosage forms tested (Shah et al., 1994). Also, the absolute bioavailability and Cmax of 
halofantrine were significantly increased when the drug was administered orally as 
SNEDDS in rats compared to an oily solution prepared in soy bean oil (Holm et al., 
2012). In addition, oral administration of docetaxel loaded SNEDDS (Seo et al., 2013) in 
mice resulted in 6.5 fold higher absolute bioavailability (17%) and significantly higher 
AUC and Cmax compared to docetaxel solution.  Another study conducted in rats showed 
more than two-fold increase in oral bioavailability of the antiepileptic drug, phenytoin, 
when this poorly water soluble drug was administered orally in stable SEDDS formulation 
in comparison to the commercially available suspension (Atef and Belmonte, 2008).  
Improved bioavailability of poorly soluble drugs may be explained on the basis of 
rapid drug release and increased drug solubilization in the GIT (Shah et al., 1994).  
During transport of the SEDDS formulation throughout the GI tract, the drug may 
partition from the droplets for delivery into the aqueous intestinal fluids. A faster rate of 
drug release from the droplets into the aqueous media may depend on the 
droplet/particle size and the polarity of the oil droplets (Shah et al., 1994). The presence 
of smaller and uniform droplets in SEDDS formulation will provide a short diffusion path 
for the drug to be released from the formulation (Shah et al., 1994). The polarity of 
SEDDS formulations is determined by the properties of oils and surfactant components, 
i.e., the hydrophile – lipophile balance (HLB), degree of unsaturation and chain length of 
the fatty acids, the molecular weight of the hydrophilic portion and concentration of the 
surfactant. Determination of oil/water partition coefficient of the lipophilic drug may give 
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an indication of the polarity of the droplets (Shah et al., 1994, Gershanik and Benita, 
2000). 
It was reported that the ability of self-emulsifying formulations to be digested 
and/or solubilized in the mixed micelles of bile salts and phospholipids in the small 
intestine may be an important factor in determining the absorption rate of the drug from 
SEDDS rather than the particle size of the formulation (Pouton, 2000). For example, 
investigation of the bioavailability of probucol in minipigs from SNEDDS and SEDDS 
differing in their mean particle diameter revealed a slight and non-significant 
improvement of absorption rate and bioavailability of the drug from SNEDDS compared 
to SEDDS (Nielsen et al., 2008).   
Lipids contribute to improvement of the oral bioavailability through different 
mechanisms that result in modification of the biopharmaceutical properties of the drug 
(Neslihan Gursoy and Benita, 2004, Gershanik and Benita, 2000). Lipids can increase 
solubility and dissolution rate of the drug in intestinal fluids, protect the drug from 
chemical and enzymatic hydrolysis in oil droplets (Kawakami et al., 2002), in addition to 
enhancement of lymphatic transport through formation of lipoproteins (Sachs-Barrable et 
al., 2008, Porter and Charman, 2001, Hauss et al., 1998).  
The degree of saturation and the fatty acid chain length of the triglycerides in 
addition to the volume of lipid administered are important factors that affect absorption 
and distribution of the drug into the blood and lymphatic circulations (Neslihan Gursoy 
and Benita, 2004). Transport of the drug into the intestinal lymph may contribute to its 
overall oral bioavailability (Caliph et al., 2000). The drug, first, must associate with the 
intestinal lipoproteins (chylomicrons) so that it can be transported to the lymphatic 
circulation. Therefore, administration of highly lipophilic drugs (triglyceride solubility > 50 
mg/ml and log P > 5) in lipid-based formulations may enhance the lymphatic transport of 
these drugs as well as their systemic absorption (Caliph et al., 2000). The extent of 
lymphatic transport of lipophilic drugs depends on the composition of the lipid vehicle in 
the formulation (Gershanik and Benita, 2000). For instance, a significantly higher 
lymphatic transport of ontazolast was obtained from a soy bean-based emulsion 
formulation in comparison to a SEDDS formulation prepared from Peceol/Tween 80 
system (Hauss et al., 1998).     
The effect of varying fatty acid chain length of triglycerides on the extent of 
lymphatic and portal absorption of the drugs from different lipid-based formulations has 
been studied (Caliph et al., 2000, Holm et al., 2003).  A study has been conducted to 
investigate the effect of varying the chain length of structured triglycerides (the glycerol 
backbone of triglyceride is esterified with different fatty acid chains) on the lymphatic 
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transport and oral absorption of halofantrine from different SMEDDS formulations (Holm 
et al., 2003). The results showed an increase in the lymphatic transport of halofantrine 
(estimated as cumulative % of the administered dose) from SMEDDS formulated with 
long chain structured triglycerides (27.4 % ± 1.3) compared to that obtained from 
SMEDDS formulated using medium chain structured triglycerides (17.9 % ± 1.3). 
However, SMEDDS formulations prepared with medium chain lipids showed higher total 
bioavailability (56.9 %) than those incorporating long chain lipids (37.2 %). It was 
assumed that the short and medium chain fatty acids cannot be incorporated well with 
intestinal lipoproteins for lymphatic transport process, but they can transported via the 
portal blood to the systemic circulation with a result of enhanced oral bioavailability 
(Neslihan Gursoy and Benita, 2004, Caliph et al., 2000). Conversely, the long chain fatty 
acids and monoglycerides enhance the lymphatic transport because they may undergo 
re-esterification within the intestinal cells to form triglycerides which can be associated 
with intestinal lipoproteins and then transported to the intestinal lymph (Neslihan Gursoy 
and Benita, 2004, Caliph et al., 2000).   
Therefore, alteration of the components in SEDDS formulations can be taken as 
a measure to optimize formulations and improve oral bioavailability of poorly soluble 
drugs. A study has reported that oral bioavailability of cyclosporine A formulated as a 
SEDDS changed with changing the type of lipid excipient and their ratio (Odeberg et al., 
2003). A SEDDS formulation prepared from fractionated oat oil and medium chain 
monoglyceride showed an absorption profile of cyclosporine A that is comparable to a 
reference commercial product (Sandimmun Neoral®), whereas formulations comprising 
sphingolipids, cholesterol and medium chain triglyceride showed almost no absorption of 
the drug (Odeberg et al., 2003).   
Incorporation of surfactants into SEDDS may also influence the dissolution 
characteristics of the formulation (Kim et al., 2000) and consequently its oral absorption. 
It has been postulated that surfactants may partition into the epithelial cell membrane 
and change the structural arrangements of its lipid bilayer leading to improved intestinal 
permeability (Neslihan Gursoy and Benita, 2004, Kommuru et al., 2001). Excess 
surfactant that may come in contact with the membrane may cause extensive damage of 
the intestinal lipid bilayer to the degree of dissolving it and forming mixed micelles from 
the surfactant and the membrane (Kommuru et al., 2001, Scott Swenson and Curatolo, 
1992). Therefore, hydrophobic surfactants, which cannot dissolve in the aqueous 
intestinal fluids, will be considered as poor absorption enhancers while surfactants that 
are too hydrophilic will not partition into the lipophilic membrane (Scott Swenson and 
Curatolo, 1992). In this instance, the HLB value of surfactants may be considered 
                                                                                                                                                         Chapter 1 
20 
 
although no general correlation has been identified between the HLB of the surfactant 
and its ability to enhance absorption (Kommuru et al., 2001). 
Inclusion of surfactant into SEDDS formulation of coenzyme Q10 has resulted in a 
two-fold enhancement of oral bioavailability of the drug in comparison to a formulation of 
powder filled into capsule. This bioavailability enhancement was partly attributed to the 
ability of the surfactant to increase mucosal permeability (Kommuru et al., 2001).  
Also, presence of surfactants in lipid formulations may prevent precipitation of the 
drug in the intestinal lumen by solubilization process. The solubilized drug will disperse 
effectively with intestinal fluids and then the drug is rapidly absorbed independently on 
lipid digestion (Gershanik and Benita, 2000). A study showed that the oral absorption of 
an oily and poorly water soluble drug increased with increasing the concentration of the 
surfactant (Tween 80) in the tested emulsion formulation (Toguchi et al., 1990). 
However, the increased absorption of the drug was proved to be due to the smaller 
droplet size of the formulation and not due to the increased amount of solubilized drug 
obtained with increasing surfactant content of the systems (Toguchi et al., 1990). Also, it 
has been shown that micellar solubilization of the drug may affect its transport through 
the intestinal membrane and, hence, the extent of oral absorption (Chiu et al., 2003). In 
vitro permeability studies of cyclosporine reported a reduction in the transport of the drug 
through a Caco-2 cell line when surfactants were incorporated into the PEG solutions 
above their critical micelle concentrations. Decreased transport of cyclosporine was 
attributed to entrapment of the drug within micelles (Chiu et al., 2003).   
Therefore, the impact of excess surfactants on the behavior of lipid formulation 
has to be determined prior to the design of formulation in order to optimize the product 
for specific performance (Yoon and Burgess, 1996).         
1.4.5. Excipients for self-emulsifying drug delivery systems 
Self-emulsifying drug delivery systems comprise a wide variety of excipients that 
differ in their physicochemical and biological properties, which therefore require careful 
consideration to obtain the most appropriate combinations in order to facilitate more 
efficient design of SEDDS (Kohli et al., 2010). Various components of self-emulsifying 
systems including oils, surfactants, and co-surfactants should be selected carefully in 
order to formulate liquids that are clear when mixed with aqueous phase at room 
temperature (Balakrishnan et al., 2009a, Balakrishnan et al., 2009b). Formulation of 
SEDDS requires a crucial consideration of the appropriate mixture of oils, surfactants 
and co-solvents that will solubilize the entire dose of the drug in a sufficient volume 
suitable for oral administration (Gupta et al., 2013, Kohli et al., 2010). Study of drug 
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solubility in various components of SEDDS is important to identify the stability of 
formulations because precipitation of drug in some formulations may take place before in 
situ solubilization (Parmar et al., 2011). However, total solubility of the drug in the whole 
lipid mixture should be considered more than its solubility in individual components of the 
lipid mixture (Rahman et al., 2013). Different factors may affect the efficiency of self-
emulsification process. These include the type and ratio of the oil and surfactant, the 
concentration of the surfactant used and the temperature at which self-emulsification 
process takes place (Rahman et al., 2013, Gupta et al., 2013, Shah et al., 1994). 
Determination of the drug’s compatibility, solubility and stability in the selected excipients 
should take place in order to define the best combinations for the drug (Rahman et al., 
2013). 
In addition to the crucial requirement of chemical and physical stability of the drug 
in the formulation, controlling the chemical and physical stability of the chosen excipients 
during formulation development is necessary for constant dissolution properties of the 
drug throughout the formulation shelf life (Gupta et al., 2013).  
In general, more efficient SEDDS may be prepared with lipid components that are 
selected to attain maximum drug loading capacity, minimum self-emulsification time, 
reduced droplet size variation due to pH and composition of the aqueous medium and 
minimum or prevented drug hydrolysis or metabolism in the gastric fluids (Rahman et al., 
2013). Determination of solubilization capacity or drug loading of a self-emulsifying 
formulation is necessary to avoid drug precipitation that may take place in vivo. Self-
emulsifying systems that contain drug concentrations exceeding its solubilization 
capacity are expected to show drug precipitation upon dilution. Therefore, much attention 
should be paid to avoid drug precipitation in diluted systems (Narang et al., 2007). In 
addition, good solubilizing capacity of self-emulsifying formulation is required for 
stabilization of the drug in solution (Wang et al., 2009). 
Particle size of an emulsion is an important factor that influences the rate and 
extent of drug release as well as in vivo absorption and consequently affects self-
emulsification performance of the formulation (Constantinides et al., 1994). It was 
suggested that the faster release rate of simvastatin from SMEDDSs, compared to 
conventional tablets, was due to smaller droplet size obtained by dissolving the drug in 
SMEDDS formulation (Kang et al., 2004). Also, smaller droplet size may contribute to 
enhanced in vivo drug absorption due to larger interfacial surface area obtained by 
smaller particles (Liu et al., 2009). 
                                                                                                                                                         Chapter 1 
22 
 
1.4.5.1. Lipids / Oils 
Lipids are considered as important excipients in the formulation of SEDDS. They 
are amphiphilic in nature comprising both lipophilic and hydrophilic portions in their 
molecular structure. Lipids differ in their fatty acid composition, melting point, HLB, and 
solubility in non-polar organic solvents (Jannin et al., 2008).  Lipids participate in the 
improvement of absorption from the GI tract due to their ability to solubilize part of the 
lipophilic drug and to increase the fraction of the drug transported by the intestinal 
lymphatic circulation (Neslihan Gursoy and Benita, 2004). Therefore, solubilization 
capacity by an oily phase is an important factor that should be considered in selecting 
the type of the oil phase (Pouton and Porter, 2008). 
1.4.5.1.1. Natural lipids (Triglycerides) 
Natural oils and fats consist of mixtures of triglycerides which contain fatty acids 
of different chain length; namely: short (< 5 carbons), medium (6 to 12 carbons) and long 
chains (> 12 carbons); with different degrees of unsaturation. The melting point of the oil 
increases with increasing the fatty acid chain length and decreases with increasing the 
degree of unsaturation of the triglyceride (Rahman et al., 2013). Triglyceride vegetable 
oils are commonly present in food and are generally regarded as safe (GRAS) excipients 
in lipid-based formulations because of their ability to be completely digested and 
absorbed from the GI tract. The solvent capacity of triglycerides depends on the effective 
concentration of the ester groups, and therefore, medium chain triglyceride (MCT) 
possesses higher solvent capacity compared to long chain triglycerides (LCT) (Cao et 
al., 2004). In addition, MCTs have higher fluidity, lower susceptibility to oxidation, and 
better self-emulsification properties.  
1.4.5.1.2. Semi-synthetic and synthetic lipids (mixed glycerides and polar oils) 
Chemical interaction of the MCTs, or glycerides derived from natural oils, with a 
single or different hydrophilic chemical entities has led to the production of wide varieties 
of liquid or semisolid (thermo softening) excipients that find wide application in lipid-
based formulations due to their solubilizing, surfactant, and wetting properties. These 
vehicles can be used in SEDDS and SMEDDS as emulsifiers and co-emulsifiers, in 
addition to their ability to be filled into soft and hard gelatin capsules while in the molten 
state (Gibson, 2007). However, semi-solid or thermo softening excipients with a melting 
range of 26 to 70 oC can be filled only into hard gelatin capsules because of their waxy 
state at ambient room temperature (Rahman et al., 2013).  
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Mixed glyceride excipients, with different contents of mono-, di- and triglycerides, 
can be obtained by partial hydrolysis of triglycerides or glycerolysis (Gibson, 2007). 
Different properties of mixed glycerides including their chemical composition, physical 
appearance, melting behavior and HLB values are affected by the original source of 
triglycerides and the degree of hydrolysis induced during production process (Gibson, 
2007). Common excipients of this type include: glyceryl monocaprylocaprate (Capmul® 
MCM); glyceryl monostearate (Geleol®, Imwitor® 191); glyceryl monooleate (Peceol™) 
and glyceryl monolinoleate (Maisine™ 35-1) (Rahman et al., 2013). Another example of 
pharmaceutical excipients, polyoxylglycerides or macrogolglycerides, are produced by 
polyglycolysis of vegetable oils with polyoxyethyleneglycols (PEG) of certain molecular 
weight. The physical appearance of these excipients may range from viscous liquids to 
solids at room temperature, depending on their composition of mono-, di- and 
triglycerides and mono- and diesters of PEG which aid their ready dispersion in water. 
Examples of this type of excipients may be composed of unsaturated long chain fatty 
acids which include oleyl polyoxylglycerides (Labrafil®M1944CS) and linoleyl 
polyoxylglycerides (labrafil®M2125CS), saturated medium chain fatty acid esters such as 
lauroyl polyoxylglycerides (Gelucire®44/14) or saturated long chain fatty acid esters such 
as steroyl polyoxylglycerides (Gelucire®50/13) (Rahman et al., 2013).  Different 
examples of polyoxylglycerides were shown to improve solubility and bioavailability 
(Chambin and Jannin, 2005, Sha et al., 2005).     
Mixed mono- and diglycerides of long chain fatty acids are suitable for liquid 
formulations when waxy materials present technical problems. Compared to 
triglycerides, mixed long chain glycerides are more useful to solubilize drugs, with 
exception of highly lipophilic drugs, especially in Type II and Type III self-emulsifying 
formulations (Pouton and Porter, 2008). Mixed glycerides of medium chain fatty acids 
have gained much attention, compared to conventional MCTs, because of their higher 
solvent capacity, lower susceptibility to oxidation and additional surfactant properties that 
enhance their emulsification power (Porter et al., 2008).  However, digestion of medium 
chain glycerides should be evaluated prior to their selection for lipid-based formulations 
(Porter et al., 2008). 
More polar oily excipients such as sorbitan fatty acid esters (Spans) resemble 
mixed glycerides in their physical properties and their ability to improve solvent capacity 
and dispersion of the formulation. Examples of polar oils include the more lipophilic 
sorbitan trioleate (Span 85), sorbitan monooleate (Span 80) and free fatty acids such as 
oleic acid (Strickley, 2007, Gibson, 2007).  




Incorporation of surfactants in SEDDS is essential for the self-emulsifying 
properties. Surfactants can dissolve high proportions of hydrophobic drug compounds in 
the formulation due to their amphiphilic nature (Kohli et al., 2010, Neslihan Gursoy and 
Benita, 2004). Also, they facilitate the dispersion process by reducing the interfacial 
tension between oil and water phases with subsequent formation of a flexible film around 
the droplets (Rahman et al., 2013).  In order for predictable self-emulsifying properties to 
take place in SEDDS formulations, surfactants are required to be incorporated in high 
concentrations ranging from 30 to 60% w/w of the formulation (Rahman et al., 2013, 
Neslihan Gursoy and Benita, 2004). However, the high risk of GI irritation associated 
with incorporation of higher concentrations of surfactants may require essential 
consideration of the safety of the used concentration of each surfactant (Gupta et al., 
2013, Rahman et al., 2013).  SMEDDS and SNEDDS formulations may have reduced 
irritation potential with high surfactant concentrations. This is due to rapid gastric 
emptying and rapid dispersion of the extremely small droplets of these SMEDDS and 
SNEDDS formulations throughout the GI fluids (Gupta et al., 2013).  Generally, natural 
emulsifiers such as lecithin and medium chain monoglycerides (MCM) are safer than 
synthetic surfactants, but with less self-emulsification properties (Constantinides, 1995). 
In addition, nonionic surfactants are less toxic than the ionic surfactants and may 
produce highly stable emulsions with a high safety profile (Gershanik and Benita, 2000).  
The surfactants used in SEDDS formulations are required to have relatively high 
HLB values and hydrophilicity in order to promote rapid dispersion in the aqueous GI 
fluids and immediate formation of fine o/w droplets (Rahman et al., 2013). In addition, 
better self-emulsifying properties can be obtained by the use of a mixture of surfactants 
rather than the use of a single surfactant (Li et al., 2005). It was proposed that an 
increase in the microemulsion area in the phase diagram and possible higher drug 
loading could be obtained if mixtures of surfactants were combined. In addition, the 
ability of the surfactant to partition into the oil-water interface may increase resulting in a 
decreased interfacial energy and a more stable formulation (Li et al., 2005). 
Furthermore, the concentration of the surfactant added to SEDDS may affect the 
droplet size. In general, a smaller mean droplet size is produced with increasing the 
concentration of the surfactant used. The surfactant molecules added will be adsorbed at 
the interface between oil and water phases resulting in stabilization of oil droplets. 
However, increasing the concentration of the surfactant may sometimes lead to 
increased water penetration into oil droplets and subsequent disruption of the interface 
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between oil and water phases resulting in removal of oil droplets into the aqueous phase 
(Kommuru et al., 2001, Pouton, 1997).     
Water-soluble surfactants are the most widely employed surfactants for SEDDS 
or SMEDDS formulations (Pouton, 2006). Having HLB values ≥ 12, micellar solutions of 
water soluble surfactants can be formed above their critical micelle concentration where 
they dissolve in water at low concentrations. Depending on the method of production, the 
lipophilic part of water-soluble surfactants may contain saturated or unsaturated fatty 
acids. For example, Cremophor® RH40 and Cremophor® EL are relative derivatives of 
castor oil but with more saturated alkyl chains in Cremophor RH40 and unsaturated alkyl 
chains in Cremophor EL, according to the degree of hydrogenation of castor oil. The use 
of water-soluble ester surfactants in pharmaceutical products is limited by their safety 
profile rather than by their advantageous effect on the physicochemical properties of the 
products (Rahman et al., 2013, Pouton and Porter, 2008).  
Other water-soluble ester surfactants include the polyalcohol esters of edible fatty 
acids which are produced by esterification of vegetable oils. These amphiphilic esters 
possess medium to high HLB, based on the process of synthesis, and can be used in 
SEDDS to enhance solubility and bioavailability (Rajebahadur et al., 2006).  Examples of 
this group include polyglyceryl oleate (Plurol™Oleique CC497), propylene glycol 
monocaprylate (Capryol™90), propylene glycol monolaurate (Lauroglycol™90), 
polyoxyethylene–8 stearate (Mirj®45), polyoxyethylene–40 stearate (Mirj®52), 
polyoxyethylene–15 hydroxystearate (Solutol®HS15), and polyoxyethylene–20 sorbitan 
monooleate or polysorbate 80 (Tween®80) (Rahman et al., 2013).  
Water-insoluble surfactants possess intermediate HLB values from 8 to 12 and 
can adsorb strongly at the interface between oil and water phases. These surfactants 
can form micelles but their hydrophilicity may not be sufficient to affect the self-
emulsification process. The solubility of these surfactants in water is generally low, but 
they may disperse in water when shear is applied to form an emulsion (Kalepu et al., 
2013). Examples of this type of surfactant are mainly oleate esters such as 
polyoxyethylene–20 sorbitan trioleate (polysorbate 85 or Tween®85) with HLB value 
equal to 11; and polyoxyethylene–25 glyceryl trioleate (Tagat TO®) with HLB value equal 
to 11.5 (Pouton and Porter, 2008). Mixing surfactants with different HLB values may 
produce systems with different properties if compared to systems prepared from a single 
surfactant. Differences in behaviour between the two systems can be explained on the 
basis that the mixture system may contain both water soluble and water insoluble 
molecules while the single surfactant system will contain only water insoluble molecules. 
For example, a mixture of Tween 80 and Span 80 with an average HLB value of 11 will 
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possess different emulsifying properties compared to a system containing only Tween 85 
with an HLB value of 11. Small fractions of water soluble components present in Tween 
85 may not be enough to affect the properties of the formulation upon dispersion, while 
the properties of systems prepared from mixtures of Tween 80 and Span 80 may be 
influenced by the more dominant water soluble portions present in the surfactant mixture 
(Pouton and Porter, 2008).   
1.4.5.3. Co-solvents or co-surfactants 
Formulation of more effective SEDDS may require incorporation of some organic 
solvents to aid in the dissolving of large quantities of either the drug or the hydrophilic 
surfactant in the lipid base. The most commonly used materials include ethanol, glycerol, 
propylene glycol and polyethylene glycol (PEG) 400. These solvents may act as co-
surfactants in the microemulsion systems (Gershanik and Benita, 2000). Also, 
incorporation of high concentrations of co-solvents may lead to improved solvent 
capacity of the formulation for drugs that dissolve freely in co-solvents. However, high 
concentrations of co-solvents may cause precipitation of the drug upon dilution and 
dispersion in water. Therefore, careful consideration of the concentration of co-solvents 
to be used in the formulation is important to avoid problems of drug precipitation and 
immiscibility of some co-solvents with lipid components (Pouton and Porter, 2008). In 
addition, incorporation of co-surfactants in lipid-based formulations may allow the 
formation of fluid and sufficiently flexible interfacial film which is capable to take different 
curvatures necessary for the development of microemulsions over a wide range of 
composition (Lawrence and Rees, 2000). Compared to alcohol-free formulations, 
conventional SEDDS containing organic solvents may develop drug precipitation due to 
evaporation of the used organic solvents into the shells of soft or hard gelatin capsules. 
However, alcohol-free lipid formulations may have limited dissolution of the drug 
(Constantinides, 1995). 
Construction of ternary phase diagram is a useful tool to optimize the amounts of 
components in SEDDS and to determine the system with the most suitable concentration 
of surfactants or surfactant/co-surfactant blends that can reduce the free energy of the 
system and increase the dispersion entropy resulting in spontaneous, and 
thermodynamically stable dispersions (Shafiq et al., 2007). Identification of minimum 
concentrations of surfactants that yield stable nanoemulsion formulations is necessary to 
avoid GI irritation that may be caused by large amounts of surfactants (Duc Hanh et al., 
2015, Shafiq et al., 2007). Also, the effect of different components on the phase behavior 
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of different systems can be determined from phase diagrams (Lawrence and Rees, 
2000). 
1.4.5.4. Other additives 
Protection of lipid-based formulations against oxidation may require the addition 
of different lipid soluble antioxidants. These may include α-tocopherol, β-carotene, 
butylated hydroxytoluene (BHT), butylated hydroxyanisol (BHA) or propyl gallate 
(Gibson, 2007). 
1.4.6. Approaches for oral delivery of SEDDSs 
Formulation of self-emulsifying drug delivery systems in an acceptable dosage 
form for oral administration represents a challenge that has to be considered. Generally, 
SEDDSs are prepared in liquid form. However, some limitations associated with these 
liquid formulations have led to the production of solid self-emulsifying drug delivery 
systems (S-SEDDSs) as alternative option for oral delivery (Gupta et al., 2013).  
1.4.6.1. Capsule filling with liquid self-emulsifying drug delivery systems 
Capsule filling offers a simple method of manufacturing for oral delivery of liquid 
SEDDSs. This method provides high drug loading capacity (up to 50% w/w), especially 
for low dose and highly potent drugs (Jannin et al., 2008, Tang et al., 2008). It involves 
filling the formulation into the capsule body which will then be sealed with the capsule 
cap either by banding with a gelatin band or by using liquid encapsulation micro-spray 
sealing (LEMS) technology (Jannin et al., 2008). Capsule filling technology has been 
utilized for development of Liquid Oros technology (Alza Corporation) based on the 
osmotic principle for controlled delivery of insoluble drug substances or peptides 
formulated in a liquid self-emulsifying formulation. This system expands when it comes 
into contact with water and then expels the drug formulation through an orifice in the 
capsule (Tang et al., 2008).  
Some factors may limit the application of capsule filling as a method of 
manufacturing of conventional liquid SEDDSs. Compatibility of the excipients with the 
capsule shell is an important factor that must be considered (Balakrishnan et al., 2009a, 
Jannin et al., 2008, Tang et al., 2008). Also, storage temperature may affect the solubility 
of different ingredients in the final product because precipitation of the drug and/or 
excipients may take place at lower storage temperatures.  These precipitated materials 
may prevent existence of the drug in solution or within fine emulsion droplets, if could not 
be dissolved again by warming the filled capsules to room temperature (Balakrishnan et 
                                                                                                                                                         Chapter 1 
28 
 
al., 2009a). In addition to possible irreversible precipitation, production of liquid SEDDSs 
may be restricted by the high cost, reduced stability of the liquid preparations, the need 
for large volumes of the dose for administration, difficult handling and transportation, in 
addition to limited choices of dosage forms (Gupta et al., 2013, Tang et al., 2008) .   
1.4.6.2.  Production of solid self-emulsifying drug delivery systems (S-SEDDSs) 
Solid self-emulsifying drug delivery systems (S-SEDDS) have been employed as 
an alternative approach for SEDDSs. These systems are produced by solidification of 
liquid SEDDSs into powders which can be formulated into different solid dosage forms 
such as tablets, capsules, pellets and beads. Transformation of liquid SEDDSs into solid 
dosage forms should not change the release characteristics of the drug or the self-
emulsification process that will take place in the GI tract. Therefore, S-SEDDSs possess 
the advantages of both SEDDS formulations and solid dosage forms. These systems are 
characterized by high stability and reproducibility of the formulation, improved drug 
solubility and bioavailability, ease of handling and transportation in addition to better 
patient compliance (Gupta et al., 2013).  
Different solidification technologies that have been utilized to produce S-SEDDSs 
from the liquid SEDDSs are discussed below. 
1.4.6.2.1. Solidification techniques to produce S-SEDDS 
i. Spray drying 
In the spray drying technique, the liquid formulation is first prepared by mixing the 
drug, lipids, surfactants and solid carriers (like silicon dioxide) with an organic or 
aqueous solvent. The prepared formulation is then sprayed or atomized into a hot air 
chamber where the organic solvent or water contained in the formulation evaporates, 
and consequently, solid microparticles are produced under controlled conditions of 
temperature and airflow pattern. The resulting microparticles can be compressed into 
tablets or alternatively filled into hard shell capsules (Jannin et al., 2008, Tang et al., 
2008).  
Solid SMEDDS of nimodipine (Yi et al., 2008) prepared by a spray drying 
technique, using dextran as a solid carrier, showed faster release rate of the drug, 
compared to conventional tablets, and improved oral bioavailability in rabbits. Also, 
enhanced anti-tumour activity and reduced toxicity of docetaxel (Seo et al., 2013) was 
observed when self-nanoemulsifying formulation was spray dried into solid SNEDDS 
using colloidal silica as an inert porous carrier. 
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Furthermore, application of spray drying to formulate solid SEDDS of 
dexibuprofen using Aerosil® 200 as a solid carrier resulted in two fold higher 
bioavailability of the drug following oral administration to rats when compared to 
dexibuprofen powder. Such results indicated that the self-emulsification properties of the 
liquid SEDDS were preserved after solidification (Balakrishnan et al., 2009a).  
ii. Adsorption onto solid carriers 
A simple adsorption process involves the addition of a liquid self-emulsifying 
formulation onto a solid carrier by mixing in a blender to obtain a free flowing powder 
which can be directly filled into capsules or compressed into tablets after mixing with 
suitable excipients (Gupta et al., 2013, Jannin et al., 2008). In this adsorption technique, 
good content uniformity can be obtained and up to 70% of lipid formulation may be 
adsorbed onto suitably selected carriers (high lipid exposure). However, decreased drug 
loading capacity may be encountered with this method due to subsequent dilutions of the 
lipid formulation during mixing with solid carriers and then during mixing with excipients 
required for compression into tablets (Gupta et al., 2013, Jannin et al., 2008).  
Solid carriers that are able to adsorb large quantities of the liquid lipid formulation 
should be selected to ensure increased drug loading capacity as well as lipid exposure. 
For example, different grades of Neusilin® (magnesium aluminometasilicate), Florite® 
(calcium silicate), Syloid® (porous silicon dioxide), Aerosil® (colloidal silicon dioxide) and 
Avicel® (microcrystalline cellulose (MCC)) were used as adsorbents to transform liquid 
SEDDS into solid SEDDS.   
Different studies have explored the use of Neusilin® (magnesium 
aluminometasilicate) as an adsorbent to transform liquid SEDDS into solid SEDDS and 
to improve the solubility, dissolution properties and bioavailability of poorly soluble drugs 
(Agarwal et al., 2009, Beg et al., 2016, Kallakunta et al., 2012, Parmar et al., 2015). For 
example, utilization of Neusilin® US2 as a solid inert carrier to formulate solid SNEDDS 
of olmesartan medoxomil (Beg et al., 2016) from optimized liquid SNEDDS, resulted in 
improvement of drug release rate compared to other adsorbents tested like Aerosil® 200. 
In addition, a 2.32 – 3.27 fold enhancement in the bioavailabilty parameters of the drug 
from solid SNEDDS formulated with Neusilin®US2 was observed compared to pure drug 
solution.   
Another study, aimed to improve the solubility of the poorly soluble drug, 
lercanidipine hydrochloride, employed Neusilin®US2 as an inert carrier to produce a self-
emulsifying powder of the drug (Kallakunta et al., 2012). The self-emulsifying powder 
was produced by simple adsorption of the optimized liquid SEDDS onto Neusilin®US2 
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using a mortar and a pestle. The formulated self-emulsifying powder showed good 
flowability, preserved the self-emulsification properties of the liquid SEDDS and exhibited 
high dissolution efficiency value, compared to the pure drug.  Further investigation of the 
produced self-emulsifying powder by DSC and XRD revealed that the drug was 
molecularly dispersed in the liquid SEDDS. 
Different grades of Florite® (calcium silicate) have been used to formulate solid 
SEDDS of gentamicin (Ito et al., 2005), nifidipine (Weerapol et al., 2015a) and 
griseofulvin (Agarwal et al., 2009). The use of calcium silicate in these formulations 
resulted in positive effects on both dissolution and bioavailability of the drug.  
The effectiveness of various grades of Syloid® (porous silicon dioxide) as carriers 
or adsorbents for different lipid-based formulations has been investigated in different 
studies (Agrawal et al., 2015, Wang et al., 2010). For example, Syloid® 244FP was 
utilized to convert liquid SEDDS of glipizide into solid SEDDS. The developed solid 
SEDDS showed a significant improvement in the dissolution rate of the drug indicating 
that the drug in the solid formulations could dissolve rapidly and completely compared to 
the pure drug. Also, in vivo evaluation of the formulated solid SEDDS proved increased 
therapeutic efficiency of the drug in reduction of blood glucose level compared to the 
pure drug. This improvement in bioavailability of glipizide was attributed to improved 
solubility and dissolution rate of the drug from the solid SEDDS (Agrawal et al., 2015). 
Similar findings were also reported for the production of self-emulsifying pellets of 
nitrendipine from liquid SEDDS formulation (Wang et al., 2010). The self-emulsifying 
pellets were produced by adsorption of the liquid SEDDS of nitendipine onto Syloid® 244 
FP, followed by extrusion/spheronization process to formulate pellets. The developed 
self-emulsifying pellets preserved the self-emulsification properties of the liquid SEDDS. 
The results of the in vitro dissolution and the oral bioavailability of the formulated pellets 
were significantly higher than that obtained for conventional tablets and were not 
significantly different than the results obtained for liquid SEDDS formulation.   
Syloid® XDP grades were specifically engineered to improve oil adsorption 
capacity of lipid-based formulations and conversion into free flowing powder from which 
tablets and capsules can be produced.   
Investigation of the utilization of microcrystalline cellulose (MCC) as an adsorbent 
to transform liquid SEDDS into solid formulations has been conducted (Abdalla et al., 
2008, Li et al., 2013). The developed solid SEDDS maintained the self-emulsification 
properties of the liquid formulations. It also showed an enhancement of the in vitro drug 
release in comparison to the pure drug.   
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Several studies have described the use of colloidal silicon dioxide as an 
adsorbent to formulate solid self-emulsifying drug delivery systems (Balakrishnan et al., 
2009a, Beg et al., 2016, Beg et al., 2012, Parmar et al., 2015). Enhancement of the in 
vitro drug dissolution and bioavailability of the tested drugs were obtained from the solid 
SEDDS formulated with Aerosil® 200, compared to the pure drug or the commercially 
available products. 
iii. Melt granulation 
In melt granulation or pelletization, a powder mix is converted into granules or 
spheronized pellets by blending a meltable binder with the powder mix using high shear 
mixing. The heat generated during mixing, due to friction, will cause melting of the solid 
or semi solid binder “melt-in process” and therefore, liquid bridges are formed with the 
powder particles leading to production of small granules. These granules can be 
transformed further into spheronized pellets under controlled conditions if high shear 
mixing is continued. Similar to conventional wet granulation, the meltable binder can be 
also sprayed, while in molten state, onto the powder particles (Jannin et al., 2008, 
Kalepu et al., 2013).  The simple process of melt granulation does not require the 
addition of solvents and may provide up to 85% drug loading capacity (Jannin et al., 
2008).  
Melt granulation process can be controlled by controlling different parameters 
that are related to the binder such as particle size, concentration and viscosity on 
melting; or those related to the process such as mixing time and impeller speed (Jannin 
et al., 2008, Kalepu et al., 2013).   
Polyoxylglycerides (Gelucires®), and partial glycerides or polysorbates are among 
the different meltable binders that can be employed for melt granulation process to 
produce solid SEDDS (Tang et al., 2008).  
iv. Extrusion spheronization 
Melt extrusion is a solvent-free method that involves forcing a material which 
possesses plastic properties through a die; under controlled conditions of temperature, 
pressure and flow rate, to produce cylindrical extrudates. High drug loading (60%) and 
good content uniformity can be obtained from this method of solidification especially if 
applied to low dose, highly potent drugs (Gupta et al., 2013, Jannin et al., 2008, Tang et 
al., 2008). The process of extrusion spheronization requires wet massing of a mixture of 
the drug and different excipients with the binder. The mixture is then extruded into rope-
like (rods) extrudates which can be cut (spheronized) into uniform spheroids. The 
produced spheroids are dried and sifted to obtain the required size distribution (Gupta et 
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al., 2013, Tang et al., 2008). The melt extrusion method may result in dispersion of drugs 
at a molecular level in the used matrix. Also, amorphous solids or different polymorphic 
forms can be processed by this method (Breitenbach, 2002).   
Different formulation variables may affect the properties of pellets produced by 
extrusion/spheronization method (Newton et al., 2001). For example, the relative 
amounts of self-emulsifying system and water may significantly affect the extrusion force, 
size spread and roughness of produced pellets. Therefore, it has been suggested that 
the maximum quantity of the liquid lipid formulation that can be solidified by extrusion 
spheronization may form 42% of the dry pellet weight (Newton et al., 2001). 
Lipid based excipients such as Gelucire® 44/14 can be added to extrusion 
formulations to improve the dissolution rate and bioavailability of poorly soluble drugs or 
to provide controlled release characteristics (Mehuys et al., 2005, Serratoni et al., 2007, 
Hülsmann et al., 2000). For example, an enhancement of the dissolution rate of two 
model drugs (methyl and propyl paraben) was obtained from pellets prepared by 
extrusion spheronization of a mixture containing a self-emulsifying mixture consisting of 
equal parts of mono-diglycerides (Imwitor® 742), polysorbate 80 and microcrystalline 
cellulose. In addition, application of a coat of ethylcellulose, talc and glycerol onto the 
pellets resulted in a reduced rate of release of the drug depending on the amount of the 
coat added to the pellets (Serratoni et al., 2007). Moreover, a significantly higher 
dissolution rate was observed for 17β-estradiol hemihydrate solid dispersions prepared 
by melt extrusion of a mixture containing 10% 17β-estradiol hemihydrate, 40% Gelucire® 
44/14 and 50% polyvinylpyrrolidone (PVP). About 57% of the drug was released in 60 
minutes from the solid dispersions compared to less than 2% of the drug dissolved from 
the pure non-micronized powder, which indicates more than 30 fold improvement in the 
release rate of the drug (Hülsmann et al., 2000).    
Utility of extrusion spheronization as a technique of solidification was 
demonstrated in the preparation of diazepam (Abdalla and Mäder, 2007), progesterone 
(Tuleu et al., 2004) and nitrendipine (Wang et al., 2010) self-emulsifying pellets. Good 
physical properties in terms of friability, shape and self-emulsifying characteristics were 
obtained from self-emulsifying pellets of diazepam produced by extrusion spheronization. 
A faster release rate of diazepam without crystallization was also observed from these 
pellets during the time of dissolution study (Abdalla and Mäder, 2007). In their study, 
Tuleu et al. (2004) found that the formulated pellets of progesterone showed nearly 
100% release of the drug within 30 minutes. In addition, oral administration of these 
pellets to dogs showed an AUC that was seven times greater than that obtained when 
progesterone aqueous suspension was administered (Tuleu et al., 2004). Furthermore, 
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significantly higher in vitro release performance of nitrendipine (more than 80% within 30 
minutes) was observed from self-emulsifying pellets prepared by extrusion 
spheronization (Wang et al., 2010) compared to conventional tablets.  Significant 
improvement in nitrendipine absorption with a relative bioavailability of 159.87% was also 
noted following oral administration of self-emulsifying pellets to dogs in comparison to 
conventional nitrendipine tablets. 
Improvements in the release rate and bioavailability of these drugs from pellets 
prepared via extrusion spheronization indicate the suitability of this method to produce 
solid self-emulsifying dosage forms from liquid SEDDS formulations.                 
v. Lyophilization  
The technique of lyophilization or freeze drying involves dissolving the drug and 
the carrier in a common solvent followed by freezing and then sublimation to obtain a 
lyophilized molecular dispersion (Gupta et al., 2013). This technique of solidification has 
been employed in the preparation of solid self-nanoemulsifying systems for oral delivery 
of a therapeutic combination of tamoxifen and quercetin (Jain et al., 2014a, Jain et al., 
2014b). The developed formulation showed improved therapeutic efficacy and reduced 
toxicity of tamoxifen citrate in comparison to free tamoxifen citrate and its combination 
with quercetin (Jain et al., 2014a, Jain et al., 2014b). Also, a stable solid self-
nanoemulsifying formulation of an anti-viral drug (adefovir dipivoxil) that was prepared 
with the lyophilization technique showed improved in vitro release performance of the 
drug in addition to enhanced ex vivo absorption from the intestine in comparison to that 
obtained from plain drug suspension (Gupta et al., 2011). 
1.4.6.2.2. Solid self-emulsifying dosage forms  
Extensive investigation of the development of S-SEDDSs has been conducted to 
study the applicability of these systems and to determine their impact on different 
physical and biopharmaceutical properties of the incorporated drugs. Application of 
different solidification technologies facilitated the transformation of liquid lipid 
formulations into different solid dosage forms and therefore become no longer limited to 
capsule filling (Jannin et al., 2008). Different self-emulsifying solid dosage forms such as 
tablets, capsules, pellets, beads, suppositories, implants and solid dispersions were 
produced from the initially formulated liquid SEDDSs.  Table 1.3 summarizes some 
examples of self-emulsifying solid dosage forms which have been developed using 
different solidification techniques.   









Model drug Solidification technique Reference 
1. Tablets  Co-enzyme Q10 Adsorption onto carrier (Nazzal et al., 2002) 
  Ketoprofen  Gelling with Aerosil® 200 (Patil et al., 2004) 
  Isradipine  Formulation of matrix with HPMC (Tran et al., 2013) 
  Carvedilol  Osmotic pump tablets (Wei et al., 2007) 
  Cyclosporine A Osmotic pump tablets (Zhang et al., 2013) 
2. Pellets  Diazepam  Extrusion / Spheronization (Abdalla and Mäder, 
2007) 
  Piroxicam  Wet granulation (Franceschinis et al., 
2011) 
  Nitrendipine  Extrusion / Spheronization (Wang et al., 2010) 
3.  Beads  Laoratadine Loading to porous polystyrene 
beads 
(Patil and Paradkar, 
2006) 
4. Microspheres Zedoary 
turmeric oil 
Quasi-emulsion solvent diffusion 
method  
(You et al., 2005) 
5. Nanoparticles Paclitaxel  Multiple emulsion (w/o/w) 
solvent evaporation method 
(Trickler et al., 2008) 
6. Phospholipid 
suspensions 
Leutin  Dispersion into a matrix of 
Phasol® 53 MCT 
(Shanmugam et al., 
2011) 
7. Suppositories Indomethacin Filling into hollow gelatin 
suppositories 
(Kim and Ku, 2000) 
8. Implants Carmustine  Incorporation into PLGA, 
poly(d,l-lactide-co-glycolide) 
wafer by compression molding 
(Chae et al., 2005) 
9. Solid 
dispersions 
Piroxicam  Melting method (Karataş et al., 
2005) 
  Nifidipine  Melting method (Vippagunta et al., 
2002) 
  Diazepam  Melt agglomeration (Seo et al., 2003) 
 
  
                                                                                                                                                         Chapter 1 
35 
 
Among the above tabulated self-emulsifying solid dosage forms, formulation of 
self-emulsifying solid dispersions appears as a prominent approach to develop solid self-
emulsifying drug delivery systems that would enhance the solubility, dissolution and 
bioavailability of poorly soluble drugs. The following section will highlight the concept of 
self-emulsifying solid dispersions and their applicability in the manufacture of S-SEDDSs 
as a part of this study.  
 Self-emulsifying solid dispersions 1.5.
1.5.1. Definition, advantages and limitations 
      Solid dispersions are formulations comprising the dispersion of one or more 
drugs into an inert hydrophilic carrier or matrix at the solid state (Vo et al., 2013, 
Vasconcelos et al., 2007). The dispersed drug may exist as dissolved molecules or 
amorphous or crystalline particles while the carrier may exist in amorphous or crystalline 
states (Vo et al., 2013). Formulation of solid dispersions has been reported as an 
approach to improve the solubility and dissolution rates of poorly soluble drugs (Leuner 
and Dressman, 2000), possibly by reducing the particle size of the drug to the molecular 
level, enhancing the wettability and porosity, and changing the drug crystallinity into an 
amorphous state (Vo et al., 2013, Vasconcelos et al., 2007).  
Solid dispersion technology, as an approach to improve the bioavailability of 
poorly soluble drugs, has many advantages over other techniques that can be used for 
the same purpose such as salt formation, micronization, nanosizing, solubilization by co-
solvents and others (Vo et al., 2013). Solid dispersions may result in reduction of particle 
size to possibly molecular level while the conventional size reduction methods produce 
particles in the range of 2–5 µm which can easily agglomerate in the formulation, during 
dissolution studies or during storage (Pouton, 2006, Vo et al., 2013). Application of more 
complicated nanosizing methods to produce drug nanocrystals may require special 
stabilizers and equipments (Möschwitzer, 2013). In addition, drug particles in solid 
dispersions will not form agglomerates due to their interaction with the carrier. Therefore, 
the drug is released or dissolved rapidly upon contact with GI fluids to form a 
supersaturation state which may facilitate rapid drug absorption (Vasanthavada and 
Serajuddin, 2007). Moreover, if the drug particles precipitated from solid dispersions, the 
precipitated particles will exhibit higher in vitro dissolution because of their preserved 
submicron size (< 1 µm) and also their higher energy state may lead to faster dissolution 
for in vivo conditions (Serajuddin, 1999).  
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Production techniques of solid dispersions are simpler and more widely 
applicable compared to other approaches applied for enhancing the bioavailability of 
poorly soluble drugs. Also, solid dispersions can be manufactured in oral solid dosage 
forms for much better patient compliance (Serajuddin, 1999). 
Solid dispersions also enhance the wettability and porosity of the drug especially 
when surfactants are added. Improved wettability of the drug is achieved due to 
absorption of water by the carrier surrounding drug particles leading to improved 
dissolution of the drug. The polymeric carriers incorporated into solid dispersions may 
also enhance the solubility of the drug. Solid dispersions prepared by the solvent method 
are characterized by their high porous structure. Some channels can be produced in 
solid dispersions structure upon solvent removal resulting in increased porosity and 
specific surface area and consequently increased dissolution rate of the drug (Vo et al., 
2013).   
Difficulties in controlling the physical and chemical stability problems of the drug 
or the solid dispersion formulation have led to limited number of commercially available 
solid dispersions (Serajuddin, 1999). The most important problem with solid dispersions 
is the recrystallization of the drug from the amorphous state, either during manufacturing 
process or subsequent storage. Recrystallization may result in reduced bioavailability of 
the drug from solid dispersions (Vo et al., 2013). Stability of amorphous drugs during 
storage is highly influenced by the moisture and humidity levels as well as by the 
increased temperature which may accelerate the mobility of the drug and hence, drug 
crystallization. Also, the carriers or the polymers used in solid dispersions can absorb 
moisture leading to phase separation, crystal growth and conversion into the crystalline 
state. Therefore, control of the storage temperature and moisture is crucial for the 
physical stability of the drug. (Vasconcelos et al., 2007). 
Different strategies were proposed to overcome the recrystallization tendency, 
which is the main disadvantage of solid dispersions, and then to maximize the stability of 
these formulations (Vasconcelos et al., 2007, Konno and Taylor, 2006, Bhugra et al., 
2007). In order to prevent drug recrystallization in solid dispersions, a suitable polymer 
that is characterized by low hygroscopicity and strong molecular interaction with the drug 
must be selected (Vo et al., 2013). Molecular interaction between the drug and the 
polymer through hydrogen bonding is required to increase the solid miscibility and thus 
prevent phase separation and drug recrystallization (Karavas et al., 2006). Low 
hygroscopicity of the polymer may reduce water absorption by the polymer and thus 
decrease drug mobility (Vo et al., 2013). 
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Furthermore, Serajuddin (1999) has proposed that the stability problems of solid 
dispersions can be reduced when self-emulsifying or surface active excipients are 
employed as carriers in production of solid dispersions. Solid dispersions incorporating 
surface active or self-emulsifying carriers are categorized as lipids or lipid-based 
formulations since these carriers are either glycerides or chemically related to glycerides. 
These formulations can be prepared by simple dispersions of drugs in dietary glycerides 
(oils) or in complex mixtures of triglycerides, partial glycerides, surfactants, co-
surfactants and co-solvents. According to formulation composition, lipid-based solid 
dispersions can be classified as non-emulsifying, self-emulsifying, or self-
microemulsifying drug delivery systems (Vasanthavada and Serajuddin, 2007). 
Alternatively, these formulations can be classified depending on the size of oil droplets 
produced when lipid-based formulations are mixed with aqueous medium. Formulations 
that produce oil droplets greater than 100 µm in size are classified as Type I lipid 
formulations, while those which produce oil droplets in the size range from 50 to 100 µm 
are classified as Type IIIB lipid formulations (Pouton, 2000).     
1.5.2. Carriers for solid dispersions  
Selection of an appropriate carrier is an important consideration in preparation of 
amorphous solid dispersions. Utilization of hydrophilic polymeric compounds in solid 
dispersions may decrease molecular mobility of the amorphous drug leading to inhibition 
of crystallization and therefore, stabilization of the system (Paudel et al., 2013). Solubility 
of the drug in the selected polymer with possible formation of strong intermolecular 
interactions such as intermolecular H-bonding may increase the resistance of the solid 
dispersion systems to recrystallization. Also, the structure of carriers has to be 
considered for poorly soluble drugs of known chemical structure (Van Eerdenbrugh and 
Taylor, 2011). Production of homogenous dispersions may require a difference between 
the solubility parameters of the drug and the carrier to be less than 7.5 (Greenhalgh et 
al., 1999).          
A wide variety of carriers (either self-emulsifying or not self-emulsifying) have 
been utilized for production of solid dispersions. Carriers that are not self-emulsifying 
include polyethylene glycols (PEGs), polyvinylpyrrolidone (PVP), cellulose derivatives,  
polymethacrylate polymers and sugars (Leuner and Dressman, 2000). On the other 
hand, self-emulsifying and surface active carriers comprise Gelucires® (Chauhan et al., 
2005b, Paudel et al., 2013), Poloxamers or Pluronics (Piao et al., 2014, Tran et al., 2013, 
Nepal et al., 2010a, Shah and Serajuddin, 2012, Passerini et al., 2002), D-α-tocopheryl 
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polyethylene glycol 1000 succinate (TPGS) (Shin and Kim, 2003, Khoo et al., 2000, 
Goddeeris et al., 2008) and phospholipids (Hussain et al., 2012, Sosada et al., 2006).   
In solid dispersions prepared with water soluble carriers that are not self-
emulsifying (such as polyethylene glycols, PEGs), rapid dissolution of the water soluble 
carrier matrix causes the formation of a highly concentrated solution of the drug that 
precipitates on the surface of the dissolving carrier matrix preventing further dissolution 
of the dispersed drug. Therefore, sifting and pulverization of these solid dispersions are 
required to enhance drug release through increasing the surface area of dispersed 
particles. In addition employment of non-surface active carriers such as soft and tacky 
PEGs may hinder pulverization and milling of the produced solid dispersions. Moreover, 
capsule filling or tableting of these conventional solid dispersions may become difficult 
due to poor flow and mixing properties of the produced powders. On the other hand, 
incorporating self-emulsifying or surface active lipids in solid dispersions prevents the 
formation of an undissolved drug surface layer on the excipient during dissolution 
process (Vasanthavada and Serajuddin, 2007). Even though the released drug particles 
may remain undissolved when their concentration exceeds their saturation solubility, 
they will usually be dissolved, emulsified or dispersed by the surface active properties of 
the dissolving carrier. The subsequent increase in surface area of these finely divided 
drug particles will promote their dissolution in GI fluids (Serajuddin, 1999). 
Self-emulsifying solid dispersions are relatively easily manufactured and can be 
filled directly into hard gelatin capsules while in the molten state to solidify upon cooling 
at ambient room temperature. Therefore, sifting, milling and mixing procedures are not 
required (Vasanthavada and Serajuddin, 2007).   
An overview of Gelucires® as self-emulsifying carriers that will be evaluated in 
this study to formulate Gelucire®-based self-nanoemulsifying formulations is given below.  
1.5.3. Gelucires® as surface active and self-emulsifying carriers 
Gelucires® are polyglycolized glycerides, waxy semi-solid, surfactants composed 
of a mixture of glyceryl and PEG 1500 esters of long chain fatty acids. Different grades 
are available for these carriers based on their HLB values (range of 1-18) and melting 
points (33-70oC). Gelucire®44/14, for which the melting point is 44oC and the HLB value 
equals 14,  and Gelucire®50/13 are the most commonly employed grades in solid 
dispersions (Paudel et al., 2013). The mechanism of drug release from these surfactants 
is determined by their HLB values. High HLB Gelucires® release the drug by diffusion 
and erosion mechanism while low HLB grades release the drug by either simple diffusion 
or complex release kinetics (Chauhan et al., 2005a).   
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Employment of Gelucires® as self-emulsifying carriers to improve the limited 
solubilizing capacity of solid dispersions may decrease recrystallization and precipitation 
of the drug upon exposure to liquid medium leading to improved dissolution and 
bioavailability of the drug (Tran et al., 2009, Barker et al., 2003, Faisal et al., 2013). For 
example, utilization of the self-emulsifying carrier, Gelucire® 44/14, in the preparation of 
solid dispersions of a poorly soluble drug, aceclofenac, by the melting method improved 
the dissolution rate of the drug due to modification of drug crystallinity into the 
amorphous form by the carrier upon exposure to aqueous media (Tran et al., 2009). 
Also, preparation of α-tocopherol solid dispersions in Gelucire® 44/14 by the melting 
method resulted in a 2-folds increase in oral bioavailability of α-tocopherol in human 
volunteers compared to a commercial product containing an equivalent amount of the 
drug. This increase in oral bioavailability of α-tocopherol was due to formation of fine 
emulsion droplets of the vitamin upon dispersion in GI fluids (Barker et al., 2003). 
Further, Faisal et al. (2013) prepared self-emulsifying solid dispersions of lycopene by 
the conventional solvent evaporation method using Gelucire® 44/14 as the dispersion 
carrier, in order to improve the oral bioavailability of the antioxidant drug.  An increase in 
the oral bioavailability of lycopene by 2.4-fold was observed in fasted pigs, relative to 
Lycovit® formulation. However, these in vivo results did not correlate with the lower in 
vitro dissolution profile obtained from the prepared self-emulsifying solid dispersions 
compared to Lycovit® formulation. The absence of in vitro/in vivo correlation was 
attributed to possible contribution of the chosen lipid excipients to stimulation of the 
intestinal lymphatic uptake of the drug and hence, to improvement of the overall 
absorption (Faisal et al., 2013).  Further, improved oral bioavailability of some drugs 
dispersed in Gelucire® 44/14, alone or in combination with other excipients, such as 
halofantrine (Khoo et al., 2000), ontazolast (Hauss et al., 1998) and piroxicam (Yüksel et 
al., 2003) was explained on the basis of enhanced lymphatic transport and intestinal 
permeability of drug particles (Hauss et al., 1998). 
Gelucire® 44/14 was also employed as a solubilizer, either alone or in 
combination with other ingredients, to enhance the solubility and dissolution properties of 
some poorly water soluble drugs such as piroxicam (Karataş et al., 2005), 
carbamazepine (da Fonseca Antunes et al., 2013), phenytoin (Kawakami et al., 2004), 
glimepiride (Makar et al., 2013), and naproxen (Nagabandi et al., 2014). Improvement in 
solubility and dissolution rate of poorly soluble drugs dispersed in Gelucire® 44/14 was 
attributed to the solubilizing effect of this carrier, improved wetting of drug particles in the 
dissolution medium, and emulsifying properties of the carrier (Gattefossé, 2012, Karataş 
et al., 2005).  
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Gelucire® 50/13 has been employed in several studies to improve the solubility 
and dissolution rate of poorly soluble compounds. For example, the solubility of 
indomethacin increased by 3.5 fold when the drug was formulated as solid dispersions in 
Gelucire® 50/13 (El-Badry et al., 2009). These solid dispersion exhibited higher drug 
release in phosphate buffer pH 7.4 compared to both the physical mixture and the pure 
drug. Enhanced solubility and dissolution rate of indomethacin from solid dispersions 
prepared in Gelucire® 50/13, at 1:4 ratio, was attributed to decreased particle size of the 
drug, improved wettability of drug particles because of hydrophilicity of the carrier and 
decreased crystallinity of the drug which was shown by DSC. 
The potential of use of Gelucire® 50/13 to enhance the solubility and dissolution 
profile of a poorly soluble drug, carvedilol (Potluri et al., 2011) was also investigated. It 
was reported that the formulated solid dispersions of carvedilol in Gelucire® 50/13 
showed significant enhancement in the solubility (60 fold) and dissolution profile of 
carvedilol compared to the pure drug. The enhanced solubility and dissolution 
characteristics of carvedilol were attributed to enhanced drug wettability and absence of 
crystalline structure of drug particles in Gelucire® 50/13 solid dispersions.   
Similar findings were also reported for solid dispersions of loratadine in Gelucire® 
50/13 (Bandari et al., 2014), where a 100 fold increase in the solubility of loratadine was 
observed, compared to the solubility of pure drug, in addition to enhanced dissolution 
performance from the solid dispersions. 
Gelucires® can also be used with other surfactants to improve properties of solid 
dispersions. For example combination of Gelucire® 50/13 with Pluronic® F68 in solid 
dispersions of nifidipine resulted in a higher dissolution rate of the drug from solid 
dispersions, compared to the crystalline drug of the same particle size, due to increase in 
wettability and solubility of the drug in the presence of the two surfactants (Vippagunta et 
al., 2002). Also, Karataş et al. (2005) have used a combination of Gelucire® 44/14 with 
Labrasol® in order to improve solubility and dissolution rate of piroxicam from solid 
dispersions. The enhanced dissolution rate of the drug from these solid dispersions was 
attributed to the solubilizing effects of Gelucire® 44/14 and possibly Labrasol®, and also 
to improved wettability of piroxicam in the dissolution medium due to the amphiphilic 
properties of the used surfactants. In addition, combining Gelucire® 44/14 with labrasol® 
in solid dispersions of piroxicam showed improved relative bioavailability of the drug in 
human volunteers as compared to pure piroxicam filled in hard gelatin capsules  (Yüksel 
et al., 2003). 
Recently, Gelucire® 48/16 was introduced into the field of pharmaceutical 
research. This Gelucire® grade possesses a melting point of 48oC and HLB value of 16. 
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Two case studies were conducted by Gattefossé (2015) on two poorly soluble, class II 
compounds (piroxicam and curcumin) to demonstrate the solubilizing properties of 
Gelucire®48/16. A significant increase in equilibrium solubility of both compounds was 
produced by Gelucire®48/16, with drug saturation levels kept below 80% to avoid the risk 
of precipitation in aqueous fluids. Evaluation of re-dispersibility of the produced 
formulations showed that micellar solutions obtained in purified water were homogenous 
and no precipitation of either drug was noticed. Also, encapsulation of both drugs within 
micelles did not change the size of the dispersion from the nanoscale range (Gattefossé, 
2015).  An in vitro lipolysis test for solid dispersions of Gelucire®48/16 with piroxicam or 
curcumin confirmed that Gelucire® 48/16 preserved its solubilizing properties during 
digestion by pancreatic enzymes. Therefore, it was proposed that Gelucire® 48/16 may 
contribute to enhanced in vivo absorption and bioavailability of both drugs as it maintains 
high drug concentration in solution during in vitro digestion for 60 minutes.     
In a statistical experimental design conducted by Ganesh (2016), it was shown 
that an optimum solid dispersion formulation of rivaroxaban (class II drug used to treat 
deep vein thrombosis and myocardial infarction) with a mixture comprising 
Gelucire®48/16, Compritol®HD5 ATO and Labrasol® produced the maximum dissolution 
profile of the drug (rivaroxaban) with 64.7% released within 5 minutes. These results 
were attributed to the emulsifying effect of Gelucire®48/16. However, another study that 
formulated solid dispersions of glimepiride utilizing different Gelucires® showed that  the 
dissolution profile obtained for solid dispersions prepared with Gelucire®55/18 was 
higher than those obtained from formulations prepared with Gelucire®48/16 or 
Gelucire®44/14 (Sambasivarao, 2016). 
In addition, the in vitro digestion testing of formulations prepared by dispersion of 
model class II drugs (piroxicam, curcumin and nifidipine) in Gelucire® 48/16 was 
evaluated in comparison to other water soluble and water dispersible surfactants such as 
Tween® 80, Cremophor® RH40 and Labrasol® ALF (Jannin et al., 2015). It was observed 
that dispersions of piroxicam and curcumin prepared with Gelucire® 48/16 showed the 
best performance during in vitro lipolysis, compared to other formulations prepared with 
different water soluble or water dispersible surfactants. The enhanced in vitro digestion 
of formulations prepared with Gelucire® 48/16 was explained on the basis that Gelucire® 
48/16 maintained both drugs in a dissolved state in the aqueous phase during the 1-h in 
vitro digestion test. The study concluded that enhanced drug solubilization affected by 
excipients like Gelucire® 48/16 is crucially required to maintain the drug in solution after 
dispersion and digestion (Jannin et al., 2015).  
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1.5.4. Manufacture of self-emulsifying solid dispersions 
Solid dispersions can be produced by three different methods: melting (fusion) 
method, solvent method and melting–solvent method. The choice among solid 
dispersion preparation methods is controlled by the physicochemical properties of drugs 
and carriers (Vo et al., 2013, Paudel et al., 2013). For example, limited application of 
melting process may arise from the crucial requirement of compatibility and miscibility of 
the drug and the carrier at the heating temperature. Phase separation may occur due to 
incompatibility and incomplete miscibility of the drug in the melted and highly viscous 
polymeric carrier (Vasconcelos et al., 2007, Vo et al., 2013). Addition of surfactants can 
maintain miscibility of the drug in the melted carrier. Also, slow cooling of the melted 
drug-carrier mixture can lead to phase separation and therefore, fast cooling can 
maintain the drug in an amorphous miscible state (Vo et al., 2013). In addition, the use of 
high temperatures in the melting method may cause degradation of thermo-labile drugs 
or carriers that are melted together at the same time. However, suspending the drug in a 
previously melted carrier may reduce the process temperature and the time of heating 
(Mehanna et al., 2010).  
Modifications in melting methods to avoid different limitations such as reduction 
of the process temperature and the time of drug heating have led to other techniques for 
production of solid dispersions. Among these new modified methods, the technique of 
hot melt extrusion (HME) appears as an alternative and promising tool for production of 
different solid dispersions.  
The following section gives a brief description of the HME technology which was 
adopted in this study to produce Gelucire®-based SNEDDS formulations.   
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1.5.5. Hot Melt Extrusion (HME) technique for production of Gelucire®-
based SNEDDS of indomethacin 
Hot melt extrusion (HME) is a novel processing technique that has been used in 
the plastics industry since 1930. Application of the HME technique in the pharmaceutical 
industry has steadily grown worldwide since the early 1980s.  HME involves conveying 
raw materials through a hopper to rotating screws under controlled heating 
temperatures, pressure and screw speed; and then forcing the melted mixture through 
an orifice or a die to produce extrudates of various shapes and sizes. This technique has 
been applied very widely in the manufacture of different pharmaceutical dosage forms 
(Crowley et al., 2007, Maniruzzaman et al., 2012). 
Generally, a hot melt extruder consists of single or twin screws placed inside a 
cylindrical stationary barrel. The twin screws rotate in the same (co-rotating) or opposite 
(counter-rotating) direction. The stationary barrel is manufactured in segments that can 
be bolted or sealed together. A die, which can determine the size and the shape of the 
extrudate, is connected at the end of the barrel. Single screw extruders are simple but do 
not possess the capability of efficient mixing compared to twin screw extruders. 
Therefore, twin screw extruders (Figure 1.3) are preferred for manufacturing of most 
pharmaceutical formulations where homogenous mixing of formulation ingredients is 
essential. Also, twin screw extruders provide the possibility to manipulate and optimize 
process conditions to accommodate the wide range of pharmaceutical formulations 
(Maniruzzaman et al., 2012).  
 
Figure  1.3 Schematic diagram of hot melt extrusion process 
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Although only a limited number of polymers and excipients can be processed by 
HME technology, HME offers several advantages over traditional manufacturing 
processes. This solvent-free technique is considered as an economic continuous 
process with fewer production steps, reduced processing time and ease of control of 
processing parameters, in addition to efficient mixing that is reflected by good content 
uniformity of the produced extrudates (Maniruzzaman et al., 2012).  Also, the risk of 
decomposition of thermolabile drugs when processed by HME can be reduced by limiting 
and controlling the residence time of the heat sensitive materials within the extruder (Vo 
et al., 2013).    
 In pharmaceutical practice, HME is mainly used to enhance the dissolution rate 
and hence the bioavailability of poorly soluble drugs by formation of solid solutions or 
solid dispersions. Improvement of dissolution rate and bioavailability by HME 
manufacturing processes could be due to the fact that crystalline drugs can be converted 
into the amorphous state that would be more water soluble. Also in HME, poorly water 
soluble compounds are dispersed at the molecular level especially with hydrophilic 
polymers to produce solid solutions or solid dispersions (Maniruzzaman et al., 2012, 
Maniruzzaman et al., 2013b). For example, the dissolution rates of two poorly soluble 
drugs, famotidine and indomethacin, from solid dispersion prepared with different 
hydrophilic polymers using HME were higher compared to the pure drug alone 
(Maniruzzaman et al., 2013b).  HME can be also used for the production of modified 
release formulations and for taste masking of bitter drugs (Maniruzzaman et al., 2012, 
Maniruzzaman et al., 2013b).  
 Pharmaceutical materials that can be processed by HME should possess 
thermoplastic behavior which is the ability to deform easily upon heating in the extruder 
and then solidify upon exiting the die part of the instrument.  Thermal stability at the 
processing temperature is an essential requirement for each material to be processed by 
HME, although the reduced processing time in this technology may not exclude all 
thermolabile compounds. In addition, pharmaceutical materials that can be used in HME 
should be pure and safe, similarly to the materials used for traditional manufacturing 
methods (Crowley et al., 2007).  
Selection of different excipients for HME processing may affect the properties of 
the final HME formulations, similarly to those used in conventional dosage forms. These 
excipients may include matrix carrier, release modifiers, bulking agents, thermal 
lubricants and antioxidants. For example, release modifiers can be incorporated in HME 
to decrease or increase the release rate of the final HME formulations. Plasticizers also 
can be added in HME to reduce the processing temperatures and hence, decrease the 
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drug and carrier decomposition. Low molecular weight polyethylene glycol and 
surfactants are examples of the materials that can be used as plasticizers during 
manufacturing by HME (Crowley et al., 2007). Therefore, surfactants can be used as 
plasticizers in HME to produce solid dispersions in addition to their effect as solubilizing 
agents (Ghebremeskel et al., 2006).   
 Aims of the study 1.6.
The aim of this study is to investigate different self-nanoemulsifying drug delivery 
systems (SNEDDSs) prepared in liquid, solid and carrier-based formulations and to 
assess the effect of these types of formulations on the solubility and dissolution 
properties of a poorly water soluble drug.  
Indomethacin was selected as a model drug for this study. Therapeutically, it is a 
potent non-steroidal anti-inflammatory and analgesic drug which is indicated for 
treatment of pain and swelling associated with rheumatoid arthritis, osteoarthritis, gout 
and other acute musculoskeletal disorders (El-Badry et al., 2009, Shakeel et al., 2013a, 
Taha, 2009). It is available commercially in the form of capsules, suspensions, 
suppositories and injections.  
According to the biopharmaceutical classification system (BCS), indomethacin is 
classified as a Class II compound because of its poor aqueous solubility and high 
permeability. The dissolution rate of Class II drugs is a limiting factor in their GI 
absorption because it affects the concentration of drugs at the absorption membrane 
surface over time (Löbenberg and Amidon, 2000). Therefore, improving the solubility of 
Class II drugs in order to improve their dissolution profile is a crucial requirement in 
enhancing their oral absorption and bioavailability. 
Many investigations have been conducted to evaluate indomethacin performance 
from self-emulsifying formulations (Taha, 2009, Kim and Ku, 2000, Stillhart and Kuentz, 
2012, Shakeel et al., 2013b, Prasad et al., 2013, Shakeel et al., 2013c). Incorporation of 
indomethacin into SEDDS was advantageous in enhancing solubility, dissolution profile 
and bioavailability of the drug. Most of these SEDDS were evaluated based on the 
solubility of the drug in lipid excipients in addition to spontaneous dispersion after 
addition to aqueous fluids. However, inhibition of drug precipitation upon dilution with GI 
fluids and sustaining supersaturation levels of the drug may remain as the main 
challenges encountered with SEDDS formulations (Prasad et al., 2013). Selection of the 
most appropriate excipients may reduce their physical and chemical interaction with the 
drug and therefore, may inhibit drug precipitation. Consequently, a well-designed 
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SEDDS formulation of indomethacin using the proper excipients may further lead to 
substantial enhancement of oral bioavailability of the drug.  
In addition, different formulations of indomethacin in solid dispersions using 
various hydrophilic carriers showed remarkable improvements in the dissolution rate of 
the drug that were attributed to reduction in drug crystallinity, solubilization effect of the 
carrier, enhancement of drug wettability, reduction of drug particle size and prevention of 
agglomeration of drug particles (El-Badry et al., 2009, Valizadeh et al., 2004, Wang et 
al., 2007). However, physical instability of these dispersions and possible conversion into 
the less soluble crystalline states may be encountered during processing, dissolution or 
under different storage conditions.  
Therefore, considering the type and the amount of the carrier employed in solid 
dispersion formulations may assist in inhibiting drug recrystallization from these 
preparations. Surface active carriers such as Gelucires® may be promising in solid 
dispersions to improve solubility and dissolution of poorly soluble drugs and minimize 
tendency of recrystallization. Also, conducting of stability studies on prepared 
formulations may contribute to identification of the most suitable storage conditions that 
will maintain stability for extended periods of time.  
With the introduction of some novel solid adsorbents and self-emulsifying 
carriers, this study aims to formulate different SNEDDSs with a view to enhance 
solubility, dissolution profiles and/or bioavailability of poorly water soluble drugs taking 
the weakly acidic indomethacin as a model drug. Approaching the most suitable 
formulation may achieve further goal of the study to aim at large scale production.  
The objectives of this study can be summarized as follows: 
1. To design and formulate suitable liquid SNEDDS of indomethacin using different 
combinations of oils, surfactant and co-surfactants, with a view to enhancing the 
solubility of the drug. Different combinations of components will be optimized for the 
best formulation by construction of ternary phase diagrams. The formulated systems 
will be evaluated for drug solubilizing potential, thermodynamic stability, self-
emulsification efficiency, droplet size, polydispersity index and zeta potential for the 
purpose of optimization of drug-loaded liquid SNEDDS. This objective will be 
presented in Chapter 3 of this thesis.     
2. To investigate the feasibility of using adsorption onto solid carriers as a solidification 
technique to convert the optimum liquid SNEDDS (developed in Chapter 3) into solid 
SNEDDS. Different categories of inert carriers or adsorbents will be utilized for this 
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purpose. The formulated solid SNEDDS will be assessed for their powder properties 
and optimum formulations will be evaluated for their drug content, redispersibility and 
dissolution properties. Different physical characterization techniques such as Fourier 
Transform Infrared (FTIR), differential scanning calorimetry (DSC), X-ray diffraction 
(XRD), and scanning electron microscopy (SEM) will be applied on optimum solid 
SNEDDS formulations to confirm amorphous or crystalline states of the drug. This 
part of the work will be presented in Chapter 4 of this thesis.   
3. To investigate the utility of Gelucire®44/14 and Gelucire®48/16 as lipidic carriers in 
formulation of Gelucire-based SNEDDS adopting the hot melt extrusion technique, 
with a view to enhance the solubility and dissolution properties of indomethacin. The 
formulated Gelucire®-based SNEDDS will be evaluated for their drug content, 
dissolution properties, redispersibility and droplet size. Also, Fourier Transform 
Infrared (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and 
scanning electron microscopy (SEM) will be conducted for physical characterization 
of the formulated products to assess crystalline and amorphous states of the drug 
and to identify optimum Gelucire-based formulations. This part of work will be 
presented in Chapter 5 of this thesis.   
4. To conduct stability studies on optimum Gelucire®-based SNEDDSs (defined from 
Chapter 5) in order to assess the tendency of these formulations for recrystallization 
and also to determine the most suitable storage conditions.  Investigation of drug 
dissolution properties, differential scanning calorimetry (DSC), X-ray diffraction 
(XRD), and scanning electron microscopy (SEM) will be carried out in order to 
determine the effect of aging on the physicochemical properties of the drug. This part 
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 Introduction  2.1.
In this study, different self-nanoemulsifying drug delivery systems (SNEDDSs) of 
indomethacin were prepared as liquid, solid, and Gelucire®-based formulations. The 
liquid SNEDDSs of indomethacin were first formulated using different mixtures of oils, 
surfactants and co-surfactants. Studies of solubility, ternary phase diagram, self-
nanoemulsification and system stability were performed to optimize the formulation 
components. In order to characterize different liquid formulations, dynamic light 
scattering (DLS) was employed for measurement of droplet size, polydispersity index 
(PDI) and zeta potential. 
Solidification of the optimum liquid SNEDDSs of indomethacin was performed by 
adsorption onto different solid adsorbents. The obtained solid SNEDDS formulations 
were evaluated for flow properties using angle of repose method in addition to 
calculation of Hausner’s ratio and Carr’s index from tapped density experiments. 
Optimum solid SNEDDS formulations were then evaluated for redispersibilty, drug 
content and dissolution properties. Calculation of the dissolution parameters (dissolution 
efficiency after 15 min (DE15min) and % drug released after 15 min (Q15min)) of solid 
SNEDDSs of indomethacin in addition to differential scanning calorimetry (DSC), X-ray 
diffraction (XRD) and Fourier Transform InfraRed (FTIR) were also conducted for 
characterization. 
Different formulations of Gelucire®-based SNEDDS of indomethacin were 
prepared by mixing the drug with Gelucire® 48/16 at both 40o and 50oC using a hot melt 
(twin-screw) extruder. All formulations were tested for self-emulsification efficiency and 
redispersibilty. The physical properties of these formulations were characterized by DSC, 
XRD and FTIR.  In addition, the dissolution parameters (mentioned above) of Gelucire®-
based SNEDDS formulations were determined and calculated.   
This chapter provides an outline of the materials used in the study in addition to 
brief description of the techniques and methods used in evaluation and physical 
characterization of different SNEDDSs of indomethacin. 
 
 




2.2.1. The model drug (Indomethacin) 
In this study, indomethacin (IND) was chosen as a model drug. It is a non-
steroidal anti-inflammatory agent that is used as antirheumatic agent to reduce pain, 
fever and swelling.  Upon oral administration, indomethacin acts to reduce inflammation 
and pain mainly by non-selective inhibition of cyclooxygenase enzymes thus reducing 
prostaglandin production, which may lead to irritation and ulceration of gastric mucosa 
upon frequent and chronic ingestion of the drug (Odabasoglu et al., 2008, Taha, 2009).  
Indomethacin is a weak acid with a pKa value of 4.5 (Beetge et al., 2000) and 
therefore, it may dissolve in the intestinal alkaline pH and precipitate in the acidic pH of 
the stomach (Shakeel et al., 2013c). Its melting point falls in the range of 158 to 162oC 
depending on its polymorphic form (Wang et al., 2007). Indomethacin was reported to 
exist in different polymorphic forms (Lin, 1992, Slavin et al., 2002). According to Slavin et 
al. (2002), the most commonly obtainable forms are the crystalline γ-form and α-form, 
while the β-form is considered as a solvate that can be obtained from different solvents 
under supersaturation conditions.  Amorphous indomethacin may undergo crystallization 
during storage to form either the more thermodynamically stable γ-form; if stored below 
its glass transition temperature (Tg) (Beetge et al.), or the less stable α-form; if stored 
above Tg (Yoshioka et al., 1994).   
The aqueous solubility of indomethacin measured in distilled water (pH 5.5) was 
reported to be 0.937 µg/ml at 298.15oK, (Shakeel et al., 2013a, Löbenberg and Amidon, 
2000) which may account only for 0.004% of the administered dose. In addition, 
indomethacin possesses high permeability because, according to FDA (2000), 90% or 
more of the administered dose of the drug is absorbed. A value of permeability of 4.167 x 
10-4 cm/sec was reported for highly permeable drugs (Levitt, 2013). 
The molecular structure of indomethacin is presented in Figure 2.1, while its 
physicochemical properties and toxicity are shown in Table 2.1. 
 




Figure  2.1  Chemical Structure of indomethacin 
 
Table  2.1 Physicochemical properties and toxicity of indomethacin (Pubchem, 2017) 
Properties  Description  
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
IUPAC name 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid 
Empirical formula  C19H16ClNO4  
Physical appearance  Pale-yellow to yellow-tan, crystalline powder 
Melting point 158 to 162oC 
Molecular weight 357.79 g/mol   
Solubility  Soluble in ethanol, ether, acetone, castor oil; practically 
insoluble in water (0.937 mg/L at 25oC) 
Toxicity  Increased risk of bleeding, ulceration, and perforation of the 
gastrointestinal tract is associated with overdosage 
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2.2.2. CapryolTM 90 (propylene glycol monocaprylate) 
Capryol 90 is a nonionic water insoluble surfactant which can be used in oral 
lipid-based formulations such as SEDDS. Also, it can be used as a co-surfactant and 
solubilizer in topical dosage forms (Gattefossé, 2012).  The chemical structure of this 
compound is given in Figure 2.2 and the physicochemical properties and toxicity are 
presented in Table 2.2. 
 
Figure  2.2 Chemical structure of CapryolTM 90 (propylene glycol monocaprylate) 
(Gattefossé, 2012, Pubchem, 2017) 
  
Table  2.2 Physicochemical properties and toxicity of CapryolTM 90 (Gattefossé, 
2012, Pubchem, 2017)  
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Propylene glycol monocaprylate 
Chemical description Propylene glycol esters of caprylic acid (C8), mainly 
composed of monoesters and a small fraction of diesters. 
Empirical formula  C11H24O4 
Physical appearance  Light yellow oily liquid with characteristic odour 
HLB 5 
Molecular weight 220.309 g/mol 
Solubility  Insoluble in water 
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2.2.3. LabrafacTM lipophile WL 1349 (medium chain triglyceride) 
LabrafacTM lipophile WL 1349 is an oily vehicle and solubilizer that can be used 
for oral, topical, and parenteral lipid-based formulations (Gattefossé, 2012). The 
chemical structure, physicochemical properties and toxicity of this compund are 
presented in Figure 2.3 and Table 2.3, respectively.  
 
Figure  2.3 Chemical structure of LabrafacTM lipophile WL 1349 (medium chain 
triglyceride) (Pubchem, 2017) 
 
Table  2.3 Physicochemical properties and toxicity of LabrafacTM lipophile WL 1349 
(medium chain triglyceride)  (Gattefossé, 2012, Pubchem, 2017) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Medium chain triglycerides or (glycerides, mixed decanoyl and 
octanoyl) 
Chemical description Consists of medium-chain triglycerides of caprylic (C8) and 
capric (C10) acids  
Empirical formula  C21H44O7 
Physical appearance  Yellow liquid with characteristic odour 
HLB 1 
Molecular weight 408.576 g/mol 
Solubility  Insoluble in water 
Toxicity  Safety of use is inferred by food additive status and 
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2.2.4. Labrafil® M 2125 CS (polyoxylglyceride) 
Labrafil® M 2125 CS is a nonionic water-dispersible surfactant that can be used 
for lipid-based formulations to solubilize and enhance oral bioavailability of poorly water-
soluble drugs. The physicochemical properties and toxicity of this compound are 
presented in Table 2.4.  
 
Table  2.4 Physicochemical properties and toxicity of Labrafil® M 2125 CS 
(polyoxylglyceride) (Gattefossé, 2012, Pubchem, 2017, Rowe et al., 2009) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Linoleoyl polyoxyl-6 glycerides (or Linoleoyl macrogol-6 
glycerides) 
Chemical description Consists of mono-, di- and triglycerides and PEG-6 (MW 300) 
mono- and diesters of linoleic (C18:2) acid 
Physical appearance  Yellow liquid with light odour 
HLB 9 
Solubility  Dispersible in water, soluble in many organic solvents 
Toxicity  Generally regarded as relatively nonirritant and nontoxic 
 
2.2.5. Transcutol® HP (diethylene glycol monoethyl ether) 
Transcutol® HP is a highly pure solvent and solubilizer that improve solubility and 
bioavailability of poorly soluble drugs.  The chemical structure, physicochemical 
properties and toxicity of this compound are presented in Figure 2.4 and Table 2.5, 
respectively. 
 
Figure  2.4 Chemical structure of Transcutol® HP (diethylene glycol monoethyl ether) 
(Pubchem, 2017) 
  




Table  2.5 Physicochemical properties and toxicity of Transcutol® HP (diethylene 
glycol monoethyl ether) (Gattefossé, 2012, Pubchem, 2017) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Diethylene glycol monoethyl ether 
Chemical description Consists of highly purified diethylene glycol monoethyl ether 
Empirical formula  C6H14O3 
Physical appearance  Colourless liquid with light odour 
Molecular weight 134.175 g/mol 
Solubility  Miscible in water and common organic solvents 
Toxicity  Safety of use and low irritancy inferred by numerous 
toxicological studies and precedence of use in approved 
pharmaceutical products 
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2.2.6. Cremophor® RH 40 (polyoxyl 40 hydrogenated castor oil) 
Cremophor® RH 40 (or Kolliphor RH40) is a polyoxyl 40 hydrogenated castor oil 
that can be used as emulsifying, solubilizing and wetting agent in lipid-based 
formulations.  The physicochemical properties and toxicity of this compound are 
presented in Table 2.6. 
 
Table  2.6 Physicochemical properties and toxicity of Cremophor RH40 (polyoxyl 40 
hydrogenated castor oil) (BASF, 2014, Rowe et al., 2009) 
Properties Description 
Manufacturer  BASF – Germany 
USP NF name Polyoxyl 40 hydrogenated castor oil 
Chemical description Nonionic solubilizer and emulsifying agent obtained by 
reacting 45 moles of ethylene oxide with 1 mole of 
hydrogenated castor oil. The main constituent of 
Cremophor®RH 40 is glycerol polyethylene glycol oxystearate, 
which, together with fatty acid glycerol polyglycol esters, forms 
the hydrophobic part of the product. The hydrophilic part 
consists of polyethylene glycols and glycerol ethoxylate. 
Empirical formula  C6H14O3 
Physical appearance  White to yellowish, thin paste at 20oC that liquefies at 30oC. It 
has a very faint characteristic odour.  
HLB 14 – 16  
Solubility  Soluble in water, ethanol, chloroform and oils 
Toxicity  Essentially non-toxic and non-irritant material as shown by 
acute and chronic toxicity tests in animals  
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2.2.7. Tween® 20 (Polysorbate 20) 
Polysorbate 20 (Tween 20) is a hydrophilic non-ionic surfactant. Polysorbate 20 
is produced by ethoxylation of sorbitan before the addition of lauric acid (Polyoxyethlene 
(20) sorbitan monolaurate). The ethoxylation process leaves the molecule with 20 units 
of polyethylene glycol. Polysorbates are widely used as emulsifying agents in 
preparation of stable oil in water pharmaceutical emulsions. They are also utilized as 
solubilizing agents for poorly soluble drugs as well as wetting agents (Rowe et al., 2009).  
The number 20 following the ‘Polysorbate’ part indicates the type of the fatty acid (lauric 
acid) linked to the polyoxyethlene sorbitan part of the molecule. The chemical structure 
of Tween 20 is given in Figure 2.5, and the physicochemical properties and toxicity are 
summarized in Table 2.7. 
 
Figure  2.5 Chemical structure of Tween® 20 (Polysorbate 20) (Pubchem, 2017, 
Rowe et al., 2009) 
  
Table  2.7 Physicochemical properties and toxicity of Tween® 20 (Polysorbate 20) 
(Pubchem, 2017, Rowe et al., 2009) 
Properties Description 
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
Chemical name Polyoxyethylene 20 sorbitan monolaurate 
Chemical description A series of partial fatty acid esters of sorbitol and its 
anhydrides copolymerized with approximately 20 moles of 
ethylene oxide for each mole of sorbitol and its anhydrides. 
Empirical formula  C58H114O26 
Molecular weight 1128 
Physical appearance  Yellow oily viscous liquid with characteristic odour  
HLB 16.7 
CMC 60 mg/L or ~ 6x10-3 mole/L 
Solubility  Soluble in water and ethanol 
Toxicity  Generally regarded as non-toxic and non-irritant material  
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2.2.8. Tween® 80 (polysorbate 80) 
Polysorbate 80 is a non-ionic surfactant that is often used in foods and 
cosmetics. It is widely used as emulsifying agent in oil in water pharmaceutical 
emulsions, a solubilizing agent for poorly soluble drugs, as well as a wetting agent.  
Polysorbate 80 is derived from polyethoxylated sorbitan and oleic acid. The hydrophilic 
group in this compound is the polyether (or polyoxyethylene) group, while the lipophilic 
group is the oleic acid. The number 20 following the ‘polyoxyethelene’ part indicates the 
total number of oxyethlene –(CH2-CH2-O)- groups in the molecule, while the number that 
follows the ‘Polysorbate’ part refers to the type of fatty acid (oleic acid) associated with 
polyoxythelene sorbitan part of the molecule  (Rowe et al., 2009).   
The chemical structure of Tween 80 is given in Figure 2.6, and the physicochemical 
properties and toxicity are summarized in Table 2.8. 
 
Figure  2.6 Chemical structure of Tween® 80 (Polysorbate 80) (Pubchem, 2017, 
Rowe et al., 2009) 
Table  2.8 Physicochemical properties and toxicity of Tween® 80 (Polysorbate 80) 
(Pubchem, 2017, Rowe et al., 2009) 
Properties Description 
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
Chemical name Polyoxyethylene 20 sorbitan mono oleate 
Chemical description A series of partial fatty acid esters of sorbitol and its 
anhydrides copolymerized with approximately 20 moles of 
ethylene oxide for each mole of sorbitol and its anhydrides. 
Empirical formula  C64H124O26 
Molecular weight 1310 
Physical appearance  Yellow oily viscous liquid with characteristic odor  
HLB 15 
CMC 13 – 15 mg/liter 
Solubility  Soluble in water and ethanol 
Toxicity  Generally regarded as non-toxic and no-irritant materials.  
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2.2.9. Polyethylene glycol 400 (PEG 400) 
Polyethylene glycols (PEGs) are widely used in formulation of pharmaceutical 
preparations such as topical, oral, parenteral, ophthalmic and rectal dosage forms. Also, 
these excipients have been used in controlled release systems as biodegradable 
polymeric matrices. Polyethylene glycols occur in different molecular weights (grades). 
Grades 200 – 600 appear as clear, colorless viscous liquids while grades 1000 and 
above are solids at room temperature. In addition to their use in different pharmaceutical 
formulations, polyethylene glycols have been also used to improve the solubility and 
dissolution properties of poorly water soluble drugs (Rowe et al., 2009). In this study, 
PEG 400, which is a low molecular weight polyethylene glycol, has been employed as an 
excipient to improve the solubility of the model drug. The chemical structure of 
polyethylene glycol is presented in Figure 2.7, while the physicochemical properties and 
toxicity of PEG 400 are summarized in Table 2.9. 
 
Figure  2.7 Chemical structure of polyethylene glycol 
  
Table  2.9 Physicochemical properties and toxicity of polyethylene glycol 400 (Rowe 
et al., 2009) 
Properties Description 
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
Chemical name α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical formula  C2nH4n+2On+1, n = 8.7 
Molecular weight 380–420 g/mole 
Physical appearance  Clear, colorless viscous liquid 
Solubility  Soluble in water, alcohol, acetone, and glycerin; insoluble in 
fats, fixed oils and mineral oil. 
Toxicity  Generally regarded as non-toxic and non-irritant material  
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2.2.10. Propylene glycol 
Propylene glycol is a commonly used solvent or co-solvent in different 
pharmaceutical formulations, cosmetics and foods. It can act to dissolve many poorly 
soluble drugs in oral solutions and parenteral formulations. It can also be used as a 
humectant in topical formulations and as a preservative in solution and semisolid 
formulations (Rowe et al., 2009). Figure 2.8 and Table 2.10 show the chemical 
structure, physicochemical properties and toxicity of propylene glycol, respectively.  
 
 
Figure  2.8 Chemical structure of propylene glycol 
  
Table  2.10 Physicochemical properties and toxicity of propylene glycol (Rowe et al., 
2009) 
Properties Description 
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
Chemical name 1,2-Propanediol 
Empirical formula  C3H8O2 
Molecular weight 76.09 g/mole 
Physical appearance  Clear, colourless, viscous, and practically odourless liquid 
Solubility  Miscible in water, ethanol, chloroform, diethyl ether and 
acetone 
Toxicity  Generally regarded as non-toxic and non-irritant material. It is 
also used extensively in foods and cosmetics. 
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2.2.11. Neusilin® US2 (Magnesium aluminometasilicate) 
Neusilin® is a multifunctional excipient that occurs as fine powder or granules of 
magnesium aluminometasilicate (MAS). This excipient is widely used in wet granulation 
and direct compression processes to improve manufacturing of tablets, capsules, 
powders and granules. Neusilin® is available in various grades that possess different 
bulk density, water content, pH and particle size. It is amorphous and characterized by 
very large specific surface area and high oil and water adsorption capacity. The general 
chemical structure of Neusilin® is presented in Figure 2.9 and its physicochemical 
properties and toxicity are presented in Table 2.11.       
 
    
 
Figure  2.9 Chemical structure of Neusilin® US2 (MAS) (Fuji Chemical Industry, 2014, 
















Table  2.11 Physicochemical properties and toxicity of Neusilin®US2 (MAS) (Fuji 
Chemical Industry, 2014, Tan et al., 2013) 
Properties Description 
Manufacturer  Fuji Chemical Industry Co. Ltd, Tokyo, Japan 
Chemical name Magnesium aluminometasilicate 
Empirical formula  Al2O3·MgO·1.7SiO2·xH2O 
Oil adsorbing capacity (ml/100g) 270 – 340   
Water adsorbing capacity (ml/100g) 240 – 310  
Particle size distribution (µm) 44 – 177 
Specific surface area (m2/g) 300 
Average pore diameter (nm) 5 – 6  
Loose bulk density (g/ml) 0.13 – 0.18  
Tapped bulk density (g/ml) 0.16 – 0.22 
Angle of repose (deg.) 30 
Physical appearance  White granules  
Solubility  Practically insoluble in water and ethanol 
Toxicity  An accepted ingredient by the US Pharmacopoeia 
/ National Formulary with no reports of adverse 
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2.2.12. Florite® PS-200 (Calcium silicate) 
Florite® is a new multifunctional excipient composed of synthetic calcium silicate. 
This excipient offers many advantages for cosmetics and pharmaceutical formulations 
(Tomita Pharmaceutical Co., 2015). It is available commercially in different grades that 
possess different oil or water absorption capacity. Florite® products are characterized by 
their high water/oil absorption ability compared to other inorganic materials such as 
silicone dioxide. Florite® could absorb up to 5 times its weight of liquid and remain a free 
flowing powder. This exceptional liquid absorbency for both water and oil is due to the 
unique petaloid crystal structure (Figure 2.10) as compared to other calcium silicate.  
Due to the petaloid crystal structure, Florite® products possess deep and large 
macropores which provide the highest liquid absorption capacity. Drug molecules loaded 
into these macropores are protected from light and oxygen which may result in enhanced 
stability of the drug. The PS grades of Florite® are suitable for tablet manufacturing and 
are characterized by low angles of repose. Moreover, Florite® can maintain the pore 
structure and therefore, preserve the liquid absorbency after compression so that no 
leaking of liquid during compression process can be observed (Tomita Pharmaceutical 
Co., 2015).  
 
 
Figure  2.10 Petaloid crystal structure of Florite® products (Tomita Pharmaceutical Co., 
2015) 
 
The physicochemical properties and toxicity of calcium silicate (Florite® PS-200) 
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Table  2.12  Physicochemical properties and toxicity of calcium silicate (Florite® PS-
200) (Rowe et al., 2009, Tan et al., 2013) (Tomita Pharmaceutical Co., 
2015)  
Properties Description 
Manufacturer  Tomita Pharmaceutical Co. Ltd, Japan 
Chemical name Calcium silicate 
Empirical formula  CaSiO3  
Molecular weight 116.2 g/mole 
Oil absorption capacity 
(ml/100g) 
370 
Particle size distribution (µm) 150 
Loose bulk density (g/ml) 0.07 
Tapped bulk density (g/ml) 0.09 
Angle of repose (deg.) 36 
Physical appearance  White or off-white granules 
Solubility  Practically insoluble in water.  
Toxicity  Calcium silicate is included in the FDA Inactive 
Ingredients Database (oral dosage forms). Practically 
nontoxic in oral formulations. The DMF submitted for 
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2.2.13. Syloid® XDP 3150 (Amorphous silicon dioxide) 
Syloid® is a chemically prepared amorphous silicon dioxide that is used in many 
pharmaceutical formulations due its unique features. It is characterized by its 
morphology, adsorption capacity, particle size, density and internal surface area. High 
density of Syloid® may aid to create less dust processes during manufacturing of 
pharmaceuticals. Also, Syloid® could improve the flow properties of pharmaceutical 
mixtures during manufacturing. In addition, the unique morphology of highly developed 
network of meso-pores allow Syloid® particles (Figure 2.11) to adsorb maximum 
amounts of liquids and eases the transformation of liquid or lipid-based formulations into 
free flowing powder. Syloid® is available in different grades that differ in their porosity, 
internal surface area and oil adsorption capacity. The XDP grades of Syloid® were 
developed with specific particle size and adsorption capacity to allow higher loading of 
lipid-based formulations and the formation of free flowing powder that can be easily 
converted into tablets or capsules.  
 
Figure  2.11 Spherical meso-pores of Syloid® particles. (Grace GmbH, 2012) 
 
The physicochemical properties and toxicity of Syloid® XDP 3150 are presented 
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Table  2.13 Physicochemical properties and toxicity of amorphous silicon dioxide 
(Syloid® XDP 3150) (Grace GmbH, 2012) 
Properties  Description 
Manufacturer  Grace GmbH & Co. KG, Germany 
Chemical name Amorphous silicon dioxide 
Pore volume (ml/100g) 174 
Mean particle size distribution (µm) 120 – 170  
Density at 20oC (g/ml) 2.17 – 2.20  
Bulk density at 20oC (Kg/m3) 200 – 600  
Angle of repose (deg.) ≈32 
Physical appearance  White odourless powder 
Solubility  Insoluble in water.  
Toxicity  Non-toxic and non-irritant  
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2.2.14. Microcrystalline cellulose (Avicel® PH 102) 
Microcrystalline cellulose (MCC) is a widely used pharmaceutical excipient 
especially in tablet manufacturing. This compound is used as a diluent or a binder in 
formulation of tablets by wet granulation or direct compression methods. It also 
possesses some disintegrant and lubricant effects which make it useful in tabletting 
processes (Rowe et al., 2009). Additionally, this material is used in cosmetic and food 
industries.  
The chemical structure, physicochemical properties and toxicity of MCC are 
shown in Figure 2.12 and Table 2.14, respectively.      
 
Figure  2.12 Chemical structure of microcrystalline cellulose (MCC) 
 
Table  2.14 Physicochemical properties and toxicity of microcrystalline cellulose 
(Rowe et al., 2009) 
Properties Description 
Manufacturer  Sigma-Aldrich Chemie GmbH, Germany 
Chemical name Cellulose  
Empirical formula  (C6H10O5)n  where n ≈ 220. 
Molecular weight ≈ 36 000  
Mean particle size (µm) 100 (Avicel® PH-102) 
Specific surface area 
(m2/g) 
1.21–1.30 m2/g (Avicel® PH-102) 
Physical appearance  White, odourless, tasteless, crystalline powder composed 
of porous particles 
Solubility  Practically insoluble in water and most organic solvents, 
slightly soluble in 5% w/v sodium hydroxide solution. 
Toxicity  Widely used in oral pharmaceutical formulations and food 
products and is generally regarded as a relatively nontoxic 
and nonirritant material. 
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2.2.15. Aerosil® 200 (colloidal silicon dioxide) 
Aerosil® (colloidal silicon dioxide) is a commonly used excipent in pharmaceutical 
formulations and cosmetics. Commercially, Aerosil® is available in different grades that 
are obtained by modifications in its manufacturing processes. Aerosil® is characterized 
by its high specific surface area and small particle size which may improve the flow 
properties of powders especially in tablet manufacturing and capsule filling (Rowe et al., 
2009).   
The physicochemical properties and toxicity of colloidal silicon dioxide used in 
this study (Aerosil® 200) are shown in Table 2.15. 
 
Table  2.15 Physicochemical properties and toxicity of colloidal silicon dioxide 
(Aerosil® 200) (Rowe et al., 2009) 
Properties Description 
Manufacturer  Evonik Industries AG, Essen, Germany 
Chemical name Silica   
Empirical formula  SiO2  
Molecular weight 60.08 
Mean particle size (µm) Primary particle size is 7–16 nm. Aerosil forms loose 
agglomerates of 10–200 µm 
Specific surface area (m2/g) 200 ± 25 
Physical appearance  Light, loose, bluish-white-colored, odourless amorphous 
powder. 
Solubility  Practically insoluble in organic solvents and water; 
soluble in hot solutions of alkali hydroxide 
Toxicity  Generally regarded as an essentially nontoxic and 
nonirritant excipient and widely used in oral and topical 
pharmaceutical products  
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2.2.16. Gelucire® 44/14 
Gelucires® are lipid-based, amphiphilic excipients that possess hydrophilic and 
hydrophobic properties due to their composition of fatty acid esters of polyethylene glycol 
(PEG) and glycerides (Svensson et al., 2004). Gelucires® are available in several grades 
with a wide range of properties due to differences in their melting point and hydrophile-
lipophile balance (HLB). Each grade of Gelucires® is denoted by two numbers at the end 
of ‘Gelucire’ indicating the values of melting point and HLB (Gattefossé, 2012). Grades 
with low HLB values are mainly composed of partial glycerides, while grades with high 
HLB values (above 10) are composed of mixtures of partial saturated glycerides and 
PEG esters (Bandari et al., 2014).  
Gelucire® 44/14 is a non-ionic surfactant produced by the reaction of 
hydrogenated palm kernel oil and PEG 1500. The final composition for Gelucire® 44/14 
comprises 72% PEG esters, 20% glycerides, and 8% pure PEG. The amount of free 
glycerol is in the range 0 – 3% (Svensson et al., 2004). Gelucire® 44/14 is characterized 
by its surface active properties and ability to self-emulsify when in contact with aqueous 
fluids to produce fine dispersion or emulsion (da Fonseca Antunes et al., 2013, 
Gattefossé, 2012). 
The physicochemical properties and toxicity of this carrier are presented in Table 2.16. 
 
Table  2.16 Physicochemical properties and toxicity of Gelucire® 44/14 (Gattefossé, 
2012) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Lauroyl polyoxyl-32 glycerides 
Chemical description Consists of a small fraction of mono, di- and triglycerides and 
mainly PEG-32 (MW 1500) mono- and diesters of lauric acid 
(C12) 
Physical appearance White semi-solid waxy material, with light odour 
Melting range (oC) 42.5 – 47.5  
Calculated/Practical HLB 14/11 
CMC (mg/L, 25 oC) 72 ± 53 
Solubility  Water dispersible  
Toxicity  Safety of use is inferred by precedence of use in approved 
pharmaceutical products and extensive toxicological 
evaluations. 




2.2.17. Gelucire® 48/16 
Gelucire® 48/16 is a pure non-ionic surfactant with no glyceride fraction. It is a 
PEG 32 ester lipid excipient comprising a mixture of stearic and palmitic acid. According 
to the manufacturer, the final composition of Gelucire®  48/16 comprises 40 – 60% of 
stearic acid (C18) and the sum of palmitic (C16)  and stearic acid (C18) is ≥90% 
(Gattefossé, 2015).  
Gelucire® 48/16 self-emulsifies in aqueous media into micellar solutions when 
used alone or in combination with low concentrations of other water miscible solvents 
(such as Transcutol® HP). The micellar solutions produced may encapsulate the active 
ingredient within micelles. Therefore, Gelucire® 48/16 can be employed as a solubilizer 
for poorly soluble drugs with low log P values (Gattefossé, 2015).  
The physicochemical properties and toxicity of Gelucire® 48/16 are given in Table 
2.17.   
Table  2.17 Physicochemical properties and toxicity of Gelucire® 48/16 (Gattefossé, 
2015) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Polyethylene glycol monostearate 
Chemical description Consists of PEG-32 (MW 1500) esters of palmitic (C16) and 
stearic (C18) acids 
Physical appearance White waxy pellets with faint odour 
Melting range (oC) 46 – 50  
Calculated/Practical HLB 16/12 
CMC (mg/L, 25 oC) 153 ± 31 
Particle size (37°C, 1g/200 
ml water) 
7 ± 1nm 
Solubility  Water dispersible  
Toxicity  Gelucire 48/16 meets the requirement of USP/NF for 
polyoxyl stearate. Polyoxyl stearates are listed in US FDA 
inactive ingredient database for different dosage forms and 
administration routes. They have been used in oral, topical, 
vaginal, and rectal pharmaceutical products. A type IV drug 
master file (DMF) is registered with the US FDA. 




2.2.18. Gelucire® 50/13 
Gelucire® 50/13 is a non-ionic water dispersible surfactant. It is a stearoyl 
polyoxyl-32 glycerides lipid excipient comprising a mixture of short, medium and long 
chain fatty acids. According to the manufacturer, the final composition of Gelucire® 50/13 
comprises  ≤ 3% caprylic acid (C8), ≤ 3% capric acid (C10), ≤ 5% lauric acid (C12), ≤ 5% 
myristic acid (C14), 40 – 50% palmitic acid (C16), and 48 – 58% stearic acid (C18). The 
sum of palmitic and stearic acid is ≥90% (Gattefossé, 2012). 
Because Gelucire® 50/13 is water dispersible, it self-emulsifies in aqueous media 
into a coarse emulsion (Gattefossé, 2012). Therefore, this excipient has been employed 
in several studies to improve the solubility and dissolution rate of poorly soluble 
compounds (Bandari et al., 2014, El-Badry et al., 2009, Potluri et al., 2011).  
The physicochemical properties and toxicity of this carrier are presented in Table 
2.18. 
 
Table  2.18 Physicochemical properties and toxicity of Gelucire® 50/13 (Gattefossé, 
2012) 
Properties Description 
Manufacturer  Gattefossé, Lyon, France 
USP NF name Stearoyl polyoxyl-32 glycerides 
Chemical description Consists of mono, di- and triglycerides and PEG-32 (MW 
1500) mono- and diesters of palmitic (C16) and stearic (C18) 
acids 
Physical appearance White waxy pellets with light odor 
Melting range (oC) 46 – 51  
Calculated/Practical HLB 13/11 
CMC (mg/L, 25 oC) 100 
Solubility  Water dispersible  
Toxicity  Safety of use is inferred by toxicological data and 
precedence of use in approved pharmaceutical products. 
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 Formulation methods 2.3.
2.3.1. Formulation of liquid self-nanoemulsifying drug delivery systems 
(SNEDDSs) 
The type and the concentration of the components of SNEDDSs greatly influence 
the properties of the produced nanoemulsions such as the self-nanoemulsification 
efficiency, the droplet size and the polydispersity index. Therefore, initial selection of the 
components of SNEDDSs should be followed by optimization of the amounts of these 
components. The primary factors that should be considered to select the appropriate 
components are their ability to dissolve the drug and their ability to form spontaneous 
nanoemulsions upon dispersion in liquid medium. After choosing the potential 
components of SNEDDSs, their phase behaviour should be evaluated to identify different 
phases in addition to phase transitions. After that, ternary phase diagrams can be plotted 
to determine the self-nanoemulsification areas (Date et al., 2010). Components that 
produce larger self-nanoemulsifying areas possess greater self-nanoemulsification 
efficiency.   
The effect of the drug on the size of self-nanoemulsification regions should be 
evaluated as well because some drugs may reduce the size of the self-
nanoemulsification areas in ternary phase diagrams. Identification of the self-
nanoemulsification regions may help to optimize the composition of SNEDDSs. In 
addition, different properties of the final SNEDDS should be evaluated including: self-
nanoemulsification time and efficiency, droplet size, polydispersity index and zeta 
potential. Determination of zeta potential of SNEDDSs may give information on 
formulation stability. The morphological properties of the droplets of the final SNEDDS 
can be studied using transmission electron microscopy (TEM), while the in vitro drug 
release of the formulated SNEDDS can be evaluated in different dissolution media (Date 
et al., 2010).  
Self-nanoemulsifying formulations can be also optimized before in vivo studies by 
subjecting it to in vitro lipolysis studies. These studies can be conducted using an in vitro 
lipolysis model that simulates digestion process in the intestine and also determines the 
possibility of drug precipitation as well as the in vitro / in vivo correlation (Date et al., 
2010). 
The above general rules for formulation of liquid SNEDDSs were applied in this 
study to prepare liquid SNEDDSs of indomethacin as follows: 
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2.3.1.1. Determination of indomethacin solubility in various components 
The solubility of indomethacin in different oils, surfactants and co-surfactants was 
determined according to the method of Date and Nagarsenker (2007). In this method, an 
excess amount of the drug was mixed with fixed amounts of the excipient and the 
mixtures were shaken for 48 hours at 25oC to attain equilibrium. Then, samples were 
centrifuged to remove undissolved drug, filtered through a 0.45 µm membrane filter, and 
the supernatant was suitably diluted before spectrophotometric analysis to determine the 
amount of the drug dissolved in each excipient.  
2.3.1.2. Screening of surfactants for emulsifying ability 
The emulsification ability of different surfactants was evaluated by mixing the 
surfactant with the selected oily phase in a 1:1 weight ratio following the method of Date 
and Nagarsenker (2007). The mixtures were vortex mixed and diluted up to 200 fold 
dilution. The ease of formation of an emulsion was assessed by observing the number of 
inversion of the volumetric flask required to obtain a uniform emulsion. The resulting 
emulsion was also examined visually for relative turbidity according to different grading 
systems (Grades A – E) described by Khoo et al. (1998) that depict the spontaneity and 
appearance of the nanoemulsion formed upon dilution. Mixtures that showed grades A 
and B upon dilution were assigned for further evaluation.     
2.3.1.3. Screening of co-surfactants for emulsifying ability 
The ability of co-surfactants (or co-solvents) to improve the emulsification ability 
of surfactants was also evaluated according to the method of Date and Nagarsenker 
(2007). Mixtures of the selected oily phase, surfactants and co-surfactants (or co-
solvents) were mixed at a ratio of 3:2:1, respectively, and then diluted with distilled water 
for 200 fold dilution. The appearance and the ease of formation of nanoemulsion were 
assessed as described above for screening of surfactants.  
2.3.1.4. Construction of ternary phase diagrams 
According to the method of Shafiq et al. (2007) and Shafiq-un-Nabi et al. (2007), 
ternary phase diagrams were constructed in the absence of indomethacin to identify the 
self-emulsifying regions and also to determine the optimum amounts of different 
components of SNEDDS. Distilled water was used as the aqueous phase for 
development of these phase diagrams. Different combinations of the oil phase 
(Capryol™ 90), surfactants (Tween®80, Tween®20 and Cremophor®RH 40) and co-
surfactant (Transcutol®HP) were prepared and grouped into 3 groups. In each group, 
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surfactants and co-surfactants mixtures (Smix) were mixed in different weight ratios so 
that the concentration of surfactant increases with respect to co-surfactant and the 
concentration of co-surfactant increases with respect to surfactant.   
For each phase diagram, oil (Capryol™ 90) and specific Smix ratio were 
prepared and mixed thoroughly in different weight ratios. Phase diagrams were 
constructed using the water titration method, in which each combination of oil and Smix 
was slowly titrated with successive and fixed portions of water to produce water 
concentration ranging from 9% to 95% w/w. After each water addition, the mixtures were 
mixed and visual observations of different physical states were marked on a three 
component phase diagram. In plotting ternary phase diagram, one axis represents the oil 
phase, the second represents the Smix and the third represents the aqueous phase.  
2.3.1.5. Selection of the best combinations from ternary phase diagrams 
After construction of the ternary phase diagrams, the combinations of oil and 
surfactant / co-surfactant mixtures (Smix) that produce the maximum nanoemulsion 
region were selected to prepare indomethacin-loaded liquid SNEDDSs. The 
nanoemulsion region is characterized by formation of a transparent and easily flowable 
nanoemulsion. In order to cover the entire range of occurrence of self-nanoemulsification 
in each phase diagram, different oil compositions with fixed Smix percentages were 
adopted to formulate different liquid SNEDDS of indomethacin.   
Prior to formulation of indomethacin-loaded liquid SNEDDSs, the effect of addition of 
indomethacin on phase behavior in the selected combinations was investigated. 
Observation of any phase behaviour changes in each formulation was recorded. 
2.3.1.6. Preparation of drug-loaded self-nanoemulsifying formulations 
Indomethacin was added to optimized blank ternary systems at a drug loading 
concentration of 2.5% w/w, which reflects the indomethacin therapeutic dose (25 mg). 
Final mixtures were mixed and shaken for 24 hours at 25oC in an isothermal shaking 
water bath to ensure complete solubilization.  
2.3.1.7. Thermodynamic stability tests 
According to the methods of Shakeel et al. (2009) and Shafiq et al. (2007), 
prepared formulations were subjected to thermodynamic stress tests (including 
centrifugation, heating cooling cycle, and freeze thaw cycle) to eliminate metastable, 
unstable and biphasic formulations. Formulations that passed the thermodynamic stress 
tests were subjected to self-nanoemulsification tests. 
                                                                                                                                                         Chapter 2 
75 
 
2.3.1.8. Self-nanoemulsification efficiency tests 
Self-nanoemulsification tests were carried out to investigate any drug 
precipitation that may take place upon dilution of formulations with different diluents. 
Each drug-loaded self-emulsifying formulation was diluted 200 fold with deionized water 
or 0.1 N HCl and the self-nanoemulsification performance was evaluated visually 
according to different grading systems described by Khoo et al. (1998). Formulations that 
showed grades A and B upon dilution were subjected for further evaluation.  
2.3.1.9. Transmission electron microscopy (TEM) studies 
Studies using transmission electron microscopy (TEM) were conducted to obtain 
information on the morphological structure of the selected indomethacin-loaded 
SNEDDS.  Samples were diluted, directly deposited on coated copper grids and stained 
with 1% uranyl acetate. The coated grid was left to dry and then observed for TEM.   
2.3.2. Formulation of solid self-nanoemulsifying drug delivery systems 
(SNEDDSs) 
Generally, development of solid SNEDDSs from liquid SNEDDSs requires 
optimization of the liquid formulation and selection of the most suitable excipients with 
the most appropriate solidification technique in order to achieve optimum product 
performance. For example, utilization of carriers with high specific surface area and/or 
high porosity would be beneficial to load the dosage in an acceptable amount of the final 
solid SNEDDS. Carriers with good flowability would be suitable for solidification by 
adsorption and for further processing steps such as direct compression or capsule filling. 
Also, selection of porous carriers will decrease the possibility of leaking of SEDDSs 
formulation during compression. Therefore, in formulation of solid SNEDDS, a 
compromise must be established between the highest amount of drug that can be 
incorporated and the best physical properties of the solid formulation (Mandić et al., 
2017).  
Adsorption of liquid SNEDDSs onto solid carriers appears as a favourable 
solidification technique due to fewer processing steps, compared to other solidification 
methods such as spray drying or wet granulation. This method of solidification can be 
implemented on an industrial level where homogenous products can be obtained by 
spraying the liquid formulation onto the carrier or by using high shear mixing technique 
(Mandić et al., 2017).  
The method of adsorption of liquid SNEDDSs onto solid carriers is simple and 
involves blending the liquid formulation with the solid carrier or adsorbent in a blender or 
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by using a mortar with pestle. The obtained powder can be directly filled into capsules or 
mixed with appropriate excipients and then compressed into tablets (Gupta et al., 2013).  
In this study, different inert carriers including Avicel® PH102 (microcrystalline 
cellulose), Aerosil® 200 (colloidal silicone dioxide), Syloid® XDP 3150 (Porous silicone 
dioxide), Florite® PS-200 (Calcium silicate) and Neusilin® US2 (Magnesium aluminometa 
silicate) which possess different physical properties were utilized to load the optimized 
liquid indomethacin SNEDDS. 
The methods adopted in this work to formulate solid SNEDDSs of indomethacin 
were as follows: 
2.3.2.1. Preparation of solid SNEDDSs of indomethacin by adsorption technique 
The solid SNEDDS of indomethacin were prepared by simple mixing of the liquid 
SNEDDS formulations with different adsorbents at different adsorbent: liquid formulation 
ratios (by weight). Mixing was performed in a mortar using a pestle. The resulting 
granular mass was passed through a 250 µm sieve for uniformity in particle size. The 
powder samples were stored over anhydrous calcium chloride in a desiccator until 
further evaluation. 
2.3.2.2. Determination of flow properties of indomethacin-loaded solid SNEDDS 
by angle of repose method 
Determination of powder flow is an important requirement prior to some 
pharmaceutical manufacturing processes such as tableting and capsule filling.  Angle of 
repose is one of the most commonly applied methods to determine flow properties of 
powder which are related to the inter-particulate friction between particles.   
In this study, the fixed funnel method was used to determine the flow properties 
of different solid self-emulsifying formulations and to calculate the angle of repose (θ).  A 
funnel was secured to a stand with its tip adjusted at a fixed height (H) above the 
horizontal surface. Powder formulation was passed through the funnel until the apex of 
pile touched the tip of the funnel. The angle of repose was calculated using the equation: 
𝑡𝑡𝑡𝑡 = 𝐻
𝑟
     (Equation 2.1) 
where (r) is the radius of the pile of powder.  
The obtained values of angle of repose for different solid SNEDDS formulations 
were compared to the general scale of flowability for angle of repose depicted in British 
Pharmacopoeia (2015).   
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2.3.2.3. Determination of packing properties of indomethacin-loaded solid 
SNEDDS by measuring Carr’s compressibility index (CI) and Hausner’s 
ratio (HR) 
Measurement of compressibility index (CI) and Hausner’s ratio (HR) can be used 
as an alternative method to predict the flow properties of powder.  The value of 
compressibility index (CI) can be influenced by the surface area, size and shape, 
moisture content, bulk density and cohesiveness of particles. Therefore, it represents an 
indirect measure of all of these properties. Measurement of the values of compressibility 
index (CI) and Hausner’s ratio (HR) is basically performed by measuring the initial 
apparent volume, (Vo), and the final tapped volume, (Vf), of the powder which is obtained 
after tapping the powder until no additional changes in the volume can be observed. The 
compressibility index (CI) and the Hausner’s ratio (HR) can be calculated from the 
following equations (British Pharmacopoeia, 2015): Compressibility index = Vo−Vt
Vo
× 100    (Equation 2.2) Hausner’s ratio = Vo
Vf
      (Equation 2.3) 
Also, the compressibility (CI) index and Hausner ratio (HR) can be calculated 
using the measured values of bulk density (ρbulk) and tapped density (ρtapped) as follows: Compressibility index = ρtapped−ρbulk
ρtapped
× 100  (Equation 2.4) Hausner’s ratio = ρtapped
ρbulk
     (Equation 2.5) 
In order to study the flow and packing properties of different indomethacin-loaded 
solid SNEDDS formulations, Carr’s compressibility index (CI) and Hausner’s ratio (HR) 
were assessed by introducing a known weight of the powder into a graduated cylinder 
through a funnel. The cylinder was dropped onto a wooden surface three times from a 
height of 1 inch at 2 seconds intervals. The bulk density (ρbulk) in g/cm3 was calculated by 
dividing the weight of the sample by the obtained initial apparent volume (Vo) of the 
sample. Then, the graduated cylinder was tapped until a constant volume is obtained 
and the final tapped volume (Vf) of the powder was recorded. The tapped density (ρtapped) 
in g/cm3, was calculated by dividing the weight of the powder by the final tapped volume 
(Vf). Finally, Carr’s compressibility index and Hausner’s ratio were calculated using the 
above mathematical relations. 
The obtained values of Carr’s compressibility index (CI) and Hausner’s ratio (HR) 
were compared to the scale of flowability for these parameters presented in the British 
Pharmacopoeia (2015). 
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2.3.2.4. Determination of drug content of indomethacin-loaded solid SNEDDS  
In this study, the drug content was determined for drug-loaded solid SNEDDSs in 
order to calculate the amount of the drug loaded upon adsorption of the liquid SNEDD 
formulations on to different carriers.  
An accurately weighed amount of the resulting drug-loaded solid SNEDDS 
formulation was dispersed in a suitable quantity of methanol and shaken thoroughly to 
ensure release and dissolution of the drug in methanol. The samples were centrifuged at 
3000 rpm for 15 minutes to separate undissolved excipients. The supernatant was 
filtered through a 0.45 µm membrane filter and the filtrate was assayed 
spectrophotometrically for the drug at a wavelength of 320 nm. The drug content in each 
sample was calculated as milligrams of the drug per gram of the product using the 
following equation:  
 𝑑𝑟𝑑𝑑 𝑐𝑐𝑡𝑡𝑐𝑡𝑡 = 𝑑𝑟𝑑𝑑 𝑐𝑐𝑐𝑑𝑐𝑐𝑑 𝑖𝑐 𝑑ℎ𝑐 𝑤𝑐𝑖𝑑ℎ𝑑 𝑑𝑡𝑡𝑐𝑐 𝑓𝑟𝑐𝑓 𝑠𝑐𝑠𝑖𝑑  𝑆𝑆𝑆𝐷𝐷𝑆
𝑤𝑐𝑖𝑑ℎ𝑑 𝑐𝑓 𝑑ℎ𝑐 𝑠𝑐𝑠𝑖𝑑 𝑆𝑆𝑆𝐷𝐷𝑆 𝑑𝑡𝑡𝑐𝑐   (Equation 2.6) 
Also, the drug content in each formulation was estimated as % of the theoretical 
amount added using the following equation: 
 % 𝑐𝑜 𝑡ℎ𝑐𝑐𝑟𝑐𝑡𝑒𝑐𝑡𝑒 = 𝑡𝑐𝑑𝑑𝑡𝑠 𝑑𝑟𝑑𝑑 𝑐𝑐𝑐𝑑𝑐𝑐𝑑
𝑑ℎ𝑐𝑐𝑟𝑐𝑑𝑖𝑐𝑡𝑠 𝑑𝑟𝑑𝑑 𝑐𝑐𝑐𝑑𝑐𝑐𝑑 × 100   (Equation 2.7) 
Calculation of theoretical drug content was based on assuming that the entire 
amount of drug present in liquid SNEDDS formulation gets adsorbed onto the carrier with 
no loss at any stage of preparation of the solid SNEDDS. 
The experiments were repeated in triplicate for each produced batch of powder 
and then the results were averaged ± standard deviation. 
 
2.3.3. Formulation of carrier-based self-nanoemulsifying drug delivery 
systems (SNEDDSs) by hot melt extrusion (HME) 
Hot melt extrusion (HME) is considered as an advanced pharmaceutical 
manufacturing technique that can be applied to overcome the poor water solubility of 
some compounds and therefore to enhance their oral delivery. This continuous process 
is solvent free, cost-effective and can be easily scaled up. It is based on mixing the drug 
with a polymeric or lipidic carrier to form molecularly dispersed or amorphous solid 
dispersions. The obtained extrudate can be milled and formulated into different dosage 
forms like tablets, capsules, pellets and implants (Repka et al., 2007).  
 In this study, a twin screw extruder (micro-compounder, MC 15, Xplore 
Instruments BV, Sittard, The Netherlands) was used to formulate Gelucire®-based 
SNEDDSs of indomethacin. This instrument is depicted in Figure 2.13.  





Figure  2.13 Left side: Twin screw extruder (micro-compounder, MC 15, Xplore 
Instruments). Right side: The vertical co-rotating twin screws. 
The extruder is equipped with vertical co-rotating twin screws which possess a 
length to diameter (L/D) ratio of 150: 18 and a volume of 15 cm3.  
In order to formulate Gelucire®-based SNEDDSs of indomethacin, physical 
mixtures of the drug with Gelucire® 44/14 or Gelucire® 48/16 were introduced into the 
twin screw extruder through the hopper. The temperature of the extruder barrel was 
adjusted at 40oC (below the melting point of both Gelucires®) or at 50oC (the melting 
point of Gelucire® 48/16). A constant screw rotational speed of 30 rpm was maintained. 
The mass was mixed for 5 minutes inside the barrel before extrusion through a die with 1 
mm diameter. After cooling the extruded products at room temperature, these were cut 
or crushed into small pieces and then sieved through 500 µm sieve to obtain a granular 
product that was used for further experiments.  
2.3.3.1. Determination of drug content of Gelucire®-based SNEDDS of 
indomethacin  
The drug content of Gelucire®-based indomethacin-loaded SNEDDS was 
determined similarly as described previously under section 2.3.2.4 for determination of 
drug content of indomethacin-loaded solid SNEDDS.  
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Determination of drug content was repeated in triplicates for each formulation and 
the results were averaged ± standard deviation. 
 Evaluation methods  2.4.
2.4.1. Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) is a technique applied for measuring the size and 
size distribution of nanoparticles especially in liquid form. Compared to imaging 
techniques such as electron microscopy that can be used for measuring the size of 
nanoparticles, DLS does not require drying of the sample and therefore, the properties of 
the particles in the liquid dispersion remain unaffected (Pecora, 2000). In DLS, the size 
of the particles is determined by measuring the changes in the intensity of light scattered 
from a liquid dispersion. This technique is also referred to as photon correlation 
spectroscopy (PCS). According to Pecora (2000), particles are illuminated with a source 
of light (laser) in DLS and the intensity of fluctuation of scattered light is analyzed by the 
instrument to calculate a correlation function that can be used to obtain the size 
distribution of the sample.  
In this study, a Malvern Zetasizer Nano-ZS (Figure 2.14), which is based on 
DLS, was used to measure the droplet size, polydispersity index (PDI) and zeta potential 
of SNEDDSs of indomethacin.  
Dynamic light scattering measures the Brownian motion of the particles and 
relates it to the size of the particles. Brownian motion of the particles takes place due to 
random collision with the molecules of the dispersion liquid. As smaller particles move 
faster and larger particles move slower, the Zetasizer uses this information to relate the 
speed of Brownian motion of the particles to their size. The relationship between the size 
of the spherical particle and its speed is defined in the Stokes-Einstein equation:   
  𝐷ℎ = 𝑡𝐵𝑇3𝜋𝜋𝐷𝑡  (Equation 2.8) 
where  Dh is the hydrodynamic diameter, Dt is the translational diffusion coefficient, kB is 
Boltzmann’s constant, T is the absolute temperature, and η is the dynamic viscosity. 




Figure  2.14 Components of a typical DLS system. The laser (1), measurement cell (2), 
detector (3), attenuator (4), correlator (5) and data handling PC (6). 
Detectors can be placed at either 90o or at a wider angle at 173o. Adapted 
from (Malvern Instruments, 2004). 
 
The polydispersity index (PDI) is another important parameter that can be 
determined by Zetasizer. This parameter is dimensionless and has to be evaluated 
especially in a multimodal distribution to describe the diameter distribution in a sample of 
SNEDDS dispersed in aqueous media. The value of polydispersity index indicates 
uniformity in droplet size distribution within the formulation. Values less than 0.05 are 
rarely seen other than with highly monodisperse standards, while values greater than 0.7 
indicate that the sample has a very broad size distribution of particles and may not be 
suitable for analysis by DLS.  
Malvern Zetasizer can be used also for measurement of the zeta potential of 
nanoparticles in liquid dispersions. Measurement of the value of the zeta potential gives 
an indication of stability of self-emulsifying formulations, which is directly related to the 
magnitude of surface charges on emulsion droplets (Balakumar et al., 2013). The 
magnitude of zeta potential of a liquid dispersion indicates the degree of electrostatic 
repulsion between adjacent, similarly charged particles in that dispersion. Formulations 
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with high values of zeta potential (in either negative or positive charge) are more stable 
with less tendency of particle aggregation than those with low values of zeta potential. In 
general, colloidal dispersions are considered as stable formulations when their zeta 
potential values range between 25 and 30 mV in either charge (Bali et al., 2011, Shakeel 
et al., 2013b).  
In practice, zeta potential can be measured using the Malvern zetasizer. The 
sample of liquid dispersion is placed in a capillary cell with electrodes at either end to 
which an electric field is applied (Figure 2.15). Then charged particles in the dispersion 
will migrate towards the electrode of opposite charge with a certain velocity that is 
proportional to the magnitude of the zeta potential (Malvern Instruments, 2004).  
 
Figure  2.15 Illustration of a folded capillary cell for measurement of zeta potential in 
DLS system. Adapted from (Malvern Instruments, 2004) 
 
The velocity of the particles moving in the electric field (known as the 
electrophoretic mobility) is dependent on the zeta potential, strength of the electric field, 
viscosity and dielectric constant of the medium. Zetasizer can obtain the zeta potential of 
a liquid dispersion by applying Henry’s equation as follows:   
  𝑈𝑆 = 2𝜀 𝑧 𝑓(𝐾𝑎) 3𝜋    (Equation 2.9)  
where UE is the electrophoretic mobility, ε is the dielectric constant, z is the zeta 
potential, f(Ka) is the Henry function, and η is the viscosity.  
The Henry’s function, f(Ka), has two values, either 1.5 or 1.0 which can be used 
as approximations in measurement of zeta potential. When zeta potential is determined 
in aqueous media with moderate concentration, the Henry’s function (f(Ka)) is considered 
as 1.5 and can be referred to as Smoluchowski approximation. On the other hand, upon 
measuring zeta potential in non-aqueous media with low dielectric constant, the Henry’s 
function (f(Ka)) takes the value of 1.0 and can be referred to as Huckel approximation.  
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In this project, Malvern Zetasizer nano-ZS was used to measure the droplet size, 
polydispersity index and zeta potential of the liquid, solid and Gelucire®-based SNEDDS 
of indomethacin. An amount of each formulation was dispersed in purified water to obtain 
a fixed final drug concentration. Samples were filled into acrylic cuvettes for 
measurement of droplet size. The light scattering was measured at a scattering angle of 
90o and a temperature of 25oC. In the case of measurement of zeta potential, the 
samples were prepared similarly and filled into folded capillary cells.  All measurements 
were repeated in triplicates and the results were averaged ± standard deviation.   
2.4.2. In vitro dissolution studies 
Dissolution is the process of transforming drug molecules from the solid state into 
solution. Different stages (or processes) are involved in the dissolution of a drug from 
solid dosage forms. When a solid dosage form is placed in contact with an aqueous 
medium, it starts to pass into solution from the intact dosage form. Also, the solid dosage 
form may disintegrate into granules which may in turn deaggregate into fine particles. 
Therefore, disintegration, deaggregation and dissolution occur simultaneously during the 
release of the drug from the solid dosage form. These processes of dissolution from solid 
dosage forms are illustrated in Figure 2.16. 
 
Figure  2.16 Different processes involved in the dissolution of solid dosage forms 
(Abdou, 1989) 
 
In pharmaceutical practice, dissolution rate can be defined as “the amount of 
drug substance that goes in solution per unit time under standardized conditions of 
liquid/solid interface, temperature and solvent composition” (Abdou, 1989). The 
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correlation between the dissolution rate and the solubility gradient of the solid particles 
has been described by Noyes-Whitney equation which can be written as follows (Sun et 





(𝐶𝑠 − 𝐶𝑥)   (Equation 2.9) 
where dC/dt is the dissolution rate, D is the diffusion coefficient of the solute in solution, 
A is the surface area of the solid, V is the volume of the dissolution medium, Cs is the 
saturation solubility of the solid, Cx is the drug concentration in the bulk solution, and h is 
the thickness of the diffusion layer.   
The in vitro dissolution test is routinely applied in pharmaceutical drug 
development to obtain information on drug release for quality control purposes in order to 
assess consistency of batch manufacturing. Also, this test can be applied to predict the 
in vivo performance of the drug formulation, and then to establish in vivo – in vitro 
relationship between drug absorption and its release from the dosage form (Qiu et al., 
2014). In addition, dissolution testing can be employed to aid in choosing among 
different formulations manufactured using various excipients, with the aim to select the 
optimum formulation that exhibits the most desirable and reproducible dissolution profile 
(Dressman et al., 1998, Qiu et al., 2014).  
Four different assemblies of dissolution apparatus were defined by the British 
Pharmacopoeia (2015) including: apparatus I (basket apparatus), apparatus II (paddle 
apparatus), apparatus III (reciprocating cylinder) and apparatus IV (flow-through cell). 
The choice of the apparatus to be used for in vitro dissolution studies is governed by the 
physicochemical properties of the dosage form. In this study, Pharma Test Dissolution 
apparatus (Paddle apparatus) was used to assess the release profiles of indomethacin 
from different solid and carrier-based SNEDDS formulations.   
Different dissolution media can be used to conduct the in vitro dissolution studies. 
Buffers, acidic solutions, surfactants and buffers or acidic solutions combined with 
surfactants are among the various dissolution media that can be used. Also, biorelevant 
media prepared with bile salts or other physiological ingredients can be used as 
dissolution media especially when in vivo – in vitro correlation studies are to be 
conducted (Fotaki et al., 2013). Selection of the most appropriate dissolution medium for 
a dissolution study is based on the dissolution properties expected for a drug and/or 
product. Before conducting a dissolution test, the solubility of the drug in the dissolution 
medium has to be evaluated.  The pH of the dissolution medium is another important 
aspect that must be considered so that the in vitro dissolution environment would be 
relevant to the physiological conditions. Generally, pharmacopeial monographs of drugs 
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specify the type, composition and pH of the dissolution medium required for dissolution 
testing of specific drugs. 
In general, selection of the dissolution medium for oral dosage forms should be 
based on drug properties such as drug solubility and stability, in addition to formulation 
(product) components (excipients) used, and interaction between the components 
(Fotaki et al., 2013).  
In this research, the in vitro dissolution studies of different indomethacin solid and 
carrier-based SNEDDS formulations were carried out in dissolution apparatus II (Paddle 
method) according to the requirements specified in the British Pharmacopoeia (2015)  for 
indomethacin capsules. The dissolution medium composed of 900 ml phosphate buffer 
pH 7.2 maintained at 37 ± 0.5oC and the rotational speed was adjusted at 50 rpm. 
Phosphate buffer pH 7.2 was prepared according to the British Pharmacopoeia (2015) 
by mixing 50 ml of 0.2M potassium dihydrogen orthophosphate with 35 ml of 
0.2M sodium hydroxide and diluting to 200 ml with water. Volumes of these solutions were 
corrected accordingly to prepare the total volumes required for dissolution studies.   An 
amount of solid SNEDDS formulation equivalent to 25 mg of indomethacin was filled in 
suitable number of hard gelatin capsules (size 000) and used for dissolution studies.  For 
Gelucire-based SNEDDSs, an amount of the formulation equivalent to 25 mg of the drug 
was directly dropped into the dissolution medium.  Samples were withdrawn at 
predetermined time intervals. An equal volume of fresh dissolution medium maintained at 
the same temperature was added to keep constant volume during dissolution study. The 
collected samples were filtered through 0.45 µm syringe filter, suitably diluted and then 
assayed for the content of indomethacin by UV spectrophotometry at 320 nm. 
Experiments were performed in triplicates and the results are averaged ± standard 
deviation (SD). 
The dissolution profile of indomethacin released from the tested formulations was 
compared to that obtained when the same quantity of pure indomethacin was filled in 
capsules.  
In order to compare the resulting drug dissolution profiles, different approaches 
can be applied for this purpose. Dissolution profiles can be compared according to the 
model of drug release, i.e., zero order, first order, Higuchi, and Hixson-Crowell. Also, the 
ANOVA approach, the difference (f1) and similarity (f2) factors (fit factors) and the 
dissolution efficiency (DE) can be used to compare different dissolution profiles. While 
the ANOVA approach identifies the statistical equivalence of formulations, the 
pharmaceutical equivalence of two formulations can be identified by the difference (f1) 
and similarity (f2) factors. However, the fit factors do not provide information on the 
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consistency of individual batches. Therefore, the dissolution efficiency (DE) can be used 
as a parameter to analyze dissolution profiles and also to compare pairs of formulations.  
The use of DE (which considers the whole dissolution process) for comparison of 
dissolution profiles is preferred over comparison that is based on a single time point 
(mean % dissolved at a selected time) (Anderson et al., 1998). 
The concept of dissolution efficiency (DE) was introduced by Khan and Rhodes 
(1972). The dissolution efficiency can be defined as “the area under the dissolution curve 
up to a certain time, t, expressed as a percentage of the area of the rectangle described 
by 100% dissolution in the same time” (Anderson et al., 1998). 
The value of DE can be calculated as follows: 
𝐷𝐷 = ∫ 𝑦.𝑑𝑑𝑡2𝑡1
𝑦100.(𝑑2−𝑑1) × 100%  (Equation 2.10) 
where y is the % of dissolved product, t1 and t2 are the time points. 
For calculation of DE, the value of t1 = 0 is generally selected while the value for t2 
can be set at the time that corresponds to 70 – 90% dissolution. However, early portions 
of the dissolution curve can be analyzed (Anderson et al., 1998).   
The mean dissolution time (MDT) is a parameter that represents an arithmetic 
mean value for any dissolution profile. Estimation of MDT can provide information on in 
vitro / in vivo correlation and can be used to compare different dissolution profiles 
statistically. Different methods based on model dependent and model independent 
approaches can be used to calculate MDT. The model independent method uses the 
amount of drug dissolved in dissolution medium after specifically defined time intervals. 
Generally, the calculation method is based on using the trapezoidal rule to calculate the 
area under the dissolution curve (Podczeck, 1993). The following equation can be used 
to calculate the MDT of a given dissolution profile (Rinaki et al., 2003):  
𝑀𝐷𝑀 = ∫ 𝑑.𝑑𝑑(𝑑)𝑊∞0
∫ 𝑑𝑑(𝑑)𝑊∞0    (Equation 2.11) 
where W(t) is the cumulative amount of drug dissolved at time (t). 
In this study, the obtained dissolution profiles of different SNEDDS formulations 
were compared using the DE and mean % drug released after specific times. The DE 
after 15 minutes (DE15min) was calculated using DDSolver as Excel add inn. This was 
chosen because of good separation of dissolution curves observed at this time interval 
for the tested formulations. Also, the mean % drug released after 15 minutes (Q15min) and 
the MDT were used to compare different dissolution profiles. 
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2.4.3. Ultraviolet/Visible spectrophotometry 
Ultraviolet/visible (UV/Vis) spectroscopy is an analytical technique that can be 
used for quantitative determination of compounds that absorb UV/Vis radiation. UV/Vis 
spectroscopy measures absorbance or reflectance in the ultraviolet (wavelength 200 – 
400 nm) and visible (400 – 800 nm) spectral regions. This technique is based on the fact 
that when organic molecules are exposed to electromagnetic radiation in the UV/Vis 
regions of the spectrum, they undergo electronic transitions in the outer orbitals (Martin 
et al., 1993).   
By application of the Beer – Lambert law, UV/Vis spectroscopy can be used to 
determine the concentration of organic molecules in a solution at a fixed path length. The 
Beer – Lambert law relates the absorbance of a solution to the concentration of the 
absorbing molecules as in the following equation (Martin et al., 1993): 
𝐴 = 𝜀𝜀𝑐      (Equation 2.11) 
where A is the measured absorbance (the amount of light absorbed by the sample), ε is 
a constant known as the molar absorbitivity (or molar extinction coefficient), b is the path 
length of the radiation passing through the sample (or the path length of the cell which 
usually equals to 1 cm), and c is the concentration of the absorbing substance.    
In this study, UV spectroscopy was used as the analyzing technique to determine 
the concentration of indomethacin in different formulated SNEDDSs. For this purpose, 
standard calibration curves of indomethacin were constructed in both methanol and 
phosphate buffer.   Different concentrations of indomethacin ranging from 2.5 to 45 µg/ml 
were prepared in the assigned medium and the absorbance of these solutions was 
determined spectrophotometrically at the maximum wavelength (λmax = 320 nm) 
corresponding to indomethacin (British Pharmacopoeia, 2015, Inada et al., 2013, Yadav 
and Yadav, 2009) using the corresponding medium as a reference. To obtain the 
standard calibration curve, the measured absorbance was plotted against the 
corresponding concentrations and the equation that describes the relationship between 
the concentration and the absorbance was estimated.   
In order to determine the concentration of indomethacin in different formulated 
SNEDDSs, scanning of each sample was carried out at a wavelength of 320 nm using a 
Libra S22 UV/Vis spectrophotometer (Biochrom Ltd., Cambridge, UK). Readings of 
absorbance were fitted into the equation of the corresponding calibration curve and the 
concentration of the drug was calculated.  
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 Solid state characterization methods 2.5.
2.5.1. Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) is the most widely applied thermal 
analysis technique. In this technique, samples are subjected to linear heating and 
cooling cycles to obtain information on their melting, decomposition, re-crystallization 
and possible glass transition. In DSC analysis, the energy changes that occur in the 
sample during these thermal processes are measured together with the time or the 
temperature at which these changes take place. This thermal analysis technique is 
simple, rapid and requires only a small sample size that can be heated over a wide 
temperature range (from – 120 to 600oC) according to the instrument used (Gabbott, 
2008, Reading and Craig, 2007).  
Two different types of DSC instruments have been identified: the heat flux and 
the power compensation. Heat flux DSC (Figure 2.17) is made of a single furnace that 
incubates the sample and empty reference pans. The sample and the reference pans 
are heated equally in the furnace and the temperature difference between the two pans 
is measured by a pair of thermocouples located beneath the pans.  The amount of heat 






  (Equation 2.12) 
where dQ/dt is the heat flow, ΔT is the temperature difference between the furnace and 
the pans, and R is the thermal resistance of the heat flow between the furnace and the 
pans (Reading and Craig, 2007).  
 
Figure  2.17 Schematic representation of heat flux DSC. A =furnace, B = thermocouple 
(Reading and Craig, 2007) 
 
The other type of DSC instrument is the power compensation DSC (Figure 2.18). 
This system utilizes two furnaces, one for the sample pan and the other for the reference 
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pan. Both furnaces have the same temperature program. In this system, the difference in 
the power supplied for both furnaces in order to keep both pans at the same temperature 
is measured and recorded. Therefore, in power compensation type, the sample is 
subjected to programmed heating, in contrast to the heat flux approach where the 
furnace is the part subjected to programmed temperature (Reading and Craig, 2007). 
 
Figure  2.18 Schematic representation of power compansation DSC. A = furnaces, B = 
sample and reference pans, C = sample and reference platinum 
resistance thermometers (Reading and Craig, 2007). 
 
Both types of DSC analysis are sensitive and accurate. However, higher heating 
and cooling rates can be achieved with the double furnaces in power compensation 
DSC, while better baseline stability can be obtained with the single furnace in heat flux 
DSC. 
The heat capacity (Cp) represents the amount of energy required to raise the 
temperature of the sample by 1K. This parameter can be expressed as: 
𝑑𝑑
𝑑𝑑
= 𝐶𝑃 × 𝑑𝑇𝑑𝑑    (Equation 2.13) 
where dQ/dt is the heat flow and dT/dt is the heating rate (Reading and Craig, 2007).  
Another DSC technique, modulated temperature differential scanning calorimetry 
(MTDSC), was introduced as an extension to the conventional DSC techniques. This 
technique involves the application of a sinusoidal heating wave to the standard linear 
temperature program. The heating rate in this technique also modulates due to 
modification of the temperature. The constant heating rate utilized in conventional DSC 
methods is not capable of separating overlapping thermal processes (Reading et al., 
2007). For example, determination of the glass transition temperature (Tg) of polymers 
requires separation of heat flow due to heat capacity from the heat flow mediated by 
other overlapping thermal events like desolvation, dehydration or other enthalpic 
relaxations that possess stronger thermal signals in comparison to the weak Tg (Knopp et 
al., 2016).  Therefore, modulation of the heating rate in MTDSC allows the separation of 
overlapped reversible (heat flow due to heat capacity differences such as melting and 
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glass transition) and non-reversible (heat flow due to a chemical or physical event such 
as crystallization and decomposition) thermal events taking place in the sample during 
heating and cooling conditions. MTDSC is more sensitive and gives higher resolution 
than the conventional DSC (Knopp et al., 2016, Reading et al., 2007).  
In this study, conventional DSC analysis was performed using a single furnace, 
heat flux DSC (DSC 4000, Perkin Elmer, US). Accurately weighed samples 
(approximately 5 – 10 mg) were placed in a standard aluminum pan and scanned at a 
controlled heating rate of 10oC/min from 25 – 300oC under nitrogen gas flow of 20 
ml/minute. The temperature and the energy changes, such as melting or crystallization 
that took place during heating were recorded. 
2.5.2. Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) is a thermal analysis technique that measures 
the changes in weight of a sample while it is heated at a constant heating rate. This 
technique is used to determine different characteristics of materials that exhibit weight 
loss or gain (such as oxidation, evaporation or decomposition) upon heating or cooling. It 
is also applied to evaluate thermal stability of pharmaceutical compounds prior to their 
use in formulation methods that involve heating. Samples are considered to be thermally 
stable if no or negligible loss in weight is observed over the temperature range selected. 
This stability can be verified in the form of no or negligible slope of the TGA curve.   
The basic TGA system consists of a precision balance and a pan to load the 
sample in addition to a furnace which can be programmed for a constant heating rate. 
The sample (about 3 – 5 mg) is placed in the pan which is hung by a wire beneath the 
sensitive balance. An inert purge gas (like nitrogen) flows over the sample to prevent 
oxidation and other undesirable reactions. The sample in the heating pan is heated at a 
constant heating rate to temperatures that may reach up to 1000oC. The instrument 
weighs the sample continuously during heating process and the results are recorded and 
presented as plots of the % weight loss against the temperature (Saunders and Gabbott, 
2011).   
TGA was employed in this study to evaluate the thermal stability of indomethacin, 
Gelucire®44/14, Gelucire®48/16 and other adsorbents before employment in formulation 
of Gelucire-based SNEDDS adopting hot melt extrusion technique.  Thermal stability 
was assessed using Pyris 1 TGA (Perkin Elmer, Waltham, Massachusetts, USA). The 
analysis was performed on samples of approximately 3 – 5 mg in the temperature range 
between 30o and 250oC and at a heating rate of 10oC / minute. 
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2.5.3. X-Ray Diffraction (XRD) analysis 
X-ray diffraction is a common analytical technique that is used for 
characterization of crystalline materials. It has been also employed for quantitative 
analysis and qualitative identification of unknown compounds. 
This technique is based on the fact that atoms in a crystal diffract X-ray beams in 
a way similar to diffraction of ordinary light by the plane of a diffraction grating. Each 
substance reflects (or diffracts) the X-ray beam and hence, a particular diffraction pattern 
can be produced and can be used as a ‘fingerprint’ for each compound and crystal form. 
Therefore, an unknown powder can be identified by comparing its diffraction pattern to 
those of known substances or by comparing its distances of various planes (interplanar 
spacing or d-spacing) obtained from the diffraction pattern to those values recorded for 
known compounds (Abdou, 1985).   
The unique diffraction pattern obtained from crystalline materials is a result of the 
arrangement of atoms or molecules in those crystalline materials in addition to the 
interatomic distance between them. In a diffraction pattern, the position of the X-ray 
diffraction peaks (expressed as their incidence angle, θ) can be obtained from Bragg’s 
equation, which relates the wavelength of the X-ray beam (λ) to the incidence angle of X-
ray beam (θ) and the interplanar spacing of a set of diffracting planes (d) as follows: 
𝑡𝑛 = 2𝑑 𝑠𝑒𝑡𝑡   (Equation 2.14) 
where n is the order of the diffractions.  
Therefore, any changes in the d-spacing (due to crystal deformation during 
different processes) will be inversely proportional to the incident angle of X-ray beam (θ). 
These changes can be observed in the form of shifting of the position of X-ray diffraction 
peaks to higher or lower θ values (Bandyopadhyay et al., 2005).  
Particles of an amorphous material usually do not possess ordered structure like 
crystalline materials and their atoms will diffract the X-rays in many directions. Therefore, 
the resulting X-ray diffraction pattern of amorphous materials contains no sharp 
crystalline (Braggs) diffraction peaks like crystalline materials but show a broad halo. 
This halo pattern is needed for characterization because it confirms that the material is 
amorphous (Gilmore, 2011).   
X-ray diffractometers are composed of three main parts including: the X-ray tube, 
the sample holder and the X-ray detector (Figure 2.19). The incident beam optics 
conditions the X-ray beam before hitting the sample, while the goniometer represents a 
platform that holds and moves the sample, optics, detector and/or the tube.  




Figure  2.19 Basic components of X-ray diffractometer with the goniometer 
 
Diffraction methods are based on generation of X-rays by a cathode ray tube by 
heating a filament to produce electrons. The X-rays produced are then filtered to produce 
monochromatic radiation, collimated to concentrate and directed to hit the sample by 
applying a high voltage for acceleration. The sample holder usually rotates in the path of 
the X-ray beam at an angle θ, while the X-ray detector collects the diffracted X-rays and 
rotates at an angle of 2θ.  As the sample and the detector rotate through their respective 
angles, the characteristic X-ray spectra are obtained by recording the intensities of the X-
rays reflected by the sample at different angles (the beam incident angle and the beam 
reflected angle).  For a typical X-ray diffraction pattern, the data are collected at 2θ from 
about 5o to 70o which represent the angles preset in the X-ray scanning. The obtained X-
ray spectrum is commonly presented as an X – Y plot (or as a table) of peak positions at 
2θ against X-ray counts or intensity (Abdou, 1985).  
XRD analysis is accurate, rapid, reliable, non-destructive and requires minimal 
sample preparation. It includes two types: the X-ray powder diffraction (XRPD) and the 
single-crystal XRD. The XRPD analysis is a commonly used technique with wide 
applications in the pharmaceutical field. This technique can be utilized during drug 
development, manufacturing and quality control of manufactured pharmaceutical 
formulations. XRPD can provide information on the degree of crystallinity and 
amorphous content of pharmaceutical mixtures. Also, this technique is useful for 
quantitative analysis of pharmaceutical mixtures and can be used to obtain accurate 
percentage of components of mixtures. This is based on the fact that the intensity of a 
diffraction peak of one component of the mixture is directly proportional to the 
concentration of that component in the mixture. In order to determine the concentration 
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of one component in a mixture by XRD, a known amount of a well characterized 
standard is added to the mixture containing the component to be quantified and the 
amount of the component is determined relative to a certain % content of the added 
standard. In addition, XRPD technique can be applied for qualitative analysis of 
compounds, based on the fact that even chemically related compounds possess different 
and unique ‘fingerprint’ diffraction patterns that can be used for their identification 
(Gilmore, 2011).  
In this work, XRPD was employed as one of the characterization techniques 
adopted for evaluation of the produced solid and carrier-based SNEDDSs of 
indomethacin. For the purpose of comparison, the XRPD analysis was also conducted 
for indomethacin and different excipients used for different formulations. Ultima IV 
diffractometer (Rigaku Co., Ltd., Tokyo, Japan) was used for this purpose. A copper X-
ray source was used and maintained at 40 kV of tube voltage and 40 mA of tube current 
to produce emissions of 0.15406 nm. The samples were scanned at 3−60° 2θ range at a 
scanning speed of 0.5 deg./min.  Data were collected using a step scan mode with step 
size of 0.02o and counting time of 1 second per step.  
2.5.4. Fourier-Transform Infra-Red (FTIR) analysis 
Infrared (IR) radiation is a type of electromagnetic radiation that starts after the 
visible region at 700 nm. The IR spectral region comprises three subdivisions that lie 
between different wavelength ranges including: the near IR, mid IR and far IR. In 
pharmaceutical analysis, the most commonly used region of the IR spectrum is the mid 
IR region because it is the region where fundamental vibrations of polyatomic molecules 
take place. This region falls in the range between 2.6 – 26 µm (wavelength) or 4000 – 
400 cm-1 (wavenumber). The wavenumber is usually used in IR spectrum rather than the 
wavelength because the wavenumber is directly related to the energy and the frequency 
of the radiation which in turn can be directly related to the molecular vibrational changes. 
Also, the low energies of IR radiation are not adequate to cause electron transitions but 
they are adequate to induce vibrational changes within molecules.  Therefore, when IR 
radiation hits a sample at particular wavelength, their low energy causes vibrational 
changes within the sample molecules, rather than causing electron transitions as seen 
with UV radiation (Bunaciu et al., 2010). 
IR spectroscopy is based on passing IR radiation through a sample and 
measuring the amount of the IR radiation absorbed by the sample molecules at particular 
wavelength or frequency.  Absorption of IR radiation by atoms of a sample causes 
atomic vibrational changes according to bond strength, atomic masses, and inter- and 
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intramolecular interactions. IR spectra usually provide information on these vibrational 
changes by displaying the percent transmittance to the wavenumber of the incident 
radiation.  
Although IR spectra are complex, it provide information about the presence or 
absence of certain functional groups and therefore it can be used as fingerprints to 
compare or identify samples or compounds. For example, the IR spectra of known 
organic compounds can be produced and used as a fingerprint library for identification of 
unknown compounds via spectral comparison. Also, the molecular structure of unknown 
compounds can be elucidated by detection of the presence of specific functional groups 
of these compounds in their IR spectra. However, IR spectra do not provide detailed 
information on the molecular formula or the structure of a compound.   
For most molecules, IR absorption peaks appear in the mid IR region between 
4000 and 400 cm-1. The position and intensity of these vibrational bands vary according 
to the type of atomic chemical bond, conformation of the chemical bonds and their 
adjacent chemical groups. Therefore, each functional group (such as C=O, C-H, N-H, O-
H) produces vibrational peaks, at specific spectral region, which can be used for 
interpretation of vibrational spectra (Bunaciu et al., 2010).  
Although the original IR spectroscopic analysis methods are rapid and non-
destructive, it had only limited applications in quantitative analysis. However, the use of 
IR spectroscopy for quantitative analysis has grown widely with the introduction of the 
concept of Fourier transform infrared (FTIR). The FTIR spectrometers combine 
interferometer or Michelson interferometer (Figure 2.20) with sensitive IR detector. The 
interferometer is placed between the source of the radiation and the sample. An IR beam 
emitted by the source is split by a beam splitter into two beams. The two reflected beams 
are then combined at the beam splitter according to the position of a movable mirror. The 
non-absorbed beam leaves the interferometer and becomes focused on the detector 
which performs complex mathematical calculations to produce the interferogram by 
relating the intensity of the combined beams to the position of the moving mirror. In 
FTIR, highly developed computer programs and software are employed to convert the 
interferograms into spectrum (Abdou, 1985, Bunaciu et al., 2010, Markovich and 
Pidgeon, 1991).  




Figure  2.20 Essential components of Michelson interferometer (Markovich and 
Pidgeon, 1991)  
 
FTIR spectra usually display the % transmittance of radiation at respective 
wavenumbers. For transmission mode measurement, the detector is usually situated 
behind the sample so that the fraction of transmitted radiation is collected. Also, solid 
samples are dispersed in potassium bromide (KBr) disc so that their particle size is 
smaller than the wavelength of the radiation to avoid scattering effect (Bunaciu et al., 
2010).   
In this study, FTIR analysis was adopted for characterization and evaluation of 
the produced solid and carrier-based SNEDDSs of indomethacin. For the purpose of 
comparison, the FTIR spectra was also obtained for indomethacin and different 
excipients used for different formulations. All FTIR spectra were recorded in the scanning 
range of 4000 – 400 cm-1 using a Fourier transform infrared (FTIR) spectrophotometer 
(Nicolet 6700, Thermo Fisher Scientific, Massachusetts, USA) to identify possible 
interactions between the drug and different excipients used in the formulations. A mixture 
of formulation sample (4 mg) and dry potassium bromide (IR grade, 200 mg) was lightly 
ground and compacted to form a disc using a hydraulic press and scanned at a speed of 
four scans/second.     
2.5.5. Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) is an imaging technique that is used widely 
for characterization of the size and the surface properties of solid samples. Images of the 
sample are produced by focusing a beam of electrons on the surface of the sample. 
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Interaction of these electrons with the sample atoms will produce different signals that 
provide information about topographical features of the sample such as cracks, crystal 
faces and surface roughness. 
SEM is widely used in the pharmaceutical industry during development and 
optimization of manufactured dosage forms, especially the solid forms. This technique is 
applied for investigation of the surface properties of active pharmaceutical ingredients 
and the excipients used in different pharmaceutical formulations. In SEM, the beam of 
electrons is generated by a cathode source, accelerated by application of high voltage 
and focused by the objective lens before it enters the sample chamber. In the SEM, 
different magnifications can be obtained for the surface of the sample. In addition, the 
linear dimensions of sample particles can be measured with a scale bar superimposed 
upon the image. The sample is mounted onto a sample holder or stub by putting an 
adhesive pad on the stub and gently dipping it into the sample to form a thin layer that 
sticks to the pad. In order to make the pharmaceutical sample electrically conductive, the 
sample is coated with a thin layer of gold or platinum using a sputter coating unit.  This 
coating aids to give brighter images at low electron voltage and also improves the 
thermal stability of the sample by conducting heat from the sample upon hitting by the 
beam of electrons (Nichols et al., 2011).    
The morphological properties of indomethacin, different excipients and the 
formulated solid and carrier-based SNEDDSs were investigated using JSM-6060LV 
scanning electron microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 10 kV. 
Samples were lightly sprinkled on double-sided sticky tape, affixed to an aluminum stub, 
and made electrically conductive with a gold coating (13 – 14 nm/min; 45 s; 20 mA) 
under vacuum using JFC-1600 Auto Fine Coater (Jeol, Tokyo, Japan). Micrographs were 
recorded at different magnifications to study the surface and morphological 
characteristics. 
2.5.6. Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is a commonly used technique that 
provides information on the surface morphology, size, shape and structure of biological 
samples as well as inorganic materials. This technology uses a beam of electrons that 
can pass through the sample to produce information on structural features, size and 
shape (Nichols et al., 2011).  
Compared to conventional light microscopy, TEM can produce images or 
micrographs of higher resolution and magnification due to shorter wavelength of 
electrons compared to photons. This instrument can be operated to produce images with 
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magnification of 1000 – 250,000x on the screen. Also, TEM can provide images of higher 
resolution than scanning electron microscope that only views and scans the surface of a 
sample. Therefore, samples for TEM are required to be of a thickness of less than 100 
nm to allow the slow electrons to penetrate the sample, while samples for scanning 
electron microscopy (SEM) can be of a thickness greater than 10 µm to obtain surface 
features (Nichols et al., 2011). In addition, TEM analysis can produce micrographs of 
particles of less than 1 nm in size.  
The TEM is composed of three main parts. The first part comprises the electron 
gun which produces the beam of electrons, and the condenser system that focuses the 
electron beam onto the sample. The second part is the image producing part that 
consists of the objective lens, the movable sample stage, and the projector lenses. In 
this part, the electrons are focused by the objective lens to pass through the sample, 
where part of the electron beam is transmitted through the sample and the other part is 
emitted and focused as an image with high magnification on the projector lens. The third 
part of the TEM is the image recording part which consists of a fluorescent screen to 
view the images and a digital camera that record images.  A vacuum system is another 
essential component in TEM to ensure that electrons will not interfere with gas atoms 
(Dykstra and Reuss, 2011).    
High resolution, black and white images are produced by TEM due to the 
interaction between the prepared sample and the beam of electrons in the vacuum 
chamber. Different parts of the image are displayed in different degrees of darkness due 
to differences in absorption of electrons caused by different thickness or different 
composition of the sample. The lighter areas reflect the places where more electrons 
were transmitted through the sample while the darker regions represent the dense areas 
of the sample. These differences may provide information on the structure, size and 
shape of the sample.   
 Generally, TEM samples are prepared according to the type of the sample and to 
the type of information required from the test. TEM samples should be prepared to be of 
less than 100 nm thick so that they can be penetrated by electrons. Usually, the diluted 
sample is deposited onto films of supporting grids. A standard TEM grid is made of 
copper, molybdenum, platinum or gold and has a size of 3.05 mm in diameter and a 
mesh size ranging between few and 100 µm. To enhance the contrast of the produced 
image, samples are stained with negative staining material such as uranyl acetate or 
with heavy metals. The staining material will absorb part of the beam of electrons or 
scatter a part of the electron beam which will be projected on the imaging system. The 
grid is then placed in the sample holder that is paired with the sample stage. After 
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insertion into the TEM, the movable sample stage may allow adjustment of the position 
of the sample to the region where electron beam can be directed (Cheville and Stasko, 
2014).  
 In this study, morphological structures of optimized liquid SNEDDS of 
indomethacin were investigated using TEM (Philips CM 120 BioTwin, USA). Samples 
were diluted, deposited on copper grids, stained with 1% uranyl acetate and left to dry 
before observation under TEM. 
 
 Statistical evaluation methods 2.6.
In this project, the data of interest were statistically evaluated using one way 
analysis of variance (ANOVA). Also, significance of difference between the mean of two 
independent samples was ddetermined using the two samples t-test. Significant 
differences were determined at a 5% significance level, unless otherwise stated 
elsewhere. Statistical differences yielding p < 0.05 were considered significant. The 
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Self-nanoemulsifying drug delivery systems (SNEDDSs) are isotropic mixtures of 
oil(s) with surfactant(s), co-surfactant(s) and the solubilized drug (Hauss, 2007, Neslihan 
Gursoy and Benita, 2004, Porter et al., 2008). These mixtures, when diluted with 
aqueous fluids and under mild agitation, form quick and spontaneous oil in water 
nanoemulsions with droplet size ranging from few nanometers to less than 100 nm 
(Kawabata et al., 2011, Kohli et al., 2010).  According to Rehman et al. (2017), these 
anhydrous formulations can be considered as preconcentrates of nanoemulsions. 
However, SNEDDSs can offer several advantages compared to nanoemulsions. 
SNEDDSs can be filled into soft or hard gelatin capsules (due to lack of water content) 
and this may lead to improved palatability as well as patient compliance. Also, improved 
physical and chemical stability of the formulation can be obtained upon long term storage 
of SNEDDSs (Date et al., 2010). 
Utilization of SNEDDS formulations is considered as one of the most important 
approaches to improve solubility and dissolution rate of poorly water soluble (Class II) 
drugs.  Dispersion of SNEDDSs in aqueous fluids leads to formation of fine droplets that 
contain already dissolved drug in the oil phase and provide large interfacial surface area 
for transfer of the drug resulting in enhanced rate and extent of absorption and therefore, 
improved bioavailability (Chakraborty et al., 2009). Also, fine nano-sized droplets may 
exhibit quick digestion and therefore, faster drug absorption in the gastrointestinal tract 
(Grove et al.). These lipid formulations can enhance the lymphatic uptake of highly 
lipophilic compounds (log P > 5 and lipid solubility > 50 mg/g) (Rehman et al., 2017). 
Compared to lipid solutions, SNEDDSs possess the advantage of increased drug loading 
capacity due to high content of surfactants and co-surfactants that contribute to 
enhanced solubility of poorly soluble drugs with intermediate partition coefficient (2 < log 
P < 4) (Pouton, 2000). In addition, SNEDDSs may provide protection for drugs against 
the enzymatic and chemical hydrolysis that take place within the aqueous environment of 
the GIT (Date et al., 2010, Gupta et al., 2013). Furthermore, inhibition of P-glycoprotein 
mediated drug efflux and improved lymphatic transport by SNEDDS formulations may 
contribute to enhanced bioavailability of poorly soluble drugs (Date et al., 2010).  
The type and the concentration of the components involved in formulation of 
SNEDDSs have a prominent effect on the final properties of nanoemulsion produced 
such as the droplet size, polydispersity index and self-nanoemulsification efficiency. 
Therefore, optimization of the amounts of these components is important for SNEDDS 
development. Initial selection of SNEDDS components must be based on their ability to 
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dissolve the model drug as well as their ability to form spontaneous nanoemulsion upon 
contact with aqueous medium. Also, the phase behavior of the constituents should be 
evaluated to determine different phases and phase transitions. Plotting of ternary phase 
diagrams is important to identify the self-nanoemulsification areas where spontaneous 
nanoemulsions with droplet size of less than 100 nm can be produced. In addition, the 
effect of the presence of the drug on the size of self-nanoemulsification zones in ternary 
phase diagrams should be evaluated, because some drugs may reduce the size of these 
regions. Therefore, optimization of SNEDDS and finalizing its composition are based on 
determination of the self-nanoemulsification areas as well as evaluation of phase 
behavior (Date et al., 2010).  Other optimization techniques of SNEDDS composition, 
such as statistical experimental design and response surface methodology, can be 
applied with lesser number of experiments (Date et al., 2010).   
Characterization of the final SNEDDS formulation for different properties must be 
also considered. Parameters such as the droplet size, polydispersity index, zeta 
potential, thermodynamic stability, self-nanoemulsification test and in vitro drug 
dissolution should be carefully evaluated. Also, the in vitro lipolysis model, which 
simulates digestion in the small intestine, can be used to study the digestion of SNEDDS 
formulations in addition to their tendency to precipitation. Application of in vitro lipolysis 
model is useful for optimization of SNEDDS formulations before in vivo studies and also 
to establish in vivo / in vitro correlation (Date et al., 2010).  
In this part of the study, development of indomethacin-loaded SNEDDS 
formulations will be carried out utilizing different combinations of oils, surfactants and co-
surfactants aiming to enhance the solubility of the poorly soluble model drug, 
indomethacin.  Composition of different formulations will be optimized using drug 
solubility, ternary phase diagram, self-nanoemulsification test and system stability. The 
formulated systems will be characterized for droplet size, polydispersity index and zeta 
potential. 
3.2. Materials 
• Indomethacin was obtained from Sigma-Aldrich Chemie GmbH, Germany. 
• CapryolTM 90 (propylene glycol monocaprylate), LabrafacTM lipophile WL 1349 
(medium chain triglyceride), Labrafil® M 2125 CS (polyoxylglyceride), and 
Transcutol® HP (diethylene glycol monoethyl ether) were kindly provided by 
Gattefosse Co., France. 
• Cremophor® RH 40 (polyoxyl 40 hydrogenated castor oil) was kindly provided by 
BASF Co. (Germany). 
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• Tween® 20 (polysorbate 20) was obtained from BDH Laboratory Supplies, Poole, 
England.  
• Tween® 80 (polysorbate 80) was obtained from Sigma-Aldrich Chemie GmbH, 
Germany. 
• PEG 400 (polyethylene glycol 400) was obtained from BDH Laboratory Supplies, 
Poole, England. 
• Propylene glycol was obtained from Riedel-de Haen AG, Sleeze – Hannover, 
Germany. 
• Hydrochloric acid was obtained from Fisher Scientific UK Limited, Leicestershire, 
UK.  
• Methanol was obtained from Fisher Scientific UK Limited, Leicestershire, UK.  
3.3. Methods 
3.3.1. Construction of standard calibration curve of indomethacin in 
methanol 
A stock solution of indomethacin (100 mg / 100 ml) was prepared in methanol. 
Diluted indomethacin solution (10 mg / 100 ml) in methanol was prepared from the stock 
solution. Then, serial dilutions were prepared from that diluted indomethacin solution in 
methanol to obtain different concentrations ranging from 2.5 to 45 µg/ml. The 
absorbance of these serial dilutions was determined spectrophotometrically at λmax 320 
nm, using methanol as a reference. Each sample was analyzed in triplicate and the 
results are presented as mean ± SD. The measured absorbance was plotted against the 
corresponding concentrations to obtain the standard calibration curve.   
The inter-day accuracy of the assay method for determination of indomethacin 
concentrations was assessed by calculating the % recovery of three different 
concentrations (10, 20, and 30 µg/ml) of the drug solution on different days. Three 
readings were recorded for each sample in methanol at λmax 320 nm. The readings were 
fitted into the regression equation and the % recovery was calculated according to 
following equation:   
 % 𝑟𝑐𝑐𝑐𝑟𝑐𝑟𝑟 = 𝑟𝑐𝑐𝑐𝑟𝑐𝑟𝑐𝑑 𝑐𝑟 𝑓𝑐𝑑𝑐𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑟𝑡𝑑𝑖𝑐𝑐
𝑡𝑑𝑑𝑐𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑟𝑡𝑑𝑖𝑐𝑐   × 100   (Equation 3.1) 
Following the method of Sawant et al. (2010), the intra-day and inter-day 
precision (reproducibility) of the assay method was evaluated by calculating the % 
relative standard deviation (%RSD) obtained on measuring the absorbance of three 
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different concentrations (10, 20, and 30 µg/ml) of the drug solution prepared and 
analyzed on the same day (three sets) or on different days (five sets).    
3.3.2. Determination of indomethacin solubility in various components 
The solubility of indomethacin in different oils, surfactants, co-surfactants, or 
mixtures of oils and surfactants was determined according to the method of Date and 
Nagarsenker (2007). An excess amount of the drug was added to 2 g of each of the 
selected excipients (or blends of excipients) in screw capped glass vials. The samples 
were mixed by vortexing to enable proper mixing of the drug with the vehicles. The vials 
were shaken for 48 hours in an isothermal shaking water bath adjusted at 25 oC. 
Equilibrated samples were then centrifuged at 5000 rpm for 15 minutes to remove 
undissolved drug. The supernatant was aspirated and filtered through a 0.45 µm 
membrane filter. Aliquots of the supernatant were diluted properly with methanol and the 
concentration of indomethacin was determined spectrophotometrically at 320 nm against 
a blank prepared from each excipient in methanol. Tests were repeated in triplicate and 
the results are presented as mean ± SD. 
3.3.3. Screening of surfactants for emulsifying ability 
Different surfactants were evaluated for their emulsification ability by mixing the 
surfactant with the selected oily phase in a 1:1 weight ratio following the method of Date 
and Nagarsenker (2007). The mixtures were homogenized by vortexing, and 100 mg of 
each mixture was accurately weighed and added to 20 ml distilled water (200 fold 
dilution) in a volumetric flask. The ease of formation of emulsion was assessed by 
observing the number of inversions of the volumetric flask required to obtain a uniform 
emulsion. The resulting emulsion was also examined visually for relative turbidity 
according to different grading systems described by Khoo et al. (1998) which can be 
summarized as follows: 
• Grade A: indicates rapid formation of clear or slightly bluish nanoemulsion that 
emulsifies within 1 minute. 
• Grade B: denotes rapid formation of less clear or bluish white nanoemulsion that 
emulsifies within 2 minutes.  
• Grade C: reveals formation of bright white, milky emulsion that emulsifies within 2 
minutes. 
• Grade D: indicates formation of dull, greyish emulsion that emulsifies slowly (more 
than 2 minutes). 
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• Grade E: represents formulations with poor emulsification and large oil globules 
present on the surface. 
Mixtures that showed grades A and B upon dilution were assigned for further 
evaluation.     
3.3.4. Screening of co-surfactants for emulsifying ability 
The relative efficacy of co-surfactants (or co-solvents) to improve emulsification 
ability of surfactants was also evaluated according to the method of Date and 
Nagarsenker (2007). Mixtures of the selected oily phase, surfactants and co-surfactants 
(or co-solvents) were mixed and homogenized at a ratio of 3:2:1, respectively. Hundred 
milligrams of each mixture was accurately weighed and added to 20 ml distilled water 
(200 fold dilution).  The relative turbidity and the ease of formation of the resulting 
emulsion were assessed as described above for screening of surfactants.  
3.3.5. Construction of ternary phase diagrams 
Ternary phase diagrams were constructed to identify the regions in which the 
formulations could self-emulsify upon dilution and gentle agitation. Also, construction of 
ternary phase diagrams may be beneficial to determine the relative amounts of different 
components of SEDDS; oil phase, surfactant and co-surfactant (Balakrishnan et al., 
2009a, Kommuru et al., 2001).  
Based on the solubility study of indomethacin, Capryol™ 90 was chosen as the 
oil phase. Tween® 80, Tween® 20 and Cremophor® RH 40 were used as surfactants 
whereas Transcutol® HP was employed as a co-surfactant. Distilled water was used as 
the aqueous phase for development of these phase diagrams. According to the method 
of Shafiq et al. (2007) and Shafiq-un-Nabi et al. (2007), ternary phase diagrams were 
constructed in the absence of indomethacin to identify the self-emulsifying regions. 
Different combinations of the oil phase, surfactants and co-surfactants were prepared 
and could be grouped into 3 groups (Table 3.1). Surfactants and co-surfactants (Smix) in 
each group were mixed in different weight ratios (1:0, 1:1, 1:2, 1:3, 2:1, 3:1, and 4:1) so 
that the concentration of surfactant increases with respect to co-surfactant and the 
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Table   3.1 Different combinations of oil, surfactants and co-surfactant used in 
construction of phase diagrams 
Group  Oil  Surfactant Co-surfactant 
I Capryol™ 90 Tween® 80 Transcutol®  HP 
II Capryol™ 90 Tween® 20  Transcutol®  HP 
III Capryol™ 90 Cremophor® RH 40  Transcutol®  HP  
 
For each phase diagram, oil (Capryol™ 90) and specific Smix ratio were 
prepared and mixed thoroughly in different weight ratios of 0.9:0.1, 0.8:0.2, 0.7:0.3, 
0.6:0.4, 0.5:0.5, 0.4:0.6, 0.3:0.7, 0.2:0.8, and 0.1:0.9 in suitable glass vials. Phase 
diagrams were constructed using the water titration method, in which each combination 
of oil and Smix was slowly titrated with water. Hundred microliter portions of distilled 
water were added, at room temperature (25 ± 2oC), to the oil and surfactant mixture to 
produce a water concentration ranging from 9% to 95% w/w. After each water addition, 
the mixtures were vortexed for 10 to 20 seconds and visual observations were recorded 
for the following physical states (Figure 3.1): 
1. Transparent, easily flowable nanoemulsion (NE). 
2. Transparent, non-flowable gel or nanogel (NG). 
3. Milky (cloudy), easily flowable emulsion (E). 
4. Milky non-flowable emulsion or emulgel (EG). 
 
Figure  3.1 Different physical states recorded from ternary phase diagram (NE = 
Nanoemulsion, NG = Nanogel, EG = Emulgel, and E = Emulsion). 
 
For each Smix ratio, the different physical states were marked on a three 
component phase diagram, with one axis representing the oil phase, the second 
representing the mixture of surfactant and co-surfactant (Smix) and the third 
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representing the aqueous phase. All experiments were repeated in duplicate and similar 
observations were recorded between repeats.      
Ternary phase diagrams were plotted using Ternary 1.37 software (ZetaWare, 
USA).  
3.3.6. Selection of formulations from phase diagrams 
Selection of different formulations from the nanoemulsion region, in specific 
phase diagrams, was based on different oil compositions. In order to cover the entire 
range of the nanoemulsion region in each specific phase diagram, different oil 
compositions of 30 % and 50 % were selected and the concentration of the 
surfactant/co-surfactant (Smix) was calculated according to their ratios. 
3.3.7. Effect of the drug on phase behaviour of formulations selected from 
phase diagrams  
The effect of the presence of the drug on phase behaviour was investigated by 
dissolving 25 mg of indomethacin in selected formulations from each phase diagram. For 
this purpose, water was added in increasing increments and the new percentages of oil, 
Smix and water were re-calculated and then re-fitted in the specific phase diagram. 
Observation of any changes in phase behavior was recorded for each formulation.    
3.3.8. Determination of indomethacin solubility in selected formulations 
An excess quantity of indomethacin was added to ternary formulations selected 
from the nanoemulsion regions in phase diagrams. Blank ternary systems were first 
prepared by mixing the oil phase with the surfactant/co-surfactant mixture. The excess 
amount of the drug was added to prepared blank systems and mixed by vortexing. The 
formed suspensions were shaken for 48 hours at 25 oC in an isothermal shaking water 
bath. Equilibrated mixtures were then centrifuged at 5000 rpm for 15 minutes to remove 
undissolved drug. The supernatant was aspirated, filtered through a 0.45 µm membrane 
filter, suitably diluted with methanol and the concentration of indomethacin was 
determined spectrophotometrically at 320 nm, against a blank prepared from each 
mixture in methanol. Triplicate samples were analyzed and the results presented as 
mean ± SD. 
3.3.9. Preparation of drug-loaded self-nanoemulsifying formulations 
Indomethacin at a drug loading concentration of 2.5% w/w was added to selected 
blank ternary formulations. The 2.5% w/w drug loading in SNEDDS reflects the 
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indomethacin therapeutic dose (25 mg) in a reasonably small volume (approximately 1 
ml). Final mixtures were mixed by vortexing until clear systems were obtained. Systems 
containing indomethacin were shaken for 24 hours at 25 oC in an isothermal shaking 
water bath to ensure complete solubilization.      
3.3.10. Thermodynamic stability tests 
According to the methods of Shakeel et al. (2009) and Shafiq et al. (2007), 
prepared formulations were subjected to thermodynamic stress tests to eliminate 
metastable, unstable and biphasic formulations.  
3.3.10.1. Centrifugation  
Prepared self-emulsifying formulations were centrifuged at 5000 rpm for 15 
minutes. Formulations that did not show phase separation were subjected to the heating 
– cooling test.  
3.3.10.2. Heating cooling cycle  
Formulations that passed the centrifugation test were subjected to six cycles 
between cooling (4oC) and heating (45oC) with storage at each temperature for not less 
than 48 hours. Formulations which were stable at these temperatures and did not show 
any phase separation were evaluated for freeze – thawing test.   
3.3.10.3. Freeze-thaw cycle 
In this stress test, formulations were exposed to three cycles of freezing and  
thawing between –21 oC and +25 oC, with storage for periods of not less than 48 hours at 
each temperature.  
Formulations that passed thermodynamic stress tests were taken for self-
nanoemulsification tests.  
3.3.11. Self-nanoemulsification efficiency tests 
Evaluation of the efficiency of self-nanoemulsification of different drug-loaded 
liquid SNEDDS was carried out to investigate any drug precipitation that may take place 
upon dilution of formulations with different diluents such as deionized water and 0.1 N 
HCl. This test was performed as similarly described for screening of surfactants and co-
surfactants emulsifying ability. One milliliter of each drug-loaded self-emulsifying 
formulation was diluted with deionized water or 0.1 N HCl at a dilution ratio of 1:200. The 
self-nanoemulsification performance of each formulation was evaluated visually 
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according to different grading systems described by Khoo et al. (1998) and summarized 
earlier. 
Formulations that showed grades A and B upon dilution were subjected for further 
evaluation.   
3.3.12. Characterization of indomethacin-loaded SNEDDSs 
3.3.12.1. Measurement of particle size 
Mean particle size and polydispersity index (PDI) of selected formulations were 
determined by photon correlation spectroscopy using Malvern Zetasizer Nano-ZS. 
Photon correlation spectroscopy utilizes the Brownian motion of the particles to analyze 
the fluctuations in light scattering that take place due to this motion. Light scattering was 
measured at a scattering angle of 90o and a temperature of 25oC. Samples of 
indomethacin-loaded SNEDDS were suitably diluted with deionized water (1:200), 
filtered through a 0.45 µm membrane filter, and then filled into an acrylic cuvette for 
measurement.  All experiments were repeated thrice and the values of z-average 
diameter were used.    
In this study, Malvern Zetasizer Nano-ZS, which is based on dynamic light 
scattering (DLS) technique, was used to measure the droplet size of diluted 
indomethacin-loaded SNEDDS.  Dynamic light scattering measures the Brownian motion 
of the particles and relates it to size of the particles. As smaller particles move faster and 
larger particles move slower, the Zetasizer uses thise information to relate the speed of 
Brownian motion of the particles to their size. According to Pecora (2000), particles are 
illuminated with a source of light (laser) in DLS technique and the intensity of fluctuation 
of scattered light is analyzed by the instrument to calculate a correlation function that can 
be used to obtain the size distribution of the sample. 
The polydispersity index (PDI) is another important parameter that can be 
determined by Zetasizer. According to Liu et al. (2009), this parameter has to be 
evaluated especially in a multimodal distribution to describe the diameter distribution in a 
sample of SNEDDS dispersed in aqueous media. The value of polydispersity index 
indicates uniformity in droplet size distribution within the formulation.  
3.3.12.2. Measurement of zeta potential 
Measurement of the value of zeta potential gives an indication of stability of self-
emulsifying formulations, which is directly related to the magnitude of surface charges on 
emulsion droplets (Balakumar et al., 2013). The zeta potential of selected formulation 
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was determined using Malvern Zetasizer Nano-ZS. Samples were properly diluted with 
deionized water (1:200) and filtered through a 0.45 µm membrane filter before 
measurement.    
3.3.12.3. Transmission electron microscopy (TEM) studies 
Studies using transmission electron microscopy (TEM) were conducted to reveal 
morphology and structure of the nanoemulsions produced from selected self-emulsifying 
formulations. To perform TEM experiments, samples of indomethacin-loaded SNEDDS 
were diluted with deionized water to a ratio of 1:200 and filtered through a 0.45 µm 
membrane filter. A drop of the diluted formulation was directly deposited on coated 
copper grids with a mesh size of 300 and stained with one drop of 1% uranyl acetate. 
The coated grid was left to dry for 30 seconds and then observed for TEM (Philips CM 
120 BioTwin, USA) equipped with AMT software.        
3.3.13. Statistical analysis 
Solubility data and characterization parameters were statistically evaluated using 
one way analysis of variance (ANOVA) with t-test. Significant differences were 
determined at a 5% significance level, unless otherwise stated elsewhere. Statistical 
differences yielding (p < 0.05) were considered significant.   
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3.4. Results and Discussion 
3.4.1. Standard calibration curve of indomethacin in methanol 
The standard calibration curve of indomethacin was constructed in methanol to 
obtain different concentrations ranging from 2.5 to 45 µg/ml, for which the absorbance 
readings were determined spectrophotometrically at λmax 320 nm (Table 3.2 and Figure 
3.2). The standard calibration curve was linear over the concentration range studied and 
obeys Beer-Lambert’s law with a correlation coefficient (r2) 0.999. The corresponding 
regression equation was found to be Y = 0.0179X – 0.0043.  
Table  3.2 Data of the standard calibration curve of indomethacin in methanol 
assayed spectrophotometrically at λmax 320 nm 
Concentration (µg/ml) Mean absorbance ±SD (n = 3) 
2.5 0.051 ± 0.003 
5 0.089 ± 0.002 
10 0.172 ± 0.001 
15 0.263 ± 0.003 
20 0.335 ± 0.002 
25 0.433 ± 0.002 
30 0.53 ± 0.005 
35 0.619 ± 0.004 
40 0.719 ± 0.003 
45 0.811 ± 0.002 
 




Figure  3.2 Standard calibration curve of indomethacin in methanol assayed 
spectrophotometrically at λmax 320 nm. (Small standard deviation bars are 
added but can’t be visualized relative to the marker size).   
 
Determination of the accuracy of the spectrophotometric measurement indicated 
that the % recoveries of indomethacin for the three concentrations (97.48% – 101.47%) 
with small %RSD values (0.44 – 1.38) were satisfactory for this analytical method. In 
addition, the %RSD values for the inter-day and intra-day precision varied from 1.07 – 
2.13, and 0.17 – 1.17, respectively.  The values of %RSD obtained for accuracy and 
precision of the assay remained within 5% which is acceptable according to ICH 
guidelines on validation of analytical procedures (ICH, 2005, Nováková et al., 2005).  
3.4.2. Solubility studies 
Results of the solubility testing of indomethacin in different oils, surfactants, co-
surfactants and water are shown in Figure 3.3. It is apparent that indomethacin was 
more soluble in various vehicles used compared to its resulting solubility in water (0.02 ± 
0.01 mg/g).   
y = 0.0179x - 0.0043 


































Figure  3.3 Solubility of indomethacin in different oils, surfactants, and co-surfactants 
at 25oC. (Mean ± SD, n=3). 
 
Figure 3.3 shows the solubility of indomethacin in three different oily phases with 
varying hydrocarbon chain lengths (C8 to C18) namely: CapryolTM 90 (C8 propylene glycol 
monocaprylate, HLB = 5), LabrafacTM lipophile WL 1349 (medium chain triglyceride, HLB 
= 1), and Labrafil® M 2125 CS (C18 polyoxylglyceride, HLB = 9).   
Among the three tested oils, indomethacin exhibited a significantly higher 
solubility (p < 0.05) in CapryolTM 90 (20.64 ± 1.97 mg/g) compared to LabrafacTM lipophile 
WL 1349 (3.66 ± 0.07 mg/g) or Labrafil® M 2125 CS (9.90 ± 0.35 mg/g). The higher drug 
solubility in CapryolTM 90 could be attributed to its HLB value and carbon chain length. 
Similar findings were reported for improved solubility of tamoxifen citrate in CapryolTM 90 
compared to that obtained in LabrafacTM lipophile WL 1349 (Elnaggar et al., 2009).  
CapryolTM 90 has a higher HLB value (HLB = 5) compared to the highly lipophilic 
LabrafacTM lipophile WL 1349 (HLB = 1) and also possesses medium carbon chain 
length compared to Labrafil® M 2125 CS (C18 polyoxylglyceride). It was reported that 
highly polar lipids are required for nanoemulsion formation (Kawakami et al., 2002) and 
that the polarity of lipids will decrease with increasing the length of the alkyl chain (Shen 
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Because drug loading capacity is the main factor that should be considered for 
choosing the oily phase (Duc Hanh et al., 2015, Pouton and Porter, 2008), CapryolTM 90 
was selected as the oil component to formulate indomethacin-loaded SNEDDS and 
consequently was subjected for further evaluation in presence of surfactants and co-
surfactants.  
Three non-ionic surfactants; Cremophor® RH 40 (polyoxyl 40 hydrogenated 
castor oil, HLB = 14), Tween®20 (polysorbate 20, HLB = 16.7), and Tween® 80 
(polysorbate 80, HLB = 15) were used in this study. All surfactants tested exhibited high 
solubilizing potential for indomethacin (Figure 3.3), with 92.32 ± 5.30 mg/g solubilized by 
Tween®20 , followed by 84.99 ± 4.52 mg/g solubilized by Tween® 80, and 80.15 ± 2.49 
mg/g solubilized by Cremophor® RH 40. A significant difference in solubility potential of 
the drug due to surfactants can be observed only between Tween®20 and Cremophor® 
RH 40.  
Selection of surfactants should be based on its emulsification efficiency for the 
selected oil more than its solubilizing potential for the drug (Duc Hanh et al., 2015).  
Therefore, the miscibility of the above surfactants with the selected oil (CapryolTM 90) at 
a 1:1 weight ratio was investigated according to the method reported by Balakrishnan et 
al. (2009a) and Date and Nagarsenker (2007). Emulsification studies showed that all 
tested surfactants (Cremophor® RH 40; HLB = 14, Tween®20; HLB = 16.7, and Tween® 
80 ; HLB = 15) were able to produce clear nanoemulsions with CapryolTM 90 upon 
dilution, and hence, these surfactants were employed in further studies.  
    Although surfactants provide a mechanical barrier against coalescence of 
emulsion droplets, by reducing the interfacial energy of these droplets, the system is still 
considered thermodynamically unstable and the separation of the two phases is only 
delayed (Craig et al., 1995). The use of a single surfactant may not be enough to 
achieve a transient negative interfacial energy or a fluid interfacial film. Hence, addition 
of a co-surfactant may provide sufficient flexibility to the interfacial film so that various 
curvatures can be available to form nanoemulsions over a wide range of composition 
(Rahman et al., 2013, Shafiq et al., 2007). Co-solvents can be incorporated into lipid-
based systems to act as co-surfactants, due to their ability to dissolve large quantities of 
either the drug or the hydrophilic surfactant in the lipid base (Neslihan Gursoy and 
Benita, 2004). 
Therefore, a co-surfactant; Transcutol® HP (diethylene glycol monoethyl ether, 
HLB = 4.2) and two co-solvents; polyethylene glycol 400 (PEG 400) and propylene glycol 
were evaluated in this study. From the results presented in Figure 3.3, it is obvious that 
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among all examined vehicles, Transcutol® HP showed the highest capacity to dissolve 
indomethacin (137.20 ± 4.06 mg/g).  
Results of the study of the ability of co-surfactants (or co-solvents) to improve the 
emulsification ability of surfactants are presented in Table 3.3. The co-surfactant and co-
solvents used were equivalent in improving emulsification ability of surfactants as 
demonstrated by grades A and B produced upon dilution with distilled water. 
The relatively high hydrophilicity of co-solvents (PEG 400 and propylene glycol) 
may lead to an increased risk of destroying the emulsion in comparison to when 
Transcutol® HP is used (Zhang et al., 2008). This is because the high water solubility of 
these co-solvents may cause them to redistribute between the aqueous phase and the 
emulsion–water interface upon dilution, leading to loss of solvent capacity of the vehicle 
(Patel and Vavia, 2007). Therefore, Transcutol® HP was selected as the co-surfactant to 
conduct further studies aiming to improve the drug loading capabilities and form 
spontaneous fine nanoemulsions. Transcutol® HP was reported by Sullivan et al. (2014) 
to be well tolerated orally by different animals in addition to its well-known safe use in 
food and cosmetics industry.    
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Table  3.3 Classification of systems composed of oil (Capryol™90): surfactant: co-
surfactant (or co-solvent) at a ratio of 3:2:1 as grade A and B upon dilution 
(200 fold) with distilled water. 
Surfactant Co-surfactant / co-solvent Visual grade 
Cremophor® RH 40 Transcutol® HP A* 
 PEG 400 A 
 Propylene glycol A 
Tween®20 Transcutol® HP A 
 PEG 400 A 
 Propylene glycol A 
Tween® 80 Transcutol® HP A 
 PEG 400 B* 
 Propylene glycol B 
*A = clear or slightly bluish nanoemulsion that emulsifies within 1 minute, *B = less clear or bluish  
white nanoemulsion that emulsifies within 2 minutes.  
 
 Based on the results of excipient screening, Capryol™ 90 (the oily phase), 
Cremophor® RH 40, Tween®20, and Tween® 80 (surfactants), in addition to Transcutol® 
HP (co-surfactant) were selected to formulate indomethacin-loaded SNEDDS. The 
appropriate amounts of the selected oil, surfactants and co-surfactant were determined 
by constructing phase diagrams.   
3.4.3. Construction of ternary phase diagrams 
In order to identify the self-emulsifying regions and to optimize the percentages of 
different liquid SNEDDS components, a ternary phase diagram was constructed in the 
absence of indomethacin.   
Based on the data obtained from solubility studies, Capryol™ 90 was used as the 
oil phase. Cremophor® RH 40, Tween®20, and Tween® 80 were used as surfactants; and 
Transcutol® HP was used as a co-surfactant to construct ternary phase diagram. For 
more detailed study of phase diagrams, these components were divided in different 
group combinations; Groups I to III; (Table 3.1). Different ratios of surfactant/co-
surfactant from each group were used to prepare different ternary systems. Ternary 
phase diagrams were constructed separately for each group (Figures 3.4 to 3.6) and the 
sizes of self-nanoemulsion regions were compared. Identification of optimal composition 
of formulation is based on comparison of the size of the self-nanoemusifying zones in 
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different phase diagrams. Larger self-nanoemusifying areas indicate greater self-
nanoemusification efficiency of the tested ternary formula (Duc Hanh et al., 2015).  
 
 
Figure  3.4 Ternary phase diagram of group I at different Smix (Tween®80; Tw80; & 
Transcutol® HP; THP) ratios. 
 




Figure  3.5 Ternary phase diagram of group II at different Smix (Tween®20; Tw20; & 
Transcutol® HP; THP) ratios. 




Figure  3.6 Ternary phase diagram of group III at different Smix (Cremophor®RH40; 
CrRH40; & Transcutol®HP; THP) ratios. 
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In Figure 3.4 (a) it can be seen that when Tween® 80 was used alone, a good 
size of nanoemulsion region along with small nanogel and emulgel areas were observed. 
Addition of a co-surfactant (Transcutol HP) to Tween® 80 in equal amounts (Smix ratio 
1:1) produced a reduction in the nanoemulsion region and a disappearance of the 
nanogel and emulgel areas (Figure 3.4 (b)). The nanoemulsion region was further 
decreased upon increasing the co-surfactant concentration to Smix ratio of 1:2 (Figure 
3.4 (c)) or 1:3 (Figure 3.4 (d)), in comparison to the ratio of 1:1.  This can be explained 
on the basis of reduction of surfactant content with increasing co-surfactant 
concentration (Duc Hanh et al., 2015). On the other hand, increasing the concentration 
of the surfactant with respect to co-surfactant (Smix ratio 2:1) showed an improvement of 
the nanoemulsion area (Figure 3.4 (e)) compared to the 1:1 ratio. Further increases in 
the area of nanoemulsification were observed upon increasing the concentration of the 
surfactant in the Smix to the ratio of 3:1 (Figure 3.4 (f)) or 4:1 (Figure 3.4 (g)). In 
addition, a small emulgel area was observed with the Smix ratio of 3:1 (Figure 3.4 (f)) 
while small nanogel and emulgel areas were apparent with the Smix ratio of 4:1 (Figure 
3.4 (g)).  Hence, surfactant/co-surfactant (Smix) ratios of 1:0, 2:1, 3:1, and 4:1 were 
selected from Group I for further evaluation, because of good size nanoemulsion areas. 
In the case of Group II illustrated in Figure 3.5 (a – g), smaller nanogel and 
emulgel areas and a reasonable nanoemulsion region were noticed when Tween® 20 
was used alone (Figure 3.5 (a)). Inclusion of co-surfactant with the surfactant at a ratio 
of 1:1 resulted in removal of nanogel and emulgel areas with slight reduction in the 
nanoemulsification area (Figure 3.5 (b)). Further reduction in the nanoemulsion area 
was observed upon increasing co-surfactant concentration to the ratios of 1:2 (Figure 
3.6 (c)) and 1:3 (Figure 3.5 (d)).  Also, increasing the concentration of surfactant in Smix 
with respect to co-surfactant to 2:1 ratio (Figure 3.5 (e)) decreased the nanoemulsion 
area compared to 1:1 ratio. Additional increase in surfactant concentration (Figure 3.5 (f 
and g)) showed smaller extent of improvement in the nanoemulsion region. Therefore, 
the surfactant/co-surfactant (Smix) ratios 1:0 and 1:1 were chosen for further studies, 
since the size of the nanoemulsion region was optimum with these ratios.    
Phase diagrams of Group III are shown in Figure 3.6 (a – g). The combination of 
Cremophor® RH 40 (surfactant) with Capryol™ 90 (oil phase) produced large nanogel 
and emulgel areas (Figure 3.6 (a)) and hence, small nanoemulsion region. When the co-
surfactant was included with the surfactant in equal amounts (Figure 3.6 (b)), the 
nanogel and emulgel areas changed to easily flowable nanoemulsion region. This could 
be explained on the basis that the co-surfactant may cause the oil phase to penetrate 
into the hydrophobic portion of the surfactant. As a result, further reduction of the 
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interfacial tension is attained and consequently the fluidity of the system increases 
(Shafiq et al., 2007). Doubling the concentration of the co-surfactant (Smix 1:2 ratio) led 
to reduction in the area of nanoemulsion region (Figure 3.6 (c)) compared to 1:1 ratio. 
This could be due to reduction of the surfactant concentration brought by increasing the 
content of co-surfactant. (Duc Hanh et al., 2015). Further reduction in the area of 
nanoemulsification was observed with further increase in co-surfactant concentration to 
Smix ratio 1:3 (Figure 3.6 (d)). In contrast, increasing surfactant concentration with 
respect to co-surfactant (Smix ratio 2:1) cause a notable increase in the area of 
nanoemulsification, compared to ratio 1:1 (Figure 3.6 (e)). Additional increase in 
surfactant amount to Smix ratio 3:1 (Figure 3.6 (f)) also increased the area of 
nanoemulsion region. However, increasing the Smix ratio to 4:1 resulted in small 
reduction in nanoemulsion region (Figure 3.6 (g)) which indicates that optimum 
emulsification was attained. 
Therefore, surfactant/co-surfactant (Smix) ratios of 2:1 and 3:1 were selected as 
optimal ratios from Group III because of maximum nanoemulsification produced by these 
Smix ratios.                
Comparing the size of the nanoemulsion regions, it appears that the self-
nanoemulsifying properties of ternary formulations containing Cremophor® RH 40 are 
better than those obtained when Tween® 80 or Tween® 20 were used. Although these 
surfactants possess high HLB values, the difference in their self-nanoemulsifying 
properties could be due to differences in their structure and chain length (Date and 
Nagarsenker, 2007). Also, differences in lipid – surfactant affinity may contribute to 
different self-emulsifying abilities (Sánchez et al., 2001).  
In addition, it is obvious from phase diagrams plotted for Tween® 80 or 
Cremophor® RH 40 (Groups I and III, Figures 3.4 and 3.6) that increasing the content of 
the surfactant led to increased clarity of the produced emulsions which was observed 
visually. This is because increasing the concentration of surfactant at the interface may 
reduce the oil content and hence the size of generated emulsion particles which may 
reflect on more clarity of the formulation (Levy and Benita, 1990). However, reduced 
clarity of ternary formulations prepared using Tween 20 (Group II, Figure 3.5) was 
observed upon increasing their content of surfactant. This may be due to the fact that 
increasing surfactant concentration may facilitate water penetration into oil droplets 
leading to their disruption and ejection of oil droplets into the aqueous phase (Pouton, 
1997). Similar observations were reported in different studies of self-emulsifying systems 
(Kommuru et al., 2001, Parmar et al., 2011, Wang et al., 2009).  
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The high HLB surfactants employed in this study (Tween® 80; HLB = 15, 
Tween®20; HLB = 16.7 and Cremophor® RH 40; HLB = 14) were mixed with low HLB co-
surfactant (Transcutol®HP, HLB = 4.2) in order to formulate more stable self-emulsifying 
formulations. The co-surfactant is reported to penetrate into the surfactant film and 
create void spaces among the molecules which may lead to increased interfacial fluidity 
of surfactant boundaries (Constantinides and Scalart, 1997).       
3.4.4. Selection of formulations from ternary phase diagram 
Because no clear basis has been reported in the literature for the selection of 
nanoemulsion formulations from the phase diagram, it is possible to prepare many 
different formulations from the nanoemulsion region of the diagram (Shafiq et al., 2007). 
Based on the results obtained from constructing ternary phase diagram, it is obvious that 
optimal nanoemulsion zones can be obtained by different Smix ratios prepared from 
each group of components (Groups I to III). The Smix ratios that produced maximum 
area of nanoemulsion region were selected for preparation of indomethacin-loaded 
SNEDDS using different groups of components.  
Based on the results obtained from the constructed phase diagrams, it can be 
seen that Smix ratios of 1:0, 2:1, 3:1, and 4:1 from Group I (containing Tween® 80), Smix 
ratios of 1:0 and 1:1 from Group II (containing Tween® 20), and Smix ratios of 2:1 and 
3:1 from Group III (containing Cremophor® RH 40) resulted in optimum emulsification. 
Therefore, these eight mixtures of different combinations of surfactants and co-
surfactants were employed for this study.   
In order to cover the entire range of self-nanoemulsification occurrence in each 
phase diagram, different oil compositions of 30% w/w and 50% w/w were selected. The 
composition of selected formulations is illustrated in Table 3.4.  
Prior to formulation of drug-loaded SNEDDS, the effect of incorporation of 
indomethacin on phase behavior of the selected formulations was investigated. It was 
found that the addition of indomethacin did not affect phase behavior of selected 
formulations or the nanoemulsion area of phase diagrams. Similar findings were reported 
by Shafiq et al. (2007) upon construction of phase diagrams of ramipril nanoemulsions.  
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Table  3.4 Composition of selected self-nanoemulsifying formulations  












F1 50 50 -- 1:0 
F2 30 70 -- 1:0 
F3 50 33.4 16.6 2:1 
F4 30 46.7 23.3 2:1 
F5 50 37.5 12.5 3:1 
F6 30 52.5 17.5 3:1 
F7 50 40 10 4:1 





F9 50 50 -- 1:0 
F10 30 70 -- 1:0 
F11 50 25 25 1:1 





F13 50 33.4 16.6 2:1 
F14 30 46.7 23.3 2:1 
F15 50 37.5 12.5 3:1 
F16 30 52.5 17.5 3:1 
 
3.4.5. Determination of indomethacin solubility in selected formulations 
The saturated solubility of indomethacin in different self-emulsifying formulations 
(F1 to F16) was determined as described earlier in experimental section, and the results 
are presented in Table 3.5. 
From the results presented in Table 3.5, it is clear that the solubility of 
indomethacin in selected SNEDDS increased by about 1500 to 2000 fold compared to its 
solubility in water. Therefore, using SNEDDS proved to enhance the solubilization 
capacity of indomethacin. However, no significant difference was detected (p > 0.05) in 
maximum drug loaded into different SNEDDS formulations studied here.  
Upon visual examination of the results, it was also noticed that the solubility of 
indomethacin in different self-emulsifying formulations increased with increasing the 
content of both oil and surfactant. This observation was more obvious in formulations 
F15 & F16.  It appeared that formulations containing 50% of oil showed higher 
indomethacin solubility than those containing 30% of oil. This may be due to high affinity 
of the drug to the oil. Also, self-emulsifying systems prepared with high content of 
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surfactant showed better indomethacin solubilizing capacity. These findings are in 
disagreement with those obtained for formulating SMEDDS of antitumor agent, oridonin 
(Liu et al., 2009).  
It is obvious that the minimal indomethacin saturated solubility observed for the 
selected formulations was 30.78 ± 2.04 mg/g. However, a fixed indomethacin 
concentration of 2.5% w/w (25 mg/g) was selected to be loaded in all self-emulsifying 
formulations. This concentration reflects the indomethacin therapeutic dose (25 mg) and 
is lower than the minimal saturated solubility observed here. Accordingly, it was 
expected to provide spontaneous emulsification of SNEDDS with a low tendency of drug 
precipitation upon aqueous dilution. Also, using fixed concentration of indomethacin in all 
formulations was proposed to exclude the effect of varying the drug concentration on the 
self-emulsifying efficiency of the systems.  
It was reported that increased drug loading in SNEDDS above the saturated 
solubility of the drug may result in increased droplet size (Wang et al., 2009). This was 
attributed to the fact that high drug concentration may cause precipitation and deposition 
of drug particles in the oil-water interface causing rigid and less flexible films that could 
hinder spontaneous emulsification of the SNEDDS (Wang et al., 2009, Park and Kim, 
1999).      
3.4.6. Formulation and thermodynamic stability studies of indomethacin-
loaded self-emulsifying formulations  
Indomethacin was loaded in a 2.5% w/w concentration to all selected self-
emulsifying systems (F1 to F16). The prepared formulations were kept in closed 
containers and tested for thermodynamic stability. 
Thermodynamic stability studies were carried out to determine the effects of 
temperature variation and centrifugation on precipitation or phase separation of the 
formulated SNEDDSs (Duc Hanh et al., 2015).  
It was found that all tested self-emulsifying formulations (F1 to F16) were stable 
and did not show evidence of phase separation in the centrifugation stress test. Also, no 
precipitation of indomethacin or phase separation was observed following cooling – 
heating or freezing – thawing cycles (Table 3.5). Therefore, all tested formulations (F1 to 
F16) were taken for self-nanoemulsification efficiency testing.  
3.4.7. Self-nanoemulsification efficiency tests 
In this study, self-nanoemulsification efficiency tests (or dispersibility tests) were 
carried out to evaluate any drug precipitation or phase separation upon dilution with 
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deionized water or 0.1N HCl. The results of these tests are shown in Table 3.5. No 
significant difference was observed in self-nanoemulsification performance between 
formulated SNEDDSs dispersed in either deionized water or 0.1 N HCl. Similar findings 
were reported for glibenclamide-loaded nanoemulsions (Shakeel et al., 2013), 
rosuvastatin calcium–loaded SNEDDS (Balakumar et al., 2013), and phyllanthin-loaded 
SMEDDS (Duc Hanh et al., 2015).  
Formulated SNEDDSs that passed this test in grades A and B were chosen for 
further evaluation. Formulations with grades A and B are expected to remain as 
SNEDDSs upon dispersion in GI fluids (Shakeel et al., 2013b).   
  
  




Table  3.5 Saturated solubility, thermodynamic stability and dispersibility of 
indomethacin in selected self-emulsifying formulations 










































Group I F1 34.78 ± 1.84     B B 
F2 30.78 ± 2.04    B B 
F3 36.63 ± 2.28    B B 
F4 34.50 ± 0.79    B B 
F5 40.65 ± 1.57     B B 
F6 38.53 ± 1.44    B B 
F7 42.18 ± 1.29    B B 
F8 40.23 ± 0.65    B B 
Group II F9 41.42 ± 1.48    B B 
F10 36.35 ± 0.94    B B 
F11 43.16 ± 0.89     B B 
F12 36.78 ± 0.44    B B 
Group III F13 38.92 ± 0.89      A A 
F14 34.88 ± 0.83    A A 
F15 45.45 ± 1.23    A A 
F16 34.21 ± 0.59    A A 
SD = Standard deviation. 
3.4.8. Characterization of indomethacin-loaded SNEDDS 
3.4.8.1. Measurement of particle size  
The mean droplet size and polydispersity index (PDI) determined for different 
indomethacin-loaded SNEDDS (F1 to F16) are shown in Table 3.6.  
Incorporation of different surfactants into indomethacin-loaded SNEDDS 
formulations resulted in significantly different droplet size (p < 0.05); as revealed by one-
way ANOVA with t-test.  Among the tested formulations, SNEDDS formulations prepared 
with Cremophor® RH 40 and Transcutol® HP as surfactant and co-surfactant, 
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respectively, showed a significantly smaller droplet size (p < 0.05) compared to other 
formulations prepared with Tween® 80 and Tween® 20 as surfactants. 
 
Table  3.6 Mean droplet size, polydispersity index (PDI) and zeta potential of 
indomethacin-loaded liquid SNEDDS formulations (n=3) 
Group Code  Mean droplet 
size (nm) ± SD 




Group I F1 102.05 ± 1.20 0.531 ± 0.008 -16.4  4.5 
F2 150.05 ± 0.64  0.449 ± 0.005 -17.2  4.0 
F3 88.06 ± 0.28 0.464 ± 0.004 -25.5  5.2 
F4 133.95 ± 0.21 0.489 ± 0.008 -21.6  4.8 
F5 98.465 ± 0.91 0.492 ± 0.004 -22.4  4.5 
F6 130.90 ± 1.98 0.453 ± 0.006 -19.8  4.4 
F7 109.65 ± 0.92 0.448 ± 0.001 -21.7  4.1 
F8 136.55 ± 0.49 0.518 ± 0.002 -19.7  4.4 
Group II F9 213.85 ± 1.63 0.391 ± 0.003 -26.8  4.9 
F10 176.75 ± 9.69 0.651 ± 0.039 -33.9  6.5 
F11 234.90 ± 5.52 0.353 ± 0.038 -29.4  4.5 
F12 323.60 ± 0.14 0.296 ± 0.001 -36.0  4.8 
Group III F13 71.44 ± 0.92 0.238 ± 0.001 -22.8  8.1 
F14 20.68 ± 0.03 0.110 ± 0.020 -25.2  8.3 
F15 70.34 ± 0.98 0.265 ± 0.001 -31.5  8.0 
F16 22.69 ± 0.06 0.130 ± 0.004 -16.2  9.9 
   
It can be noted that formulations prepared with a high percentage (50%) of oil 
phase (Capryol™ 90) showed smaller droplet diameters compared to formulations 
prepared with lower oil content (30%). Larger droplets obtained with low oil 
concentrations may be because formulations prepared with lower oil content may 
consequently contain higher proportions of the surfactant/co-surfactant mixture. Higher 
surfactant concentrations relative to the oil phase may in turn give multiple micelles or 
closely packed surfactant molecules around the particles which may lead to formation of 
larger dense particles.  
For SNEDDS formulations (F1 to F8) prepared with different ratios of Tween® 80 
and Transcutol® HP as surfactant/co-surfactant mixture (Smix), it was noted that 
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increasing the surfactant concentration in Smix resulted in significantly smaller droplet 
sizes, until the Smix ratio 3:1 where only a slight increase in droplet size was observed 
with further increasing concentration of surfactant. This can be explained on the basis of 
adsorption of the surfactant around the oil-water interface of a droplet with subsequent 
reduction of interfacial tension of the system (Wang et al., 2009). Also, high 
concentrations of surfactant may lead to formation of closely-packed films at the oil-water 
interface which may stabilize the oil droplets (Kommuru et al., 2001, Parmar et al., 2011). 
When the concentration of the surfactant was increased beyond that in Smix ratio of 2:1, 
an increase in droplet size was observed for formulations F5 to F8. Similar findings were 
observed with SEDDS of coenzyme Q10 (Kommuru et al., 2001), SNEDDS of ibuprofen 
(Wang et al., 2009) and lercanidipine-loaded SNEDDS (Parmar et al., 2011). The 
increase in droplet size with increased surfactant concentration can be explained based 
on the fact that high concentrations of surfactants may cause breakage of the oil-water 
interface due to increased water penetration with resultant ejection of oil droplets into the 
aqueous phase (Parmar et al., 2011). Also, increased viscosity of the system by addition 
of higher amounts of surfactant may lead to high rigidity of the interface which may 
require more energy to produce fine dispersions (Wang et al., 2009, Pouton, 1997). 
Furthermore, increasing the concentration of surfactant will subsequently decrease the 
content of the co-surfactant in the Smix leading to a decrease in the flexibility of the 
interfacial film with consequent increased bending stress and rigidity of the interface 
(Kawakami et al., 2002).   
Incorporation of co-surfactant (Transcutol® HP) in formulations F3 and F4 led to a 
reduction in their droplet size compared to formulations F1 and F2 prepared without co-
surfactant (Table 3.6). Reduction in the mean droplet size upon addition of co-surfactant 
could be due to the fact that co-surfactants may lower the bending stress of the interface 
by decreasing the interfacial tension and thus increasing fluidity of that film (Kommuru et 
al., 2001). Also, co-surfactants participate to form a mechanical barrier against 
coalescence or aggregation of dispersed particles. Moreover, depending on their 
structure and chain length, co-surfactants possess the ability to penetrate the interfacial 
surfactant monolayer which may lead to improvement of emulsification of surfactants 
(Parmar et al., 2011). 
Indomethacin self-emulsifying formulations (F9 to F12) prepared with Tween® 20 
and Transcutol® HP as the surfactant/co-surfactant mixture (Smix) exhibited larger 
droplet size compared to formulations prepared with Tween® 80 (F1 to F8) or 
Cremophor® RH 40 (F13 to F16). It is apparent that the use of different surfactants with 
different HLB values produced different droplet size of the microemulsion upon dilution. 
                                                                                                                                                         Chapter 3 
128 
 
In this study, the droplet size was smaller in formulations prepared with of Cremophor® 
RH 40, followed by those containing Tween® 80, and the largest droplet size was 
observed for systems prepared with Tween® 20.     
Similarly, Vitamin D (Guttoff et al., 2015) and Vitamin E (Saberi et al., 2013) 
loaded nanoemulsion formulations prepared with Tween® 80 showed smaller droplet size 
than nanoemulsion systems prepared with Tween® 20.    
Larger droplet size observed for self-emulsifying formulations prepared with 
Tween® 20, compared to those observed with formulations containing Tween® 80 could 
be attributed to differences in the molecular geometry of both surfactants (Saberi et al., 
2013, Guttoff et al., 2015). Molecular geometry of a surfactant can be described by a 
packing parameter, which relates the cross sectional area of the tail group to that of the 
head group of the surfactant. The packing parameter is believed to affect packing of the 
surfactant molecules at the oil-water interface, which in turn may reflect differences in 
interfacial properties such as surface energy and dynamics which affect the formation of 
ultrafine oil droplets (Guttoff et al., 2015, Hashem et al., 2011, Saberi et al., 2013).   
The differences in chemical structure between Tween® 20 and Tween® 80 might 
be also considered. Tween® 80 possesses a large cross sectional area of its 18 carbon 
atoms non-polar tail groups, therefore, it has a higher packing parameter than Tween® 
20 (12 carbon atoms). Also, Tween® 80 has unsaturated and curved (kinked) non-polar 
tail groups of long chain oleic acid, while Tween® 20 has saturated and linear non-polar 
tail groups of medium chain lauric acid. These differences will affect packing of the 
surfactant molecules at the oil-water boundaries which in turn affect the tendency of 
spontaneous formation of ultrafine oil droplets upon dilution of the formulation (Saberi et 
al., 2013, Guttoff et al., 2015, Marasini et al., 2012).     
An increased droplet size of F11 and F12 upon incorporation of the co-surfactant 
(Transcutol® HP), compared to F9 and F10 prepared without co-surfactant, was 
observed. Increased droplet size by increasing the concentration of co-surfactant could 
be due to expansion of the interfacial film produced by the co-surfactant (Gao et al., 
1998). Similar findings were reported for microemulsion systems of cyclosporine A 
prepared with Cremophor® EL as surfactant and Transcutol® HP as co-surfactant (Gao et 
al., 1998). 
  Indomethacin-loaded SNEDDS formulations (F13 to F16) prepared with 
Cremophor® RH 40 as a surfactant, and Transcutol® HP as a co-surfactant, showed the 
lowest droplet size (p < 0.05) ranging between 20.68 ± 0.03 nm and 71.44 ± 0.92 nm, 
compared to all other formulations. The droplet size distribution of nanoemulsions 
generated from these indomethacin-loaded SNEDDS formulations is presented in Figure 
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3.7. It was observed that decreasing the oil content of the formulations resulted in a 
decrease in the size of formulation droplets. Similar results were reported for 
lercanidipine-loaded SNEDDS (Parmar et al., 2011). However, formula F16 showed 
larger droplet size (22.69 ± 0.06 nm) compared to that exhibited by formula F14 (20.68 ± 
0.03 nm) although both formulations contain the same oil content. Such finding may be 
attributed to the high surfactant content used in formula F16 (Smix ratio = 3:1) compared 
to that used in formula F14. Higher surfactant concentrations may enhance water 
penetration into the oil droplets leading to interfacial disruption and subsequent expulsion 
of oil droplets into the aqueous phase (Parmar et al., 2011).     
Addition of Transcutol® HP to Cremophor® RH 40 in SNEDDS formulations of 
indomethacin (F13 to F16) could also lead to the smaller droplet size of these 
formulations. Again, Transcutol® HP may play a role in further reduction of interfacial 
tension and may provide more flexibility for the interfacial film leading to reduced droplet 
size (Shakeel et al., 2013, Bali et al., 2011). 
Overall, it appears that the smallest droplet size was obtained from systems 
prepared with Cremophor® RH 40, while those systems containing Tween® 80 or Tween® 
20 produced larger droplet sizes. The small droplet size obtained from systems 
containing Cremophor® RH 40 could be attributed to the molecular structure of the 
surfactant and co-surfactant. As reported by Nepal et al. (2010b), effective arrangement 
of the co-surfactant (Transcutol® HP) with Cremophor® RH 40 in mixed films at the oil-
water interface appears to be the reason for marked reduction of droplet size as a 
consequence of great reduction in interfacial tension.  
 




Figure  3.7 Droplet size distribution of nanoemulsions generated from indomethacin-
loaded liquid SNEDDS formulations (F13 – F16).  
3.4.8.2. Zeta potential measurements 
Another property of SEDDS to be evaluated is the zeta potential or the magnitude 
of surface charges on the surface of particles. It was reported that the surface charge 
carried by oil droplets may affect in vivo absorption of the drug from the lipid-based 
formulation (Gershanik et al., 1998).  
The magnitude of zeta potential indicates the degree of repulsion between 
adjacent, similarly charged particles and can be related to stability of the SEDDS 
formulation (Bali et al., 2011, Parmar et al., 2011). High zeta potential values indicate 
stable formulations that can resist coalescence of particles, whilst formulations with low 
values of zeta potential may exhibit flocculation of particles when attraction exceeds 
repulsion (Parmar et al., 2011).  In general, formulations with zeta potential values 
between 25 and 30 mV in either charge are regarded as stable formulations (Bali et al., 
2011, Shakeel et al., 2013b). Self-emulsifying formulations possess a negative charge 
on the oil droplets due to the presence of anionic groups of free fatty acids contained in 
their composition; the oil, surfactant and co-surfactant (Balakrishnan et al., 2009b).  
The values of zeta potential of the formulated indomethacin-loaded SNEDDS (F1 
to F16) are presented in Table 3.6. The obtained high negative values of zeta potential 
                                                                                                                                                         Chapter 3 
131 
 
indicate that the tested formulations are less likely to flocculate or aggregate during 
storage or in biological environment (Bali et al., 2011).    
Therefore, SNEDDS formulations of indomethacin comprising Cremophor® RH 40 
as a surfactant and Transcutol® HP as a co-surfactant (F13 – F16) were selected among 
all formulations to be subjected for further evaluation. Formulations with Cremophor® RH 
40 exhibited the highest self-emulsification efficiency and the smallest droplet size. 
Generated nanoemulsions from diluted indomethacin-loaded SNEDDS (F13 to F16) 
possessed a mean droplet diameter in the range between 20.68 ± 0.03 and 71.44 ± 0.92 
nm with polydispersity index (PDI) between 0.11 ± 0.02 and 0.265 ± 0.001. As indicated 
by Pouton and Porter (2008), smaller PDI values indicate that systems possess narrow 
size distribution and can be considered as adequate formulations. Additionally 
formulations F13 to F16 showed zeta potential values which suggested that the 
nanoemulsions would be stable.  
The differences in the performance of Tween 20®, Tween 80® and Cremophor® 
RH 40 as surfactants in this study are somewhat surprising.  The HLB values of the three 
surfactants quoted by their manufacturers are 16.7, 15, and 14-16 for Tween 20®, Tween 
80® and Cremophor® RH 40, respectively.  Hence, it may be reasonable to expect that 
Tween 20®-based formulations would behave differently to those based on the other two 
surfactants, if HLB is the main determinant of performance, and this is in fact seen in this 
study in both the particle size and zeta potential data.  As the HLB values for Tween 80® 
and Cremophor® RH 40 overlap, it would be expected that their formulations would be 
similar.  However, this was not observed in this study, with the mean droplet size being 
significantly smaller for the Cremophor® RH 40-based formulations than the Tween 80®-
based formulations, although the zeta potential values were more similar between the 
two sets of samples. 
The observed difference in performance may be attributed to the different 
chemical structures of Tween 80® and Cremophor® RH 40.  Tween 80® is a bulkier 
molecule, whereas Cremophor® RH 40 is a more linear molecule, hence it would be 
expected that the packing of the Cremophor® RH 40 components into the emulsion 
droplet would be more regular and consistent, leading to smaller droplets.  Additionally, 
Nepal et (2010b) have suggested that Cremophor® RH 40 has greater affinity for the oil 
phase than the Tweens® and would thus have greater contact with the Capryol™ 90 in 
these formulations, leading to reduced interfacial tension and smaller droplets after 
dilution.  Finally, the larger polyethylene oxide content of Cremophor® RH 40 compared 
to the other surfactants may help to increase the solubility of the drug and prevent drug 
precipitation as suggested by (Elnaggar et al., 2009).   
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3.4.8.3. Transmission electron microscopy (TEM) studies 
The structure and morphology of selected indomethacin-loaded SNEDDS (F13 – 
F16) were evaluated using TEM. The photographs obtained are presented in Figure 3.8. 
It is evident that all particles possessed spherical shape after dilution. The particles in 
F14 formulation showed the smallest size while those in formulations F13 and F15 
exhibited larger size. These results are consistent with that obtained in droplet size 
analysis.   
 
 
Figure  3.8 TEM photographs of selected indomethacin-loaded liquid SNEDDS. 
 
3.5. Conclusion  
In view of the above results, it can be seen that SNEDDS formulations of 
indomethacin (F13 to F16) prepared with Cremophor® RH 40 and Transcutol®HP as 
surfactant/co-surfactant mixture were thermodynamically stable over a relatively short 
time period and exhibited the highest self-emulsification efficiency. These systems 
utilizing Cremophor® RH 40 showed the smallest droplet size (less than 100 nm) with 
good polydispersity index (0.11 ± 0.02 to 0.265 ± 0.001) compared to all other tested 
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formulations. SNEDDS formulations prepared with Cremophor® RH 40 may possess 
some advantages due to this particular surfactant. It was reported that the use of 
Cremophor® RH 40 as a surfactant in systems designed for oral administration could be 
more suitable and advantageous because it is less readily digested due to the low 
reactivity of its saturated backbone. Also, the larger polyethylene oxide content of 
Cremophor® RH 40 may be responsible for its lower susceptibility to hydrolysis by 
pancreatic enzymes. These preferential properties of Cremophor® RH 40 may contribute 
to prevent drug precipitation from formulations designed with this surfactant (Porter et al., 
2008, Elnaggar et al., 2009). Additionally, Cremophor® RH 40 was reported as a 
bioavailability enhancer through its action as an inhibitor of cytochrome P450 (CYP) 3A 
enzyme that can diminish bioavailability of some lipophilic drugs (Elnaggar et al., 2009). 
Improved bioavailability of some drugs formulated as self-emulsifying formulations 
comprising Cremophor® RH 40 include atorvastatin (Shen and Zhong, 2006), tamoxifen 
citrate (Elnaggar et al., 2009), and probucol (Nielsen et al., 2008). As a result of studies 
of improvement of bioavailability due to Cremophor® RH 40, this surfactant was utilized 
in one of the commercially available SEDDS products; Neoral® (Elnaggar et al., 2009).        
Added to the above characteristics that could be related to Cremophore® RH 40, 
formulations F13 to F16 were prepared with surfactant concentrations between 33.4% 
and 52.5% (w/w) which were in the range of 30 to 60% that was reported to be 
necessary to formulate stable SNEDDS (Neslihan Gursoy and Benita, 2004, Tang et al., 
2008). Moreover, these systems contained effective surfactant/co-surfactant ratios of 2:1 
and 3:1 which resulted in maximum self-nanoemulsifying regions that are devoid of any 
gel-like zones as presented in their particular phase diagrams.  
Accordingly, these four different indomethacin-loaded SNEDDS were found with 
all of the above properties and hence, selected for further studies that will be focused on 
transforming these liquid formulations into solid SNEDDS formulations in order to 
combine the advantages of both lipid-based formulations and solid dosage forms. 
Different techniques can be used for this purpose. Adsorption onto solid carriers will be 
utilized in the next part of this study to formulate solid SNEDDS formulations from the 
optimized liquid formulations. Use of suitable carriers such as silica or silica compounds 
can be adopted for solidification purposes. The effect of the solidification process on 
various physicochemical properties of the drug will be evaluated using different 
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Filling of liquid SNEDDSs into hard or soft gelatin capsules is the simplest way for 
oral administration of these formulations. Capsule filling is suitable for highly potent 
drugs and provides high drug loading which is determined by the solubility of the drug as 
well as the capacity of the capsule. However, encapsulation of liquid SNEDDSs may be 
associated with various limitations. Possible interaction between the formulation 
excipients and the capsule shell is likely to occur especially if co-solvents were used in 
production of the formulation. Also, the components may leach or leak out the capsule 
shell and the drug may precipitate out the formulation at lower storage temperatures. In 
addition, the components of the liquid fill may be susceptible for solidification at lower 
storage temperatures. Higher costs, slow production capacity and difficult handling 
compared to solid dosage forms may also add to these limitations (Mandić et al., 2017). 
Therefore, transformation of liquid SNEDDS into solid dosage forms may be beneficial to 
avoid different disadvantages associated with production or encapsulation of liquid 
formulations. Solid self-emulsifying systems produced from liquid formulations are 
usually filled into capsules or alternatively, processed into different solid dosage forms 
such as tablets or pellets. Hence, solid SNEDDS formulations comprise the advantages 
of both liquid SNEDDSs (improved solubility and bioavailability) as well as those of solid 
dosage forms including high stability, ease of handling and storage, low production cost, 
reproducibility, accurate dosing, and as a result better patient compliance (Date et al., 
2010, Mandić et al., 2017, Rehman et al., 2017).   
The simplest method to convert liquid SNEDDS formulations into solid ones is by 
adsorption of the liquid formulation onto the surface of solid carriers that are highly 
porous and/or possess high specific surface area. Also, solid carriers used for 
solidification of liquid SNEDDSs should be inert, compatible (Gupta et al., 2013), provide 
high drug loading and reasonable dissolution profile, in addition to adequate flowability 
and compressibility that may be necessary for further manufacturing procedures (Mandić 
et al., 2017).  
Solidification of liquid SNEDDS by adsorption onto solid carriers involves the 
addition of successive increments of liquid formulation onto inert adsorbent followed by 
mixing to obtain free-flowing powder that can be directly filled into capsules or 
alternatively, compressed into tablets after addition of suitable excipients (Gupta et al., 
2013, Mandić et al., 2017). The method of adsorption onto solid carriers can achieve 
high levels of drug loading which may reach up to 80% w/w (Ito et al., 2005) although 
some studies have reported that loading of 50% w/w of lipid formulation did not affect the 
flow properties of the obtained self-emulsifying powder (Jannin et al., 2008, Weerapol et 
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al., 2015a). Also, this method of solidification does not utilize organic solvents and can 
produce formulations with good content uniformity (Mandić et al., 2017).  
Different solid carriers can be utilized for adsorption of liquid SNEDDS 
formulations. These include: (i) microcrystalline cellulose; (ii) silicon dioxide under the 
trade name Aerosil® (Evonik Industries AG, 2017)  with different grades of various 
specific surface area; (iii) amorphous silicon dioxide under the trade name of Syloid® 
(Grace GmbH, 2012) or Sylysia® (Fuji Silysia Chemical Ltd., 2011) with different grades 
of pore volume; (iv) magnesium aluminometasilicate under the trade name of Neusilin® 
(Fuji Chemical Industry, 2014) with different grades of particle size and surface 
properties (neutral or alkaline); (v) calcium silicate under the trade name of Florite® 
(Tomita Pharmaceutical Co., 2015); and (vi) porous dibasic calcium phosphate 
anhydrous under the trade name of Fujicalin®  (Fuji Chemical Industry Co. Ltd., 2007). 
These adsorbents are generally recognized as safe materials and were effectively 
employed for production of solid SNEDDS formulations by the adsorption method 
(Agarwal et al., 2009, Agrawal et al., 2015, Beg et al., 2016, Ito et al., 2005, Weerapol et 
al., 2015a).  
Different physical properties of solid carriers such as specific surface area, 
particle size and pore size and shape could influence the rate of drug dissolution from 
formulated solid SNEDDSs (Agarwal et al., 2009, Weerapol et al., 2015a). For example, 
the release rate of gentamycin sulfate from solid SEDDS formulated by adsorption of 
liquid formulation to different carriers differed according to the specific surface area of 
the carrier used. Higher release rate of the drug was observed from solid SNEDDS 
formulations prepared with low specific surface area carrier (Sylysia® 320) compared to 
formulations prepared with high specific surface area (Florite® RE) (Ito et al., 2005).  On 
the other hand, Agarwal et al. (2009) have reported that the dissolution rate of 
griseofulvin-loaded solid SEDDS prepared by adsorption onto different carriers increased 
with increasing the specific surface area of the carrier. In that study, it was shown that 
solid SEDDS of griseofulvin prepared with two different particle size grades of Neusilin® 
US2 having similar specific surface area (≈ 300 m2/g) showed higher release rate than 
formulations prepared with different particle size grades of silicon dioxide (specific 
surface area ≈ 150 – 230 m2/g) or calcium silicate (specific surface area ≈ 50 m2/g). 
These results were explained on the basis of the size and depth of the pores of the 
carrier which are dependent on the specific surface area and particle size of the 
adsorbent material. The authors hypothesized that liquid lipid formulation may fill the 
pores of the adsorbent in different ways which may affect their dissolution. It was 
suggested that lipid formulation may fill the pores either partially, completely or just 
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adsorbed on the surface of adsorbents depending on the specific surface area of the 
adsorbent.  For instance, adsorbents with high specific surface area (≥ 300 m2/g) like 
Neusilin® may possess large number of narrow and long intraparticular pores that 
contribute to high surface area. Lipid formulation may partially fill the pores of this type of 
adsorbents and a decreased release rate may be observed due to increased pore length 
in which the lipid formulation get entrapped.  Limited access of dissolution medium to the 
formulation retained inside the pores may be responsible for decreased release rate of 
the drug. In addition, the use of larger particle size adsorbents such as Neusilin® US2 
(particle size ≈ 80 µm) resulted in decreased release rate of griseofulvin from solid 
SNEDDS compared to that obtained when smaller particle size adsorbents such as 
Neusilin® UFL2 (particle size ≈ 5 µm) were used. Again, this was attributed to greater 
pore length in adsorbents with larger particle size than in those having small particle 
size. On the other hand, it was proposed that lipid formulation will completely fill the 
pores of adsorbents having intermediate specific surface area (≈ 150 – 230 m2/g) like 
silica-based adsorbents, so that a greater portion of the lipid formulation will interact with 
the adsorbent pores through hydrophobic interaction and this may lead to possible 
precipitation of the drug and subsequently, decreased dissolution rate was observed. In 
the case of adsorbents with low specific surface area (≤ 50 m2/g), limited area will be 
available for adsorption of lipid formulations so these formulations will be adsorbed as 
thin film through hydrophobic interaction with the surface of the adsorbent and this may 
lead to precipitation of griseofulvin from the lipid formulation resulting in reduced 
dissolution rate of the drug.  The authors also explained the results based on the affinity 
of griseofulvin to the surface of the adsorbent used. It was proposed that griseofulvin 
possess high affinity to interact with the hydrophobic surface of silica-based adsorbents 
and this may result in precipitation of griseofulvin due to its low solubility in the 
dissolution medium. Therefore, highest precipitation is likely to occur with adsorbents 
having low specific surface area (≤ 50 m2/g), while lowest precipitation rate is expected 
with highly porous adsorbents possessing high specific surface area (≥ 300 m2/g) in 
which lipid formulations are incorporated as droplets in the pores and a minimal contact 
and interaction between the adsorbent and the lipid formula can be obtained.    
Therefore, careful consideration of the specific surface area, particle size, the 
amount and the type of the adsorbent is important in development of solid SNEDDS 
formulations using the adsorption method. Also, possible interaction between lipid 
formulation and the carrier should be estimated carefully because it may lead to 
incomplete or delayed drug release (Agarwal et al., 2009).                
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Enhancement of the dissolution rate of the drug obtained from solid SNEDDSs 
prepared by the adsorption method may be attributed to the fact that the drug is 
maintained in a solubilized form after preparation of the solid product (Date et al., 2010, 
Raval et al., 2012). The solubilized form of the drug may contribute to rapid formation of 
very small droplets and faster drug release upon contact with the dissolution medium.  
The final solid SNEDDS should be evaluated for different parameters before 
formulation into solid dosage forms such as tablets or capsules. For example, the ratio of 
the liquid SNEDDS: adsorbent should be carefully determined. Also, the flow properties 
such as angle of repose, compressibility index in addition to particle size distribution 
must be evaluated prior to final conversion into tablets or capsules. Formation of 
spontaneous nanoemulsion upon dispersion of the final product in a liquid medium may 
be the rate-limiting step for both in vitro dissolution and in vivo absorption of the drug. 
Therefore, determination of the self-nanoemulsifying properties of the final product and 
droplet size of the formed nanoemulsion should be carefully considered as it would 
determine the in vivo performance of the formulation. The globule size of the obtained 
nanoemulsion may be affected by the type of the carrier as well as the components of 
SNEDDS formulation (Date et al., 2010). Generally, solidification procedures should not 
change the self-emulsifying properties and the droplet size of liquid SNEDDS 
formulations. This is important to ensure that improved bioavailability of the drug 
achieved with liquid formulations will be preserved after solidification (Mandić et al., 
2017).  
Furthermore, physical characterization of the formulated solid SNEDDSs using 
DSC, XRD and scanning electron microscopy is important to reveal any precipitation of 
the drug that may have occurred during preparation. For instance, the absence of drug 
melting endotherms in DSC traces indicates that the drug has remained in a solubilized 
form within solid SNEDDS formulations and has not precipitated in a crystalline form. 
Similarly, an absence of crystalline peaks related to the drug in XRD diffractograms also 
suggests that the drug remains in a dissolved state in the solid SNEDDSs. Investigation 
of solid SNEDDSs with scanning electron microscopy may provide information on the 
surface characteristics of particles, while in vitro dissolution studies may give information 
on possible performance of solid SNEDDS formulation in the GI tract (Date et al., 2010).   
In this part of study, solidification by adsorption onto solid carriers was utilized to 
formulate solid SNEDDSs of indomethacin. Liquid SNEDDS formulations of 
indomethacin (F13 – F16) that were optimized in Chapter 3 were employed for this 
purpose. Different types of solid carriers or adsorbents were used to transform these 
liquid SNEDDS formulations into solid ones. The potential of use of different types of 
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adsorbents was assessed by evaluation of powder flow properties, self-emulsification 
efficiency and dissolution rate of the resulting solid indomethacin-loaded SNEDDSs. In 
addition, physical characterization of formulated solid SNEDDSs was carried out to 
evaluate the usefulness of this technique of solidification in production of solid 
SNEDDSs.   
 Materials 4.2.
• Indomethacin was obtained from Sigma-Aldrich Chemie GmbH, Germany. 
• CapryolTM 90 (propylene glycol monocaprylate), and Transcutol® HP (diethylene 
glycol monoethyl ether) were kindly provided by Gattefosse Co., France. 
• Cremophor® RH 40 (polyoxyl 40 hydrogenated castor oil) was kindly provided by 
BASF Co. (Germany). 
• Microcrystalline cellulose (Avicel PH 102) was obtained from FMC BioPolymer (PA, 
USA), 
• Aerosil® 200 (silicon dioxide) was obtained from Evonik Industries AG (Germany). 
• Syloid®XDP3150 (amorphous silicon dioxide) was kindly provided by Grace GmbH, 
(Germany). 
• Neusilin®US2 (magnesium aluminometasilicate) was kindly provided by Fuji 
Chemical Industry (Japan). 
• Florite®PS-200 (calcium silicate) was kindly provided by Tomita Pharmaceutical Co. 
(Japan). 
• Potassium dihydrogen orthophosphate anhydrous was obtained from Loba Chemie 
Pvt. Ltd. (Mumbai, India). 
• Sodium hydroxide was obtained from Fluka Chemie GmbH (Germany). 
• Calcium chloride was obtained from Sigma Aldrich (U.K.). 
• Methanol was obtained from Fisher Scientific UK Limited (Leicestershire, UK).  
• Deionized water was purified using an Ultra-purification Water System, Millipore Co. 
Ltd. (Bedford, MA, USA). 
• Hard gelatin capsules were obtained from pharma tradechem (Mumbai, India).   
  




4.3.1. Construction of standard calibration curve of indomethacin in 
phosphate buffer pH 7.2 
The standard calibration curve of indomethacin was constructed in phosphate 
buffer similarly to the standard curve constructed in methanol which was described 
previously in Chapter 3. Briefly, a stock solution of indomethacin was prepared in 
phosphate buffer pH 7.2 and serial dilutions were then prepared from the stock solution 
to obtain different drug concentration ranging from 2.5 to 45 µg/ml. The absorbance of 
these serial dilutions was determined in triplicates at 320 nm, using phosphate buffer pH 
7.2 as a reference standard. The standard calibration curve was obtained by plotting the 
mean absorbance of these dilutions against the corresponding concentrations.  
The inter-day accuracy of the assay method for determination of indomethacin 
concentrations in phosphate buffer was determined as explained in Chapter 3. Similarly, 
the intra-day and inter-day precision (reproducibility) of the assay procedure was 
evaluated according to the method of Sawant et al. (2010) presented previously in 
Chapter 3.   
4.3.2. Preparation of liquid SNEDDSs of indomethacin (optimized from 
Chapter 3) 
Liquid SNEDDS formulations of indomethacin (F13 – F16) that were optimized in 
Chapter 3 were employed for transformation into solid SNEDDSs. The liquid 
formulations were prepared as described in Chapter 3. Briefly, blank ternary mixtures of 
oil (Capryol™ 90), surfactant (Cremophor® RH40) and co-surfactant (Transcutol® HP) 
were first mixed in borosilicate glass vials using a magnetic stirrer for 10 minutes. The 
composition of theses formulations is summarized in Table 4.1.  After preparation of 
blank ternary systems, indomethacin was added at a concentration of 2.5% w/w. Final 
mixtures were vortex mixed until clear mixtures were obtained. To ensure complete 
solubilization, the prepared mixtures were shaken for 24 hours at 25 oC in an isothermal 
shaking water bath.  
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Table  4.1  Composition of optimized liquid Indomethacin SNEDDS formulations. 
Formulation 
Code 








F13 50 33.4 16.6 2:1 
F14 30 46.7 23.3 2:1 
F15 50 37.5 12.5 3:1 
F16 30 52.5 17.5 3:1 
Smix : Cremophor® RH40  (surfactant) & Transcutol® HP (co-surfactant)  
 
4.3.3. Formulation of indomethacin-loaded solid SNEDDS 
The adsorption method was employed to transform the optimized liquid SNEDDS 
of indomethacin into solid SNEDDS formulations. Different solid carriers namely: 
microcrystalline cellulose, Aerosil® 200, Syloid® XDP3150, Neusilin® US2 and Florite® 
PS-200 were used to load the liquid SNEDDSs of indomethacin.  The liquid lipid 
formulation was added in portions and mixed with different adsorbents at the following 
fixed adsorbent to liquid SNEDDS ratios by weight: 1:0.25, 1:0.5, 1:1; 1:1.5 and 1:2. A 
successive constant portion of liquid SNEDDS formulation was added to the adsorbent 
placed in a mortar and mixed with a pestle.  The granular mass obtained was then 
passed through 250 µm mesh screen for the purpose of uniformity in particle size. The 
powder samples were stored in a desiccator over anhydrous calcium chloride until 
further evaluation. 
4.3.4. Evaluation of formulated indomethacin-loaded solid SNEDDS 
4.3.4.1. Flow properties (angle of repose method) 
 Flow properties of the used adsorbents alone and different solid SNEDDS 
formulations were determined by angle of repose (θ) method as previously described in 
Chapter 2.  All experiments were performed in triplicates and results were averaged ± 
SD.  
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4.3.4.2. Carr’s compressibility index (CI%) and Hausner’s ratio (HR) 
The flow and packing properties of blank adsorbents and different indomethacin-
loaded solid SNEDDS powder formulations were also assessed by measuring Carr’s 
compressibility index (CI%) and Hausner’s ratio (HR).  Measurements and calculations 
of these values were performed as previously described in Chapter 2.  
All experiments were done in triplicates, and the resulting mean values of CI% and HR 
were  compared to the scale of flowability for these parameters presented in the British 
Pharmacopoeia (2015).  
Powder formulations that showed adequate flow properties according to the 
pharmacopoeial scale of flowability were subjected for further evaluation.    
4.3.4.3. Determination of drug content 
The drug content in each indomethacin-loaded solid SNEDDS formulation was 
determined as previously stated in Chapter 2.  All experiments were performed in 
triplicates and the results were averaged ± Standard deviation (SD).   
4.3.4.4. Redispersibility of solid SNEDDS formulations (Droplet size 
measurement) 
Redispersibility of optimized indomethacin-loaded solid SNEDDS formulations 
was evaluated by measuring the globule size using a Malvern Zetasizer nano-ZS 
(Malvern Instruments, Worchestershire, UK). According to the method of Kanaujia et al. 
(2014), each formulation sample was dispersed in deionized water to obtain a final 
indomethacin concentration of 100 µg/ml. The mixtures were shaken gently for 5 minutes 
and then centrifuged at 3000 rpm for 15 minutes and filtered through a 0.45 µm syringe 
filter. The average globule size, polydispersity index and zeta potential of the 
nanoemulsion formed from S-SNEDDS were determined by Malvern Zetasizer. All 
measurements were made in triplicates and the results are presented as mean ± 
standard deviation (SD).  
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4.3.4.5. Solid state characterization of indomethacin-loaded solid SNEDDS 
formulations 
4.3.4.5.1. Fourier transform infrared spectroscopy (FTIR) 
In order to identify possible interaction between the drug and different excipients 
used in the formulations, FTIR spectra of optimized drug-loaded solid SNEDDS 
formulations were recorded in the scanning range of 4000 – 400 cm-1 using Fourier 
transform infrared (FTIR) spectrophotometer (Nicolet 6700, Thermo Fisher Scientific, 
USA).  The FTIR spectra of indomethacin and different carriers used for different 
formulations were also obtained for the purpose of comparison. To perform the test, an 
amount of each formulation sample (4 mg) was mixed with dry potassium bromide (IR 
grade, 200 mg), lightly ground and compacted into a disc using hydraulic press and then 
scanned at a speed of 4 scans/second.     
4.3.4.5.2. Differential scanning calorimetry (DSC) 
Thermal behavior of indomethacin, solid carriers and optimized drug-loaded solid 
SNEDDS formulations was studied using a single furnace, heat flux DSC (DSC 4000, 
Perkin Elmer, US). An accurately weighed sample (5 – 10mg) was placed in a flat 
bottomed standard aluminum pan and scanned at a heating rate of 10oC/ minute from 25 
– 300 oC under a nitrogen gas flow rate of 20 ml/min. 
4.3.4.5.3. Powder X-ray diffraction (XRD) 
  The X-ray diffraction patterns of indomethacin, solid carriers and optimized drug-
loaded solid SNEDDS formulations were recorded at ambient temperature using Ultima 
IV diffractometer (Rigaku Co., Ltd., Tokyo, Japan) equipped with a copper X-ray source 
maintained at 40 kV of tube voltage and 40 mA of tube current to produce emissions of 
0.15406 nm. The samples were scanned at 3−60° 2θ range at a scanning speed of 0.5 
deg. /min. Data were collected using a step scan mode with step size of 0.02o and 
counting time of 1 second per step. 
4.3.4.5.4. Scanning electron microscopy (SEM)  
The morphological characteristics of indomethacin, solid carriers and optimized 
drug-loaded solid SNEDDS formulations were investigated using JSM-6060LV scanning 
electron microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 10 kV. Prior to 
observation under SEM,  double-sided sticky tape with lightly sprinkled sample was 
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affixed to aluminum stub and made electrically conductive with a gold coating (13 – 14 
nm/min; 45 s; 20 mA) under vacuum using JFC-1600 Auto Fine Coater (Jeol, Tokyo, 
Japan). Micrographs were recorded at different magnifications and analyzed for the 
surface and morphological characteristics.  
4.3.4.6. In vitro dissolution studies 
In vitro dissolution studies of optimized drug-loaded solid SNEDDS formulations 
were performed according to British Pharmacopoeia (2015) using dissolution type II 
apparatus (Pharma Test, Hainburg, Germany) with 900 ml phosphate buffer pH 7.2 
maintained at 37 ± 0.5 oC and at a rotation speed of 50 rpm. An amount of drug-loaded 
solid SNEDDS formulation equivalent to 25 mg of indomethacin was filled in suitable 
number of hard gelatin capsules (size 000) and used for dissolution studies. Samples (5 
ml) were withdrawn at predetermined time intervals. An equal volume of fresh dissolution 
medium maintained at the same temperature was added to keep constant volume during 
dissolution study. The collected samples were filtered through 0.45 µm syringe filters and 
then assayed for the content of indomethacin by UV spectrophotometry at 320 nm. For 
the purpose of comparison, the experiment was repeated with the same quantity of 
indomethacin (25 mg) taken from the optimized liquid SNEDDS formulation as well as 
from pure drug powder and filled in hard gelatin capsules. All experiments were 
performed in triplicates and results were averaged ± SD. Dissolution efficiency after 15 
minutes (DE15min), mean dissolution time (MDT) and % released after 15 minutes 
(%Q15min) were used to compare the dissolution performance of different drug-loaded 
solid SNEDDS formulations. The DE15min was determined for the time intervals of 
dissolution study (from 0 – 15 min) while MDT was calculated for all dissolution time 
interval (from 0 - 60 min) using DDSolver as Excel add inn.   
4.3.4.7. Statistical analysis 
One way analysis of variance (ANOVA) was used with t-test to detect differences 
between the data of interest. Significant differences were determined at a 5% 
significance level, unless otherwise stated elsewhere. Statistical differences yielding (p < 
0.05) were considered significant.   
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 Results and Discussion 4.4.
4.4.1. Standard calibration curve of indomethacin in phosphate buffer pH 
7.2 
The standard calibration curve of indomethacin was constructed in phosphate 
buffer pH 7.2 to obtain different concentrations ranging from 2.5 to 45 µg/ml. The 
absorbance readings of these concentrations were determined spectrophotometrically at 
λmax 320 nm and the results were plotted against the corresponding concentrations as 
presented in Table 4.2 and Figure 4.1. The standard calibration curve was linear over 
the concentration range studied and obeys Beer-Lambert’s law with a correlation 
coefficient (r2) 0.999. The corresponding regression equation was found to be Y = 
0.0227X + 0.0047.  
Table  4.2 Data of the standard calibration curve of indomethacin constructed in 
phosphate buffer pH 7.2 assayed at 320 nm. 
Concentration (µg/ml) Mean absorbance ±SD (n = 3) 
2.5 0.063 ± 0.002 
5 0.114 ± 0.001 
10 0.228 ± 0.001 
15 0.345 ± 0.001 
20 0.455 ± 0.004 
25 0.579 ± 0.004 
30 0.699 ± 0.003 
35 0.805 ± 0.003 
40 0.923 ± 0.001 
45 0.998 ± 0.001 
 




Figure  4.1  Standard calibration curve of indomethacin in phosphate buffer pH 7.2 
assayed at 320 nm. (Small standard deviation bars were added but can’t 
be visualized relative to the marker size). 
 
The spectrophotometric assay in phosphate buffer showed accuracy with % 
recoveries of indomethacin in the range of 97.05 – 101.57% for the three concentrations 
selected. Also, small %RSD values (0.78 – 1.20) were satisfactory for this analytical 
method. In addition, determination of inter-day and intra-day precision of the assay 
method revealed %RSD values of 0.90 – 2.24 and 0.44 – 1.35, respectively. The values 
of %RSD obtained for accuracy and precision of the assay remained within 5% which is 
acceptable according to ICH guidelines on validation of analytical procedures (ICH, 
2005, Nováková et al., 2005).  
4.4.2. Formulation of Indomethacin-loaded solid SNEDDS 
Drug-loaded solid SNEDDS formulations were formulated by adsorbing the 
optimized liquid SNEDDS of indomethacin onto different solid carriers selected for this 
study. The liquid lipid formulation was added in successive constant portions to the 
adsorbent at different adsorbent: liquid SNEDDS ratios of 1: 0.25, 1: 0.5, 1: 1; 1: 1.5 and 
1: 2. The resulting granular mass varied in their consistency and appearance according 
to the type and/or the amount of the liquid SNEDDS formulation added to the adsorbent. 
For example, utilization of MCC as a solid adsorbent resulted in greasy mixtures upon 
y = 0.0227x + 0.0047 
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addition of any of the liquid SNEDDS formulations. The greasiness of these mixtures 
increased with increasing the amount of the liquid SNEDDS formulation (at the ratios of 
1: 1.5 and 1: 2). Also, the addition of any of the liquid SNEDDS to Aerosil® 200 at all the 
ratios tested, produced solid mixtures that were fluffy and difficult to handle.  
On the other hand, the appearance and consistency of solid mixtures produced 
with Neusilin® US2 or Florite® PS-200 varied according to the type of liquid SNEDDS 
added. Greasy solid mixtures were obtained upon the addition of F13 or F15 to any of 
these two carries, while less greasy blends were produced when F14 or F16 were added 
to these carriers, especially at high adsorbent: liquid SNEDDS ratios (1: 1.5 and 1: 2). 
In addition, the solid mixtures obtained by adding any of the liquid SNEDDS 
formulations (F13 – F16) to Syloid® XDP3150 at different ratios were not too greasy and 
could be handled easily.  
In order to confirm the above differences in the physical appearance of different 
solid mixtures, the flow properties of different drug-loaded solid SNEDDS were evaluated 
in the next section.     
4.4.3. Flow properties of different indomethacin-loaded solid SNEDDS 
formulations 
Determination of the flow properties of solid SNEDDS powder formulations helps 
to identify the most appropriate formulation that can be successfully filled into capsules 
or alternatively, compressed into tablets. The flowability of different indomethacin-loaded 
solid SNEDDS formulations was determined using angle of repose (θ), Carr’s 
compressibility index (CI%) and Hausner’s ratio (HR) and the results are presented in 
Table 4.3 until Table 4.7. According to the scale of flowability presented in British 
Pharmacopoeia (2015), powder formulations possessing angle of repose in the range of 
25o – 35o are considered as having acceptable flow properties although powder 
formulations that show angle of repose in the range of 40o – 50o may be adequately 
manufactured. Also, powder formulations having CI% values below 25 are considered to 
possess good flow properties. In addition, HR values less than or equal to 1.25 indicate 
good flow properties although HR values less than 1.34 denote passable flow.    
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Table  4.3   Flowability  parameters of different indomethacin solid SNEDDSs loaded 























PH 102  ---- 34.15±0.29 0.32±0.01 0.39±0.00 17.95±1.78 1.22±0.02 
F13 1:0.25 47.54±0.47 0.31±0.01 0.40±0.01 22.37±2.28 1.29±0.04 
  1:0.5 46.02±0.30 0.33±0.00 0.42±0.01 21.43±2.89 1.27±0.04 
  1:1 48.02±0.47 0.40±0.01 0.54±0.02 25.79±2.48 1.35±0.05 
  1:1.5 N/A N/A N/A N/A N/A 
  1:2 N/A N/A N/A N/A N/A 
F14 1:0.25 48.12±0.64 0.31±0.01 0.41±0.02 24.39±3.28 1.32±0.09 
  1:0.5 49.53±0.51 0.34±0.01 0.43±0.01 16.35±2.34 1.26±0.03 
  1:1 46.07±0.37 0.42±0.01 0.56±0.02 24.60±2.37 1.33±0.04 
  1:1.5 N/A N/A N/A N/A N/A 
  1:2 N/A N/A N/A N/A N/A 
F15 1:0.25 48.07±0.40 0.32±0.01 0.42±0.00 23.82±2.83 1.31±0.04 
  1:0.5 49.20±0.41 0.32±0.01 0.43±0.01 25.58±2.41 1.34±0.04 
  1:1 47.44±0.50 0.41±0.01 0.54±0.02 24.28±2.26 1.32±0.04 
  1:1.5 N/A N/A N/A N/A N/A 
  1:2 N/A N/A N/A N/A N/A 
F16 1:0.25 46.82±0.38 0.30±0.01 0.39±0.01 23.08±2.53 1.30±0.04 
  1:0.5 49.03±0.25 0.35±0.01 0.47±0.01 24.60±2.37 1.33±0.04 
  1:1 47.35±1.15 0.39±0.02 0.50±0.01 22.10±3.10 1.28±0.07 
  1:1.5 N/A N/A N/A N/A N/A 
  1:2 N/A N/A N/A N/A N/A 
N/A: Not Applicable. 
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Table  4.4  Flowability  parameters of different indomethacin solid SNEDDSs loaded 























200  ---- 29.67±0.12 0.07±0.00 0.09±0.00 24.89±1.31 1.33±0.02 
F13 1:0.25 38.92±0.28 0.36±0.00 0.49±0.01 25.41±1.27 1.34±0.02 
 1:0.5 41.72±0.15 0.06±0.00 0.08±0.00 24.23±1.02 1.32±0.02 
  1:1 43.74±0.63 0.07±0.00 0.10±0.00 27.06±0.69 1.42±0.01 
  1:1.5 44.48±0.16 0.14±0.00 0.22±0.00 36.59±0.31 1.58±0.01 
  1:2 46.62±0.55 0.23±0.00 0.34±0.01 32.90±1.84 1.49±0.04 
F14 1:0.25 39.19±0.29 0.20±0.00 0.26±0.00 22.28±1.52 1.29±0.03 
 1:0.5 44.62±0.36 0.39±0.01 0.50±0.02 21.69±1.50 1.28±0.02 
  1:1 45.63±0.59 0.08±0.00 0.11±0.00 27.28±1.03 1.39±0.02 
  1:1.5 43.74±0.50 0.12±0.00 0.17±0.00 29.43±0.86 1.42±0.02 
  1:2 41.59±0.32 0.07±0.00 0.10±0.00 30.82±1.96 1.43±0.04 
F15 1:0.25 39.38±0.24 0.19±0.00 0.25±0.00 25.26±0.80 1.34±0.01 
  1:0.5 45.34±0.37 0.34±0.00 0.46±0.01 25.01±1.60 1.33±0.03 
 1:1 45.53±0.22 0.06±0.00 0.08±0.00 24.45±0.69 1.32±0.01 
 1:1.5 45.77±0.22 0.08±0.01 0.12±0.01 32.33±0.78 1.48±0.02 
  1:2 46.33±1.18 0.11±0.00 0.17±0.00 35.68±1.02 1.55±0.02 
F16 1:0.25 43.92±0.35 0.12±0.00 0.16±0.00 25.53±1.21 1.34±0.02 
  1:0.5 44.62±0.36 0.37±0.01 0.47±0.01 20.85±2.33 1.26±0.04 
  1:1 44.16±0.74 0.07±0.00 0.09±0.00 24.89±1.31 1.33±0.02 
  1:1.5 41.93±0.32 0.08±0.00 0.11±0.00 27.29±0.64 1.38±0.01 
  1:2 46.22±0.74 0.18±0.00 0.26±0.00 30.14±1.29 1.43±0.03 
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Table  4.5  Flowability  parameters of different indomethacin solid SNEDDSs loaded 
























 ---- 29.51±0.31 0.18±0.00 0.19±0.00 6.45±1.36 1.07±0.02 
F13 1:0.25 41.93±0.32 0.15±0.01 0.21±0.02 28.57±2.48 1.41±0.10 
  1:0.5 42.28±0.65 0.20±0.01 0.29±0.01 31.03±1.44 1.45±0.04 
  1:1 44.31±1.20 0.14±0.01 0.20±0.01 30.15±2.27 1.43±0.05 
  1:1.5 42.11±1.99 0.27±0.01 0.40±0.01 32.82±0.45 1.49±0.01 
  1:2 44.07±1.05 0.35±0.02 0.51±0.01 31.37±3.97 1.46±0.06 
F14 1:0.25 42.95±1.33 0.19±0.00 0.25±0.01 24.17±1.18 1.32±0.06 
  1:0.5 42.43±1.48 0.21±0.00 0.28±0.01 24.75±2.10 1.33±0.05 
  1:1 43.65±2.05 0.29±0.00 0.37±0.01 21.63±1.20 1.28±0.03 
  1:1.5 40.01±1.33 0.35±0.00 0.46±0.02 23.91±2.79 1.31±0.07 
  1:2 39.81±0.59 0.40±0.01 0.51±0.02 23.21±1.41 1.30±0.02 
F15 1:0.25 41.86±0.98 0.17±0.01 0.23±0.00 26.63±2.71 1.36±0.05 
  1:0.5 45.37±1.61 0.20±0.00 0.28±0.01 28.56±3.17 1.40±0.07 
  1:1 44.55±1.45 0.25±0.00 0.36±0.01 30.18±1.76 1.43±0.04 
  1:1.5 43.99±1.14 0.33±0.01 0.44±0.02 26.33±3.80 1.36±0.07 
  1:2 43.67±0.17 0.36±0.00 0.49±0.03 26.03±3.57 1.35±0.07 
F16 1:0.25 42.07±0.75 0.20±0.01 0.26±0.01 23.08±1.75 1.32±0.04 
  1:0.5 44.30±0.70 0.18±0.01 0.23±0.01 22.21±1.19 1.29±0.02 
  1:1 44.96±1.13 0.26±0.01 0.34±0.02 24.95±3.54 1.33±0.06 
  1:1.5 39.27±0.26 0.33±0.01 0.42±0.01 21.43±3.34 1.27±0.04 
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Table  4.6  Flowability  parameters of different indomethacin solid SNEDDSs loaded 























PS 200  ---- 33.89±1.78 0.07±0.01 0.07±0.01 7.39±2.29 1.08±0.03 
F13 1:0.25 40.44±0.42 0.09±0.00 0.12±0.00 24.05±0.33 1.33±0.00 
  1:0.5 45.53±0.51 0.11±0.00 0.13±0.00 20.72±1.95 1.26±0.03 
  1:1 49.03±0.34 0.14±0.00 0.18±0.00 20.77±2.04 1.26±0.03 
  1:1.5 49.14±0.33 0.17±0.00 0.22±0.01 21.03±1.78 1.27±0.03 
  1:2 48.71±0.83 0.21±0.01 0.27±0.01 20.77±2.04 1.26±0.03 
F14 1:0.25 43.92±0.35 0.09±0.00 0.12±0.01 24.83±3.07 1.33±0.06 
  1:0.5 43.97±0.34 0.09±0.00 0.12±0.00 22.36±2.09 1.29±0.03 
  1:1 44.87±0.41 0.13±0.01 0.17±0.01 22.36±2.09 1.29±0.03 
  1:1.5 38.35±1.78 0.16±0.00 0.17±0.01 15.54±3.62 1.19±0.05 
  1:2 39.65±1.43 0.21±0.01 0.26±0.01 19.44±3.54 1.24±0.05 
F15 1:0.25 41.23±0.34 0.10±0.01 0.13±0.02 22.70±7.13 1.30±0.12 
  1:0.5 43.98±0.83 0.11±0.00 0.14±0.00 21.43±1.31 1.27±0.02 
  1:1 48.87±0.41 0.14±0.00 0.18±0.01 25.57±1.79 1.34±0.03 
  1:1.5 48.44±0.40 0.18±0.01 0.23±0.01 23.64±3.48 1.31±0.06 
  1:2 48.23±0.67 0.19±0.01 0.24±0.01 19.74±0.44 1.26±0.01 
F16 1:0.25 44.58±0.37 0.10±0.01 0.13±0.02 22.36±2.09 1.29±0.03 
  1:0.5 43.03±0.49 0.12±0.02 0.15±0.03 23.33±3.47 1.31±0.06 
  1:1 44.97±0.34 0.15±0.01 0.20±0.02 23.19±2.40 1.30±0.04 
  1:1.5 37.78±1.08 0.18±0.01 0.22±0.00 18.83±3.26 1.23±0.05 
  1:2 38.24±0.42 0.19±0.01 0.23±0.01 17.43±1.11 1.21±0.02 
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Table  4.7  Flowability  parameters of different indomethacin solid SNEDDSs loaded 

























 ---- 32.70±0.63 0.25±0.01 0.26±0.01 3.80±0.08 1.04±0.00 
F13 1:0.25 38.92±0.28 0.30±0.01 0.33±0.01 8.42±2.73 1.09±0.03 
 1:0.5 37.47±0.69 0.37±0.01 0.41±0.01 10.00±0.00 1.11±0.00 
 1:1 38.01±0.71 0.50±0.01 0.54±0.01 6.84±2.73 1.07±0.03 
 1:1.5 40.86±0.87 0.58±0.06 0.69±0.05 16.02±2.89 1.19±0.03 
  1:2 42.36±0.53 0.50±0.03 0.61±0.02 18.04±3.03 1.22±0.06 
F14 1:0.25 38.71±1.13 0.31±0.00 0.34±0.01 8.33±2.89 1.09±0.03 
  1:0.5 39.52±0.82 0.36±0.00 0.40±0.01 8.33±2.89 1.09±0.03 
  1:1 37.93±0.32 0.51±0.00 0.54±0.00 5.26±0.00 1.06±0.00 
 1:1.5 36.23±0.50 0.63±0.00 0.66±0.02 3.51±3.04 1.04±0.03 
  1:2 38.22±0.39 0.45±0.01 0.55±0.02 18.42±4.69 1.23±0.07 
F15 1:0.25 38.59±0.34 0.31±0.01 0.34±0.00 8.42±2.73 1.09±0.03 
  1:0.5 36.26±0.25 0.36±0.00 0.39±0.01 8.33±2.89 1.09±0.03 
 1:1 43.48±0.89 0.49±0.01 0.52±0.00 6.67±2.89 1.07±0.03 
 1:1.5 41.51±0.45 0.57±0.03 0.68±0.05 16.18±2.89 1.19±0.03 
  1:2 42.00±0.42 0.44±0.03 0.55±0.03 18.92±2.88 1.23±0.04 
F16 1:0.25 39.93±0.32 0.30±0.01 0.32±0.02 4.84±0.14 1.05±0.00 
  1:0.5 38.92±0.28 0.37±0.00 0.40±0.01 8.33±2.89 1.09±0.03 
  1:1 39.08±0.42 0.51±0.01 0.53±0.01 5.18±0.15 1.05±0.00 
  1:1.5 37.25±0.31 0.61±0.00 0.65±0.00 5.00±0.00 1.05±0.00 
  1:2 39.30±0.31 0.48±0.01 0.58±0.02 17.93±3.58 1.22±0.05 
 
  




From the results presented in Table 4.3, it appears that the addition of 
microcrystalline cellulose (MCC) or Avicel PH 102 to all liquid indomethacin-loaded 
SNEDDS formulations (F13 – F16) in the ratios of 1: 0.25, 1: 0.5, and 1: 1 produced 
mixtures with poor flowability as indicated by the values obtained for angle of repose 
(46.02 ± 0.30 to 49.53 ± 0.51). The values of CI% (16.35 ± 2.34 to 25.79 ± 2.48) and HR 
(1.26 ± 0.03 to 1.34 ± 0.04) for these mixtures indicated passable flow which means that 
these formulation may hang up during filling into capsules or upon further processing into 
compressed tablets. Further incorporation of higher amounts of the liquid SNEDDS 
formulations (adsorbent: liquid formulation ratios of 1: 1.5 and 1: 2) resulted in very 
greasy mixtures for which flowability parameters could not be determined.  This may be 
attributed to reduced porosity of the carrier upon addition of further amounts of the liquid 
formulation. Lower amounts of drug-loaded liquid SNEDDS formulation may adsorb onto 
the rough and porous surface of the particles of MCC to produce smoother and less 
porous surface, while higher amounts of the liquid SNEDDSs may not associate with the 
solid adsorbent due to reduced porosity of the powder formulation (Abdalla et al., 2008). 
Similar findings have been reported for incorporation of a self-emulsifying mixture of 
progesterone onto MCC or Avicel PH 101 to produce pellets (Abdalla et al., 2008), where 
higher concentrations of the liquid formula incorporated within the cellulose fibers 
network of MCC as revealed by  environmental scanning electron microscopy (ESEM).   
Due to the poor flow properties of indomethacin-loaded solid SNEDDS formulated by 
adsorption of liquid SNEDDS onto MCC and because of difficulty to incorporate higher 
amounts of the liquid formulation, and hence higher content of the drug, these 
formulations were excluded from further evaluation studies.  
The flowability parameters obtained for drug-loaded solid SNEDDS formulations 
prepared by adsorption of liquid SNEDDS formulations (F13 – F16) onto Aerosil® 200 are 
shown in Table 4.4. All solid SNEDDS formulations produced by adsorption onto 
Aerosil® 200 at the adsorption ratios of 1: 0.25, 1: 0.5 and 1: 1 exhibited fair to poor flow 
properties according to the estimated values of angle of repose (38.92 ± 0.28 to 46.62 ± 
0.55). Incorporation of the liquid SNEDDS formulations onto Aerosil® 200 at higher 
adsorbent: liquid formulation ratios (1: 1.5 and 1: 2) resulted in solid SNEDDS products 
that were difficult to manipulate and showed higher values of CI% (20.85 ± 2.33 to 36.59 
± 0.31) and HR (1.26 ± 0.04 to 1.58 ± 0.01). Difficult handling of solid formulations 
prepared using Aerosil® 200 may be attributed to the fluffy nature of this carrier due to 
the inter-particulate voids present in its structure (Beg et al., 2016). Because of the poor 
flow behaviour of formulations prepared at low concentrations in addition to difficulty of 
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handling of solid mixtures prepared at higher ratios, these solid mixtures were excluded 
from further studies. 
The results of determination of flow parameters of solid SNEDDS formulations 
produced using Neusilin® US2 as an adsorbent for indomethacin liquid SNEDDS 
formulations (F13 – F16) are summarized in Table 4.5. The estimated values of angle of 
repose (39.27 ± 0.26 to 44.96 ± 1.13) indicated that all indomethacin-loaded solid 
SNEDDS formulations prepared at different carrier: liquid SNEDDS ratios exhibited fair 
to passable flow.  On the other hand, the determined values of CI% (21.43 ± 3.34 to 
32.82 ± 0.45) and HR (1.27 ± 0.04 to 1.49 ± 0.01) for these solid SNEDDS formulation 
indicated a flow behavior ranging from passable to very poor flow.  It was also noticed 
that addition of Neusilin® US2 to liquid SNEDDS formulations (F13 or F15) resulted in 
solid mixtures with high values of CI% and HR and hence, poor to very poor flow 
characteristics. Higher oil content of liquid SNEDDS formulations: F13 and F15 (as 
presented in Table 4.1) may contribute to production of greasy solid mixtures upon their 
addition to Neusilin® US2. These greasy solid mixtures may not fill properly into capsules 
and may not be easily processed into tablet dosage forms. On the other hand, solid 
mixtures produced by adsorption of liquid SNEDDS formulations (F14 or F16) onto 
Neusilin® US2 exhibited passable flow as indicated by their CI% (21.43 ± 3.34 to 24.95 ± 
3.54) and HR (1.27 ± 0.04 to 1.33 ± 0.06) values. Acceptable flow potential of solid 
mixtures produced using Neusilin® US2 may be due to high adsorption capacity of this 
carrier (2.7 to 3.4 ml/g) in addition to its larger surface area (≈300 m2/g) (Tan et al., 
2013). Thus, drug-loaded solid SNEDDS formulations prepared using Neusilin® US2 and 
liquid SNEDDS (F14 & F16) at the ratios of 1: 1.5 and 1: 2 were selected for further 
investigation because of their free flowing characteristics and higher content of the drug.  
Flow parameters of solid SNEDDS formulations prepared using Florite® PS-200 
(calcium silicate) as a carrier for loading indomethacin liquid SNEDDS formulations (F13 
– F16) are presented in Table 4.6. It can be noticed that incorporation of liquid SNEDDS 
formulations, F13 or F15, onto Florite® PS-200 resulted in solid SNEDDS formulations 
with flow potential ranging between passable and poor flow characteristics as designated 
by angle of repose (40.44 ± 0.42 to 49.14 ± 0.33), CI% (19.74 ± 0.44 to 25.57 ± 1.79) 
and HR (1.26 ± 0.01 to 1.34 ± 0.03). These poor flow properties could be due to higher 
oil content of liquid SNEDDS formulations F13 & F15 (Table 4.1) that may lead to 
formation of excessively greasy solid mixtures that may be difficult to manipulate during 
further conversion into capsules or tablets. However, incorporation of liquid SNEDDS 
formulations F14 or F16 onto Florite® PS-200 produced solid SNEDDS formulation with 
improved flow properties as shown by the values obtained for angle of repose (37.78 ± 
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1.08 to 44.97 ± 0.34), CI% (15.54 ± 3.62 to 24.83 ± 3.07) and HR (1.19 ± 0.05 to 1.33 ± 
0.06). Addition of higher amounts of liquid formulations F13 and F14 to the carrier (in 
adsorbent: liquid SNEDDS ratios of 1: 1.5 and 1: 2) resulted in solid mixtures with much 
improved flow characteristics. This may be due to the deep and large macropores of 
Florite® PS-200 that may provide high oil adsorption capacity (3.7 ml/g) (Tan et al., 
2013). Therefore, indomethacin-loaded solid SNEDDS formulations prepared with 
Florite® PS-200 and liquid SNEDDS (F14 & F16) at higher ratios (1: 1.5 and 1: 2) were 
chosen for further evaluation because of their free flowing properties and higher content 
of the drug.   
The flowability parameters obtained for drug-loaded solid SNEDDS formulations 
prepared by adsorption of liquid SNEDDS formulations (F13 – F16) onto Syloid® XDP 
3150 (mesoporous or amorphous silicon dioxide) are shown in Table 4.7. It was 
observed that addition of liquid SNEDDS formulations of indomethacin (F13 – F16) to 
Syloid® XDP 3150 resulted in solid SNEDDS formulations with acceptable flow properties 
(angle of repose: 36.23 ± 0.50 to 43.48 ± 0.89; CI%: 3.51 ± 3.04 to 18.92 ± 2.88; HR: 
1.05 ± 0.00 to 1.23 ± 0.07). This could be due to the characteristic network of meso-
pores of this grade of Syloid® excipient which provides high oil adsorption capacity (≈3.8 
ml/g) for this carrier (Grace GmbH, 2012). Also, better flow properties were noticed for 
solid SNEDDS formulations produced upon incorporation of F14 or F16 onto Syloid® 
XDP 3150 at adsorbent: liquid SNEDDS ratios of 1: 1.5 and 1: 2. Therefore, these solid 
formulations were selected for additional investigation.    
Overall, different flow properties of various solid SNEDDS formulations produced 
by adsorption onto different solid carriers could be due to differences in physicochemical 
properties as well as oil adsorption capacity of these materials. Inadequate flow 
characteristics observed for indomethacin-loaded solid SNEDDSs developed using MCC 
or Aerosil® 200; and confirmed by estimated values of angle of repose, CI% or HR; 
suggested that these groups of formulations may not be suitable for further processing 
into solid dosage forms like capsules or tablets. Hence, these formulations were 
excluded from further analysis or evaluation tests.   
On the other hand, indomethacin-loaded solid SNEDDSs developed using 
Neusilin® US2, Florite® PS-200 or Syloid® XDP 3150 as solid carriers showed better flow 
properties as indicated by the determined values of different flowability parameters. 
Specifically, the use of these adsorbents for loading liquid formulations F14 & F16 at 
adsorbent: liquid SNEDDS ratios of 1: 1.5 and 1: 2 resulted in solid mixtures with 
optimum flow characteristics.  These free flowing solid SNEDDS formulations of 
indomethacin prepared with higher amounts of liquid SNEDDS formulations will 
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consequently contain higher amounts of the drug and therefore, an amount equivalent to 
the pharmacological dose of the drug can be weighed from theses formulations and filled 
into capsules for additional analysis.   Thus, these optimum 12 indomethacin-loaded 
solid SNEDDS formulations prepared from F14 & F16 (highlighted in red in Tables 4.5 – 
4.7) that showed the smallest droplet size of nanoemulsion among other optimized liquid 
SNEDDS formulations (F13 & F15) were selected to be subjected for further 
characterization to investigate the effect of solidification method on different properties of 
the produced solid SNEDDS formulations such as self-emulsifying properties, droplet 
size, dissolution characteristics, in addition to identification of crystalline or amorphous 
state of the drug. 
New formulation codes were given for the selected optimum indomethacin-loaded 
solid SNEDDS formulations. These formulation codes, in addition to formulation 
composition, are shown in Table 4.8 and will be used in the following sections of this 
chapter to designate different solid SNEDDS formulations of indomethacin prepared from 
the corresponding carrier and liquid indomethacin-loaded SNEDDS formulations.  
 
Table  4.8  Codes and composition of optimum indomethacin-loaded solid SNEDDS 
formulations 
Code  Adsorbent used  Liquid Indomethacin 
loaded-SNEDDS 
Ratio of (adsorbent: 
liquid SNEDDS) 
S1 Syloid® XDP 3150 F14 1:1.5 
S2   1:2 
S3  F16 1:1.5 
S4   1:2 
N1 Neusilin® US2 F14 1:1.5 
N2   1:2 
N3  F16 1:1.5 
N4   1:2 
R1 Florite® PS-200 F14 1:1.5 
R2   1:2 
R3  F16 1:1.5 
R4   1:2 
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4.4.4. Drug content of different indomethacin-loaded solid SNEDDS 
formulations 
The results of drug content of different indomethacin-loaded solid SNEDDS 
formulations are summarized in Table 4.9. It was observed that all solid SNEDDS 
formulations prepared using any of the three solid adsorbents (Syloid® XDP 3150, 
Neusilin® US2 or Florite® PS-200) revealed values ranging from 94.79% ± 2.23% to 
98.84% ± 1.12% calculated as % of theoretical amount added. According to the U.S. 
FDA (2003) on ‘blend uniformity’, a given batch of powder may pass drug content 
uniformity test if the assay of 60 samples or more from that batch showed a relative 
standard deviation (RSD) ≤ 4%.  Although analysis of large number of samples was 
difficult and not possible with lab scale experiments, results of drug content obtained for 
various powder formulations (Table 4.9) with acceptable values of RSD <3% may 
indicate that the method adopted in this work is capable of producing solid SNEDDS 
formulations with reasonable values of content uniformity. Less than 100% drug content 
values obtained for the tested solid SNEDDS formulations may possibly be attributed to 
adherence (or sticking) of liquid SNEDDS formulation to the sides of the mortar, and 
hence loss of drug, during mixing and preparation of different formulations. Similar 
findings and interpretation were given by Gumaste et al. (2013a) in the evaluation of 
drug content of various powder formulations prepared by adsorption of liquid SEDDS of 
probucol onto Neusilin® US2 at 1:1 w/w ratio.   
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Table  4.9  Results of drug content (Mean ± SD) of different indomethacin-loaded 
solid SNEDDS formulations   
Code  
Drug content (Mean ± SD) 
RSD (%) 
mg / g % of theoretical  
S1 14.26 ± 0.39 95.06 ± 2.59 2.73 
S2 16.11 ± 0.17 96.65 ± 1.05 1.09 
S3 14.32 ± 0.40 95.47 ± 2.65 2.78 
S4 15.91 ± 0.32 95.47 ± 1.89 1.98 
N1 14.22 ± 0.33 94.79 ± 2.23 2.35 
N2 16.10 ± 0.42 96.61 ± 2.53 2.62 
N3 14.56 ± 0.18 97.06 ± 1.22 1.26 
N4 15.87 ± 0.42 95.20 ± 2.54 2.67 
R1 14.83 ± 0.17 98.84 ± 1.12 1.13 
R2 16.14 ± 0.43 96.80 ± 2.59 2.68 
R3 14.24 ± 0.42 94.93 ± 2.81 2.96 
R4 16.07 ± 0.37 96.42 ± 2.23 2.31 
 
4.4.5. Redispersibility of solid SNEDDS formulations (Droplet size 
measurement) 
The redispersibility of the formulated indomethacin-loaded solid SNEDDS was 
evaluated by reconstituting the powder formulation in deionized water followed by 
measuring the droplet size, polydispersity index and zeta potential of the resulting 
nanoemulsions and then comparing the values obtained to those recorded previously for 
liquid SNEDDS formulations, from which powder formulations were generated.  The 
droplet size is an important factor in immediate self-emulsification performance because 
it provides information on the rate and extent of in vitro drug dissolution as well as the in 
vivo absorption. Smaller droplet size allows faster dissolution rate and provides larger 
interfacial surface area for in vivo drug absorption (Weerapol et al., 2015a).   
The results of measurement of droplet size, polydispersity index and zeta 
potential obtained for solid SNEDDS formulations prepared with Syloid® XDP 3150 (S1 –
S4), Neusilin® US2 (N1 – N4) or Florite® PS-200 (R1 – R4) as well as those obtained for 
optimized liquid SNEDDS formulations (F14 & F16) are presented in Table 4.10. 
Obtained results confirmed insignificant difference (p > 0.05) in the mean droplet size of 
nanoemulsions generated from all solid SNEDDS prepared using the three silicate-
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based adsorbents. Also, results showed that the mean droplet size of nanoemulsions 
produced from dispersed solid SNEDDS formulations (18.49 ± 1.15 to 24.24 ± 0.18 nm) 
were not significantly different (p > 0.05) from the mean droplet size obtained for liquid 
formulations; F14 (20.68 ± 0.03 nm) and F16 (22.69 ± 0.06 nm).  
In addition, low PDI values (0.12 ± 0.004 to 0.31 ± 0.02) were observed for all 
indomethacin-loaded solid SNEDDS formulations which indicate uniform size distribution 
of nanoemulsions generated from tested powder formulations. This could be due to the 
optimized properties of liquid SNEDDS (F14 & F16), shown previously in Chapter 3, 
such as high surfactant content (46.7% – 52.5%), low oil content (30%) in addition to 
high polarity of their oil component; Capryol™ 90 (C8, HLB = 6) (Elkadi et al., 2017).    
The values of zeta potential of the formulated indomethacin-loaded solid 
SNEDDS are also presented in Table 4.10. The zeta potential values observed for all 
solid SNEDDS formulations were comparable to the reasonable zeta potential values 
noticed for the original liquid SNEDDS formulations.  High negative values of zeta 
potential observed for all solid formulations indicate that nanoemulsions produced from 
tested formulations are highly stable and may less likely flocculate in liquid medium or in 
GI fluids (Bali et al., 2011).   
The results of redispersibility indicate that the self-emulsification ability of liquid 
SNEDDS formulations was preserved and maintained even after solidification by 
adsorption onto suitable solid carriers. Similar findings were reported for self-
nanoemulsifying powders of isradipine (Ramasahayam et al., 2015), solid self-
microemulsifying dispersible tablets of celastrol (Qi et al., 2014) and oral self-emulsifying 
powder of lercanidipine hydrochloride (Kallakunta et al., 2012).  
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Table  4.10 Mean droplet size, PDI and zeta potential of formulated indomethacin-












F14* 20.68 ± 0.03 0.11 ± 0.020 -25.2 8.31 
F16* 22.69 ± 0.06  0.13 ± 0.004 -16.2 9.95 
S1 23.90 ± 0.06 0.24 ± 0.001 -20.6 7.31 
S2 24.24 ± 0.18 0.27 ± 0.003 -16.5 3.78 
S3 20.08 ± 0.66 0.26 ± 0.020 -28.0 4.19 
S4 21.33 ± 1.35 0.23 ± 0.030 -21.7 5.35 
N1 22.06 ± 0.16 0.14 ± 0.010 -22.9 4.27 
N2 22.38 ± 0.02 0.30 ± 0.020 -21.0 6.35 
N3 20.62 ± 0.12 0.23 ± 0.002 -21.5 5.27 
N4 19.23 ± 0.49 0.22 ± 0.020 -18.0 6.02 
R1 21.80 ± 0.07 0.12 ± 0.004 -23.1 4.13 
R2 20.96 ± 1.44 0.31 ± 0.020 -24.2 5.77 
R3 18.49 ± 1.15 0.26 ± 0.050 -24.8 5.60 
R4 20.41 ± 0.76 0.31 ± 0.010 -23.4 5.23 
* Optimized indomethacin–loaded  liquid SNEDDS formulations. 
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4.4.6. Solid state characterization of indomethacin-loaded solid SNEDDS 
formulations 
4.4.6.1. FTIR spectroscopy 
FTIR studies were performed to ascertain if there was any incompatibility and/or 
interaction between the drug and the adsorbents used in preparation of indomethacin-
loaded SNEDDS formulations. FTIR is used for this purpose because each compound 
absorbs specific radiation frequencies according to its molecular structure. In an FTIR 
spectrum, the two most important regions to be examined are located in the ranges 
between 4000 – 1300 and 900 – 650 cm-1. The intermediate region of the spectrum that 
falls in the range of 1300 – 900 cm-1 is known as the ‘fingerprint’ region (Dupeyrón et al., 
2013). Mixing of a drug with an excipient at the molecular level may cause changes in 
FTIR spectrum of the formulation comprising the drug and the excipient. These changes 
can be observed in the form of disappearance, shifting or broadening of the 
characteristic peaks of the drug and the excipient used (Lim et al., 2013).   
FTIR spectra of indomethacin, different drug-loaded solid SNEDDS formulations 
and the corresponding carrier used in various formulations are shown in Figures 4.2, 4.3 
and 4.4. The resulting FTIR spectrum of pure indomethacin showed specific peaks for 
the γ-polymorph of indomethacin (Dupeyrón et al., 2013). Two strong peaks were 
observed in drug FTIR spectrum with the peak appearing at 1716 cm-1 related to 
asymmetric acid C=O of a cyclic dimer, while the peak showing at 1692 cm-1 related to 
the benzoyl C=O (Taylor and Zografi, 1997). Also, other absorption peaks were recorded 
at 2925 cm-1 (C-H stretching vibrations), 1223 cm-1 (asymmetric aromatic O-C 
stretching), and 1068 cm-1 (symmetric aromatic O-H stretching). The absorption patterns 
of indomethacin in the region of 1300 – 650 cm-1 are complex because of the aromatic 
structure of this compound. Therefore, strong or medium intensity bands appearing in 
this region may be non-specific and less useful for structural characterization, while a 
weak intensity band in the region above 2000 cm-1 may be group-specific (Dupeyrón et 
al., 2013). 
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Syloid® XDP 3150 (amorphous silicon dioxide) showed principal peaks at 3346, 
1630, 1086, 799 and 458 cm-1 (Figure 4.2). The FTIR spectrum of all solid SNEDDS 
formulations prepared with this carrier (S1 – S4) exhibited all characteristic peaks of 
Syloid® XDP 3150 at the same positions in addition to characteristic drug peaks at 2925, 
1716, 1223 and 1068 cm-1. Presence of specific drug peaks in the spectra of different 
solid SNEDDS formulations indicates that the molecular structure of indomethacin 
remained intact. Absence of some drug peaks in the spectra of these solid SNEDDS 
formulations may be because these peaks are more likely to be hidden in the baseline of 
the corresponding spectra. In addition, no chemical interaction occurred between the 
drug and the carrier in drug-loaded solid SNEDDS formulations (S1 – S4) because no 
new extra peaks were observed in their FTIR spectra. Similarly, solid SEDDS of glipizide 
prepared with the adsorbent; Syloid® 244 FP which is similar to Syloid® XDP 3150 used 
in this study; did not exhibit chemical interaction upon investigation of the corresponding 




Figure  4.2 FTIR spectra of indomethacin, Syloid® XDP3150 and various drug-loaded 
solid SNEDDS formulations. 
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The FTIR spectrum of Neusilin® US2 (magnesium aluminometa silicate) shown in 
Figure 4.3 is characterized by the absorption peaks at 3444, 1638, 1380, 1041 and 472 
cm-1. All solid SNEDDS formulations prepared using Neusilin® US2 (N1 – N4) showed 
the absorption peaks of the carrier at the same position as well as the characteristics 
peaks of the drug mentioned earlier. No chemical interaction was detected within these 
solid SNEDDS formulations as evidenced by absence of new extra peaks in their 
corresponding spectra. Similar FTIR findings were reported for solid SNEDDS 
formulated with Neusilin® US2 such as isradipine-loaded self-nanoemulsifying powders 
(Ramasahayam et al., 2015) and Valsartan-loaded solid self-nanoemulsifying granules 
(Beg et al., 2012).  
 
 
Figure  4.3 FTIR spectra of indomethacin, Neusilin® US2 and various drug-loaded 
solid SNEDDS formulations.  
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The FTIR spectrum of Florite® PS-200 (calcium silicate) presented in Figure 4.4 
showed absorption peaks at 3448, 1637, 1348, 1039, 784, 607 and 467 cm-1. All 
absorption peaks of Florite® PS-200 were observed at the same position in FTIR spectra 
of solid SNEDDS formulations prepared using this carrier (R1 – R4). Also, the 
characteristics peaks of the drug mentioned before were present in the spectra of 
Florite® PS-200-based formulations. In addition, absence of new peaks in these spectra 
indicates that no chemical interaction occurred between the drug and Florite® PS-200 in 




Figure  4.4 FTIR spectra of indomethacin, Florite® PS-200 and various drug-loaded 
solid SNEDDS formulations. 
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4.4.6.2. Differential scanning calorimetry (DSC) studies 
DSC studies allow determination of physical state, thermotropic phase transition 
and thermal behaviour of drug within the formulation (Kallakunta et al., 2012, 
Ramasahayam et al., 2015). DSC traces of different indomethacin-loaded solid SNEDDS 
powder formulations prepared by adsorption of optimized drug-loaded liquid SNEDSs 
onto different solid adsorbents are shown in Figures 4.5, 4.6 and 4.7.  
The DSC trace of pure indomethacin reflects the presence of the drug in the 
crystalline state with a sharp endothermic peak at 162.31oC which corresponds to its 
melting point, with ΔH (enthalpy) of 106.2950 J/g. In Figure 4.5, it appears that Syloid® 
XDP 3150 (amorphous silicon dioxide) showed no thermal transitions over the entire 
range of temperature examined. Also, no representative peaks of indomethacin were 
observed in the DSC traces of drug-loaded solid SNEDDS prepared with Syloid® XDP 
3150 (S1 – S4).  
 
 
Figure  4.5 DSC traces of indomethacin, Syloid® XDP 3150 and various drug-loaded 
solid SNEDDS formulations. 
  





The broad endothermic peak of Neusilin® US2 (magnesium aluminometa silicate) 
observed at 228.61oC (Figure 4.6) indicates the amorphous nature of this solid carrier. 
No representative peaks of crystalline indomethacin were detected for drug-loaded solid 
SNEDDS prepared with Neusilin® US2 (N1 –N4).  
 
 








In Figure 4.7, the DSC trace of the solid carrier; Florite® PS-200 (calcium 
silicate); did not present any prominent peak over the entire range of the tested 
temperature. Also, no obvious endothermic peak relating to the melting of crystalline 
indomethacin was noticed in all drug-loaded solid SNEDDS powder formulations 
prepared with Florite® PS-200 (R1 – R4). 
 
Figure  4.7  DSC traces of indomethacin, Florite® PS-200 and various drug-loaded 
solid SNEDDS formulations.  
 
Overall, it can be anticipated that absence of a characteristic endothermic peak 
corresponding to the melting of crystalline indomethacin in all drug-loaded solid 
SNEDDS formulations prepared with the employed solid carriers; Syloid® XDP 3150, 
Neusilin® US2 and Florite® PS-200; indicates that the drug remained in a molecularly 
dissolved state within the self-nanoemulsifying powder formulations. Previous reports 
suggested that the use of similar grades of the above carriers to formulate different solid 
SEDDS maintained the drug in a dissolved state within differently formulated solid 
SEDDS.  For example, utilization of Syloid® 244FP (porous silicon dioxide) (Agrawal et 
al., 2015, Weerapol et al., 2015a), Neusilin® US2 (magnesium aluminometasilicate) 
(Inugala et al., 2015, Kallakunta et al., 2012, Parmar et al., 2015, Ramasahayam et al., 
2015), or Florite® RE (porous calcium silicate) (Weerapol et al., 2015a, Weerapol et al., 
2015b) to formulate solid SEDDS produced formulations that did not show any crystalline 
peak of the corresponding drugs as confirmed by the DSC studies.      
  




4.4.6.3. Powder X-ray diffraction (XRD) studies 
XRD analysis is a technique that provides information on the degree of 
crystallinity and amorphous content of pharmaceutical formulations. It is also useful for 
quantitative analysis of pharmaceutical mixtures to determine exact percentage of 
components of a formulation (Gilmore, 2011). In this study, qualitative XRD studies were 
carried out in order to evaluate the crystallinity of the drug within the formulated products. 
Different XRD patterns obtained for different indomethacin-loaded solid SNEDDS 
powder formulations prepared with different solid carriers are depicted in Figures 4.8, 
4.9 and 4.10. For the purpose of comparison, XRD patterns of indomethacin and carriers 
employed in different formulations were also obtained. 
Indomethacin diffractogram showed characteristics narrow and sharp diffraction 
peaks at 2θ values of 11.9o, 13o, 17.2o, 19.9o, 20.6o, 21.2o, 22.1o, 23.4o, 24.3o, 26.9o, 
29.7o and 31.9o which correspond to the crystalline nature of the drug. The obtained 
diffractogram of indomethacin is similar to those reported in previous studies (Dupeyrón 
et al., 2013, Lim et al., 2013).  
  




The XRD pattern of Syloid® XDP 3150 (amorphous silicon dioxide) which is 
presented in Figure 4.8, showed no sharp intrinsic peaks. Instead, a halo peak appears 
centred on 2θ value of 21o which indicates the amorphous nature of this carrier. Also, it 
was noticed that the XRD patterns of all solid SNEDDS formulations prepared with 
Syloid® XDP 3150 (S1 – S4) showed an amorphous halo at 2θ values of 21o as observed 
for the amorphous carrier. In addition, absence of distinctive crystalline peaks of 
indomethacin in the diffrctograms of solid SNEDDS (S1 – S4) indicates that the drug 
remained in a molecularly dissolved state within solid powder formulations prepared with 
Syloid® XDP 3150.  Similar findings were reported for solid-SEDDS of glipizide 
formulated with porous silicon dioxide (Syloid® 244FP) as an adsorbent. The XRD 
patterns of glipizide-loaded solid SEDDS revealed the absence of crystalline peak of the 
drug which confirmed the presence of the drug in a solubilized state within the solid 
SEDDS formulation (Agrawal et al., 2015).  
 
Figure  4.8 XRD diffractograms of indomethacin, Syloid® XDP 3150 and various drug-
loaded solid SNEDDS formulations. 
  




The X-ray diffractograms of Neusilin® US2 (magnesium aluminometa silicate) and 
the solid SNEDDS formulated with this adsorbent are presented in Figure 4.9. Neusilin® 
US2 showed no high intensity peaks but two halo peaks were noticed centred on 2θ 
values of 20.6o and 35o. No obvious peaks of crystalline indomethacin were observed for 
all solid SNEDDS formulations prepared with Neusilin® US2 (N1 – N4). This may be 
because the drug remained in a dissolved state within the self-emulsifying liquid 
formulation even after adsorption onto Neusilin® US2. Similar observations were reported 
for self-nanoemulsifying powder of isradipine (Ramasahayam et al., 2015) and self-
emulsifying powder of lercanidipine hydrochloride (Kallakunta et al., 2012) prepared 
using Neusilin® US2 as adsorbent. Investigation of the XRD patterns of these two self-
emulsifying powder formulations revealed absence of characteristic drug peaks which 
was attributed to the fact that the drug remained in a molecularly dissolved state upon 
adsorption of the liquid self-nanoemulsifying formulations onto Neusilin® US2 (Kallakunta 
et al., 2012, Ramasahayam et al., 2015).   
 
 
Figure  4.9 XRD diffractograms of indomethacin, Neusilin® US2 and various drug-
loaded solid SNEDDS formulations. 
 
  




Figure 4.10 shows the X-ray diffractograms of Florite® PS-200 (calcium silicate) 
and indomethacin-loaded solid SNEDDS prepared with this carrier. Florite® PS-200 
diffractogram showed sharp diffraction peaks at 2θ values of 5.6o, 10.6o, 21.2o, 28.5o, 
38.1o, 44.3o and 50o which correspond to partial crystalline nature of this carrier. 
Diffraction peaks of Florite® PS-200 were obvious in XRD diffractograms of all drug-
loaded solid SNEDDS formulated with this adsorbent (R1 – R4).  Again, absence of 
sharp crystalline peaks of the drug in diffractograms of Florite® - based solid powder 
formulations indicates that the drug remained molecularly solubilized within the self-
emulsifying liquid formulation after solidification process. Similarly, absence of crystalline 
peaks of the drug was observed in XRD patterns of self-emulsifying powder of nifidipine 
formulated using a similar grade of porous calcium silicate (Florite® RE) (Weerapol et al., 
2015a). 
 
Figure  4.10 XRD diffractograms of indomethacin, Florite® PS-200 and various drug-
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4.4.6.4. Scanning electron microscopy (SEM) studies 
Surface morphology of pure indomethacin powder, Syloid® XDP 3150, Neusilin® 
US2, Florite® PS-200 and their corresponding solid SNEDDS powder formulations was 
studied using scanning electron microscopy. The micrographs obtained are presented in 
Figures 4.11, 4.12 and 4.13.  
 
Figure  4.11 SEM micrographs of indomethacin, Syloid® XDP 3150 and various drug-
loaded solid SNEDDS formulations. 
 
 




Figure  4.12 SEM micrographs of indomethacin, Neusilin® US2 and various drug-











Figure  4.13 SEM micrographs of indomethacin, Florite® PS-200 and various drug-
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SEM of pure indomethacin particles revealed multi-faceted structures with 
smooth surfaced rectangular crystals. As depicted in Figure 4.11, irregularly shaped 
granules of various sizes were observed in SEM of Syloid® XDP 3150 particles and drug-
loaded solid SNEDDS prepared with this adsorbent (S1 – S4). In addition, no crystals of 
indomethacin were obvious on the surface of solid SNEDDS powder formulations after 
adsorbing the liquid SNEDDS formulations onto Syloid® XDP 3150. Similar SEM 
observations were reported for glipizide-loaded solid SEDDS prepared by adsorption of 
optimized liquid SEDDS onto Syloid® 244FP (Agrawal et al., 2015).  
Micrographs of Neusilin® US2 and its corresponding indomethacin-loaded solid 
SNEDDS formulations (N1 – N4) are presented in Figure 4.12. Neusilin® US2 appeared 
as highly porous granular material with a pore size that may reach up to 1µm in 
diameter. These large pores may classify this carrier as highly macroporous (Gumaste et 
al., 2013b).  However, Neusilin® US2 has been classified as a mesoporous material with 
pore size in the range of 2 – 50 nm, while materials with pore size < 2 nm are considered 
microporous (Qian and Bogner, 2012). SEM of drug-loaded solid SNEDDS formulated 
with Neusilin® US2 (N1 – N4) showed rough surfaced particles which may be due to 
partial spreading of part of the liquid formulation on the surface of the carrier after 
adsorption of most of the liquid formulation into the mesopores and deep into the 
channels of the macropores (Gumaste et al., 2013b). Also, no obvious precipitation of 
indomethacin was noticed on the surface of these powder formulations. Similar SEM 
observations were reported for solid SNEDDS of darunavir (Inugala et al., 2015) and 
self-nanoemulsifying powder of isradipine (Ramasahayam et al., 2015) prepared using 
Neusilin® US2 as adsorbent.   
Figure 4.13 shows the SEM micrographs of Florite® PS-200 and drug-loaded 
solid SNEDDS prepared with this carrier (R1 – R4). Florite® PS-200 appeared as 
granular and highly porous material. This carrier is considered as a mesoporous and 
macroporous adsorbent (Qian and Bogner, 2012, Weerapol et al., 2015b).  The 
appearance in the micrographs of powder formulations prepared with Florite® PS-200 
(R1 – R4) was similar to that obtained for the carrier raw material. This indicates that 
most of the liquid SNEDDS formulations were adsorbed deeply into the macropores and 
also into the mesopores of the carrier. Also, no evidence of crystals of indomethacin was 
observed in the micrographs of solid SNEDDS tested (R1 – R4). These findings are 
consistent with previous SEM results obtained for self-emulsifying powder formulations 
loaded with different drugs such as nifidipine, felodipine, manidipine and itraconazole 
and prepared using porous calcium silicate (Florite® RE) as adsorbent (Weerapol et al., 
2015b).   
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Absence of any crystals of indomethacin on the surface of the drug-loaded solid 
SNEDDS prepared with the above mentioned carriers indicates that the drug remained in 
a molecularly dissolved state within formulations even after adsorption onto the surface 
of different carriers. 
The effect of the addition of higher amounts of liquid SNEDDS formulation on the 
appearance of particles of different solid carriers was also examined in the SEM 
micrographs of various solid SNEDDS formulations presented in Figures 4.11, 4.12 and 
4.13. When liquid SNEDDS formulation was mixed with the adsorbent in adsorbent: 
liquid SNEDDS ratio of 1: 1.5, the liquid formula adsorbed into most the pores and also 
deposited on the surface of the particles of the carrier and resulted in the surface 
roughness observed in the corresponding micrographs of S1, S3 (Figure 4.11), N1, N3 
(Figure 4.12), R1 and R3 (Figure 4.13). Upon further addition of the liquid formulation to 
the carrier in an adsorbent: liquid SNEDDS ratio of 1: 2, additional adsorption into the 
pores and covering of the surface of the carrier were observed as the solid SNEDDS 
powder mixtures were still flowable and their corresponding micrographs of S2, S4 
(Figure 4.11), N2, N4 (Figure 4.12), R2 and R4 (Figure 4.13) were still showing rough 
surfaced granules. These findings are in agreement with previous report (Gumaste et al., 
2013b) that has found that increasing the lipid content in a mixture of Cremophor® EL 
and Neusilin US2 resulted in further deposition and covering of the surface of silicate 
carrier after adsorption of most of the liquid into the pores of the carrier as confirmed by 
the SEM analysis of the obtained powder mixtures.    
4.4.7. In vitro dissolution studies 
Dissolution of indomethacin from different drug-loaded solid SNEDDS prepared 
with different solid carriers was carried out in phosphate buffer pH 7.2 and compared to 
the dissolution from pure drug.  The dissolution profiles obtained are shown in Figures 
4.14, 4.15 and 4.16. It was observed that hard gelatin capsules disintegrated and 
released its content after 90 seconds of the start of the dissolution studies. Different solid 
SNEDDS showed maximum percentage of the drug release within 15 – 20 minutes, 
however, the dissolution studies were continued for 1 hour to detect any precipitation or 
variation that may occur over a period of time (Kallakunta et al., 2012). Pharmacopoeial 
standards of the dissolution of active substance filled in capsule dosage forms require 
not less than 80% of the active ingredient to go into solution within 45 minutes (British 
Pharmacopoeia, 2015).  However, comparison of different dissolution profiles based on 
this approach of single point measurement may not sufficiently characterize the 
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dissolution process (Podczeck, 1993). Therefore, different dissolution parameters such 
as the mean dissolution time (MDT), the dissolution efficiency after 15 minutes (%DE15) 
in addition to the % released after 15 minutes (%Q15) were calculated for different tested 
formulations and are presented in Table 4.11.  
 
 
Figure  4.14 In vitro dissolution profiles of pure indomethacin, drug-loaded solid 
SNEDDS formulations (S1 – S4) and optimized liquid SNEDDS 































Figure  4.15  In vitro dissolution profiles of pure indomethacin, drug-loaded solid 
SNEDDS formulations (N1 – N4) and optimized liquid SNEDDS 




Figure  4.16  In vitro dissolution profiles of pure indomethacin, drug-loaded solid 
SNEDDS formulations (R1 – R4) and optimized liquid SNEDDS 
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Table  4.11  Mean dissolution time (MDT), mean dissolution efficiency (%DE15) and % 
released after 15 minutes (%Q15) calculated for pure indomethacin, drug-





(mean ± SD) 
%DE15  
(mean ± SD) 
%Q15  
(mean ± SD) 
F14 3.54 ±  1.03 76.32 ± 3.71 99.01 ± 2.41 
F16 4.12 ± 0.78 74.05  ± 2.85 97.10 ±1.87 
S1 5.18 ± 1.84 49.24 ± 3.50 74.17 ± 2.11 
S2 10.03 ± 0.66 32.96 ± 1.38 56.62 ± 2.25 
S3 7.97 ± 1.32 43.07 ± 2.66 66.77 ± 1.40 
S4 8.85 ± 0.44 37.11 ± 4.51 61.86 ± 1.20 
N1 4.50 ± 1.89 56.23 ± 2.24 78.87 ± 3.19 
N2 11.77 ± 1.70 34.57 ± 4.66 55.20 ± 4.95 
N3 5.52 ± 1.19 50.88 ± 2.46 67.47 ± 2.14 
N4 9.21 ± 0.87 42.27 ± 3.27 62.65 ± 3.38 
R1 5.62 ± 0.98 68.63 ± 0.74 95.46 ± 1.11 
R2 4.05 ± 1.60 60.91 ± 1.09 82.14 ± 1.02 
R3 5.23 ± 1.11 67.62 ± 0.77 89.01 ± 0.80 
R4 4.31 ± 0.43 64.27 ± 0.80 86.05 ± 0.32 
Pure drug 27.32 ± 4.32* 7.28 ± 1.08* 14.64 ± 2.47* 
*Significant difference at p < 0.05. 
 
Indomethacin-loaded liquid SNEDDS formulations (F14 & F16) exhibited optimal 
dissolution performance when compared to other formulations. This was indicated by 
significantly higher %DE15 and significantly lower values of MDT (p < 0.05) when 
compared to those of solid SNEDDS formulations or to that obtained for pure drug filled 
in capsules (Table 4.11). High dissolution profiles of liquid SNEDDS are due to quick 
formation of o/w nanoemulsions with small droplet size upon exposure to dissolution 
medium with gentle agitation. In addition, the presence of the drug in a dissolved state in 
liquid SNEDDS formulations avoids the dissolution rate-limiting step required for 
crystalline drugs (Agrawal et al., 2015). However, the dissolution of indomethacin from 
the pure drug was significantly lower and slower (p < 0.05), compared to that observed 
for all of the various drug-loaded liquid and solid SNEDDS formulations, because of poor 
aqueous solubility and poor wettability of the drug. Poor wetting properties of 
indomethacin could be due to high surface free energy which may lead to predominant 
cohesive forces between drug particles over the adhesive forces between the drug and 
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aqueous medium which then inhibits the development of an interface (Ramasahayam et 
al., 2015).  
On the other hand, the dissolution of indomethacin from different solid SNEDDS 
formulations (Figures 4.14 – 4.16) was intermediate between the maximum dissolution 
shown by liquid SNEDDS formulations (F14 & F16) and the minimum dissolution 
exhibited by pure drug powder. Higher dissolution profiles were observed for solid 
SNEDDS formulations prepared with Florite® PS-200 (R1 – R4) (Figures 4.16) 
compared to that obtained for solid formulations prepared with Syloid® XDP 3150 (S1 – 
S4) (Figures 4.14) or Neusilin® US2 (N1 – N4) (Figures 4.15).  These differences could 
be due to that part of the drug remained adsorbed within the formulations prepared with 
Syloid® XDP 3150 or Neusilin® US2 and when equilibrium was attained between the 
amount of the drug dissolved and the amount remained within the solid carrier, no further 
dissolution was observed.   
It is evident from the dissolution parameters presented in Table 4.11 that the 
dissolution efficiency (%DE15) of indomethacin from different solid SNEDDS formulations 
prepared with different carriers showed 4.5 – 9.4 fold increase in comparison to %DE15 of 
pure drug. Rapid drug release from solid SNEDDS powder formulations may be due to 
rapid emulsification caused by low surface free energy of self-emulsifying systems which 
may result in quick formation of an interface between oil droplets and the dissolution 
medium (Craig et al., 1995). Also, it was proposed that decreased droplet size caused by 
swelling of oil/surfactant/co-surfactant and water phases may lead to increased 
dissolution rate (Balakrishnan et al., 2009b).  In addition, increased dissolution of the 
drug from solid SNEDDS formulations could be attributed to high surface area and high 
porosity of the carriers used in different formulations. High surface area of the carrier 
may improve wettability and molecular dispersion of the drug while high porosity may 
allow quick entrance of the dissolution medium into the pores with subsequent rapid 
emulsification. Furthermore, rapid drug release from solid SNEDDS powder formulations 
may be due to that the drug remained in a dissolved state after adsorption of the liquid 
SNEDDS on to adsorbents and this was apparent from the physicochemical 
characterization of various solid SNEDDS studied.      
From the dissolution parameters calculated and presented in Table 4.11, it was 
observed that indomethacin-loaded solid SNEDDS formulations prepared with Florite® 
PS-200 (R1 – R4) exhibited higher dissolution profiles and, consequently, higher 
dissolution efficiency (%DE15 ) when compared to formulations prepared with Neusilin® 
US2 (N1 – N4) or Syloid® XDP 3150 (S1 – S4). These differences could be attributed to 
differences in specific surface area of the used carriers. Florite® PS-200 (calcium silicate) 
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possesses the lowest specific surface area (120 m2/g) compared to Neusilin® US2; 
magnesium aluminometasilicate (300 m2/g) or Syloid® XDP 3150; amorphous silicon 
dioxide (320 m2/g). According to Ito et al. (2005), porous carriers with low specific 
surface area may enhance dispersion of the drug in the dissolution medium and lead to 
faster dissolution and hence, faster absorption. However, adsorbents with high specific 
surface area may not sufficiently disperse the drug and therefore may result in lower 
dissolution rate and bioavailability. Similar findings were reported for gentamycin sulfate 
dispersed in Labrasol® and adsorbed onto the surface of different silicate-based 
adsorbents (Ito et al., 2005). Higher dissolution rate and bioavailability of the drug was 
obtained from formulations prepared with the low specific surface area carrier; Florite® 
RE; compared to formulations prepared with Neusilin® US2 or Sylysia® 320 which 
exhibited higher specific surface area. However, the use of another grade of calcium 
silicate (Hubersorb® 5121), with low specific surface area (50 m2/g), to adsorb SEDDS of 
griseofulvin resulted in slow dissolution profile of the drug compared to other solid 
SEDDS of griseofulvin prepared with larger surface area carriers such as Neusilin® US2  
or silicon dioxide (Agarwal et al., 2009). This observation was ascribed to adsorption of 
larger amount of the formulation onto the surface of calcium silicate leading to increased 
contact and, hence, hydrophobic interaction between the drug and the adsorbent surface 
with subsequent precipitation of the drug (Agarwal et al., 2009).   
The dissolution performance of indomethacin-loaded solid SNEDDS produced 
with Neusilin® US2 (N1 – N4) was intermediate (Figure 4.15 & Table 4.11) between 
those observed for formulations produced with Florite® PS-200 (R1 – R4) or Syloid® XDP 
3150 (S1 – S4). This could be due to intermediate specific surface area of Neusilin® US2 
(300 m2/g), compared to other adsorbents, which may result in lesser dispersibility of the 
drug and hence, lower dissolution rate (Ito et al., 2005). Also, decreased dissolution 
profiles of formulations produced with Neusilin® US2 may be due to entrapment of liquid 
SNEDDS formulation in the characteristic long and narrow pores of this carrier which 
may reduce drug release. Greater pore length may reduce the rate of leaching of the 
formulation to the surrounding medium and also diminish access of the dissolution 
medium to rehydrate the entrapped liquid formulation (Agarwal et al., 2009). Similar 
findings were reported for the dissolution of loratadine from porous polystyrene beads 
(Patil and Paradkar, 2006) and also for dissolution of griseofulvin from solid SEDDS 
prepared using magnesium aluminometasilicate as adsorbent (Agarwal et al., 2009). The 
release of indomethacin from solid SNEDDS formulations increased gradually due to 
gradual access of the dissolution medium to the self-emulsifying formulation present in 
the pores of the carrier.   
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Solid SNEDDS formulations prepared with Syloid® XDP 3150 (S1 – S4) showed 
lower dissolution performance (Figure 4.14 & Table 4.11) compared to formulations 
prepared with Neusilin® US2 (N1 – N4) or Florite® PS-200 (R1 – R4). This may be due to 
high specific surface area of this carrier (320 m2/g), compared to other adsorbents used, 
which may lead to insufficient dispersion of the drug and consequent lower dissolution 
rate (Ito et al., 2005).  Also, possible gelation of silicon dioxide may lead to formation of a 
barrier that may retard drug release from the corresponding formulations (Weerapol et 
al., 2015a). Additionally, insufficient porosity of this carrier may cause ineffective wetting 
of drug particles entrapped in the pores (Krupa et al., 2015). Similar findings were 
reported for nifidipine-loaded self-emulsifying powder prepared with similar grade of 
porous silicon dioxide (Syloid® 244FP) (Weerapol et al., 2015a).   
In general, it appears that drug release from solid SNEDDS powder formulations 
depends on the physical characteristics of solid adsorbents in addition to the molecular 
interaction between the drug, lipid/surfactant/co-surfactant mixture and the solid carrier 
(Tan et al., 2013).  According to Agarwal et al. (2009), different factors may affect the 
dissolution performance from solid SEDDS prepared by adsorption onto silica-based 
carriers. Increased length of the pores may decrease access of water to entrapped drug 
and diminish hydration of the formulation (Agarwal et al., 2009). The effect of specific 
surface area of the carrier on the dissolution profile of solid SEDDS formulations may be 
variable. Some authors (Agarwal et al., 2009) showed that low specific surface area may 
lead to adsorption of liquid formulation onto the surface of the carrier in the form of thin 
films rather than entrapping inside the pores. Presence of thin films of the formulation on 
the surface of the adsorbent may increase hydrophobic interaction between the drug and 
the adsorbent and therefore the drug precipitates on the surface of the adsorbent 
resulting in lower dissolution performance. However, Ito et al. (2005), have proposed that 
carriers with low specific surface area may facilitate dispersion of the drug in the 
dissolution medium leading to faster dissolution performance, while carriers with high 
specific surface area may not adequately disperse the drug and this may result in 
reduced dissolution behavior. In addition, high affinity of drug particles towards the 
carrier may increase the risk of drug precipitation and hence, reduce the extent of drug 
dissolution (Agarwal et al., 2009). 
Higher values of dissolution efficiency (Table 4.11) were observed for solid 
SNEDDS formulations (S1, S3, N1, N3, R1 and R3) prepared from the liquid formula; 
F14, than that calculated for powder formulations (S2, S4, N2, N4, R2 and R4) produced 
from the liquid formula; F16.  This may be attributed to smaller droplet size observed for 
F14 (20.68 ± 0.03 nm) in comparison to that observed for F16 (22.69 ± 0.06 nm), which 
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may lead to rapid emulsification of liquid formulation entrapped in the pores of the carrier 
with quick formation of an interface between oil droplets and dissolution medium 
(Balakrishnan et al., 2009a, Craig et al., 1995).   
Further inspection of the dissolution parameters presented in Table 4.11 
revealed that increasing the amount of indomethacin-loaded liquid SNEDDS in 
formulation of solid SNEDDS powders S2, S4, N2, N4, R2 and R4 resulted in decreased 
dissolution performance. This was evident by decreased dissolution efficiency (%DE15) 
and increased MDT values of these formulation when compared to solid SNEDDS 
formulations prepared with lesser amount of liquid SNEDDS (S1, S3, N1, N3, R1 and 
R3). This could be due to the fact that increasing the amount liquid formulation will fill all 
the pores of the carrier and may result in difficult wetting of excess drug molecules 
entrapped in the pores of the solid carrier and this may lead to decreased drug 
dissolution (Krupa et al., 2015). These results are similar to those obtained for ibuprofen-
loaded solid self-emulsifying powders prepared with different Neusilin® grades, where 
increasing the amount of liquid lipid formulation adsorbed on the surface of Neusilin 
resulted in a decrease in the amount of drug released (Krupa et al., 2015). However, 
increasing the amount of griseofulvin SEDDS adsorbed onto silicon dioxide resulted in 
increased dissolution profiles which was ascribed to different levels of pore filling and 
entrapment of the lipid formulation droplets within the pores with minimal interaction with 
the carrier (Agarwal et al., 2009). 
It is also worthy to note that changes in MDT values upon incorporation of higher 
amounts of liquid SNEDDS formulations were less noticeable in formulations prepared 
with Florite® PS-200 (R1 – R4) even though the pattern of changes in the values of 
%DE15 or %Q15 was consistent with those calculated for other solid SNEDDS prepared 
with Neusilin® US2 (N1 – N4) or Syloid® XDP 3150 (S1 – S4). These insignificant 
changes in MDT may be due to high dissolution rate produced by Florite® PS-200 as a 
carrier and the slight differences observed between dissolution profiles of these 
formulations (R1 – R4)  
 Conclusions 4.5.
In this part of the study, formulation of solid SNEDDS formulations from liquid 
SNEDDS was investigated in order to avoid different disadvantages associated with 
conventional filling of liquid formulations into capsules. Drug-loaded solid SNEDDS were 
developed by adsorption of liquid SNEDDS formulations onto solid carriers. 
Indomethacin-loaded liquid SNEDDS (F14 & F16) composed of appropriate 
concentrations of Capryol™ 90 as oil phase, Cremophor® RH40 as surfactant and 
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Transcutol® HP as co-surfactant were selected as optimized formulations because they 
exhibited good self-nanoemulsifying properties with robustness to dilution, rapid 
emulsification,  thermodynamic stability and nano sized globules.   
 The optimized liquid SNEDDS (F14 & F16) were transformed into solid SNEDDS 
powder formulations by physical adsorption onto different solid carriers including Syloid® 
XDP 3150 (amorphous silicon dioxide), Neusilin® US2 (magnesium aluminometasilicate) 
and Florite® PS-200 (calcium silicate). Evaluation of different indomethacin-loaded solid 
SNEDDS powder formulations revealed good flowability and reasonable values of drug 
content. In addition, formulated solid SNEDDS preserved self-nanoemulsification 
properties and produced clear nanoemulsion with droplet size similar to that of the liquid 
SNEDDS formulations.        
Physicochemical characterization of produced solid SNEDDS concluded the 
presence of the drug in a dissolved state within powder formulations, as indicated by 
DSC measurement and XRD analysis.  
In addition, all drug-loaded solid SNEDDS formulated with different carriers 
exhibited improved dissolution profiles compared to that of the pure powder of drug 
because of their ability to introduce liquid SNEDDS formulations into the dissolution 
medium and subsequent formation of nanoemulsions by gentle agitation. Enhanced 
dissolution behaviour was dependent on the physicochemical properties of carriers used 
in formulations and this variation was supported by dissolution parameters calculated for 
different formulations. Powder formulations produced by adsorption of liquid SNEDDS 
formulation (F14) onto Florite® PS-200 (R1 & R3) showed optimum dissolution behaviour 
compared to other solid SNEDDS formulations tested. This was due to low specific 
surface area of the carrier which enhanced dispersion of the drug in the dissolution 
medium and led to rapid formation of spontaneous nanoemulsion with small droplet size.  
Therefore, properties of solid carriers have great impact on drug dissolution profile from 
solid SNEDDS and thus must be considered in rationalizing development of solid 
SNEDDS formulations.  
Overall, it could be concluded that indomethacin-loaded solid SNEDDS 
formulations may successfully introduce the drug in an immediate-release capsule 
dosage forms with enhanced solubility and dissolution behaviour. Increased dissolution 
of indomethacin from solid SNEDDS formulations suggests that these formulations may 
represent promising systems for oral administration of poorly soluble (BCS class II) 
drugs such as indomethacin.    
 
     
 
 
Chapter 5  
Development and evaluation of Gelucire®-based solid 
SNEDDS formulations of indomethacin 




Lipid based formulations are one of the most widely investigated approaches for 
delivering BCS class II drugs that possess low solubility and high permeability and 
therefore, reduced oral bioavailability. Self-emulsifying systems were considered as a 
popular approach for administration of poorly water soluble drugs for which absorption is 
dissolution rate-limited. Self-emulsifying systems are isotropic mixtures of oil, surfactant 
and co-surfactant which emulsify spontaneously to give fine oil in water emulsion upon 
exposure to liquid medium under gentle agitation. Conventionally, these mixtures are 
filled in hard or soft gelatin capsules for ease of oral administration. However, interaction 
of the components of self-emulsifying systems with the capsule shell and possible 
leaking of the formulation from the capsule are common problems with liquid-filled 
capsules (Patil and Paradkar, 2006). Therefore, solidification of liquid formulations was 
proposed to avoid stability and handling problems. Various approaches of solidification 
have been reported in literature to formulate solid SEDDS such as using goat fat as an 
oil phase (Attama et al., 2003), loading into porous polystyrene beads (Patil and 
Paradkar, 2006) or formulation of gelled SEDDS that can act as an intermediate to 
develop solid sustained release SEDDS (Patil et al., 2004). In addition, different studies 
in literature have discussed transformation of liquid self-emulsifying systems into solid 
formulations using the method of blending liquid systems with solid excipients such as 
cellulose or silicate-based excipients to produce powder mixtures that are free-flowing 
and can be compressed into tablets (Agrawal et al., 2015, Inugala et al., 2015, 
Ramasahayam et al., 2015, Wang et al., 2010). However, these solidification methods 
require higher ratios of solidifying materials to SEDDS to produce solid mixtures with 
suitable processing characteristics, which may not be suitable for drugs with limited 
solubility in oil phase (Patil and Paradkar, 2006). Also, incomplete drug dissolution and 
low drug loading (Nazzal and Khan, 2006) in addition to poor flow characteristics of 
resulting powder (Agarwal et al., 2009) may be encountered with these different 
solidification approaches.   
Solidification of liquid lipid formulations can be also achieved by direct dispersion 
of poorly water soluble drugs in solid or semi-solid carriers which could be lipids in nature 
or possess surface active properties. Such methods of solidification may exclude the 
need for filing liquid lipid formulation into hard or soft gelatin capsules. For example, 
direct dissolving of a poorly water soluble compound in a solid matrix of PEG 3350 and 
Polysorbate 80 resulted in physically and chemically stable formulation (Li et al., 2009). 
Also, utilization of a mixture of PEG 6000 and vitamin E (TPGS) as solubilizing carrier 
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matrix to formulate solubilizing solid dispersions of antimalarial drug, halofantrine, 
resulted in 5 – 7 folds increase in absolute oral bioavailability in beagle dogs (Khoo et al., 
2000). However, the proportion of surfactants or lipids used in these studies was not 
adequate to maintain the drug in a solubilized state in the formulation or after dispersion 
in aqueous medium (Li et al., 2009).  On the other hand, Shah and Serajuddin (2012) 
have demonstrated that mixing various lipids with PEG 8000 or Poloxamer 188 
(Pluronic® F68 NF) produced solid systems depending on the composition of lipids used. 
Only lipids with high percentage of monoesters or monoglycerides in their structure were 
able to form solid products with PEG 8000 or Poloxamer 188, while lipids containing 
higher proportion of di- and tri-glycerides or propylene glycol diesters were unable to 
form solid systems. Addition of solid systems prepared with Poloxamer 188 to water 
resulted in emulsification and dispersion of oil globules, while solid systems prepared 
with PEG 8000 did not emulsify upon dispersion in water indicating that Poloxamer 188 
possess surfactant properties that lead to emulsification (Shah and Serajuddin, 2012).    
Therefore, utilization of solidifying vehicles that possess self-emulsifying or 
surface active properties may assist in producing solid self-emulsifying systems that may 
instantaneously self-emulsify upon dispersion in a liquid phase leading to improved 
solubility of incorporated poorly soluble drugs and therefore, enhanced dissolution and 
oral bioavailability.  
Gelucires® are novel excipients that possess the ability to solidify upon cooling 
and to self-emulsify upon dispersion in aqueous medium.  These excipients are inert, 
solid (or semisolid), waxy and amphiphilic materials with surface active properties that 
spontaneously form fine emulsions upon contact with water. These polymeric materials 
are saturated polyglycolized glycerides that consist of mono-, di- and tri-glycerides in 
addition to mono- and di-fatty acid esters of PEG. The proportion and type of each 
component can determine the hydrophobicity and hydrophilicity of the carrier and may 
control drug release properties from the dosage form.  Different types of Gelucires® can 
be identified by two numeric values referring to their melting point (33°C – 65°C) and 
hydrophilic – lipophilic balance (HLB) values (1–18).  The wide range of the melting 
points and different proportions of hydrophilic and lipophilic components of Gelucires® 
contribute to the wide applicability of these carriers in formulation of different dosage 
forms with different release characteristics (Kalpana et al., 2015).   
Generally, Gelucire® grades with high HLB values are employed to enhance the 
solubility of poorly soluble drugs and subsequently improve their in vitro dissolution and 
in vivo bioavailability (Barker et al., 2003, da Fonseca Antunes et al., 2013, Karataş et 
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al., 2005, Yüksel et al., 2003), while those with low HLB values are used to formulate 
controlled release matrices (Dennis et al., 1990, Galal et al., 2004).  
In this study, Gelucire® 44/14 and Gelucire® 48/16 were evaluated as self-
emulsifying vehicles in formulation of solid SNEDDS of indomethacin.  Each of these two 
carriers possesses unique properties upon contact with aqueous solutions due to their 
characteristic chemical composition. For instance, Gelucire® 44/14 combines mono and 
di-esters of PEG which may act as surfactants, monoglycerides which may perform as 
co-surfactants and di- and triglycerides which constitute the oily portion of the molecule 
(Chambin and Jannin, 2005). Gelucire® 44/14 spontaneously emulsifies upon contact 
with aqueous fluids due to its well-balanced proportions of short, medium and long chain 
fatty acids. The resultant fine oil in water emulsion droplets show a size ranging from few 
nanometers up to 300 nm (Chambin and Jannin, 2005).  This carrier is considered as a 
non-ionic surfactant (Abdul-Fattah and Bhargava, 2002) that has the ability to form 
micelles at concentrations of 2 µg/ml or 10 µg/ml (Kawakami et al., 2004, Schamp et al., 
2006). The ability of Gelucire® 44/14 to form micelles may allow this carrier to increase 
the solubility of poorly soluble compounds in aqueous media by the micellar 
solubilization approach. Also, Gelucire® 44/14 may decrease the interfacial tension 
between poorly soluble drugs and aqueous fluid resulting in decreased contact angle 
between drug particles and dissolution medium and hence, leading to improved wetting 
and dissolution by preventing aggregation of particles (Damian et al., 2000).  
On the other hand, Gelucire® 48/16 is also a non-ionic surfactant that does not 
contain glyceride components. It is mainly composed of PEG esters of stearic and 
palmitic fatty acids. Similarly to Gelucire® 44/14, this carrier self-emulsifies into fine oil in 
water emulsions upon contact with aqueous medium. It also has the ability to form 
micelles at a concentration of 153 µg/ml and therefore, may improve solubility of poorly 
soluble drugs by micellar solubilization (Gattefossé, 2015).         
Several previous studies have reported the use of different Gelucire® grades to 
enhance the solubility and oral bioavailability of various drugs. For example, Gelucire® 
44/14 was successfully employed alone or in combination with other excipients to 
improve solubility and dissolution performance of piroxicam (Karataş et al., 2005), 
carbamazepine (da Fonseca Antunes et al., 2013), aceclofenac (Kalpana et al., 2015) 
and naproxen (Nagabandi et al., 2014). Also, improved oral bioavailability of α–
tocopherol (Barker et al., 2003), halofantrine (Khoo et al., 2000), and piroxicam (Yüksel 
et al., 2003) upon dispersion in Gelucire® 44/14 was reported(Yüksel et al., 2003)(Yüksel 
et al., 2003). Further utilization of different grades of Gelucires® such as Gelucire® 50/13 
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to formulate solid dispersions of indomethacin (El-Badry et al., 2009), loratadine (Bandari 
et al., 2014) and carvedilol (Potluri et al., 2011) has resulted in significant increase in 
solubility and dissolution behavior of these poorly water soluble drugs. Moreover, 
investigation of the solubilizing properties of the newly introduced grade, Gelucire® 
48/16, when used in formulation of solid dispersions of piroxicam or curcumin revealed 
significant increase in solubility of both compounds (Gattefossé, 2015).  
Improvement of solubility and dissolution rate of poorly soluble drugs by different 
grades of Gelucires® was attributed to solubilizing effects and self-emulsifying properties 
of these carriers (Gattefossé, 2012, Karataş et al., 2005). It was reported that Gelucire® 
48/16 self-emulsifies in aqueous liquids to form micellar solutions that may encapsulate 
drug particles within micelles leading to solubilization of poorly soluble drugs (Ganesh, 
2016, Gattefossé, 2015).  Gelucires® may also improve wetting of drug particles in the 
dissolution medium resulting in enhanced solubility and dissolution performance (El-
Badry et al., 2009, Karataş et al., 2005, Potluri et al., 2011). Furthermore, enhancement 
of oral bioavailability of poorly soluble drugs when dispersed in Gelucires® was explained 
on the basis of improvement of lymphatic transport and intestinal permeability of drug 
particles (Hauss et al., 1998).   
Literature data lack information on the development of solid self-nanoemulsifying 
formulations using Gelucires® alone. Therefore, based on the self-emulsifying properties 
of Gelucires® and their ability to solidify upon cooling, it was proposed to investigate the 
feasibility of using Gelucires® as single self-emulsifying carriers to produce solid 
SNEDDS of indomethacin by direct dispersion of the drug in the carrier. Because of the 
self-emulsifying and solidifying properties of Gelucires®, utilization of a certain grade of 
Gelucires® as a single carrier may replace the components of the liquid SNEDDS (lipid, 
surfactant and co-surfactant) that were investigated in Chapter 3 of this project and also 
may replace using solid carriers utilized to solidify the liquid SNEDDS formulations that 
was described previously in Chapter 4.  Application of Gelucires® as self-emulsifying and 
solidifying agents may bypass the problems associated with the production of liquid self-
emulsifying formulations and exclude the need for further solidification processes 
because solidification can be simply achieved upon cooling of the melted mixture of the 
drug and the surface active excipient.  Also, the use of a single excipient with self-
emulsifying properties to formulate solid SNEDDS is expected to allow higher drug load 
to be incorporated in the formulation because no other liquid or solid excipients will be 
needed. Further, this work aims to investigate the applicability of the hot melt extrusion 
(HME) technique as a means of scaling up the production of Gelucire®-based solid 
SNEDDS. HME allows more efficient melting, mixing and temperature control to produce 
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stable formulations. Compared to traditional melting and solvent techniques, HME 
provides a continuous process with controlled processing parameters, doesn’t require 
solvents and can be scaled to produce appropriate pharmaceutical batch sizes.  
As a part of this study, the potential of using Gelucire® as a self-emulsifying 
vehicle was assessed by evaluating the self-nanoemulsification efficiency, droplet size 
and dissolution profiles of the produced indomethacin-loaded solid SNEDDS 
formulations. Further, various solid SNEDDS formulations produced were physically 
characterized to determine the effect of the used carrier on crystallinity of the drug as 
well as the in vitro dissolution.   
5.2. Materials 
• Indomethacin was obtained from Sigma-Aldrich Chemie GmbH, Germany. 
• Gelucire® 44/14, Gelucire® 50/13 and Gelucire® 48/16 were kindly provided by 
Gattefossé Co., France. 
• Neusilin®US2 (magnesium aluminometasilicate) was kindly provided by Fuji 
Chemical Industry (Japan). 
• Florite®PS-200 (calcium silicate) was kindly provided by Tomita Pharmaceutical Co. 
(Japan). 
• Potassium dihydrogen orthophosphate anhydrous was obtained from Loba Chemie 
Pvt. Ltd. (Mumbai, India). 
• Sodium hydroxide was obtained from Fluka Chemie GmbH (Germany). 
• Calcium chloride was obtained from Sigma Aldrich (U.K.). 
• Methanol was obtained from Fisher Scientific UK Limited (Leicestershire, UK).  
• Deionized water was purified using an Ultra-purification Water System, Millipore Co. 
Ltd. (Bedford, MA, USA). 
• Hard gelatin capsules were obtained from pharma tradechem (Mumbai, India). 
  




5.3.1. Construction of a standard calibration curve of indomethacin in 
phosphate buffer pH 7.2 
The standard calibration curve of indomethacin constructed in phosphate buffer 
pH 7.2, as described in Chapter 4, was utilized for this part of the study. The inter-day 
accuracy as well as the intra-day and inter-day precision (reproducibility) of the assay 
procedure for determination of indomethacin concentrations in phosphate buffer were 
evaluated as previously presented in Chapter 3.   
5.3.2. Phase solubility study of indomethacin in different Gelucires® 
Phase solubility studies were conducted according to the method of Damian et al. 
(2000) to determine the grade of Gelucires® (Gelucire® 44/14, Gelucire® 50/13 or 
Gelucire® 48/16) that may exhibit maximum solubilizing potential for indomethacin. 
Different concentrations of each Gelucire® grade (1%, 3%, 5%, 10% and 15%) were 
prepared in purified water. An excess amount of the drug was added to each of these 
concentrations. All systems were mixed and kept shaking for 48 hours in an isothermal 
shaking water bath adjusted at 25oC. After equilibrium, samples were centrifuged at 3000 
rpm for 15 minutes to remove undissolved drug and then filtered through a 0.45 µm 
membrane filter. Parts of the filtered samples were suitably diluted and assayed for the 
drug at 320 nm against a blank prepared from each carrier in purified water. Three 
determinations of indomethacin solubility were carried out for each sample and the 
results are presented as mean ± SD.   
From the results of phase solubility studies, Gelucire® grades that showed 
maximum solubility of the drug were selected for further investigation.        
5.3.3. Thermogravimetric analysis (TGA) 
Thermal stabilities of indomethacin, Gelucire® 44/14, Gelucire® 48/16, Neusilin® 
US2 and Florite® PS-200 were determined in the temperature range of 30oC to 250oC, at 
a heating rate of 10oC/min using TGA 7 (Perkin Elmer, USA) fitted with Pyris manager 
software (version 5.00.02, Perkin Elmer, USA). Samples of approximately 10 mg were 
used and the percentage loss in weight was calculated at different temperatures.  
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5.3.4. Formulation of Gelucire®-based solid SNEDDS of indomethacin 
 Based on the results of phase solubility studies, Gelucire® 44/14 and Gelucire® 
48/16 were selected to formulate Gelucire®-based solid SNEDDS of indomethacin. 
Different physical mixtures of indomethacin and any Gelucire® were prepared at the 
drug: carrier ratios of 0.5: 10, 1: 10, 2: 10 and 3: 10.  The amount of the carrier in each 
formulation was kept constant in order to evaluate the effect of increasing drug load on 
the self-emulsifying properties as well as the dissolution performance of different 
formulations. Further investigation of the effect of addition of solid adsorbents on 
dissolution behaviour of Gelucire®-based solid SNEDDS formulations was also 
proposed. Therefore, adsorbents such as Neusilin® US2 or Florite® PS-200 (optimized 
from Chapter 4) were added to the optimized Gelucire®-based formulations. For this 
purpose, new physical mixtures of indomethacin, Gelucire® 48/16 and any of the 
proposed adsorbents were also prepared in the ratios of 2: 10: 0.12 and 2: 10: 0.36, 
respectively. The added amounts of the adsorbent constituted about 1% w/w or 3% w/w 
of the total formulation.  
 HME processing of different physical mixtures prepared with Gelucire® 44/14 was 
carried out at 40oC, while mixtures prepared with Gelucire® 48/16 were processed at 
both 40oC and 50oC. Therefore, the temperature of the extruder barrel was adjusted at 
either 40oC (below the melting point of both Gelucire® grades) or at 50oC which 
corresponds to the melting point of Gelucire® 48/16, while the rotational speed of the 
screws was adjusted at 30 rpm. Each physical mixture was introduced into a co-rotating 
twin screw extruder (micro-compounder, MC15, Xplore Instruments BV, Sittard, The 
Netherlands) through the hopper. The introduced mass was mixed for 5 minutes inside 
the barrel before extrusion through a die with 1 mm diameter. The collected mass was 
allowed to cool at room temperature, then cut or crushed into small pieces. The crushed 
mass was then sieved through a 500 µm sieve and the obtained granular product was 
stored in a desiccator over anhydrous calcium chloride until further evaluation. Codes 
and composition of different indomethacin solid SNEDDS formulations produced by HME 
using Gelucire® 44/14, Gelucire® 48/16 and adsorbents are presented in Table 5.1.   
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Table  5.1 Codes and composition of different Gelucire®-based solid SNEDDS of 











40 Gelucire® 44/14 ……. 
0.5: 10: 0 
G2 1: 10: 0 
G3 2: 10: 0 
G4 3: 10: 0 
G5 
40 Gelucire® 48/16 ……. 
0.5: 10: 0 
G6 1: 10: 0 
G7 2: 10: 0 
G8 3: 10: 0 
G9 
50 Gelucire® 48/16 ……. 
0.5: 10: 0 
G10 1: 10: 0 
G11 2: 10: 0 
G12 3: 10: 0 
G13 
40 Gelucire® 48/16 Neusilin® US2   
2: 10: 0.12 
G14 2: 10: 0.36 
G15 
40 Gelucire® 48/16 Florite® PS-200 
2: 10: 0.12 
G16 2: 10: 0.36 
 
5.3.5. Evaluation of produced Gelucire®-based solid SNEDDS of 
indomethacin 
5.3.5.1. Determination of drug content 
As previously mentioned in Chapter 2, drug content was determined for 
Gelucire®-based solid SNEDDSs to ensure equal distribution of the powdered drug within 
different formulations produced (Gumaste et al., 2013a). An accurately weighed amount 
of each formulation was dispersed in a suitable quantity of methanol and mixed 
thoroughly for 10 minutes to confirm dissolution of the drug into the methanol. The 
samples were filtered through a 0.45 µm membrane filter, suitably diluted and assayed 
for the drug at 320 nm against a reference standard. The drug content in each sample 
was calculated as previously described in Chapter 4 using the following equation: 
 % 𝑑𝑟𝑑𝑑 𝑐𝑐𝑡𝑡𝑐𝑡𝑡 = 𝑑𝑟𝑑𝑑 𝑐𝑐𝑐𝑑𝑐𝑐𝑑 𝑐𝑓 𝑑ℎ𝑐 𝑓𝑐𝑟𝑓𝑑𝑠𝑡𝑑𝑖𝑐𝑐
𝑤𝑐𝑖𝑑ℎ𝑑 𝑐𝑓 𝑑ℎ𝑐 𝑓𝑐𝑟𝑓𝑑𝑠𝑡𝑑𝑖𝑐𝑐 𝑑𝑡𝑡𝑐𝑐 × 100  (Equation 5.1) 
All experiments were repeated in triplicates and the results were presented as mean ± 
SD. 
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5.3.5.2. Self-nanoemulsification efficiency tests 
Self-nanoemulsification tests were carried out to determine the possibility of drug 
precipitation that may take place upon dilution of formulations with purified water. These 
tests were carried out using a method similar to that adopted for liquid SNEDDS 
formulations described previously in Chapter 3. An amount equivalent to 25 mg of 
indomethacin was weighed from each Gelucire®-based solid SNEDDS formulation and 
added to 200 ml of purified water (maintained at 37oC) in dissolution apparatus and 
stirred at 50 rpm until complete dissolving. Signs of precipitation of the drug in each 
formulation sample were recorded and self-nanoemulsification performance of the 
formulation was evaluated visually according to different grading scales defined by Khoo 
et al. (1998) and described earlier in Chapter 3. 
5.3.5.3. Determination of droplet size  
Redispersibility and droplet size of all Gelucire®-based solid SNEDDSs of 
indomethacin were assessed according to the method of Kanaujia et al. (2014) using 
Malvern Zetasizer nano-ZS (Malvern Instruments, Worchestershire, UK). Each 
formulation sample was dispersed in deionized water to obtain a final drug concentration 
of 100 µg/ml. Mixtures were shaken gently for 5 minutes, centrifuged at 3000 rpm for 15 
minutes and then filtered through a 0.45 µm syringe filter. The average globule size, 
polydispersity index and zeta potential of the nanoemulsion formed from Gelucire®-based 
solid SNEDDSs were determined by Malvern Zetasizer. All measurements were made in 
triplicates and the results are presented as mean ± SD. 
5.3.5.4. Determination of solubility of the drug in Gelucire®-based solid SNEDDS 
formulations 
Measurement of the solubility of the drug in different formulations obtained was 
carried out according to the method of El-Badry et al. (2009). An excess amount of each 
Gelucire®-based solid SNEDDS formulation was added to phosphate buffer pH 7.2. The 
samples were mixed and shaken for 48 h at 37oC in an isothermal shaking water bath. 
After equilibrium, samples were filtered through 0.45 µm membrane filter, suitably diluted 
and assayed for the drug at 320 nm against a blank prepared with the excipient used. All 
determinations were repeated in triplicates and the results were presented as mean ± 
SD.  
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5.3.6. Solid state characterization of Gelucire®-based solid SNEDDS of 
indomethacin 
5.3.6.1. Fourier transform infrared spectroscopy (FTIR) 
In order to identify possible interactions between indomethacin, different 
Gelucires® and adsorbents used in formulation of Gelucire®-based solid SNEDDSs, FTIR 
spectra of the different formulations obtained were recorded in the scanning range of 
4000 – 400 cm-1 using a Fourier transform infrared (FTIR) spectrophotometer (Nicolet 
6700, Thermo Fisher Scientific, USA).  The individual FTIR spectra of indomethacin, 
Gelucires® and the adsorbents were also obtained for the purpose of comparison. The 
test was performed by mixing an amount of each formulation sample (4 mg) with dry 
potassium bromide (IR grade, 200 mg) and compaction of the lightly ground mixture into 
a disc using hydraulic press. Scanning was performed at a speed of 4 scans/second.     
5.3.6.2. Differential scanning calorimetry (DSC) 
In order to determine the physical state of indomethacin in the formulated 
Gelucire®-based solid SNEDDS, the thermal behavior of indomethacin, Gelucires®, 
adsorbents and different formulations was studied using conventional DSC analysis 
(DSC 4000, Perkin Elmer, US). An accurately weighed sample (5 – 10 mg) was sealed in 
a flat bottomed standard aluminum pan and scanned at a heating rate of 10oC/ minute 
from 25 – 300 oC under a nitrogen gas flow rate of 20 ml/min. 
5.3.6.3. Powder X-ray diffraction (XRD) 
To characterize the physical state of the drug in different formulations obtained, 
the X-ray diffraction studies were performed for indomethacin, Gelucires®, adsorbents 
and Gelucire®-based solid SNEDDS formulations using an Ultima IV-diffractometer 
(Rigaku Co., Ltd., Tokyo, Japan) equipped with a copper X-ray source maintained at 40 
kV of tube voltage and 40 mA of tube current to produce emissions of 0.15406 nm. The 
samples were scanned at 3 − 60° 2θ range at a scanning speed of 0.5 deg. /min. Data 
were collected using a step scan mode with step size of 0.02o and counting time of 1 
second per step. 
5.3.6.4. Scanning electron microscopy (SEM) 
The surface morphology of indomethacin, Gelucires®, and Gelucire®-based solid 
SNEDDS formulations were investigated using a JSM-6060LV scanning electron 
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microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 10 kV. Samples were 
lightly sprinkled onto double-sided sticky tape which then was affixed to an aluminum 
stub and made electrically conductive with a gold coating (13 – 14 nm/min; 45 s; 20 mA) 
under vacuum using JFC-1600 Auto Fine Coater (Jeol, Tokyo, Japan). Micrographs at 
different magnifications were recorded and analyzed for the surface morphological 
properties.  
5.3.7. In vitro dissolution studies 
In vitro dissolution studies of Gelucire®-based solid SNEDDS formulations were 
performed according to British Pharmacopoeia (2015) as previously described in 
Chapter 4. Briefly, an amount of each formulation equivalent to 25 mg of indomethacin 
was filled in a hard gelatin capsule and used for dissolution studies. Samples (5 ml) were 
withdrawn at predetermined time intervals, filtered through  a 0.45 µm syringe filter and 
assayed for indomethacin at 320 nm. An equal volume of fresh dissolution medium kept 
at 37oC was added to keep constant volume during dissolution study. For the purpose of 
comparison, the experiment was repeated with the same quantity of pure indomethacin 
powder (25 mg) filled in hard gelatin capsules. All experiments were performed in 
triplicates and results were averaged ± SD.  
Different dissolution parameters such as dissolution efficiency after 15 minutes 
(DE15min), mean dissolution time (MDT) and % released after 15 minutes (%Q15min) were 
used to compare the dissolution performance of different Gelucire®-based solid SNEDDS 
formulations. The DE15min was determined for the time intervals of dissolution study (from 
0 – 15 min) while MDT was calculated for all dissolution time interval (from 0 – 60 min) 
using DDSolver as Excel add inn. 
5.3.8. Statistical analysis 
Differences between the data of interest were detected using one way analysis of 
variance (ANOVA) and t-test. Significant differences were determined at a 5% 
significance level, unless otherwise stated elsewhere. Statistical differences yielding (p < 
0.05) were considered significant.   
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5.4. Results and discussion 
5.4.1. Phase solubility study of indomethacin in different Gelucires® 
The aqueous solubility of a drug is an important factor that determines its 
dissolution rate and hence, its bioavailability. Therefore, poorly water soluble drugs with 
aqueous solubility lower than 0.1 mg/ml show poor oral absorption due to limited 
dissolution (Horter and Dressman, 2001). Indomethacin, a weakly acidic drug, with a pKa 
value of 4.5, is considered as “practically insoluble” in simulated gastric fluid (pH 1.2) and 
“slightly insoluble” in simulated intestinal fluid (pH 7.4) (Nokhodchi et al., 2005). Variable 
or inconsistent estimations of aqueous solubility of indomethacin in purified water were 
reported in different studies (Palanisamy and Khanam, 2014, Shakeel et al., 2013a, 
Yadav and Yadav, 2009). These studies have reported aqueous solubility values for 
indomethacin, in water at 25oC, ranging between 0.00094 – 0.367 mg/ml.  The reported 
aqueous solubility of indomethacin in water was found to increase gradually with 
increasing temperature (Palanisamy and Khanam, 2014, Shakeel et al., 2013a). In this 
study, and as indicated previously in Chapter 3, the solubility of indomethacin in distilled 
water at 25oC was found to be 0.02 ± 0.01 mg/g, and therefore, improvement of solubility 
by the use of different grades of Gelucires® was investigated. Different types of 
Gelucires® increased the solubility of indomethacin based on their HLB values and 
concentrations used, as can be seen in the phase solubility diagrams of the drug 
depicted in Figure 5.1.  
 
Figure  5.1 Phase solubility diagram of indomethacin in aqueous solutions of different 
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It can be observed that at 25oC the solubility of indomethacin in purified water 
(0.02 ± 0.01 mg/ml) was significantly increased in aqueous mixtures prepared with 
increased concentrations of Gelucires®. For example, 5% aqueous solutions prepared 
with Gelucire® 50/13, Gelucire® 44/14 or Gelucire® 48/16 resulted in increased solubility 
of indomethacin by 47.5, 76.5 or 142.5 folds, respectively. An almost linear increase in 
solubility of the drug was observed with increasing the concentration of each Gelucire® 
grade.  
Improvement of the solubility of indomethacin in the presence of these 
amphiphilic carriers could be attributed to increased wettability and micellar solubilization 
of the drug (Damian et al., 2000, Horter and Dressman, 2001, Leuner and Dressman, 
2000). An indication of the transfer process of indomethacin from pure water to the 
aqueous solutions of different Gelucires® was obtained from the values of the Gibbs free 
energy change. The Gibbs free energy of transfer (ΔGotr) of indomethacin from pure 
water to aqueous solutions of Gelucires® can be calculated from the equation below 
(Damian et al., 2000):  
∆𝐺𝑑𝑟
𝑐 = −2.303 𝑅𝑀 𝑒𝑐𝑑 𝑆𝑜
𝑆𝑠
  (Equation 5.1) 
where So/Ss is the ratio of molar solubility of indomethacin in aqueous solutions of 
Gelucires® to that in pure water. The calculated values of Gibbs free energy presented in 
Table 5.2 provide information of increased solubility of indomethacin in the presence of 
different Gelucires®. The negative values of ΔGotr indicate spontaneous solubilization of 
indomethacin, and the decrease of these values with increasing the concentration of 
each Gelucire® grade indicates that the reaction became more favourable as the 
concentration of Gelucires® increased (Damian et al., 2000, Potluri et al., 2011). 
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Table  5.2 Solubility and thermodynamic parameters of indomethacin in aqueous 
solutions of different Gelucires® prepared at 25oC. 
Gelucire® 
(% w/v) 
















0% 0.02 ± 0.01 ….. 0.02 ± 0.01 ….. 0.02 ± 0.01 ….. 
1% 0.18 ± 0.09 -5.45 0.33 ± 0.11 -6.95 1.45 ± 0.28 -10.62 
3% 0.36 ± 0.21 -7.16 0.77 ± 0.08 -9.05 2.45± 0.17 -11.92 
5% 0.95 ± 0.09 -9.57 1.53 ± 0.33 -10.75 2.85 ± 0.29 -12.29 
10% 1.76 ± 0.25 -11.10 2.34 ± 0.40 -11.80 4.21 ± 0.52 -13.26 
15% 2.35 ± 0.32 -11.81 3.15 ± 0.31 -12.54 5.68 ± 0.33 -14.00 
 
In addition, the presence of Gelucires® in aqueous solutions may decrease the 
contact angle between drug particles and water leading to improved wettability of drug 
particles and hence, improved solubility. It was reported that larger contact angles (> 
65o) between particles and tested medium indicates a hydrophobic surface, while smaller 
contact angles (< 65o) represent a hydrophilic surface (Chambin et al., 2009). This 
suggests that when a poorly soluble drug is present in contact with a hydrophilic carrier, 
less hydrophobicity of the surface of drug particles is produced and this may promote 
contact with aqueous medium leading to increased solubility (Kallakunta et al., 2013).   
From Figure 5.1, it was also noticed that enhancement of indomethacin solubility 
in the presence of different grades of Gelucires® showed the following order: Gelucire® 
48/16 > Gelucire® 44/14 > Gelucire® 50/13. Among different amphiphilic carriers used, 
Gelucire® 48/16 showed the maximum solubilizing effect of indomethacin when 
compared to Gelucire® 44/14 or Gelucire® 50/13. Differences in enhancement of drug 
solubility by different grades of Gelucires® may be due to differences in the composition 
and HLB values of used carriers. Gelucire® 50/13 comprises a high percentage of long 
chain palmitic (C16) and stearic (C18) fatty acids, while Gelucire® 44/14 includes high 
proportions of lauric (C12) and myristic (C14) fatty acids (Gattefossé, 2012). On the other 
hand, Gelucire® 48/16 is mainly a PEG ester of palmitic (C16) and stearic (C18) fatty acids 
(Gattefossé, 2015). Differences in chemical compositions may influence the degree of 
hydrophobic interaction between drug particles and the core of the micelles produced by 
these surface active carriers. Additionally, it has been proposed that Gelucire® 50/13 is 
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able to exist in different crystalline forms which may influence the solubilizing properties 
of this carrier (Gattefossé, 2012, Karataş et al., 2005), while Gelucire® 44/14 possesses 
surface active properties and has the ability to self-emulsify when in contact with 
aqueous medium to produce fine emulsions (da Fonseca Antunes et al., 2013, 
Gattefossé, 2012). Similarly, Gelucire® 48/16 can self-emulsify when in contact with an 
aqueous fluid leading to formation of micellar solutions that may encapsulate drug 
particles within micelles (Gattefossé, 2015). 
Differences in the HLB values of different grades of Gelucires® may also be 
responsible for differences in their solubilizing potential of indomethacin. Enhancement 
of indomethacin solubility was more pronounced with aqueous solutions of Gelucire® 
48/16 than that obtained from aqueous solutions of Gelucire® 44/14 or Gelucire® 50/13. 
This could be due to higher HLB values of Gelucire® 48/16 which may enhance 
miscibility and dispersibility of the drug within the carrier leading to increased solubility 
(Kalpana et al., 2015).  
Based on the results obtained from phase solubility studies, Gelucire® 44/14 and 
Gelucire® 48/16 were selected to formulate Gelucire®-based solid SNEDDS of 
indomethacin by direct dispersion of the drug in these carriers. These carriers showed 
the maximum solubilizing potential for indomethacin due to their self-emulsifying 
properties, high HLB value and formation of micellar solutions that may entrap the poorly 
soluble drug molecules inside the micelles. Gelucire® 50/13 was not employed for further 
formulations because its solubilizing potential for indomethacin was lower than that 
obtained by Gelucire® 48/16 or Gelucire® 44/14. Also Gelucire® 50/13 does not possess 
self-emulsification properties when in contact with aqueous fluids and hence, will not be 
useful to formulate self-emulsifying formulations.        
5.4.2. Thermogravimetric analysis (TGA) 
TGA was performed to evaluate thermal stability of the drug and the carrier prior 
to their use in hot melt extrusion to produce carrier-based solid SNEDDS formulations. In 
the heating range (30oC – 250oC), an almost constant weight of indomethacin was 
observed until the temperature of 170oC which may indicate that the drug is stable and 
non-hygroscopic. However, about 0.5% loss in weight was observed at 200oC. In 
literature, it was reported that indomethacin is stable up to 248oC (Rusu et al., 2000).  
Also, a constant weight was maintained for both Gelucire® 44/14 and Gelucire® 48/16 
until 100 oC, while loss of weight by about 1.3% and 4% were observed for both carriers 
at 200 oC, respectively. Based on these TGA results, an optimum temperature of melting 
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at 50 oC (which approximates the melting point of Gelucire® 48/16) was selected for hot 
melt extrusion of different blends of indomethacin and Gelucire® 48/16. HME processing 
of different mixtures of indomethacin and Gelucires® at 40 oC (below the melting point of 
both forms of Gelucire®) was also proposed for the purpose of comparison of the two 
carriers and evaluation of the effect of temperature on the extrudability of the mixtures as 
well as their dissolution behavior and crystalline state of the drug. 
TGA plots of the adsorbents, Neusilin® US2 and Florite® PS-200, revealed about 
1.5% loss in weight (that is possibly due to water evaporation) at the maximum proposed 
temperature of melting (50oC) which indicate thermal stability of these adsorbents at 
selected temperatures for hot melt extrusion process.   
 
Figure  5.2 TGA plots of indomethacin, Gelucire® 44/14, Gelucire® 48/16, 
Neusilin® US2 and Florite® PS-200. 
5.4.3. Hot melt extrusion of Gelucire®-based solid SNEDDS of indomethacin 
Extrusion of physical mixtures of indomethacin and any of the Gelucires® was 
carried out at two different temperatures (below and approximately at the melting point of 
the carrier) in order to evaluate the effect of different extrusion temperatures on the drug-
carrier interaction, drug crystallinity and drug dissolution performance. Extrusion 
processing of physical mixtures of indomethacin with Gelucire® 44/14 or Gelucire® 48/16 
below the melting point of the excipients may also allow comparison of the self-
emulsifying formulations prepared with the two Gelucires® in addition to investigation of 
the possibility of processing both Gelucires® by softening instead of complete melting.  
In this study, two temperatures (40oC and 50oC) were selected for HME 
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determination of the melting point of untreated Gelucire® 48/16 by conventional DSC 
revealed an onset of melting at 41.53 ± 0.34oC and a peak of melting recorded at 50.74 ± 
0.15oC.  On the other hand, the onset of melting of untreated Gelucire®44/14 was 
observed at 36.78 ± 0.28oC while a peak of melting was shown at 46.49 ± 0.25oC.    
A residence time of 5 minutes was sufficient to allow thorough softening of 
mixtures of indomethacin and both Gelucires® when the temperature of the barrel was 
adjusted to 40oC and the speed of rotation adjusted to 30 rpm. All formulations prepared 
from indomethacin and Gelucire® 44/14 at different drug: carrier ratios (G1 – G4) were 
successfully extruded at 40oC through the die in the form of curled threads which 
solidified upon cooling. In the case of formulations prepared from indomethacin and 
Gelucire® 48/16, only the mixtures prepared in drug: carrier ratios of 0.5: 10 or 1: 10 (G5 
and G6) were successfully extruded at 40oC and formed a product of curled threads 
which solidified upon cooling, while the mixtures (G7 and G8) prepared at higher drug: 
carrier ratios (2: 10, or 3: 10) did not extrude through the die and required removal of the 
die part to collect the melt in the form of a transparent viscous mass that hardened at 
room temperature. Visually, the formulations with high drug contents (G7 and G8) had a 
thicker consistency and appeared more viscous than the formulations with lower drug 
contents (G5 and G6). Although not measured experimentally, this increased viscosity is 
likely to be too great for the extrusion processing parameters used here; hence the 
formulations could not be extruded through the die here. Extrusion may be possible if the 
shearing force inside the HME barrel could be increased, for example, by increasing the 
rotational speed and barrel pressure. On the other hand, all formulations of indomethacin 
and Gelucire® 48/16 (G9 – G12) prepared at different drug: carrier ratios and processed 
by HME at 50oC did not extrude in the form of threads but remained as a thin liquid in the 
barrel and collected in the form of a transparent liquefied mass which transformed into a 
solid opaque mass on cooling. Processing of mixtures at a temperature that corresponds 
to the melting point of the carrier resulted in complete melting of the carrier and formation 
of a liquefied mass inside the extruder barrel which in turn may require increased 
pressure to force the melt through the die, which did not work in this case and removal of 
the die was crucial.   
Preparation of different Gelucire®-based solid SNEDDS with different drug loads 
may allow evaluation of the effect of increased drug loading on the dissolution 
performance and self-emulsifying properties of different formulations.  
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5.4.4. Evaluation of Gelucire®-based solid SNEDDS of indomethacin 
produced by HME 
5.4.4.1. Determination of drug content 
Drug content was determined for Gelucire® 48/16-based solid SNEDDSs to 
confirm equal distribution of the drug within the carrier used to produce different 
formulations. The results of drug content calculated as both % w/w and mg/g for different 
Gelucire®-based solid SNEDDS formulations of indomethacin prepared at different 
temperatures are illustrated in Table 5.3.  All tested formulations prepared at 40oC or 
50oC showed good drug content values ranging from 95.40 ± 0.91% to 99.95 ± 1.28% 
with no significant difference (p < 0.05) observed between formulations prepared at 
different temperatures.  As mentioned previously in Chapter 4, the U.S. FDA (2003) 
indicates that a given batch of a blend may pass drug content uniformity test if a relative 
standard deviation (RSD) ≤ 4% was obtained from the assay of 60 samples or more from 
that batch.  
 Although analysis of large number of samples was not possible with lab scale 
experiments, the results of drug content obtained from the assay of 3 samples of 
Gelucire®-based solid SNEDDS formulations (Table 5.3) showed acceptable values of 
RSD <3% which may indicate that the adopted hot melt extrusion process produced 
Gelucire®-based solid SNEDDS formulations with reasonable values of drug content. 
Less than the expected 100% drug content values that were observed for the tested 
formulations may be due to loss of the drug during extrusion process which in turn can 
be ascribed to adherence of drug particles to the sides of the barrel of the extruder 
during mixing of different blends. Similar interpretation was given by Gumaste et al. 
(2013a) to explain the less than 100% drug content values obtained for various powder 
formulations prepared by adsorption of liquid SEDDS of the model drug, probucol, onto 
Neusilin® US2 at 1:1 w/w ratio. The authors proposed that increasing the batch size of a 
formulation may reduce the drug loss and hence improve the drug content of different 
formulations.   
  




Table  5.3 Results of mean drug content (calculated as % w/w and mg/g) ± SD 
obtained for different Gelucire®-based solid SNEDDS formulations of 





Mean drug content ± SD 
RSD 
(%) (mg/g)   (% w/w)  
G1 
40 
47.71 ± 1.17 95.42 ± 2.35 2.46 
G2 97.49 ± 0.94 97.49 ± 0.94 0.96 
G3 191.67 ± 2.71 95.84 ± 1.35 1.41 
G4 292.38 ± 4.13 97.46 ± 1.38 1.41 
G5 
40 
48.88 ± 0.59 97.77 ± 1.17 1.20 
G6 96.67 ± 1.63 96.67 ± 1.63 1.68 
G7 192.34 ± 1.40 96.17 ± 0.70 0.73 
G8 288.02 ± 1.83 96.01 ± 0.61 0.63 
G9 
50 
48.30 ± 1.02 96.95 ± 2.03 2.10 
G10 99.95 ± 1.28 99.95 ± 1.28 1.28 
G11 193.68 ± 3.31 96.84 ± 1.65 1.71 
G12 292.38 ± 4.00 97.46 ± 1.33 1.37 
G13 
40 
195.00 ± 3.05 97.50 ± 1.53 1.57 
G14 194.25 ± 3.65 97.13 ± 1.83 1.88 
G15 
40 
192.07 ± 3.34 96.03 ± 1.67 1.74 
G16 190.80 ± 1.83 95.40 ± 0.91 0.96 
 
5.4.4.2. Self-nanoemulsification efficiency tests 
Since Gelucire® 44/14 and Gelucire® 48/16 are considered as self-emulsifying 
vehicles (Gattefossé, 2015); self-nanoemulsification efficiency tests (or dispersibility 
tests) were conducted to evaluate any tendency of the formulated Gelucire®-based solid 
SNEDDS to show drug precipitation or phase separation when in contact with aqueous 
fluids. The results of these tests are shown in Table 5.4. Formulations prepared with 
Gelucire® 44/14 (G1 – G4) showed grade B appearance that indicates rapid formation of 
hazy or less clear bluish white nanoemulsions after dilution and mixing with purified 
water. On the other hand, Gelucire® 48/16- based SNEDDS formulations prepared at 
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40oC (G5 – G7) or 50oC (G9 – G11) using the drug: carrier ratios of 0.5: 10, 1: 10 and 2: 
10 showed rapid formation of clear nanoemulsions (grade A) upon dilution with water. 
This could be due to higher HLB value of Gelucire® 48/16, compared to Gelucire® 44/14, 
which may facilitate dispersibility of the drug within the carrier leading to increased 
solubility (Kalpana et al., 2015). Formulations prepared with Gelucire® 48/16 and 
containing adsorbents (G13 – G16) showed grade B appearance which may be 
attributed to the intense mixing of the adsorbent with the drug and the carrier that took 
place inside the extruder barrel and this might cause embedding of the adsorbent within 
the carrier and led to the formation of less clear nanoemulsion. Signs of precipitation 
were observed in Gelucire®-based solid SNEDDS prepared with Gelucire® 48/16 or 
Gelucire® 44/14 at the drug: carrier ratio of 3: 10 (G4, G8 and G12). The higher content 
of indomethacin in these formulations may have exceeded the solubilizing ability of the 
carriers leading to precipitation of excess drug upon dilution.  
  
Table  5.4 Results dispersibility tests and mean solubility ± SD obtained for different 
Gelucire®-based solid SNEDDS formulations of indomethacin prepared at 
different temperatures 








B* No  1.53 ± 0.02 
G2 B No  1.79 ± 0.05 
G3 B No  1.85 ± 0.05 
G4 B Yes  2.11 ± 0.07 
G5 
40 
A** No  2.10 ± 0.02 
G6 A No  2.25 ± 0.08 
G7 A No  3.08 ± 0.03 
G8 B Yes  2.81 ± 0.08 
G9 
50 
A No  2.38 ± 0.04 
G10 A No  2.46 ± 0.02 
G11 A No  3.13 ± 0.02 
G12 B Yes  3.01 ± 0.02 
G13 
40 
B No  3.11± 0.06 
G14 B No  2.88 ± 0.03 
G15 
40 
B No  3.09 ± 0.03 
G16 B No  3.03 ± 0.03 
Drug   … … … 1.07 ± 0.07 
* Rapid formation of less clear or bluish white nanoemulsion that emulsifies within 2 minutes. 
** Rapid formation of clear or slightly bluish nanoemulsion that emulsifies within 1 minute. 
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5.4.4.3. Determination of droplet size  
The droplet size is an important factor in spontaneous self-emulsification 
behaviour, because it provides information on the rate and extent of in vitro drug 
dissolution and the likely in vivo absorption. In general, smaller droplets allow faster 
dissolution rates and at the same time provide larger interfacial surface area for in vivo 
drug absorption (Weerapol et al., 2015a).   
The results of measurement of droplet size, polydispersity index and zeta 
potential obtained for different Gelucire®-based solid SNEDDS formulations prepared by 
HME using Gelucire® 44/14 (G1 – G4), Gelucire® 48/16 (G5 – G12) as well as those 
prepared using Gelucire® 48/16 and different adsorbents (G13 – G16) are presented in 
Table 5.5. 
Table  5.5 Mean droplet size, PDI and zeta potential of formulated Gelucire®-based 













Gelucire® 44/14 15.47 ± 0.16 0.26 ± 0.01 --- --- 
G1 18.46 ± 0.24 0.40 ± 0.03 -21.9 6.21 
G2 26.96 ± 1.22 0.57 ± 0.07 -20.7 5.18 
G3 45.33 ± 0.37 0.67 ± 0.01 -20.6 9.56 
G4 34.09 ± 6.67 0.68 ± 0.20 -29.3 5.42 
Gelucire® 48/16 11.78 ± 0.12 0.11 ± 0.01 --- --- 
G5 19.62 ± 0.42 0.53 ± 0.020 -23.4 7.93 
G6 29.41 ± 1.26  0.78 ± 0.010 -23.1 7.46 
G7 60.23 ± 11.12  0.86 ± 0.060 -22.4 3.35 
G8 30.32 ± 1.88 0.81 ± 0.001 -34.4 3.62 
G9 29.38 ± 2.16 0.68 ± 0.004 -27.3 5.84 
G10 75.76 ± 1.57 0.43 ± 0.010 -23.6 6.59 
G11 125.90 ± 3.25  0.34 ± 0.040 -24.5 4.08 
G12 110.95 ± 3.75 0.28 ± 0.010 -29.2 8.66 
G13 78.59 ± 1.12 0.75 ± 0.080  -21.0 6.94 
G14 182.25 ± 1.06 0.51 ± 0.001 -19.6 6.35 
G15 92.01 ± 13.42 0.87 ± 0.180 -20.1 6.78 
G16 136.45 ± 1.48 0.73 ± 0.010 -19.8 6.22 
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The sizes of Gelucire® 44/14 and Gelucire® 48/16 globules produced in the 
dispersion medium (purified water) showed values of 15.47 ± 0.16 nm and 11.78 ± 0.12 
nm, respectively. The presence of the drug in different solid SNEDDS formulations 
prepared with these carriers resulted in significant increase (p < 0.05) in the droplet size.  
It can be observed that increasing the drug load of different Gelucire®-based 
SNEDDS formulations (G1 – G12) resulted in larger droplets diameter. Based on the 
surface active properties of both Gelucires® used, higher drug loading possibly led to 
formation of multiple micelles or closely packed Gelucire® molecules around the 
dispersed particles which in turn may have led to formation of larger dense particles.  
When the drug content was increased beyond the drug: carrier ratio of 2: 10, a decrease 
in the droplet size was noticed for formulations G4, G8 and G12. This may be ascribed to 
breakage or rupture of the micelles entrapping excessive amount of drug particles and 
hence, ejection of excess drug particles into the aqueous phase and production of 
smaller droplets.  
Gelucire®-based solid SNEDDS formulations prepared with Gelucire® 48/16 (G5 – 
G12) exhibited larger droplet size compared to formulations prepared with Gelucire® 
44/14 (G1 – G4). This could be explained on the basis that different surface active 
Gelucires® with different HLB values may produce different droplet size of the 
nanoemulsion upon dilution. Similarly, smaller droplets were observed for nanoemulsion 
formulations of Vitamin D (Guttoff et al., 2015) and Vitamin E (Saberi et al., 2013) 
prepared with Tween® 80 compared to those prepared using Tween® 20.  
Also, differences in the molecular geometry (or critical packing parameter) of 
molecules of both Gelucires® may explain the larger droplets produced by Gelucire® 
48/16-based SNEDDS formulations compared to those observed for formulations 
prepared using Gelucire® 44/14. Critical packing parameter that relates the cross 
sectional area of the tail group to that of the head group of a surfactant, may affect 
packing of the surfactant molecules at the oil-water interface and in turn may reflect 
differences in interfacial properties such as surface energy which influence the formation 
of ultrafine droplets (Guttoff et al., 2015, Saberi et al., 2013).   
Further, differences in chemical structure between Gelucire® 48/16 and Gelucire® 
44/14 may affect packing of the surfactant molecules at the boundaries between drug 
particles and aqueous medium (Guttoff et al., 2015, Marasini et al., 2012, Saberi et al., 
2013). Gelucire® 44/14 is composed of fatty acid (C8, C10, C12, C14, C16 and C18) esters of 
glycerol with high proportions of lauric (C12) and myristic (C14) fatty acids, PEG esters 
and free PEG (Chambin and Jannin, 2005, Gattefossé, 2012).  On the other hand, 
Gelucire® 48/16 is mainly a PEG ester of palmitic (C16) and stearic (C18) fatty acids and 
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contains no glyceride portion (Gattefossé, 2015). It might be possible that absence of 
glyceride portion in Gelucire® 48/16 led to enhanced spontaneous formation of ultrafine 
droplets upon dilution of the formulation.   
Larger droplets observed for Gelucire® 48/16-based SNEDDS formulations 
prepared at 50oC (G5 – G8) compared to formulations prepared at 40oC (G9 – G12) may 
be attributed to more efficient incorporation and dissolving of drug particles in carrier 
molecules that may have occurred at elevated temperatures more than that occurred at 
lower temperature of melting. Consequently, increased encapsulation of drug particles 
inside micelles led to formation of larger droplets (Rangel-Yagui et al., 2005).  
Incorporation of adsorbents in Gelucire® 48/16-based solid SNEDDS formulations 
such as Neusilin® US2 (in formulations G13 and G14) or Florite® PS-200 (in formulations 
G15 and G16) resulted in increased droplet size compared to the formulation prepared 
without adsorbents (G7). These two adsorbents could have been embedded in the 
carrier along with the incorporated drug particles (Vithani et al., 2013) leading to 
formation of larger droplets.   
5.4.4.4. Determination of solubility of the drug in Gelucire®-based solid SNEDDS 
formulations 
Measurement of solubility of the drug in different Gelucire®-based solid SNEDDS 
formulations was carried out to investigate the effect of the type of the carrier as well as 
the drug loading on the solubility of indomethacin upon incorporation into different 
Gelucires®. The results of drug solubility in various formulations are presented in Table 
5.4.  It was observed that solubility of indomethacin in phosphate buffer pH 7.2 from all 
Gelucire®-based solid SNEDDS formulations was increased by 1.4 – 2.9 folds compared 
to the solubility of pure indomethacin in the same buffer (1.07 ± 0.07 mg/ml). Enhanced 
solubility of indomethacin from Gelucire®-based solid SNEDDS formulations could be 
attributed to decreased contact angle, increased wettability and micellar solubilization of 
drug particles by the carriers adopted in different formulations (Chambin et al., 2009, 
Damian et al., 2000, Horter and Dressman, 2001, Leuner and Dressman, 2000). A 
significant difference (p < 0.05) in the solubility of the drug was detected when 
formulations prepared with Gelucire® 44/14 (G1 – G4) were compared to formulations 
prepared with Gelucire® 48/16 (G5 – G8) using one way ANOVA. However, statistical 
comparison of formulations prepared with Gelucire® 48/16 either at 40oC (G5 – G8) or 
50oC (G9 – G12) yielded no significant difference (p > 0.05) in the solubility of the drug. 
Only slight reductions in the solubility of indomethacin from Gelucire® 48/16-based solid 
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SNEDDS formulations containing Neusilin® US2 (G13 and G14) or Florite® PS-200 (G15 
and G16) were observed. 
5.4.5. Solid state characterization of Gelucire®-based solid SNEDDS of 
indomethacin 
5.4.5.1. Fourier transform infrared spectroscopy (FTIR) 
FTIR studies were carried out to detect any incompatibility and/or interaction 
between the drug, the carriers and the adsorbents used in preparation of Gelucire®-
based solid SNEDDS formulations of indomethacin. As mentioned earlier in Chapter 4, 
FTIR is used for this purpose because each compound absorbs specific radiation 
frequencies according to its molecular structure. Therefore, formulations comprising the 
drug and different excipients may exhibit changes in their FTIR spectrum. These 
changes may appear in the form of disappearance, shifting or broadening of the 
characteristic peaks of each component used in the formulation (Lim et al., 2013).  
FTIR spectra of indomethacin, Gelucire®-based solid SNEDDS formulations and 
the corresponding carriers and adsorbents used in different formulations are presented 
in Figures 5.3 – 5.6.   
As explained earlier in Chapter 4, the obtained FTIR spectrum of pure 
indomethacin showed specific peaks for the γ-polymorph of the drug (Dupeyrón et al., 
2013). Two strong peaks were observed at 1716 cm-1 related to asymmetric acid C=O of 
a cyclic dimer, while the peak showing at 1692 cm-1 related to the benzoyl C=O (Taylor 
and Zografi, 1997). Other absorption peaks were recorded at 2925 cm-1 (C-H stretching 
vibrations), 1223 cm-1 (asymmetric aromatic O-C stretching), and 1068 cm-1 (symmetric 
aromatic O-H stretching). Complex absorption patterns were observed in the region of 
1300 – 650 cm-1 which is related to the aromatic structure of indomethacin. Therefore, 
strong or medium intensity bands appearing in this region may be less useful for 
structural characterization, while a weak intensity band in the region above 2000 cm-1 
may be group-specific (Dupeyrón et al., 2013).  
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Gelucire® 44/14 showed principal peaks at 2887, 1737, 1460, 1341, 1106, 957 
and 841 cm-1 (Figure 5.3). The FTIR spectrum of all solid SNEDDS formulations 
prepared with this carrier at 40oC (G1 – G4) exhibited all characteristic peaks of 
Gelucire® 44/14 in addition to the characteristic peaks of the drug at 1716, 1223 and 
1068 cm-1.  Presence of specific drug peaks in the spectra of different Gelucire® 44/14-
based solid SNEDDS formulations indicates that the molecular structure of indomethacin 
remained intact during melt processing at 40oC. Absence of some drug peaks in the 
spectra of these solid SNEDDS formulations may be because these peaks are more 
likely to be hidden in the baseline of the corresponding spectra. In addition, no new extra 
peaks were observed in the FTIR spectra of drug-loaded solid SNEDDS formulations 
(G1 – G4) which indicate that no chemical interaction occurred between the drug and the 
carrier. 
 
Figure  5.3 FTIR spectra of indomethacin, Gelucire® 44/14 and various 
Gelucire® 44/14-based solid SNEDDS of indomethacin prepared 
by HME at 40oC. 
  
  Chapter 5  
211 
 
The FTIR spectrum of Gelucire® 48/16 is shown in Figures 5.4 – 5.6 and is 
characterized by the main peaks appearing at  2887, 1735, 1467, 1343, 1113, 963, 842 
and 529 cm-1. As presented in Figure 5.4 and Figure 5.5, all solid SNEDDS 
formulations prepared with Gelucire® 48/16 either at 40oC (G5 – G8) or at 50oC (G9 – 
G12) showed the absorption peaks of the carrier at the same position as well as the 
specific peaks of indomethacin mentioned earlier. Also, no chemical interaction was 
obvious within these Gelucire®-based solid SNEDDS formulations as evidenced by 
absence of new extra peaks in their corresponding spectra.  
 
Figure  5.4 FTIR spectra of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 40oC. 




Figure  5.5 FTIR spectra of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 50oC. 
 
 
The FTIR spectra of Gelucire® 48/16-based solid SNEDDS of indomethacin in 
which Neusilin® US2 (G13 & G14) or Florite® PS-200 (G15 and G16) were incorporated 
are shown in Figure 5.6. Formulations G13 and G14 showed the characteristic peaks of 
Gelucire® 48/16 and the drug at the same frequencies, in addition to the specific peaks of 
Neusilin® US2 (magnesium aluminometa silicate) appearing at 3444, 1638, 1380, 1041 
and 472 cm-1.  Also, the characteristic peaks of Florite® PS-200 (calcium silicate) 
observed at 3448, 1637, 1348, 1039, 784, 607 and 467 cm-1 in addition to absorption 
peaks of the drug and the carrier were noticed in formulations G15 and G16 prepared 
with these three components. The presence of the absorption peaks specific for the 
drug, the carrier and the adsorbent in Gelucire® 48/16-based solid SNEDDS (G13 – G16) 
indicates compatibility of components used in different formulations.       




Figure  5.6 FTIR spectra of indomethacin, Gelucire® 48/16, Neusilin® US2, 
Florite® PS-200 and various Gelucire® 48/16-based solid SNEDDS 
of indomethacin prepared by HME at 40oC. 
   
Similar FTIR findings were reported for solid dispersions of flurbiprofen prepared 
in Gelucire® 44/14, where the optimized formulation showed absorption peaks of the 
drug and the carrier at the same frequencies indicating compatibility and absence of 
interaction between the drug and the carrier (Daravath et al., 2015).   
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5.4.5.2. Differential scanning calorimetry (DSC) 
Thermal behaviour and physical state of a drug within a formulation can be 
determined by DSC studies (Kallakunta et al., 2012, Ramasahayam et al., 2015). DSC 
traces of different Gelucire®-based solid SNEDDS formulations of indomethacin are 
depicted in Figures 5.7 – 5.10.  
Pure indomethacin exhibited a sharp endothermic peak, that corresponds to its 
melting point, at 162.31oC and this indicates that the drug is present in a crystalline form.  
The value of ΔH (enthalpy) was found to be equal to 106.2950 J/g. In Figure 5.7, 
Gelucire® 44/14 showed an endothermic melting peak at 46.49oC which is also the only 
peak that appeared in the DSC trace of different solid SNEDDS formulations prepared 
with this carrier (G1 – G4) with no peaks representing indomethacin.  
 
Figure  5.7 DSC traces of indomethacin, Gelucire® 44/14 and various Gelucire® 
44/14-based solid SNEDDS of indomethacin prepared by HME at 40oC. 
 
As can be seen in Figures 5.8, 5.9 and 5.10, Gelucire® 48/16 exhibited an 
endothermic melting peak at 51.10oC. As can be observed in Figure 5.8 & Figure 5.9, 
all solid SNEDDS formulations of indomethacin prepared using Gelucire® 48/16 at 40oC 
(G5 – G8) or at 50oC (G9 – G12) did not show an obvious endothermic peak 
corresponding to the melting of crystalline indomethacin. In addition, a kink (step 
change) appeared in the DSC traces of formulations G10, G11 and G12 (Figure 5.9) 
below the main melting point of Gelucire® 48/16 which possibly indicates a Tg of 
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indomethacin (42oC). Therefore, these formulations probably contain an amorphous 
component of the drug which wasn’t observed in the other formulations.   
 
 
Figure  5.8 DSC traces of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 40oC.   
 
 
Figure  5.9 DSC traces of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 50oC. 
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In Figure 5.10, Neusilin® US2 (magnesium aluminometa silicate) showed a broad 
endothermic peak at 228.61oC, while Florite® PS-200 (calcium silicate) did not show any 
prominent peak over the entire range of the tested temperature. In addition, no peaks of 
crystalline indomethacin were noticed in solid SNEDDS formulations prepared with 
Gelucire® 48/16 at 40oC and incorporated Neusilin® US2 (G13 and G14) or Florite® PS-
200 (G15 and G16).  
 
Figure  5.10 DSC traces of indomethacin, Gelucire® 48/16, Neusilin® US2, Florite® PS-
200 and various Gelucire® 48/16-based solid SNEDDS of indomethacin 
prepared by HME at 40oC. 
Therefore, the absence of a specific endothermic peak corresponding to the 
melting of crystalline indomethacin in all drug-loaded solid SNEDDS formulations 
prepared with Gelucire® 44/14 or Gelucire® 48/16 at different temperatures (except 
formulations G10 – G12 which showed a possible Tg of the drug as observed in Figure 
5.9) may indicate that the drug exists in a molecularly dispersed state within the carrier. 
This assumption can be supported by the measured solubility values presented earlier in 
Table 5.4.  
Overall, these results of DSC analysis are not conclusive to determine if the drug 
is present in crystalline or amorphous states within different Gelucire®-based 
formulations. If a crystalline drug is present in the final formulation, it will dissolve in the 
melted Gelucire® during heating of the sample in the DSC and hence no melting peak of 
the crystalline drug can be observed. On the other hand, if the drug is dissolved in the 
carrier and then solidified in an amorphous form, the expected Tg of the drug will be 
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obvious in the DSC trace of the formulation. In the case of Gelucire® formulations of 
indomethacin and because the Tg of the drug is about 42oC, it is expected that the peak 
corresponding to the Tg of indomethacin will be overlapped with the broad peak of 
melting of Gelucire®. Therefore, the results of DSC should be combined with the results 
of other characterization tests such as the X-ray diffraction and the SEM to determine the 
presence of crystalline drug within different Gelucire®-based formulations.   
Also, it is important to note that although the DSC analysis is a widely used 
technique to determine the crystallinity of amorphous formulations, it still has a low limit 
of sensitivity to detect smaller amounts of crystals that is less than 10% (w/w) (Nagapudi 
and Jona, 2008, Saleki-Gerhardt et al., 1994).       
DSC analysis of various drugs dispersed in Gelucire® 44/14 or Gelucire® 48/16 
have shown that absence of the endothermic melting peak of the drug may indicate 
transformation of the crystalline drug to an amorphous state. For example, the DSC 
analysis of solid lipid dispersion formulation of rivaroxaban (BCS Class II drug) prepared 
by spray drying method using Gelucire® 48/16, Compritol HD5 and Labrasol as the 
dispersion matrix, showed that the endothermic peak of the drug disappeared in the DSC 
traces of the solid lipid dispersion formulation and this was attributed to conversion of the 
drug into an amorphous form (Ganesh, 2016). Also, the DSC studies of semi-solid 
dispersions of piroxicam prepared in Gelucire® 44/14 showed absence of the crystalline 
melting peak of the drug and appearance of a new sharp melting peak. Absence of 
crystalline piroxicam melting peak was explained on the basis that the drug was present 
in amorphous state rather than a crystalline phase within the semi-solid dispersion 
formulation, while the resulting new sharp melting peak was attributed to a chemical 
reaction between –OH group on the benzothiazine ring of piroxicam and the fatty acids 
of Gelucire® 44/14 that took place because of heating applied during preparation of semi-
solid dispersion formulation (Karataş et al., 2005).  In addition, solid self-emulsifying 
formulation of lercanidipine hydrochloride prepared by adsorption of liquid self-
emulsifying formulations of the drug (comprising Gelucire® 44/14 as an oil phase, 
labrasol® as a surfactant and Transcutol®-P as a co-surfactant) onto Neusilin®US2 
showed a DSC trace without representative peak of the drug and this was related to 
maintaining of the drug in a dissolved state within the emulsifying ingredients and hence, 
inhibiting drug recrystallization (Kallakunta et al., 2013).      
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5.4.5.3. X-ray diffraction (XRD) 
The degree of crystallinity and amorphous content of pharmaceutical formulations 
can be detected by XRD analysis. This technique is also useful to determine the 
percentage of components in a formulation so it can be applied for quantitative analysis 
of pharmaceutical mixtures (Gilmore, 2011).  
Qualitative XRD analysis was conducted in this study to confirm crystallinity of 
the drug within different formulations. The XRD diffractograms obtained for different 
Gelucire®-based solid SNEDDS of indomethacin prepared with different Gelucires® and 
adsorbents are presented in Figures 5.11 – 5.14.  The XRD patterns of indomethacin, 
carriers and adsorbents employed in different formulations were also obtained for the 
purpose of comparison.   
In the indomethacin diffractogram, the characteristic narrow and sharp diffraction 
peaks appearing at 2θ values of 11.9o, 13o, 17.2o, 19.9o, 20.6o, 21.2o, 22.1o, 23.4o, 24.3o, 
26.9o, 29.7o and 31.9o indicate the crystalline nature of the drug. The resulting 
diffractogram of indomethacin is similar to those reported in previous studies (Dupeyrón 
et al., 2013, Lim et al., 2013).  
The XRD pattern of Gelucire® 44/14 presented in Figure 5.11 showed intrinsic 
sharp peaks at 2θ values of 19.2o, 23.4o, 26.5o, 32.7o, 36.3o and 39.8o. Also, it was 
observed that solid SNEDDS formulations prepared with Gelucire® 44/14 at 40oC (G1 – 
G4) showed the peaks noticed for the carrier. Formulations G1 – G3 exhibited an 
absence of representative crystalline peaks of the drug which indicates that the drug 
remained in a molecularly dissolved state within the carrier. However, formulation G4 
prepared with higher ratio of drug: Gelucire® 44/14 (3: 10) showed sharp peaks related to 
crystalline indomethacin at 2θ values of 11.9o, 17.2o, 21.2o and 29.7o. It could be possible 
that the presence of excess drug particles in this formulation have exceeded the 
solubilizing capacity of the carrier at 40oC and therefore, remained incompletely 
dissolved in the carrier. Also, the absence of an amorphous halo and the appearance of 
extra peaks of the drug in the XRD diffractogram of formulation G4 may suggest that the 
formulation is semi-crystalline. Combining the results of XRD analysis for formulations 
G1 – G4 (Figure 5.11) together with the DSC results of the same formulations (Figure 
5.7) may suggest that the drug exists in a molecularly dispersed state within the carrier 
especially when added at lower concentrations (as in formulations G1 – G3) but not 
when added at higher concentrations (as in formulation G4). 
 




Figure  5.11 XRD diffractograms of indomethacin, Gelucire® 44/14 and various 
Gelucire® 44/14-based solid SNEDDS of indomethacin prepared by HME 
at 40oC. 
 
On the other hand, the XRD pattern of Gelucire® 48/16 presented in Figure 5.12, 
5.13 and 5.14 exhibited high intensity peaks at 2θ values of 19.4o and 23.5 o. Solid 
SNEDDS formulations prepared with Gelucire® 48/16 at 40oC (G5 – G8) or at 50oC (G9 – 
G12) showed the characteristic peaks of the carrier and no crystalline peaks related to 
the drug. However, formulations G8 (Figure 5.12) and G12 (Figure 5.13) prepared with 
increased drug load (drug: carrier ratio 3: 10) showed peaks of crystalline drug at 2θ 
values of 11.9o and 26.9o. This could be due to that excess drug may have exceeded the 
solubilizing potential of the carrier at either 40oC or 50oC and hence, excess crystalline 
drug particles remained incompletely dissolved. Again, visualizing the XRD 
diffractograms of formulations G5 – G12 (Figures 5.12 and 5.13) with the DSC traces of 
the same formulations (Figures 5.8 and 5.9) may indicate that the drug exists in a 
molecularly dispersed state within the carrier only when added at lower concentrations 
(as in formulations G5 – G7 and G9 – G11) but not at higher concentrations (as in 
formulations G8 and G12). 
     




Figure  5.12 XRD diffractograms of indomethacin, Gelucire® 48/16 and various 
Gelucire® 48/16-based solid SNEDDS of indomethacin prepared by HME 
at 40oC. 
   
 
Figure  5.13 XRD diffractograms of indomethacin, Gelucire® 48/16 and various 
Gelucire® 48/16-based solid SNEDDS of indomethacin prepared by HME 
at 50oC. 
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The XRD diffractograms of Gelucire® 48/16-based solid SNEDDS formulations of 
indomethacin prepared at 40oC and incorporated Neusilin® US2 (magnesium 
aluminometa silicate) or Florite® PS-200 (calcium silicate) as adsorbents are shown in 
Figure 5.14. Neusilin® US2 diffractogram showed two halo peaks centered on 2θ values 
of 20.6o and 35o with no high intensity peaks, while Florite® PS-200 diffractogram 
showed sharp diffraction peaks at 2θ values of 5.6o, 10.6o, 21.2o, 28.5o, 38.1o, 44.3o and 
50o which indicate partial crystalline nature of this adsorbent. Diffractograms of 
formulations that contained different amounts of Neusilin® US2 (G13 and G14) or Florite® 
PS-200 (G15 and G16) exhibited the specific peaks of Gelucire® 48/16 in addition to 
crystalline peaks of indomethacin appearing at 2θ values of 11.9o and 26.9o. Adsorbents 
added to these formulations might have been embedded within Gelucire® 48/16 and 
therefore, the amount of the carrier available to dissolve the drug is reduced and part of 
the crystalline drug remained undissolved. In addition, absence of the peaks of the two 
adsorbents in the diffractograms of their corresponding formulations may be due to their 
small amounts present relative to the amount of the carrier in formulations examined. 
Appearance of the peaks of crystalline indomethacin in the XRD diffractograms of 
Gelucire® 48/16-based solid SNEDDS formulations containing Neusilin® US2 (G13 and 
G14) or Florite® PS-200 (G15 and G16) (Figure 5.14) contradicts the DSC traces of the 
same formulations (Figure 5.10) and this confirms that XRD and DSC analyses should 
be visualized together to indicate any crystallinity of the drug in the final tested 
formulations.   
 




Figure  5.14 XRD diffractograms of indomethacin, Gelucire® 48/16, Neusilin® US2, 
Florite® PS-200 and various Gelucire® 48/16-based solid SNEDDS of 
indomethacin prepared by HME at 40oC. 
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5.4.5.4. Scanning electron microscopy (SEM) 
Surface morphology of indomethacin, Gelucires®, Neusilin® US2, Florite® PS-200 
and their corresponding Gelucire®-based solid SNEDDS formulations were investigated 
by scanning electron microscope. The micrographs obtained are presented in Figures 
5.15 – 5.18.  
 
Figure  5.15 SEM micrographs of indomethacin, Gelucire® 44/14 and various Gelucire® 
44/14-based solid SNEDDS of indomethacin prepared by HME at 40oC. 
 




Figure  5.16 SEM micrographs of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 40oC. 
  
 




Figure  5.17 SEM micrographs of indomethacin, Gelucire® 48/16 and various Gelucire® 
48/16-based solid SNEDDS of indomethacin prepared by HME at 50oC. 
 
 




Figure  5.18 SEM micrographs of indomethacin, Gelucire® 48/16, Neusilin® US2, 
Florite® PS-200 and various Gelucire® 48/16-based solid SNEDDS of 
indomethacin prepared by HME at 40oC. 
 




Scanning electron micrograph of indomethacin particles revealed multifaceted 
structures with smooth surfaced rectangular crystals. The surface topographies of 
Gelucire® 44/14 (Figure 5.15) and Gelucire® 48/16 (Figure 5.16, 5.17 & 5.18) appeared 
similar with comparatively smooth textures despite differences in their consistency at 
room temperature, where Gelucire® 44/14 exists as a sticky and semi-solid mass while 
Gelucire® 48/16 exists in the form of solid pellets. Micrographs of solid SNEDDS 
formulations prepared at 40oC using Gelucire® 44/14 (G1 – G4) showed relatively 
homogenous mixtures that looked like a matrix due to dispersion of the drug in the 
softened carrier at the molecular level. However, formulation G4 showed some crystals 
of the drug and this confirms its XRD studies.  
In addition, scanning electron microscopy of formulations prepared using 
Gelucire® 48/16 at 40oC (Figure 5.16) or at 50oC (Figure 5.17) revealed that the drug 
was homogenously dispersed within the carrier at both melting temperatures as 
indicated by the absence of drug particles in different micrographs obtained for 
formulations G5 – G7 and formulations G9 – G11. On the other hand, micrographs 
obtained for formulations G8 and G12 prepared with increased drug loading at 40oC or at 
50oC, respectively, showed drug particles that did not disperse completely within the 
carrier possibly due to increased viscosity of both formulations due to the presence of 
high drug loadings. These observations for G8 and G12 support their XRD studies. 
 
SEM micrographs of Neusilin® US2 and Florite® PS-200 (Figure 5.18) showed 
highly porous granular materials.  Formulations prepared with Gelucire® 48/16 that 
included adsorbents like Neusilin® US2 (G13 and G14) or Florite® PS-200 (G15 and 
G16) exhibited the matrix appearance observed for different formulations prepared with 
Gelucire® 48/16 with no adsorbents added (G5 – G8). The matrix-like appearance 
observed may be due to homogenous dispersion of the drug within the carrier at the 
melting temperature in addition to the relatively small amount of adsorbent incorporated 
if compared to the amount of the carrier used in different formulations. Even with the 
matrix-like appearance, some drug particles did not disperse completely within the 
carrier and these particles were obvious in the micrographs of G13 – G16 (Figure 5.18). 
These observations appear to be in accordance with the XRD analysis of these 
formulations (Figure 5.14).  
SEM observations were previously reported for different solid dispersions 
prepared for various drugs in different Gelucire® grades. For instance, scanning electron 
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micrographs of carvedilol (Potluri et al., 2011), glimepiride (Makar et al., 2013) and 
indomethacin (El-Badry et al., 2009) solid dispersions prepared using Gelucire® 50/13 
revealed homogenous formulations which were attributed to dispersion of the drug in the 
molten carrier.  
5.4.6. In vitro dissolution studies 
Dissolution of indomethacin from different Gelucire®-based solid SNEDDS 
formulations was conducted in phosphate buffer pH 7.2  and compared to the dissolution 
from pure drug. The dissolution profiles obtained are presented in Figures 5.19 – 5.22. 
Although the tested formulations showed maximum percentage of drug release within 15 
– 20 minutes, the dissolution studies were continued for 1 hour, as suggested by 
Kallakunta et al. (2012), to observe any precipitation or changes that may develop over a 
period of time. Different dissolution parameters such as the mean dissolution time 
(MDT), the dissolution efficiency after 15 minutes (%DE15) in addition to the % drug 
released after 15 minutes (%Q15) were calculated to compare different dissolution 
profiles obtained for different formulations.  These parameters are presented in Table 
5.6. Comparison based on these dissolution parameters was considered, as indicated by 
Podczeck (1993), to avoid inadequate characterization of the dissolution process that 
may take place if dissolution profiles are compared based on single point measurement 
as specified in the British Pharmacopoeia (2015) for the dissolution of active substance 
filled in capsule dosage forms.   




Figure  5.19 In vitro dissolution profiles of pure indomethacin, Gelucire® 44/14-based 
solid SNEDDS formulations prepared by HME at 40oC (G1 – G4) in 




Figure  5.20 In vitro dissolution profiles of pure indomethacin, Gelucire® 48/16-based 
solid SNEDDS formulations prepared by HME at 40oC (G5 – G8) in 


























































Figure  5.21 In vitro dissolution profiles of pure indomethacin, Gelucire® 48/16-based 
solid SNEDDS formulations prepared by HME at 50oC (G9 – G12) in 
phosphate buffer pH 7.2 (mean ± SD, n=3). 
 
 
Figure  5.22 In vitro dissolution profiles of pure indomethacin, Gelucire® 48/16-based 
solid SNEDDS formulations prepared by HME at 40oC incorporating 
different amounts of Neusilin® US2 (G13 and G14) or Florite® PS-200 
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Table  5.6 Mean dissolution time (MDT), mean dissolution efficiency (%DE15) and % 
released (%Q15) after 15 minutes calculated for pure indomethacin and 




(mean ± SD) 
%DE15  
(mean ± SD) 
%Q15  
(mean ± SD) 
G1 17.07± 1.43 29.04 ± 1.61 50.58 ± 2.05 
G2 13.25 ± 1.05 30.23 ± 4.96 58.90 ± 2.02 
G3 11.16 ± 0.83 43.16 ± 2.16 75.59 ± 2.35 
G4 13.50 ± 1.24 34.42 ± 1.64 65.63 ± 7.36 
G5 11.17 ± 1.09 40.35± 1.37 59.27 ± 3.21 
G6 4.19 ± 1.76 56.25 ± 1.94 70.26 ± 3.58 
G7 3.70 ± 1.53 71.51 ± 2.35 87.92 ± 2.67 
G8 7.02 ± 1.34 51.21 ± 1.85 65.49 ± 3.45 
G9 7.80 ± 1.12 48.02 ± 1.25 71.46 ± 2.48 
G10 5.25 ± 1.23 66.60 ± 1.23 84.88 ± 1.45 
G11 0.98 ± 0.53 73.27 ± 1.88 90.07 ± 2.46 
G12 4.11 ± 1.05 63.29 ± 2.13 82.16 ± 2.68 
G13 3.09 ± 1.03 67.77 ± 1.46 85.02 ± 2.58 
G14 4.01 ±  1.12 61.13 ± 2.33 76.22 ± 1.69 
G15 3.87 ± 1.06 59.35 ±1.58 79.05 ± 2.44 
G16 6.83 ± 1.30 52.76 ±1.77 72.78 ± 2.46 
Pure drug 27.32 ± 4.32* 7.28 ± 1.08* 14.64 ± 2.47* 
*Significant difference at p < 0.05. 
 
All Gelucire®-based solid SNEDDS formulations of indomethacin exhibited 
significantly higher dissolution performance as presented by significantly higher %DE15 
and significantly lower values of MDT (p < 0.05) compared to that obtained for pure drug 
filled in capsules (Table 5.6). For example, it is evident from the data presented in Table 
5.6 that the %DE15 calculated for Gelucire®-based solid SNEDDS formulations showed 
3.99 – 9.82 folds increase in comparison to %DE15 of pure drug. 
High dissolution profiles of Gelucire®-based solid SNEDDS formulations could be 
attributed to increased wettability and micellar solubilization of drug in the presence of 
Gelucires® (Damian et al., 2000, Horter and Dressman, 2001, Leuner and Dressman, 
2000) resulting in improved solubility of indomethacin. The presence of Gelucires® in 
aqueous solutions may decrease the contact angle between drug particles and water 
leading to improved wettability of drug particles and therefore, enhanced dissolution rate. 
Also, the presence of hydrophilic carriers, such as Gelucire®44/14 and Gelucire®48/16, 
along with poorly soluble drug may lead to decreased hydrophobicity of the surface of 
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drug particles and then increased contact with the aqueous medium resulting in 
increased dissolution rate (Kallakunta et al., 2013).  In addition, rapid drug dissolution 
from Gelucire®-based SNEDDSs may be ascribed to the low surface free energy of these 
self-emulsifying systems leading to rapid emulsification and quick formation of an 
interface between drug particles and the dissolution medium (Craig et al., 1995). 
Furthermore, increased dissolution of the drug from Gelucire®-based SNEDDSs could be 
attributed to the micellar solubilzation of the drug. Both Gelucire® 44/14 and Gelucire® 
48/16 possess surface active properties and have the ability to self-emulsify when in 
contact with aqueous medium to produce fine emulsions or micellar solutions (da 
Fonseca Antunes et al., 2013, Gattefossé, 2015) which may entrap poorly soluble drug 
particles within micelles leading to solubilization. 
The obtained dissolution performance of indomethacin from pure drug was 
significantly low (p < 0.05) compared to dissolution performance of different Gelucire®-
based solid SNEDDS formulations. This is due to poor aqueous solubility and poor 
wettability of the drug. Poor wetting of indomethacin particles could be due to high 
surface free energy that may lead to increased cohesion between drug particles; than 
the adhesion between drug particles and dissolution medium; which then inhibits the 
formation of an interface (Ramasahayam et al., 2015). 
From the dissolution parameters calculated and presented in Table 5.6, it was 
observed that Gelucire®-based solid SNEDDS formulations prepared with Gelucire® 
48/16 (G5 –G12) exhibited higher dissolution profiles and hence, higher dissolution 
efficiency (%DE15) when compared to SNEDDS formulations prepared with Gelucire® 
44/14 (G1 –G4). These differences could be ascribed to differences in the HLB values of 
each Gelucire® grade. Gelucire® 48/16 possesses higher HLB value compared to 
Gelucire® 44/14 and therefore, this may enhance dispersion and miscibility of the drug 
within the carrier resulting in increased solubility and faster dissolution (Kalpana et al., 
2015). These dissolution observations are supported by the results obtained previously 
in Section 5.4.1 for phase solubility study of indomethacin in different Gelucires® as well 
as the results of determination of solubility of the drug in Gelucire®-based solid SNEDDS 
formulations presented in Section 5.4.4.4.  
Similar findings were reported for solid dispersions of flurbiprofen prepared by 
solvent evaporation method using Gelucire® 44/14 and Gelucire® 50/13 (Daravath et al., 
2015). Formulations prepared with Gelucire® 44/14 showed enhanced solubility and 
dissolution rate of the drug more than that obtained from formulations prepared with 
Gelucire® 50/13. These differences were attributed to differences in wettability and 
emulsifying properties of both carriers used (Daravath et al., 2015).  
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The dissolution performance of Gelucire®-based solid SNEDDS formulations 
prepared with Gelucire® 48/16 at 50oC (G9 – G12) was numerically higher than that 
observed for formulations prepared at 40oC (G5 – G8) even though no significant 
difference (p > 0.05) was observed between the dissolution parameters of these 
formulations (Figures 5.20, 5.21 and Table 5.6). Increased heating during extrusion 
processing may have led to increased dispersion of drug particles inside the matrix of the 
carrier and resulted in enhanced solubilization of the drug at the molecular level and 
hence, increased dissolution. From this observation, it appears that melt extrusion 
processing of different formulations at temperatures that are close to or higher than the 
melting point of the carrier may result in improved dissolution profiles of the drug 
compared to extrusion processing carried out by only softening of the carrier at a 
temperature that is well below its melting point.  
Similarly, the effect of extrusion conditions on drug crystallinity, drug-lipid 
interaction and dissolution patterns were evaluated and compared in the manufacture of 
sustained release tablets of diclofenac sodium based on solid lipid matrices of the drug 
(Vithani et al., 2014, Vithani et al., 2013). Mixtures of diclofenac sodium and Compritol® 
888 ATO were extruded either with “cold” extrusion process; where the barrel 
temperature was kept below the lipid melting point of 70oC, or by hot melt extrusion 
where the barrel segments heated to temperatures above the melting point of the solid 
lipid. The drug dissolution studies revealed that tablets prepared with lipid matrices that 
were developed by cold extrusion process showed faster dissolution rate of the drug 
compared to tablets  obtained from lipid matrices produced by hot melt extrusion process 
(Vithani et al., 2013). The authors concluded that extrusion conditions may play an 
important role in determination of drug dissolution behavior. In another study, this group 
of authors demonstrated that tablets composed of extrudates of diclofenac sodium and 
Compritol® 888 ATO produced by hot melt extrusion showed slightly faster dissolution 
rate; although no significant difference was observed upon comparison to the dissolution 
rate of tablets developed from “cold” processed extrudates (Vithani et al., 2014). In 
addition, it was reported that extrudates prepared from mixtures of Dynasan 114® and 
theophylline and extruded at a temperature above the melting point of the solid lipid 
showed faster dissolution profile compared to extrudates prepared at temperatures 
below the melting point of the carrier. This result was attributed to the highly porous 
surface structure of the extrudates obtained upon extrusion above the melting point of 
the carrier (Reitz and Kleinebudde, 2007). Furthermore, the dissolution performance of 
hot melt extruded solid dispersions of 17β-estradiol-hemihydrate prepared in 
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polyvinylpyrrolidone by extrusion at 180oC  was higher than that obtained for solid 
dispersions extruded at lower temperatures (100oC or 160oC) (Hülsmann et al., 2001).     
From the dissolution profiles presented in Figure 5.22 and the dissolution 
parameters shown in Table 5.6, it was observed that incorporation of different 
adsorbents into Gelucire®-based solid SNEDDS formulations such as Neusilin® US2 
(G13 and G14) and Florite® PS-200 (G15 and G16) resulted in lower dissolution 
performance of the drug compared to the Gelucire®-based solid SNEDDS formulation 
prepared without adsorbent (G7).  Also, it was noticed that increased content of the 
adsorbent in the formulation led to further reduction of the dissolution behavior of 
corresponding formulations.  This may be explained on the basis of embedding of these 
adsorbents (Neusilin® US2 or Florite® PS-200) within Gelucire® matrix during thermal 
processing and this may have led to molecular immobilization and decreased matrix 
wetting which then resulted in decreased drug dissolution  (Vithani et al., 2013). This 
explanation may be supported by the observation of further reduction of drug dissolution 
profile upon increasing the amount of incorporated adsorbent.    
This possible explanation may be supported by the XRD diffractograms of these 
formulations (G13 – G16), presented previously in Figure 5.14, where crystalline peaks 
of indomethacin were observed which may indicate that the drug did not dissolve 
completely in the carrier probably because of embedding of the adsorbent in the carrier 
and consequent reduction of the amount of the carrier available for dissolving the drug.  
Similar findings were reported for sustained release tablets produced by HME of pre-
mixed solid lipid matrices of diclofenac sodium/Compritol® 888 ATO with Neusilin® US2, 
Fujicalin® and magnesium stearate. These pre-mixed extruded tablets showed sustained 
dissolution profiles compared to the dissolution profile obtained for tablets prepared from 
lipid matrices and excipients without co-extrusion of tablet ingredients (Vithani et al., 
2013). The authors suggested that thermal processing may have accelerated embedding 
of tablet excipients within the hydrophobic lipid matrix and led to decreased matrix 
wetting and hence, reduced dissolution profiles.   
From the dissolution parameters calculated and presented in Table 5.6, it was 
observed that increase of the drug loading in Gelucire®-based solid SNEDDS 
formulations (G1 – G12) prepared at 40oC or 50oC, using drug: Gelucire® ratios of 0.5: 
10, 1: 10 and 2: 10, resulted in increased dissolution performance of the corresponding 
formulations. On the other hand, formulations prepared using higher drug loadings (drug: 
Gelucire® ratios of 3: 10) showed reduced dissolution performance. 
These observations could be explained based on the surface active properties of 
Gelucires® used and therefore, their ability to increase the solubility of poorly soluble 
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compounds in aqueous medium through micelle formation (Kalpana et al., 2015). 
Micellar solubilization occurs at surfactant concentrations above the critical micelle 
concentration (CMC) and involves the spontaneous dissolving of a substance by 
interaction with the micelles in water to produce thermodynamically stable isotropic 
solutions (Rangel-Yagui et al., 2005). The improved dissolution performance of 
Gelucire®-based solid SNEDDS formulations could be attributed to micellar solubilization 
of indomethacin by the surface active carriers. Also, the increased dissolution profiles of 
Gelucire®-based SNEDDS formulations obtained upon increasing the drug load could be 
related to the capacity of the surface active carrier to solubilize drugs as well as some 
important parameters of micelles.  
Generally, the number of drug molecules that can be solubilized in each micelle 
increase with increasing aggregation number of micelles or when micelles grow from a 
spherical shape to an elongated or disc like structure. Elongated or disc-like micelles are 
considered as larger micelles and may readily solubilize more than one drug molecule 
(Tehrani-Bagha and Holmberg, 2013). Usually, the aggregation number of micelles, 
which corresponds to the average number of surfactant monomers in each micelle, is 
approximately constant over a wide concentration range that might reach up to 100 times 
the CMC. However, in some cases when micelles grow in shape, the aggregation 
number may vary as well. Because micelles are labile and unstable entities, they can 
change their shape and size depending on several factors such as their chemical 
structure, their concentration, in addition to solution conditions including the temperature, 
ionic strength and pH. In particular, the surfactant type and the solution conditions may 
determine the change of the spherical micelles into cylindrical or discoidal ones (Rangel-
Yagui et al., 2005).   
Moreover, the extent of solubilization of a drug into a particular micelle depends 
on the shape of the micelle which is determined by the critical packing parameter (CPP). 
The CPP relates the geometry of the surfactant molecule to its ability to form particular 
aggregates, and can be calculated from the following equation (Lawrence and Rees, 
2000): 
     𝐶𝐶𝐶 = 𝑟 𝑡. 𝑒𝑐⁄    (Equation 5.1) 
where, 𝑟 is the molar volume of the hydrophobic portion of surfactant, 𝑡 is the optimal 
head group area and 𝑒𝑐 is the length of surfactant tail (or the critical length of the 
hydrophobic chain) which is generally assumed to be 70 – 80% of its full extended 
length.  The CPP provides a measurement of the preferred geometry adopted by the 
surfactant and therefore, predicts the type of the aggregates that it is likely to form 
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(Lawrence and Rees, 2000). As the value of CPP increases, the micelles become more 
asymmetrical and the volume of the inner core increases relative to that of the outer 
portion. Therefore, the solubilization of the drug in the core of the micelle will increase 
while the solubilization in the outer region will decrease with increased asymmetry 
(Rangel-Yagui et al., 2005).   
Furthermore, the temperature and the pH of micellar solutions can affect the 
extent of micellar solubilization. The amount of drug solubilized in the inner core of 
micelles increases as the temperature of micellar systems is increased. Increasing the 
temperature may lead to an increase in the space available for solubilization in the 
micelles and also may result in micellar growth. The pH of the micellar solutions can also 
influence the extent of solubilization of drugs because it may change the equilibrium 
between ionized and non-ionized forms of the drug. Weakly acidic drugs may exhibit 
increased solubility at elevated pH values due to increase in the ionized form of the drug 
(Rangel-Yagui et al., 2005).  
Based on the overview above, it could be assumed that increased solubilization 
of indomethacin in Gelucire®-based solid SNEDDS formulations may be due to the fact 
that thermal processing of different mixtures of the drug and Gelucires® may have 
facilitated incorporation of the drug molecules within the surfactant molecules because of 
increased space available for solubilization in the micelles imparted by heating which 
also performed to increase the solubility of the drug within the carrier. Subsequently, 
possible changes in the shape of micelles influenced by increased drug load along with 
thermal treatment have occurred. Changes in micelles shape and hence their size, may 
lead to increased CPP and this probably have allowed encapsulation and solubilization 
of more drug particles within the micelles.  The role of thermal processing in increasing 
the inclusion and solubilization of drug within micelles can be observed in the enhanced 
dissolution performance of Gelucire®-based SNEDDS formulations prepared with 
Gelucire 48/16 at 50oC (G9 – G12) compared to the dissolution profiles obtained for 
similar formulations prepared at 40oC (G5 – G8), even though no significant difference (p 
> 0.05) existed between their dissolution parameters.       
 Decreased dissolution profiles of Gelucire®-based SNEDDS formulations of 
indomethacin (G4, G8 and G12) prepared with higher drug loads (at drug: Gelucire® 
ratios of 3: 10) compared to other formulations could be due to exceeding the solubilizing 
capacity of the carrier for excess drug (as indicated in the XRD diffractograms of the 
corresponding formulations). Also, increased dug loading in these formulations resulted 
in formulations with thick consistency which possibly retarded the passage of the 
dissolved drug particles into the dissolution medium.  
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 The results of measurement of droplet size of nanoemulsions generated from 
different Gelucire®-based solid SNEDDS formulations which were presented in section 
5.4.4.3 may coincide with the results of dissolution studies of these formulations. As 
explained in that section, increased drug loading between different formulations resulted 
in the formation of larger dense particles probably because increased amount of drug 
particles were solubilized during thermal processing of different mixtures of the drug and 
the carrier.  
 
5.5. Conclusions 
In this part of the study, formulation of solid SNEDDS of indomethacin was 
carried out using different grades of Gelucires® as single self-emulsifying vehicles that 
possess the ability to solidify upon cooling to room temperature. Based on the results of 
phase solubility studies conducted using different grades of Gelucires®, it was found that 
Gelucire®44/14 and Gelucire®48/16 exhibited highest solubilizing potential of the drug 
and therefore, these two carriers were selected as self-emulsifying vehicles to formulate 
solid SNEDDS of indomethacin adopting the HME technique. Different Gelucire®-based 
solid SNEDDS formulations were prepared at different drug: carrier ratios in which the 
amount of the drug was increased relative to a constant amount of the carrier. The effect 
of incorporation of different types and concentrations of adsorbents on the dissolution 
behaviour of selected formulations was also investigated. Hot melt extrusion of different 
physical mixtures prepared from the drug, specific Gelucire® grade with or without 
adsorbent was carried out at a barrel temperature adjusted at 40oC or at 50oC with 
rotational speed of 30 rpm.  
Evaluation of different Gelucire®-based solid SNEDDS formulations prepared by 
HME at barrel temperature of 40oC or 50oC revealed good drug content with acceptable 
values of RSD <3%. Also, these formulations manifested good self-nanoemulsifying 
properties as indicated by the clear to hazy nanoemulsion produced upon dilution with 
liquid medium. No signs of precipitation were observed upon dilution except with 
formulations prepared with high drug: carrier ratios (3: 10).  Further, all Gelucire®-based 
solid SNEDDS formulations showed increased solubility of the drug in phosphate buffer 
pH 7.2 when compared to the solubility of pure drug in the same medium.  
DSC studies and XRD analysis of different Gelucire®-based solid SNEDDS 
formulations demonstrated that the drug might have remained in a molecularly dissolved 
state within the carrier. 
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All Gelucire®-based solid SNEDDS formulations of indomethacin showed 
improved dissolution profiles when compared to that obtained for the pure powder of the 
drug. Enhanced dissolution performance of these formulations was due to increased 
wettability, micellar solubilization of drug particles in addition to decreased 
hydrophobicity of the surface of drug particles influenced by the presence of Gelucires®. 
Also, solid SNEDDS formulations prepared with Gelucire® 48/16 (G5 – G12) exhibited 
higher dissolution profiles when compared to formulations prepared with Gelucire® 44/14 
(G1 – G4). These differences could be ascribed to differences in the HLB values of both 
carriers. In addition, the dissolution performance of Gelucire®-based solid SNEDDS 
formulations prepared with Gelucire® 48/16 at 50oC (G9 – G12) was higher than that 
observed for formulations prepared at 40oC (G5 – G8). This was attributed to enhanced 
solubilization of the drug in the completely melted carrier obtained upon increasing the 
processing temperature. Moreover, incorporation of different types and amounts of 
adsorbents into Gelucire®-based solid SNEDDS formulations such as Neusilin® US2 
(G13 and G14) and Florite® PS-200 (G15 and G16) led to reduced dissolution of the drug 
compared to the formulation prepared without adsorbent (G7). The incorporated 
adsorbents might have been embedded within Gelucire® matrix during thermal 
processing and therefore, resulted in reduced wetting of the carrier and consequently 
decreased drug dissolution.    
Furthermore, the dissolution performance of Gelucire®-based solid SNEDDS 
formulations prepared at 40oC (G1 – G3, G5 – G7) and those prepared at 50oC (G9 – 
G11) increased with increasing the drug load. This was explained based on micellar 
solubilization of indomethacin by the surface active carriers in addition to some important 
properties of micelles such as their aggregation number, shape, size and critical packing 
parameter that might be affected by the temperature and the pH of micellar solutions.     
On the other hand, reduced dissolution performance was observed for Gelucire®-
based solid SNEDDS formulations when the drug load was increased to the drug: carrier 
ratio of 3: 10 (G4, G8 and G12). This was assumed to be due to exceeding the 
solubilizing capacity of the carrier influenced by increased drug load which resulted in 
incomplete solubilization of excess drug by the melted or softened carrier and hence led 
to reduced dissolution performance. Also high viscosity of these formulations may have 
retarded the passage of the dissolved drug particles into the dissolution medium. 
Determination of droplet size of nanoemulsions generated from different Gelucire®48/16-
based solid SNEDDS formulations (G1 – G12) was consistent with the results of 
dissolution studies obtained for these formulations.  
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Overall, it appears that production of Gelucire®-based solid SNEDDS of 
indomethacin by HME requires careful selection of the barrel temperature at which the 
carrier will be completely melted. Also, monitoring the drug load in each formulation is 
essential to ensure complete molecular solubilization of the drug molecules in the 
completely melted carrier. This will then lead to a higher self-emulsification efficiency of 
the formulation, in addition to enhanced solubility and improved dissolution performance 
of the poorly water soluble drug.  
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Drug stability is one of the most critical quality attributes that need to be 
evaluated during pharmaceutical development. Stability studies provide information on 
different changes in the quality of drug substance or drug product that may develop with 
time under controlled conditions of temperature and relative humidity (RH).  This 
information will help to establish the shelf-life of a drug substance or drug product, or 
define the storage conditions suitable for the formulation product (Guo et al., 2013).   
Development of a stable formulation that will exhibit minimal or no degradation of 
the active compound throughout the formulation’s shelf life is of a great importance for 
any dosage form.  Incorporation of numerous excipients in formulating conventional 
dosage forms may increase the potential for drug-excipients incompatibilities which in 
turn may lead to drug degradation. Also, the rate of chemical reaction and hence drug 
decomposition within a formulation is greatly influenced by the temperature at which the 
formulation was produced. Therefore, production of formulations at the lowest possible 
temperature is advisable to avoid chemical instability (Maddineni et al., 2015).  
Investigation of physical stability is required to ensure that the dosage form will 
maintain its proposed performance during the shelf-life and that the drug potency is not 
altered so that the effectiveness of the formulation will be preserved. Therefore, an 
understanding of the physical and chemical mechanisms of any physical change is 
important in achieving high quality and stable drug formulations. Physical instability of 
some pharmaceutical dosage forms may be due to the solid-state physical instability of 
drug substances, such as recrystallization of an amorphous drug, or may be due to 
changes in the formulation matrix itself, or a combination of both issues. 
More novel drug delivery approaches such as the lipid-based formulations, nano-
based systems and solid dispersions often face greater physical stability challenges 
compared to conventional oral drug formulations. Many of these formulation technologies 
are based on supersaturated drug delivery systems, and hence maintaining this 
supersaturation is important to maintaining product performance.  Proper understanding 
of the solid-state properties of the formulation and how these may be affected by the 
manufacturing process and storage conditions is fundamental for the development of 
highly stable formulations (Guo et al., 2013). 
During pharmaceutical manufacturing processes, crystalline drug substances 
may be converted either partially or totally into amorphous forms which possess 
increased apparent solubility, dissolution rate and possibly bioavailability. Conversely, an 
initial amorphous form may revert back to the stable crystalline form during 
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manufacturing or during storage (Guo et al., 2013), altering its physical behaviour and 
likely bioavailability.  
Hot melt extrusion (HME) technology has been successfully used to enhance the 
aqueous solubility of poorly water-soluble drugs (Alshahrani et al., 2015, Lee et al., 2015, 
Liu et al., 2010, Tho et al., 2010). In a HME product, the poorly soluble drug is mixed 
with a polymeric (or lipid) carrier matrix to form a solid dispersion, with the drug being 
present either in the monomolecular state, i.e., a solid solution, or as amorphous clusters 
within the polymeric matrix. Enhancement of solubility then results from one or more of 
the following effects: increased drug specific surface area, higher saturation solubility 
and increased free energy. Successful solubilization by HME is determined by several 
factors related to the physicochemical properties of the drug and the carrier in addition to 
manufacturing considerations such as the processing temperature, shearing forces and 
other operating conditions. For example, the ideal processing temperature is selected to 
allow softening of the carrier and often melting so that its low viscosity permits extrusion 
(Shah et al., 2013).  
Therefore, in formulations produced by HME technology the drug is either 
converted from its crystalline form into an amorphous state or involved in the formation of 
a solid solution or molecular dispersion in hydrophilic carriers (Alshahrani et al., 2015). 
Crystalline drugs are commonly converted to amorphous state by the effect of heating 
and high shear forces which are typically utilized in hot melt extrusion process (Alsulays 
et al., 2015). High shear mixing during HME process contributes to high drug–polymer 
interactions and consequently high solubility (Sarode et al., 2014). Compared to 
crystalline drugs, increased solubility and dissolution rate can be achieved from an 
amorphous drug because no energy is required to break up the crystalline lattice 
(Vasconcelos et al., 2007). However, increased free energy of amorphous drugs may 
influence their thermodynamic stability upon storage, and this may lead to 
recrystallization of drug particles which may result in decreased dissolution rate and 
solubility of the drug and hence, decreased pharmacological efficacy. Therefore, 
amorphous solid dispersion systems are thermodynamically unstable and tend to change 
to stable state through recrystallization process. Reduced physical stability of amorphous 
dispersions could be responsible for the limited number of products formulated by 
extrusion that can be found in the market. For this reason, formulation of stable solid 
dispersions is of a prime importance as that required for solubility enhancement 
(Alshahrani et al., 2015).  
A number of different factors may play an important role in the physical and 
chemical stability of amorphous solid dispersions. These factors may include: molecular 
  Chapter 6  
243 
 
mobility, environmental stress, thermodynamic properties and preparation methods and 
conditions (Baghel et al., 2016).  
The crystallization process of amorphous solid dispersions takes place in two 
steps that occur simultaneously: nucleation which occurs at lower temperatures and 
crystal growth which needs higher temperatures. Nucleation of supersaturated solutions 
will occur only at a certain degree of supersaturation in order to overcome the high 
interfacial tension between small particles. The range of supersaturated concentrations 
where no nucleation occurs is defined as the metastable zone. Polymeric carriers that 
may extend this region by increasing the degree of supersaturation or decreasing the 
interfacial energy are considered more suitable to prevent crystallization (Baghel et al., 
2016). Polymeric carriers that increase the aqueous solubility, and hence inhibit the 
precipitation of dissolved drug, can retard the rate of nucleation by reducing the amount 
of free drug available to form nuclei (Surwase et al., 2015). Also, polymers increase the 
viscosity of the dispersion system and therefore, alter the frequency of molecular 
transport at the surface of nucleus. In addition, high molecular weights of polymers and 
their ability to exist in different conformations may play a role in reducing the tendency of 
drug recrystallization by reducing the free energy of amorphous solid dispersions 
(Baghel et al., 2016).  
Intermolecular interactions between the drug and the carrier molecules that take 
place through H-bonding, ionic bonding or weak van der Waals forces contribute to the 
physical stability of the systems by limiting the molecular mobility of drug molecules in 
the polymer matrix. Also, drug-polymer interactions play an important role in inhibiting 
crystallization by interfering with the process of nucleation or by inhibiting the crystal 
growth (Baghel et al., 2016). The magnitude of these intermolecular interactions was 
reported to be dependent on the miscibility of the drug and the polymer in addition to the 
drug / polymer ratio in the formulation (Maniruzzaman et al., 2013a). 
Physical stability of amorphous systems is also affected by the molecular mobility 
of drug molecules. Restriction of the molecular mobility of the amorphous drug can be 
achieved by the polymer molecules included in amorphous formulations. The polymer 
matrix may act as a physical barrier to the molecular motion leading to increased stability 
(Baghel et al., 2016). Generally, utilization of polymers having high glass transition 
temperature (Tg) in formulating amorphous solid dispersions may contribute to reducing 
the molecular mobility of the drug and hence reducing the tendency for recrystallization 
at specific storage temperatures. Also, preservation of the drug-polymer intermolecular 
interactions is important for stability of solid dispersions.  These considerations require 
the drug to be soluble at the molecular level in the polymer (Qian et al., 2010). 
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Therefore, physical stability of amorphous solid dispersions is determined by the 
molecular level of interaction that occurs between the drug molecules and the carrier. 
Other factors that must be considered to achieve physically stable formulation may 
include: (1) the physicochemical properties of the carrier such the molecular weight, 
melting point or glass transition temperature, hydrophilicity, hygroscopicity, capability of 
H-bonding and acidic or basic functional groups available for ionic interaction; (2) the 
drug to carrier ratio or the drug load used in the formulation, where low drug loading lead 
to more physically stable formulation. Low drug loading will minimize interaction between 
drug molecules themselves and hinder drug recrystallization. However, chemical 
instability or degradation is usually linked with low drug concentrations. In this case, a 
balance between physical and chemical stability should be determined especially for 
chemically labile drugs; and (3) the manufacturing method should be monitored for both 
process development and in-process control because crystallization of the amorphous 
form during manufacturing process will significantly affect the performance of the solid 
dispersion and the subsequent dosage form (Guo et al., 2013). 
Formulation of solid dispersions by hot melt extrusion (HME) is similar to the 
traditional melting (fusion) method and involves intense mixing of the drug and the carrier 
inside the extruder. HME offers the possibility to shape the molten mixture into pellets, 
implants or oral dosage forms and requires complete miscibility of the drug and the 
carrier in the molten phase.  Intense mixing at high shear forces and temperatures may 
result in uniform distribution of drug molecules in the carrier matrix leading to formation 
of dispersions at the molecular level (Baghel et al., 2016). Theoretically, a homogenous 
blend of the drug and the carrier forms a stable one-phase system in which the 
molecularly dispersed drug does not require the breakdown of the lattice structure before 
dissolution (Chan et al., 2015). In HME, different process parameters such as the 
heating temperature, the screw speed and residence time play an important role in the 
extrusion process as well as the properties of resulting solid dispersion. The influence of 
these parameters is dependent on the physicochemical properties of the drug and the 
carrier (Maddineni et al., 2015).  
In this part of the project, investigation of physical stability of selected Gelucire® 
48/16-based solid SNEDDS of indomethacin was carried out. These formulations were 
selected based on their different drug: carrier ratios (or different drug loading) in addition 
to different HME processing temperatures. These formulations had shown high 
dissolution performance as determined from the in vitro dissolution studies conducted in 
Chapter 5. In order to evaluate the physical stability, these formulations were stored 
after manufacturing at controlled conditions of temperature and relative humidity (RH) for 
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6 months. Assessment of physical stability of stored formulations was carried out after 1, 
3 and 6 months of storage using the XRD, SEM and dissolution studies. The results 
were compared to those obtained for the corresponding initial formulations that were 
evaluated immediately after production. 
6.2. Materials 
• Indomethacin was obtained from Sigma-Aldrich Chemie GmbH, Germany. 
• Gelucire® 48/16 was kindly provided by Gattefossé Co., France. 
• Potassium dihydrogen orthophosphate anhydrous was obtained from Loba Chemie 
Pvt. Ltd. (Mumbai, India). 
• Sodium hydroxide and sodium chloride were obtained from Fluka Chemie GmbH 
(Germany). 
• Hard gelatin capsules were obtained from pharma tradechem (Mumbai, India). 
6.3. Methods 
6.3.1. Construction of a standard calibration curve of indomethacin in 
phosphate buffer pH 7.2 
The standard calibration curve of indomethacin constructed in phosphate buffer 
pH 7.2, as described in Chapter 4, was utilized for this part of the study. The accuracy 
as well as the precision (reproducibility) of the assay procedure for determination of 
indomethacin concentrations in phosphate buffer were evaluated as previously 
presented in Chapter 3.   
6.3.2. Formulation of Gelucire®-based solid SNEDDS of indomethacin 
Gelucire® 48/16-based solid SNEDDS formulations of indomethacin described 
previously in Chapter 5 were selected for investigation of the physical stability. These 
formulations were prepared by HME at 40oC (G5 – G7) or at 50oC (G9 – G11) using 
different drug: carrier ratios. The selection of these formulations for physical stability 
studies was based on their relatively high dissolution performance, good drug content 
with acceptable values of %RSD and good self-nanoemulsifying properties. In addition, 
the XRD diffractograms of these formulations demonstrated that the drug existed in a 
molecularly dissolved state within the carrier following manufacture. On the other hand, 
Gelucire® 48/16-based solid SNEDDS formulations of indomethacin prepared at 40oC 
(G8) or at 50oC (G12) using higher drug: carrier ratio (3: 10) were excluded from physical 
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stability studies because these formulations showed crystalline drug particles that 
remained undissolved in the carrier as demonstrated by their XRD diffractograms and 
SEM micrographs. Codes and composition of formulations subjected to physical stability 
studies are given in Table 6.1. Selection of formulations that were processed at two 
different temperatures and contained different drug loading would be useful to identify 
the effect of different processing temperatures as well as different drug loadings on 
stability of obtained formulations.    
 Compounding of Gelucire® 48/16-based solid SNEDDS of indomethacin for the 
purpose of evaluation of physical stability was carried out in the same manner as 
described in Chapter 5.  Briefly, different physical mixtures of indomethacin and 
Gelucire®48/16 were prepared at the drug: carrier ratios of 0.5: 10, 1: 10 and 2: 10.  Each 
physical mixture was introduced into co-rotating twin screw extruder (micro-compounder, 
MC 15, Xplore Instruments BV, Sittard, The Netherlands) through the hopper. The barrel 
temperature was adjusted at either 40oC (below the melting point of Gelucire® 48/16) or 
50oC (at the melting point of Gelucire® 48/16) while the rotational speed was fixed at 30 
rpm. The introduced blend was mixed for 5 minutes inside the barrel before extrusion 
through a die with 1 mm diameter. The collected mass was allowed to cool at room 
temperature, then cut or crushed into small pieces which were sieved through 500 µm 
sieve to obtain the granular product.  
 
Table  6.1 Codes and composition of different Gelucire®48/16-based solid SNEDDS 










G6 1: 10 




G10 1: 10 
G11 2: 10 
 
6.3.3. Stability studies of Gelucire®-based solid SNEDDS of indomethacin 
Stability studies were conducted at 30oC/75% RH for 6 months. According to the 
International Conference on Harmonization (ICH) guidelines, the standard elevated 
storage conditions for accelerated stability of a pharmaceutical formulation are 40oC/75% 
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RH for 6 months (ICH, 2003). However, the physical stability of different Gelucire®48/16-
based solid SNEDDS formulations of indomethacin was evaluated here at 30oC/75% RH 
for 6 months to avoid any issues relating to softening and melting of the Gelucire® 48/16 
carrier that might be expected given its nominal melting point and observed physical 
behaviour (Chapter 5). Re-softening of formulations had been observed in a preliminary 
experiment upon storage of samples at 40oC. All samples were therefore stored at 30oC 
(which is 10 degrees below the minimal processing temperatures used) to avoid possible 
re-softening of formulations, especially those produced at a barrel temperature of 40oC, 
during storage period. The humidity condition of 75% RH was maintained to be as close 
as possible to ICH guidelines.  
Manufactured formulations of Gelucire®48/16-based solid SNEDDS of 
indomethacin were placed in closed glass vials and stored at 30oC in a desiccator 
containing a saturated salt solution of sodium chloride to generate the required relative 
humidity.  Stored samples were removed after 1, 3, and 6 months and tested for 
dissolution behaviour as well as for crystallinity of the drug using XRD and SEM. The 
results of different evaluation tests obtained for stored samples were compared to the 
results obtained for the initial formulations tested immediately after production.      
6.3.4. Evaluation of stored Gelucire®48/16-based solid SNEDDS of 
indomethacin 
6.3.4.1. Powder X-ray diffraction (XRD) 
The physical state of the drug in the stored formulations was determined using  
X-ray diffraction after 1, 3 and 6 months of storage. The results were compared to the X-
ray diffraction pattern obtained previously for the initial Gelucire®48/16-based solid 
SNEDDS formulations directly after production. X-ray diffraction studies were performed 
using Ultima IV diffractometer (Rigaku Co., Ltd., Tokyo, Japan) equipped with a copper 
X-ray source maintained at 40 kV of tube voltage and 40 mA of tube current to produce 
emissions of 0.15406 nm. The samples were scanned at 3 − 60° 2θ range at a scanning 
speed of 0.5 deg./min. Data were collected using a step scan mode with step size of 
0.02o and counting time of 1 second per step. 
6.3.4.2. Scanning electron microscopy (SEM) 
The surface morphology of stored solid SNEDDS formulations was investigated 
after 1, 3 and 6 months of storage using JSM-6060LV scanning electron microscope 
(JEOL, Tokyo, Japan) at an accelerating voltage of 10 kV. Samples were lightly sprinkled 
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onto double-sided sticky tape which then was affixed to aluminum stub and made 
electrically conductive with a gold coating (13 – 14 nm/min; 45 s; 20 mA) under vacuum 
using JFC-1600 Auto Fine Coater (JEOL, Tokyo, Japan). Micrographs obtained for 
stored formulations were recorded and compared to those obtained for fresh solid 
SNEDDS formulations directly after manufacture.  
6.3.4.3. In vitro dissolution studies 
In vitro dissolution studies of stored Gelucire®48/16-based solid SNEDDS 
formulations were performed after 1, 3 and 6 months of storage according to British 
Pharmacopoeia (2015) as previously described in Chapter 4. Briefly, an amount of each 
formulation equivalent to 25 mg of indomethacin was filled in hard gelatin capsule and 
used for dissolution studies in phosphate buffer pH 7.2. Samples (5 ml) were withdrawn 
at fixed time intervals, filtered through a 0.45 µm syringe filter, suitably diluted and 
assayed for the drug at 320 nm. An equal volume of fresh dissolution medium kept at 
37oC was added to keep constant volume during dissolution study. All experiments were 
performed in triplicates and results were averaged ± SD.  
Different dissolution parameters such as dissolution efficiency after 15 minutes 
(DE15min), and % released after 15 minutes (%Q15min) were calculated using DDSolver 
(Excel add inn) and used to compare the dissolution performance of different Gelucire®-
based solid SNEDDS formulations after storage. Evaluation of physical stability by 
dissolution test was carried out by comparing the dissolution parameters obtained for 
stored samples to those obtained for initial formulations. 
6.3.4.4. Statistical analysis 
One way analysis of variance (ANOVA) and t-test were used to detect differences 
between the data of interest. Significant differences were determined at a 5% 
significance level, unless otherwise stated elsewhere. Statistical differences yielding (p < 
0.05) were considered significant. 
6.4. Results and discussion 
Different Gelucire® 48/16-based solid SNEDDS of indomethacin that showed 
optimum dissolution performance (Chapter 5) were taken for further evaluation of 
physical stability. Specifically, formulations prepared with different drug: carrier ratios 
using Gelucire® 48/16 that were processed at 40oC (G5 – G7) or at 50oC (G9 – G11) 
were selected to conduct stability studies at 30oC/75% RH for 6 months. Stored samples 
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were removed after 1, 3, and 6 months of storage and tested for crystallinity of the drug 
using XRD and SEM as well as for the dissolution performance.  
In this part of the study, the differential scanning calorimetry (DSC) and the 
Fourier Transform Infrared (FTIR) analyses were not adopted for evaluation of physical 
stability of different Gelucire® 48/16-based solid SNEDDS of indomethacin. As shown in 
Chapter 5, the conventional DSC analysis of different Gelucire® formulations was not 
reliable to detect the presence of crystalline particles of the drug within different 
formulations, and therefore the DSC results were combined with the results of other 
characterization tests such as the XRD and SEM analyses to confirm the presence of 
crystalline drug. On the other hand, the FTIR analysis was used in Chapter 5 to detect 
any chemical interaction between the drug and the carrier in different formulations. Since 
only physical stability is to be studied in this Chapter, the FTIR analysis was not adopted. 
The results of XRD and SEM as well as the dissolution performance obtained for 
stored samples compared to those obtained for initial formulations are presented in the 
following sections. 
6.4.1. X-ray diffraction (XRD)  
The XRD diffractograms of stored Gelucire®48/16-based solid SNEDDS 
formulations prepared at 40oC (G5 – G7) and at 50oC (G9 – G11) are presented in 
Figures 6.1 and 6.2, respectively.  
  





Figure  6.1 XRD diffractograms of initial and stored Gelucire® 48/16-based solid 
SNEDDS formulations of indomethacin prepared by HME at 40oC. 
  





Figure  6.2 XRD diffractograms of initial and stored Gelucire® 48/16-based solid 
SNEDDS formulations of indomethacin prepared by HME at 50oC. 
As depicted in Figure 6.1, it is obvious that Gelucire®48/16-based solid SNEDDS 
formulations prepared by HME at 40oC (G5 – G7) behaved differently upon storage at 
30oC/75% RH.  The diffractograms of formulation G5 showed no signs of drug 
crystallization during the 6 months storage, while the diffractograms of formulations G6 
and G7 showed peaks of crystalline indomethacin during storage for the same period. 
On the other hand, the XRD diffractograms of all Gelucire®48/16-based solid SNEDDS 
formulations prepared by HME at 50oC (G9 – G11) and stored at 30oC/75% RH, as 
presented in Figure 6.2, did not show any specific peaks related to crystalline 
indomethacin.     
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The XRD diffractogram of stored formulations G6 and G7 (Figure 6.1) exhibited 
specific peaks of crystalline indomethacin at 2θ values of 11.9o, 17.2o and 26.9o at all 
time points, although these peaks were more pronounced for the higher drug loading 
formulation and for the later time points, indicating progressive indomethacin 
crystallization. Therefore, it appears that Gelucire®48/16-based solid SNEDDS prepared 
by softening of the carrier at 40oC (G6 & G7) were not stable at 30oC/75 RH for 6 
months. Since formulations G6 and G7 were prepared with higher drug loading (drug: 
carrier ratios of 1: 10 and 2: 10, respectively), it could be possible that the higher drug 
concentration may have led to close contact and interaction between drug molecules 
themselves which in turn initiated recrystallization during storage period. This 
assumption can be supported by the absence of crystalline peaks of the drug in the X-
ray diffraction of formulation G5 (Figure 6.1) that was prepared with lower drug 
concentration (drug: carrier ratio of 0.5: 10) and stored for the same period of time under 
the same storage conditions. Low drug loading allowed drug molecules to remain 
completely dissolved at the molecular level within the softened carrier during storage 
period because of the high shear forces applied in the extruder. Molecular level of mixing 
of the drug and the carrier may lead to the formation of homogenous solid solution 
structure (Wlodarski et al., 2015). Also, the presence of low drug loading will minimize 
interaction between drug molecules themselves and hinder drug recrystallization leading 
to more physically stable formulation (Guo et al., 2013).  
On the other hand, the absence of signs of crystallization in the XRD 
diffractograms of all Gelucire®48/16-based solid SNEDDS prepared by HME at 50oC (G9 
– G11) and stored at 30oC/75% RH, which are presented in Figure 6.2, confirms that all 
of these formulations were stable at 30oC/75% RH for 6 months.   
Differences in the XRD diffractograms of stored Gelucire®48/16-based solid 
SNEDDS formulations prepared by HME at 40oC (Figure 6.1) or at 50oC (Figure 6.2) 
indicate that processing mixtures of indomethacin and Gelucire®48/16 at a temperature 
that corresponds to the melting point of the carrier (50oC) is preferably required to 
solubilize high drug loadings at a molecular level within the completely melted carrier and 
to produce a physically stable single phase homogenous formulations. It was reported 
that high shear mixing during HME process will lead to high drug-carrier interaction and 
therefore, high solubility (Sarode et al., 2014). Intermolecular interactions occurring 
between drug and carrier molecules via hydrogen or ionic bonding contribute to the 
physical stability of the system and prevention of crystallization by hindering the 
nucleation process and thus inhibiting the crystal growth (Baghel et al., 2016).     
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6.4.2. Scanning electron microscopy (SEM) 
Scanning electron microscopy was also used to assess the stability of selected 
Gelucire®48/16-based solid SNEDDS formulations of indomethacin processed at both 
40oC (G5 – G7) and at 50oC (G9 – G11). Different micrographs obtained for initial and 
stored formulations are presented in Figure 6.3 and Figure 6.4.   
 
 
Figure  6.3 SEM micrographs of initial and stored Gelucire® 48/16-based solid 
SNEDDS formulations of indomethacin prepared by HME at 40oC. 
 
 




Figure  6.4 SEM micrographs of initial and stored Gelucire® 48/16-based solid 
SNEDDS formulations of indomethacin prepared by HME at 50oC. 
 
Scanning electron micrographs obtained after 1, 3 and 6 months of storage of 
formulations prepared by HME at 40oC (G5 – G7) are shown in Figure 6.3. The absence 
of drug crystals in different micrographs obtained for formulation G5 throughout the 
storage period indicates that this formulation retained its homogeneity during storage 
and was physically stable at 30oC/75% RH for 6 months. On the other hand, inspection 
of the SEM micrographs obtained for stored formulations G6 and G7 revealed the 
presence of crystals of the drug inside the Gelucire® matrix after 1 and 3 months of 
storage, while a high degree of crystallization was obvious in the SEM micrographs of 
these two formulations after 6 months of storage. These observations coincide with the 
  Chapter 6  
255 
 
XRD diffractograms obtained for formulations G5 – G7 after storage for the same time 
period (Figure 6.1).  
Scanning electron micrographs recorded after 1, 3 and 6 months of storage of 
Gelucire® 48/16-based solid SNEDDS prepared by HME at 50oC (G9 – G11) are 
presented in Figure 6.4. It was obvious that none of these formulations developed any 
crystallization during 6 months of storage which indicates that these formulations 
preserved their homogenous dispersion characteristic.  This observation for stored 
formulations G9 – G11 is consistent with their XRD diffractograms obtained during 
storage period (Figure 6.2) that showed an absence of peaks of crystalline drug. 
Therefore, it can be concluded that solid SNEDDS prepared by HME at the melting point 
of Gelucire® 48/16 are physically stable at 30oC and 75% RH for 6 months. Absence of 
crystallization in formulations G9 – G11 during storage could be due to complete 
solubilization of the drug in the completely melted carrier with consequent intermolecular 
interactions between the drug and the carrier molecules. High intermolecular interactions 
may inhibit recrystallization by inhibiting nucleation and crystal growth (Baghel et al., 
2016, Sarode et al., 2014). 
An alternative explanation for the appearance of crystals in formulations G6 and 
G7 is that not all the drug was completely dissolved initially during processing at 40oC, 
leaving extremely small drug deposits which then acted as foci for nucleation and growth 
on storage. These deposits would have been below the limit of detection for the 
techniques used, i.e., SEM and XRD. It was reported that the longest dimension of 
indomethacin unit cell is about 25 Angstrom (or 2.5 nm) and therefore, a crystal of at 
least 50 nm in length can be detected by microscopy analysis (Chen, 2002). Based on 
this, it can be assumed that crystals less than 10 nm in length may not be detected by 
SEM. In addition, the poor limit of detection by XRD analysis may render this technique 
unreliable to detect an amount of crystals that is less than 10% (w/w) (Saleki-Gerhardt et 
al., 1994). On the other hand, the higher temperature (50oC) used in processing of 
formulations G9 – G11 allowed a greater degree of dissolution of the drug initially, hence 
no recrystallization was seen on storage for 6 months. 
6.4.3. In vitro dissolution studies 
The dissolution performance of Gelucire® 48/16-based solid SNEDDS 
formulations that were subjected to stability testing was evaluated after 1, 3 and 6 
months of storage and compared to the dissolution properties obtained for the 
corresponding formulations right after manufacturing. Comparison of the dissolution 
behavior of different formulations was based on the % drug released after 15 minutes 
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(%Q15) in addition to the dissolution efficiency after 15 minutes (%DE15).  For the purpose 
of clarity, these dissolution parameters were found to be best presented in the bar 
graphs shown in Figure 6.5 and Figure 6.6, respectively.  
 
Figure  6.5 Comparison of mean % drug released after 15 minutes (%Q15) from initial 
and stored Gelucire®48/16-based solid SNEDDS formulations of 
indomethacin prepared by HME at 40oC and 50oC.  

















Initial 1 month 3 months 6 months




Figure  6.6 Comparison of mean dissolution efficiency after 15 minutes (%DE15) from 
initial and stored Gelucire® 48/16-based solid SNEDDS formulations of 
indomethacin prepared by HME at 40oC and 50oC. 
   
 
From the results shown in Figure 6.5 and Figure 6.6, it was noticed that 
Gelucire® 48/16-based solid SNEDDS formulations of indomethacin processed at 40oC 
(G5 – G7) showed slight decreases in the % drug released after 15 minutes (% Q15) as 
well as the dissolution efficiency after 15 minutes (%DE15) upon storage at 30oC/75% RH 
for 6 months, although no significant difference (P>0.05) was detected between these 
dissolution parameters calculated for the initial and stored formulations. Reduced values 
of dissolution parameters during storage were more prominent in formulations G6 and 
G7. Decreased dissolution of these formulations could be attributed to recrystallization of 
the drug that occurred during storage possibly because of high drug loading that initiated 
interaction between the adjacent drug molecules themselves. The presence of crystalline 
peaks of indomethacin in the XRD diffractograms (Figure 6.1) as well as the appearance 
of crystals of the drug in the SEM micrographs (Figure 6.3) of formulations G6 and G7 
confirm the recrystallization process that occurred during storage. Presence of crystalline 
drug within these formulations during storage probably has reduced the amount of 
molecularly dissolved drug available for dissolution and resulted in reduced dissolution 
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On the other hand, Gelucire® 48/16-based solid SNEDDS formulations of 
indomethacin processed at 50oC (G9 – G11) did not exhibit significant changes in the % 
drug released after 15 minutes (% Q15) (Figure 6.5) or in the dissolution efficiency after 
15 minutes (%DE15) (Figure 6.6) when stored at 30oC/75% RH for 6 months. This 
indicates that these formulations were physically stable for 6 months at the storage 
conditions. Physical stability of formulations G9 – G11 may be due to intimate mixing of 
the drug and the carrier in these formulations which was achieved by HME processing at 
a higher temperature (50oC) and in turn, this may have contributed to complete 
molecular solubilization of the drug within the completely melted carrier. Inhibition of 
recrystallization was due to high intermolecular interactions between drug and carrier 
molecules obtained upon molecular solubilization of the drug (Baghel et al., 2016, 
Sarode et al., 2014).   
Similar findings were reported for hot melt extruded solid dispersions of 17β-
estradiol-hemihydrate prepared in polyvinylpyrrolidone at different extrusion 
temperatures (Hülsmann et al., 2001). It was found that batches extruded at higher 
temperature (180oC) showed higher dissolution profiles compared to batches prepared at 
lower temperatures (100oC or 160oC). In addition, the dissolution profiles of formulations 
prepared at higher temperature did not change significantly during storage while 
formulations prepared at lower extrusion temperatures exhibited decreased dissolution 
on storage.  This was ascribed to the fact that the drug remained dissolved in the carrier 
when processed at higher temperature and therefore, dissolution profiles remained 
unchanged, while formulations prepared at lower temperatures developed crystals that 
acted as nuclei and resulted in recrystallization and hence, reduced dissolution on 
storage (Hülsmann et al., 2001).    
Overall, it appears that Gelucire® 48/16-based solid SNEDDS formulations 
processed by HME at 50oC were more physically stable than formulations processed at 
40oC upon storage at 30oC/75% RH for 6 months. The results obtained from the XRD 
analysis, SEM as well as the dissolution studies conducted for stored formulations 
processed at 50oC indicated that processing of mixtures of indomethacin and Gelucire® 
48/16 at high temperature is preferable for complete melting of the carrier so that 
molecular solubilization of the drug in the melted carrier can be achieved and hence, 
physically stable formulations can be produced.  
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6.5. General reflection on adsorbent-based and Gelucire®-based solid 
SNEDDS formulations of indomethacin 
At this point, it may be useful to highlight on the overall performance of optimum 
solid SNEDDS of indomethacin produced in this study either as adsorbent-based 
(presented in Chapter 4) or as carrier-mediated (presented in Chapter 5) formulations. 
Specifically, solid SNEDDS formulations of indomethacin (R1 – R4) prepared by 
adsorption of drug-loaded liquid SNEDDS formulations onto the inert carrier, Florite® PS-
200 (Chapter 4) in addition to Gelucire® 48/16-based solid SNEDDS formulations (G9 – 
G12) produced by HME technology (Chapter 5) were selected for this focus and 
comparison.  
All adsorbent-based and carrier-mediated solid SNEDDS formulations mentioned 
above showed reasonable drug content and preserved the self-nanoemulsification 
properties of the original liquid SNEDDS or the solid self-emulsifying carrier which were 
used originally in their production.  These formulations produced clear nanoemulsions 
upon dilution with an aqueous medium. The exception here is for formulation G12 that 
showed precipitation upon dilution because of its high drug loading that might exceeded 
the solubilizing ability of the carrier (Gelucire® 48/16). 
Physicochemical characterization of both adsorbent-based (R1 – R4) and carrier-
mediated (G9 – G12) formulations revealed that these two types of formulations 
maintained the drug in a dissolved state as indicated by their DSC traces, XRD 
diffractograms and SEM micrographs (except for formulation G12 which showed crystals 
of indomethacin in its XRD diffractogram as well as the SEM micrographs possibly due 
to the high drug loading in this formulation).    
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In Chapter 4, solid SNEDDS formulations of indomethacin prepared by 
adsorption of drug-loaded liquid SNEDDS formulations onto the inert carrier, Florite® PS-
200 (R1 – R4) showed optimum dissolution behaviour compared to other powder 
formulations produced using different adsorbents such as Neusilin® US2 or Syloid® XDP 
3150. This was due to the low specific surface of Florite® PS-200 which enhanced the 
dispersion of the drug in the dissolution medium leading to rapid formation of 
spontaneous nanoemulsions with small droplet size. On the other hand, solid SNEDDS 
formulations of indomethacin prepared by HME at 50oC (G9 – G12) (Chapter 5) 
exhibited optimum dissolution performance compared to other Gelucire® 48/16-based 
formulations produced by melting at 40oC using HME technology. High dissolution 
behaviour obtained for these formulations was due to micellar solubilization of the drug 
within the carrier which increased with increasing the melting temperature to 50oC. 
The dissolution parameters of Florite® PS-200-based (R1 – R4) and Gelucire® 
48/16-based (G9 – G12) solid SNEDDS formulations are summarized in Table 6.2. It 
can be observed that the dissolution efficiency (%DE15) of solid SNEDDS formulations 
prepared with Gelucire® 48/16 using HME was generally higher than that noticed for 
powder formulations prepared by adsorption of liquid SNEDDS onto Florite® PS-200. 
Although the drug was in a completely dissolved state within the liquid SNEDDS before 
adsorption onto the solid carrier, reduced dissolution behaviour of formulations prepared 
by adsorption of liquid SNEDDS onto Florite® PS-200 (R1 – R4) could be due to the high 
affinity of the adsorbent to the drug, which therefore may retard drug dispersion in the 
dissolution medium. However, formulation R1 showed high dissolution efficiency (%DE15) 
compared to other Florite® PS-200-based formulations which could be due to its low 
content of liquid SNEDDS (adsorbent: liquid SNEDDS ratio of 1: 1.5) which was released 
from the pores of the carrier at a much faster rate. On the other hand, higher dissolution 
performance observed for Gelucire® 48/16-based formulations (G9 – G12) may be due to 
direct availability of the molecularly dissolved drug from the micelles of the carrier.  
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Table  6.2 Mean dissolution time (MDT), mean dissolution efficiency (%DE15) and % 
released (%Q15) after 15 minutes calculated for pure indomethacin, 
Florite® PS-200-based (R1 – R4) and Gelucire®48/16-based (G9 – G12) 




(mean ± SD) 
%DE15  
(mean ± SD) 
%Q15  
(mean ± SD) 
R1 5.62 ± 0.98 68.63 ± 0.74 95.46 ± 1.11 
R2 4.05 ± 1.60 60.91 ± 1.09 82.14 ± 1.02 
R3 5.23 ± 1.11 67.62 ± 0.77 89.01 ± 0.80 
R4 4.31 ± 0.43 64.27 ± 0.80 86.05 ± 0.32 
G9 7.80 ± 1.12 48.02 ± 1.25 71.46 ± 2.48 
G10 5.25 ± 1.23 66.60 ± 1.23 84.88 ± 1.45 
G11 0.98 ± 0.53 73.27 ± 1.88 90.07 ± 2.46 
G12 4.11 ± 1.05 63.29 ± 2.13 82.16 ± 2.68 
 
Overall, utilization of HME in the production of solid SNEDDS formulations of 
indomethacin using Gelucire®48/16 as a single self-emulsifying carrier, which solidifies 
on cooling to room temperature, appears to be direct and more advantageous over the 
use of adsorption method to adsorb a drug-loaded liquid SNEDDS onto inert solid 
adsorbents. Higher drug loadings could be directly dissolved to the molecular level in 
Gelucire®48/16 by the effect of controlled heating at 50oC and efficient mixing that can be 
obtained during HME processing of different formulations. Selection of the most 
appropriate HME conditions such as the melting temperature, the speed of rotation and 
the pressure in the barrel may contribute to the production of highly physically stable 
formulations. In addition, adoption of HME to manufacture solid SNEDDS of 
indomethacin offers a scalable method that can be taken to an industrial level.  
On the other hand, production of solid SNEDDS formulations of indomethacin 
using the adsorption method resulted in high dissolution performance of different 
formulations depending on the type of the adsorbent used. However, adsorption method 
is an indirect method that first involves the formulation of a liquid SNEDDS which is then 
adsorbed onto the inert adsorbent. Also, many formulation ingredients that are used to 
produce liquid SNEDDS formulations may interact and increase the susceptibility of the 
final solid formulation to chemical or physical instability. In addition, filling of solid 
SNEDDS powder formulations into hard gelatin capsules may be restricted by the bulk 
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density of the adsorbent used. The use of adsorbents with low bulk density may in turn 
lead to reduced therapeutic dose of the drug that can be filled in each capsule. 
6.6. Conclusions  
In this part of the study, investigation of physical stability of different 
Gelucire®48/16-based solid SNEDDS of indomethacin prepared by HME at different 
extrusion temperatures was carried out. For this purpose, formulations G5 – G7 
processed at 40oC and formulations G9 – G11 processed at 50oC were stored at 
30oC/75% RH for a period of 6 months. Physical stability of these formulations was 
assessed using XRD analysis, SEM and dissolution studies after 1, 3, and 6 months of 
storage.  
All formulations prepared by HME at 50oC (G9 – G11) appeared to be stable over 
the study period, with no sign of recrystallization on XRD or SEM analysis and their 
dissolution parameters did not change after 6 months of storage. Of the formulations 
processed at 40oC, only that with the lowest drug loading appeared to be equally stable. 
The formulations with higher drug loadings showed evidence of recrystallization over 
time by XRD and SEM analysis; however, although the dissolution parameter showed a 
decreasing trend, this was statistically insignificant.     
The results obtained revealed that formulations prepared at 50oC (G9 – G11) 
were more physically stable at 30oC/75% RH for 6 months than formulations processed 
at 40oC. This indicates that processing of mixtures of indomethacin and Gelucire® 48/16 
by HME at a temperature that corresponds to the melting point of the carrier is required 
for complete melting in order to obtain complete molecular solubilization of the drug in 
the melted carrier.    
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This project aimed to explore different self-nanoemulsifying drug delivery systems 
(SNEDDSs) prepared in liquid, solid and carrier-based formulations and to evaluate the 
effect of these types of formulations on the solubility and dissolution performance of a 
poorly water soluble drug. For this purpose, indomethacin (BCS Class II compound) was 
utilized as the model drug in this study.   
It is well documented that the aqueous solubility of an active pharmaceutical 
ingredient is the major factor that determines its dissolution properties and consequently 
its oral bioavailability.  Poorly water soluble drugs that exhibit an aqueous solubility of 
less than 100 µg/ml also exhibit slow dissolution rate and incomplete bioavailability. 
Therefore, improvement of solubility of these compounds by different formulation 
approaches is crucial for their oral absorption and bioavailability (Horter and Dressman, 
2001, Kawabata et al., 2011).  
According to the biopharmaceutics classification system (BCS), class II drugs are 
characterized by their low solubility and high permeability. Oral bioavailability of this 
class of drugs is dissolution rate limited and enhancement of the dissolution rate of the 
drug will maximize its oral absorption (Kawabata et al., 2011, Pouton, 2006). Therefore, 
different formulation approaches can be applied to improve the solubility, dissolution rate 
and hence, bioavailability of BCS class II drugs either during preformulation studies or 
during development of formulation product (Kawabata et al., 2011). The lipid formulation 
approach appears as a promising approach that can be utilized for improving the 
solubility, dissolution properties and oral bioavailability of poorly soluble drugs.  
Lipid-based formulations may enhance the solubility of poorly soluble drugs by 
different attributes. The presence of these formulations in the gastrointestinal tract (GIT) 
promotes secretion of biliary products which, together with gastric movement, leads to 
formation of fine emulsions that improve the solubility of poorly soluble drugs. Also, this 
type of formulations may undergo enzymatic degradation in the GIT and the resulting 
hydrolytic products may interact with biliary secretions to form micellar structures that 
could dissolve the poorly soluble drug. In addition, the surfactant content of these lipidic 
formulations may contribute to dissolving the poorly soluble drug. Furthermore, 
prolonged residence time of these formulations in the GIT may contribute to increased 
dissolution at the site of absorption and consequently, increased absorption (Dahan and 
Hoffman, 2008).        
Self-nanoemulsifying drug delivery systems (SNEDDSs) are lipid-based 
formulations that consist of a drug dissolved in a mixture of excipients including oil, 
surfactant and co-surfactant. This anhydrous formulation can rapidly form fine oil in water 
nanoemulsions upon dispersion in the gastrointestinal fluids under mild agitation 
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imparted by the gastric motility (Hauss, 2007, Neslihan Gursoy and Benita, 2004, Porter 
et al., 2008). Formation of submicron droplets upon dilution produce a large interfacial 
surface area for transfer of the drug which may result in increased rate and extent of 
absorption and hence, improved bioavailability (Chakraborty et al., 2009). Also, it 
possesses the potential of increased drug loading capacity because of increased 
solubility of poorly soluble drugs in the amphiphilic surfactants, co-surfactants and co-
solvents constituents of the formulation (Pouton, 2000). These formulations maintain the 
drug in a dissolved state throughout the GI tract and therefore, may enhance the 
bioavailability of poorly soluble drugs, for which absorption is dissolution rate limited 
(Chakraborty et al., 2009, Tang et al., 2008).  
The main objectives of this study were generally focused on enhancement of the 
solubility of indomethacin to improve the dissolution performance which consequently, 
may reflect on enhancement of oral bioavailability of this poorly water soluble drug.  In 
this context, this research was designed to investigate the effect of different formulations 
of SNEDDSs of indomethacin on drug solubility as well as dissolution performance. For 
this purpose, different liquid, solid and carrier-based SNEDDS formulations were 
adopted to incorporate the drug.  
Liquid SNEDDS formulations are considered as anhydrous preconcentrates of 
nanoemulsions that can be filled into hard or soft gelatin capsules for improved 
palatability and patient compliance in addition to physical and chemical stability upon 
long term of storage (Date et al., 2010). Liquid SNEDDSs of indomethacin were 
successfully developed as described in Chapter 3. The type and the concentration of the 
components used in formulating liquid SNEDDS greatly affect the properties of the final 
nanoemulsion produced upon dilution such as the droplet size, polydispersity index and 
self-nanoemulsification efficiency. Therefore, selection of components of SNEDDS is 
based on their ability to dissolve the drug and to quickly produce spontaneous fine 
nanoemulsions upon contact with aqueous fluids. In addition, the phase behaviour of the 
constituents should be evaluated to determine different phases and phase transitions by 
plotting ternary phase diagrams to determine the areas of self-nanoemulsification where 
spontaneous nanoemulsions with droplet size of less than 100 nm can be produced.  In 
this section, it was demonstrated that indomethacin exhibited significant increase in 
solubility upon incorporation into different blends of oil (CapryolTM 90), surfactant 
(Cremophor® RH 40) and co-surfactant (Transcutol® HP). These three constituents were 
optimized according to their maximum solubilizing abilities of the drug compared to other 
relative components tested, and also according to their ability to improve emulsification 
of different systems so that clear nanoemulsions can be produced. Ternary phase 
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diagrams plotted for ternary formulations produced from these three components at the 
most effective surfactant/co-surfactant ratios showed the maximum self-nanoemulsifying 
regions within which spontaneous nanoemulsion was produced upon contact with 
aqueous medium.   
Incorporation of indomethacin in the optimized SNEDDS formulations resulted in 
significant enhancement of the solubility of the drug, compared to its solubility in water, 
which was directly proportional to the content of both oil and surfactant in the self-
nanoemulsifying formulation.  
All drug-loaded liquid SNEDDSs were prepared with 25 mg of indomethacin to 
represent the therapeutic dose and to ensure spontaneous emulsification of the 
formulation without drug precipitation upon aqueous dilution. It was shown that these 
formulations were thermodynamically stable and exhibited self-nanoemulsification 
properties.    
Compared to different formulations produced with different surfactants, 
formulations F13 – F16 prepared with Capryol® 90, Cremophor® RH 40 and Transcutol® 
HP produced the maximum self-nanoemulsifying regions when formulated at effective 
surfactant/co-surfactant ratios of 2:1 and 3:1, and also showed smaller PDI values and a 
significantly smaller droplet size. Therefore, formulations F13 – F16 were employed in 
further studies.   
The work reported in this chapter described the effect of various oils, surfactant 
and co-surfactant combinations to increase the solubility of indomethacin. Enhancement 
of solubility of indomethacin has been extensively investigated in the literature but this 
study focused on different blends of constituents that can be used to produce liquid 
SNEDDS formulations that improved the solubility of the poorly soluble drug and proved 
to be thermodynamically stable.  It is possible that further investigation of a wider range 
of blends prepared from different oils, surfactants and co-surfactants available from 
different sources may identify other optimum constituents that may further improve the 
solubility of the drug. At this point, it can be suggested that the utilization of in vitro 
lipolysis model, which simulates digestion in the small intestine, could provide 
information on the digestion of SNEDDS formulations in addition to their tendency to 
precipitation. The importance of the in vitro lipolysis test comes from the fact that lipids 
can be digested in the GIT by the effect of lipases and their digestion may lead to loss of 
solvent capacity and subsequent reduction of solubility of the drug in the GIT which may 
result in precipitation of the drug and reduction of the absorption rate (Pouton, 2000, 
Pouton and Porter, 2008).  Although the presence of surfactants in lipid formulations may 
inhibit the digestion of the oil within these formulations (Pouton, 2000), the necessity for 
  Chapter 7  
267 
 
in vitro lipolysis testing to evaluate different types of lipid-based formulations is due to the 
fact that surfactants may also undergo digestion (Pouton and Porter, 2008).  
Application of in vitro lipolysis model could be useful to optimize SNEDDS 
formulations before taking them into in vivo studies because it may predict the possibility 
of in vivo precipitation (Dai, 2010, Dahan and Hoffman, 2008)(Dai, 2010, Dahan and 
Hoffman, 2008)(Dai, 2010, Dahan and Hoffman, 2008). Also, in vitro – in vivo correlation 
of different SNEDDS formulations can be established by application of in vitro lipolysis 
assay (Date et al., 2010).  
Indomethacin-loaded liquid SNEDDS formulations (F13 – F16) developed in 
Chapter 3, using different blends of Capryol® 90, Cremophor® RH 40 and Transcutol® 
HP at the most effective ratios of surfactant/co-surfactant of 2:1 and 3:1, were used in 
further studies conducted in Chapter 4 to investigate the possibility of conversion of 
liquid SNEDDS into solid powder formulations that will maintain the self-nanoemulsifying 
properties of the original liquid formulations and at the same time provide an alternative 
technique to avoid different limitations associated with encapsulation of liquid SNEDDS 
that is essential for ease of oral administration.  Solid SNEDDS produced from liquid 
SNEDDS combine the advantages of liquid SNEDDS formulations like improved 
solubility and bioavailability in addition to those advantages related to the solid dosage 
forms such as high stability and better patient compliance. For this purpose, adsorption 
of liquid SNEDDS of indomethacin onto solid adsorbents was utilized as a solidification 
method with anticipation of achieving high level of drug loading and good drug content.   
It was demonstrated that different indomethacin-loaded solid SNEDDS powder 
formulations prepared with specific adsorbents (Syloid® XDP 3150, Neusilin® US2 and 
Florite® PS-200) showed good flow properties. Microcrystalline cellulose (Avicel PH 102) 
and Aerosil® 200 (silicon dioxide) failed to produce free flowing powder formulations and 
were difficult to manipulate especially at high adsorbent: liquid SNEDDS ratios. This 
indicated that careful selection of adsorbents with the most suitable physical properties is 
important to achieve highly flowable formulations. Utilization of Syloid® XDP 3150 
(amorphous silicon dioxide), Neusilin® US2 (magnesium aluminometasilicate) and 
Florite® PS-200 (calcium silicate) as adsorbents resulted in solid SNEDDS powder 
formulations that exhibited reasonable drug content and maintained the self-
nanoemulsification properties of the original liquid SNEDDS formulations.  In addition, 
physicochemical characterization of these powder formulations by DSC and XRD 
indicated that the drug remained in a dissolved state after adsorption onto different solid 
carriers. Moreover, improved dissolution profiles of these solid SNEDDS compared to 
pure powder of the drug indicated the ability of these formulations to deliver the liquid 
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SNEDDS to the dissolution medium with spontaneous formation of nanoemulsions. It 
was shown that this enhancement of dissolution profiles was dependent on the 
physicochemical properties of the adsorbents used in development of different 
formulations.  
Even though powder formulations are designed primarily for filling into hard 
gelatin capsules, a limitation related to the amount of the powder that can be filled into a 
capsule may occur. This limitation has been encountered during this study when the free 
flowing solid SNEDDS powder formulations needed to be filled into capsules for the 
purpose of conducting the in vitro dissolution studies. Larger amounts of the produced 
powder formulations were needed to achieve the therapeutic dose of the drug and these 
high amounts could not be filled into a single capsule (size 000) because most of the 
silicate adsorbents possess low bulk density. The need for more than one capsule to 
achieve the therapeutic dose of the drug means that a reduced drug load is present in 
each unit dose and additionally that patient compliance is likely to be low.  
Therefore, compression of solid SNEDDS powder formulations into tablets may 
present a better alternative than filling into hard gelatin capsules for delivering SNEDDS 
formulations in a solid dosage form.  Tablet dosage forms are more preferable by 
patients and more economical for the manufacturer than gelatin capsules. Good physical 
and chemical stability can be achieved from both tablet and capsule dosage forms. 
However, higher drug loading can be achieved with tablets because more powder can be 
compressed into tablets than can be filled into hard gelatin capsules. Despite the 
advantages of tablets over capsule dosage forms, there are still only limited studies in 
the literature discussing the development of tablet dosage forms for self-emulsifying 
systems, which may be due to different obstacles.  
In this context, it is possible to suggest extension of this study to formulate self-
nanoemulsifying tablet dosage forms from the produced powder formulations. Finding a 
suitable carrier that can adsorb adequate amount of the liquid SNEDDS formulation and 
at the same time possess good flowability and tabletability may be the most challenging 
factor that need to be overcome.  Also, low compressibility of silicates and the possibility 
for the adsorbed liquid lipid formulation to leak out of the porous adsorbent upon 
compression may need to be addressed prior to tablet formulation. With various grades 
of silicates used in this study as adsorbents that possessed different physical properties 
and proved to adsorb reasonable amounts of the liquid SNEDDS, it could be possible to 
overcome some of the proposed limitations associated with production of self-
emulsifying tablets.      
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In Chapter 5, another method was proposed to formulate solid SNEDDS of 
indomethacin in a direct way which excludes the need to formulate liquid SNEDDS and 
then fill it into hard gelatin capsules or adsorb it on to solid adsorbents. This came from 
the fact that some vehicles may possess surface active properties (like Poloxamer 188) 
and can form solid systems with certain types of lipids. With the increased availability of 
self-emulsifying vehicles that are solid or semisolid at room temperature, it was assumed 
that direct dispersion of the drug in vehicles that possess the properties of self-
emulsification upon contact with aqueous fluids and at the same time have the ability to 
solidify upon cooling may be beneficial to achieve stable solid self-emulsifying 
formulations of the drug. These solid self-emulsifying formulations may quickly self-
emulsify upon contact with liquid phase leading to improved solubility and consequently, 
dissolution and bioavailability of the incorporated poorly soluble drug.  The directly 
formed solid self-emulsifying formulations could be further processed into solid dosage 
forms such as tablets or capsules.  
In order to investigate this idea, Gelucires® which possess the ability to solidify 
upon cooling to room temperature and to self-emulsify upon dispersion in aqueous 
media were suggested as possible vehicles or carriers to formulate Gelucire®-based 
solid SNEDDS of indomethacin. Gelucires® also possess the ability to dissolve poorly 
soluble drugs due to their surface active properties. Therefore, utilization of Gelucires® in 
this study was primarily to affect solubilization of indomethacin when in melted form and 
then to produce solid self-emulsifying systems upon cooling. The use of Gelucires® as 
single vehicles to develop solid SNEDDS formulations would replace the need for a 
combination of oil, surfactant and co-surfactant to produce liquid SNEDDS formulations 
and consequently, exclude the need for solid adsorbents to solidify the resulting liquid 
SNEDDS by adsorption technique. Development of a formulation with the least number 
of components may help to achieve a chemically stable product. Also, the use of a single 
excipient to formulate solid SNEDDS is assumed to allow higher drug load to be 
incorporated in the formulation because no other liquid or solid excipients will be needed. 
Solubilization of the drug in different Gelucires® was carried out by the melting 
method. Hot melt extrusion (HME) technology was applied for this purpose and was 
proposed to be more effective over traditional melting methods to produce stable 
formulations. This is justified by the controlled processing parameters of heating and 
mixing that can be set for an operation in addition to the possibility of scaling up the 
process to produce pharmaceutical batch sizes.   
In Chapter 5, Gelucire®44/14 and Gelucire®48/16 were used as carriers to 
produce Gelucire®-based solid SNEDDS of indomethacin by the HME technique 
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because these two carriers exhibited high solubilizing potential of the drug. It was shown 
that different Gelucire®-based solid SNEDDS of indomethacin manufactured by the HME 
technique at a barrel temperature of 40oC or 50oC and a rotational speed of 30 rpm 
manifested acceptable drug content and showed good self-nanoemulsifying properties 
without signs of precipitation upon dilution with liquid medium, except in formulations 
prepared with high drug: carrier ratios (3: 10). Also, increased solubility of the drug in 
phosphate buffer pH 7.2 was obtained from these Gelucire®-based formulations 
compared to the solubility of pure drug in the same buffer. Physicochemical 
characterization of different Gelucire®-based solid SNEDDS formulations demonstrated 
that the drug remained in a molecularly dissolved state within the carrier as indicated by 
DSC studies and XRD analysis.  
Improved drug dissolution profiles were obtained from all Gelucire®-based solid 
SNEDDS formulations of indomethacin and this was attributed to increased wettability 
and micellar solubilization of drug particles influenced by the presence of Gelucires®. The 
type of Gelucire®, HME processing temperature and drug loading obviously affected the 
degree of enhancement of drug dissolution profiles of differently manufactured 
formulation.  Higher dissolution profiles observed for formulations prepared with 
Gelucire® 48/16 compared to those prepared with Gelucire® 44/14 were due to 
differences in hydrophile lipophile balance (HLB) values of these two carriers.  In 
addition, HME processing of Gelucire®48/16-based solid SNEDDS formulations at a 
barrel temperature of 50oC produced better dissolution performance than formulations 
processed at 40oC.  This indicated that complete melting of the carrier at 50oC, rather 
than softening at 40oC, is more preferable for complete molecular dissolving of the drug. 
Moreover, it was demonstrated that the dissolution performance of Gelucire®-based 
formulations of indomethacin increased with increasing the drug load up to the drug: 
carrier ratio of 2: 10 in different formulations. However, further increase in drug loading 
exceeded the solubilizing capacity of the carriers and resulted in viscous formulations 
with reduced dissolution. Further, it was shown that incorporation of different types and 
amounts of adsorbents into Gelucire®48/16-based solid SNEDDS formulations may not 
improve the dissolution performance of the corresponding formulations depending on the 
interaction of the adsorbent with the drug and/or the carrier.  
Although Gelucire®-based formulations could have been prepared with high drug 
loadings, careful setting of optimum HME processing conditions need to be considered 
to improve the extrudability of Gelucires®-based formulations without affecting the 
performance of final formulations. Processing different mixtures at 40oC resulted in 
variation in the extrudability of various mixtures, where mixtures with low drug loading 
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passed easily through the die part while those with high drug loading could not be 
extruded through the die part but collected in the form of viscous masses. Increased risk 
of recrystallization of undissolved drug after extended period of storage is possible for 
these formulations prepared with high loads of the drug and processed at 40oC.  
Similarly, mixtures that were processed at 50oC were retrieved from the extruder in the 
form of a transparent melt indicating complete melting of the carrier and consequently 
complete dissolving of the drug. From this observation, it could be possible to suggest 
careful monitoring of the processing temperature as well as the speed of rotation and die 
diameter to obtain an extrudable mixture in which the carrier is completely melted and 
the drug is maximally solubilized.  
The observed effect of different drug loading on the in vitro dissolution and the 
physicochemical characterization of differently prepared Gelucire®-based formulations 
may require further investigation of micellar solubilization of the drug by these surface 
active carriers. Different properties of micelles that can be characterized by different 
parameters such as the aggregation number, critical packing parameter, solubilization 
capacity and micelle-water partition coefficient may contribute to micellar solubilzation of 
poorly soluble drugs. Careful estimation and calculation of these parameters may 
provide better understanding of micellar solubilzation of indomethacin by Gelucires® as 
well as the molecular interactions occurring between the drug and the carrier.   
Overall, the research presented in Chapter 5 indicates that there is a possibility 
to formulate solid SNEDDS by HME technology using solid or semi-solid vehicles. 
Adjustments of process variables and formulation parameters are crucial to obtain a 
stable product with high self-emulsification efficiency. It also proved that Gelucire®48/16 
maintained its maximum self-emulsification properties when completely melted inside the 
extruder.  
All observations recorded from the in vitro dissolution studies performed on 
Gelucires®-based formulations revealed the importance of melting temperature and the 
drug load to ascertain maximum solubilization of the drug in the carrier. Controlling these 
two parameters may retard recrystallization of dissolved drug and hence, sustain the 
physical stability of produced formulations.  
Lipid-based formulations are often susceptible to physical stability problems and 
therefore, require proper understanding of the solid-state physical instability of drug 
substance that occurs during shelf-life of the formulation in addition to the manufacturing 
process parameters and the storage conditions in order to produce highly stable 
formulations.  The work conducted in Chapter 6 was carried out to investigate the effect 
of different formulation and process parameters on the physical stability of the final solid 
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SNEDDS formulation. This was performed because HME parameters (like heating 
temperature and mixing) as well as the formulation parameters (such as the drug load) 
could greatly influence the physical stability of different formulations produced. For this 
purpose, some Gelucire® 48/16- based solid SNEDDS that were produced at 40oC or at 
50oC using different drug: carrier ratios were adopted for physical stability studies that 
were carried at 30oC/75% RH for 6 months.  
It was shown that all Gelucire® 48/16- based solid SNEDDS produced at 50oC 
with drug: carrier ratios up to 2: 10 were more physically stable at 30oC/75 RH for 6 
months than formulations produced at 40oC because of maintaining of complete 
molecular solubilization of the drug within the completely melted carrier during storage. 
Formulations developed by softening of the carrier at 40oC with low drug loading (drug: 
carrier ratio of 0.5: 10) were more physically stable at 30oC/75 RH for 6 months than 
formulations prepared with higher drug loadings (drug: carrier ratios of 1: 10 and 2: 10) 
which showed crystallization after 3 months of storage. High drug concentrations in 
these formulations possibly led to interaction between the adjacent molecules of the drug 
and hence initiated crystal growth during storage. Alternatively, processing of these 
formulations at 40oC may have left extremely small drug deposits, which were below the 
limit of detection of the analyzing techniques initially, and these deposits acted as foci for 
nucleation and crystal growth on storage. These observations concluded that different 
processing temperatures during HME manufacturing of Gelucire® 48/16- based solid 
SNEDDS formulations affected the physical stability of the final products especially when 
high drug loadings were used. HME processing temperatures at which the carrier will be 
completely melted is essentially required to achieve and maintain complete molecular 
dissolving of the drug.  
Conductions of accelerated stability studies for a short period of time may not be 
adequate to provide a complete picture of changes in the formulation throughout its 
shelf-life. Unlike chemical stability, changes that may occur due to physical instability are 
less quantitative and their predictability is low. Also, prediction of physical stability at 
ambient storage conditions using the results obtained from accelerated physical stability 
is often unreliable. Therefore, achievement of robust drug formulation development 
requires important understanding of the chemical and physical processes that may lead 
to physical instability (Guo et al., 2013). In this context, it is possible to suggest that 
physical stability studies be conducted for longer periods of time to assess physical 
changes that may develop during the shelf-life of the formulation.  
Because of complexity of the analysis of solid state products and because there 
is no single analytical method that could provide all the information required on a drug 
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product or drug substance, most of these methods are used together to complement 
each other (Guo et al., 2013).  
The XRD analysis and SEM used in this study to follow the changes due to 
physical instability provided good information on the solid state of the formulation. 
However, there is still a need for further assessment of physical stability, adopting other 
analytical techniques such as the thermal analysis methods. These methods like high 
speed DSC and modulated DSC may provide information on the rate and extent of drug 
crystallization, molecular mobility of the drug as well as miscibility of the drug in the 
excipients. Combining thermal analysis techniques with other methods such as hot stage 
microscopy may allow identification of the effect of temperature change on real-time solid 
state of drug product. Also, the atomic force microscopy (AFM) enables visualization of a 
surface at the nanoscale resolution and at the same time record thermal behavior of the 
surface when heat is applied locally (Guo et al., 2013).  
In this study, investigation of physical stability of different samples of Gelucire® 
48/16- based solid SNEDDS of indomethacin was carried out at 30oC/75 RH for 6 
months. The results of this accelerated stability study were obtained while the samples 
were stored in closed vials at the proposed conditions. Although formulations produced 
by HME do not contain water and therefore could be more physically stable, investigation 
of physical stability of these formulations while exposed to different relative humidity 
values may allow understanding of the interaction of water with the formulation 
components and its subsequent effects on molecular interactions present between 
different ingredients.   
The most original point in this research was the applicability of hot melt extrusion 
technique to produce solid self-emulsifying systems by direct dispersion of the poorly 
soluble drug in the melted carrier. This work showed that this was possible with the 
availability of self-emulsifying vehicles that exist in a solid form and has the ability to 
solidify upon cooling of the molten phase. 
 
Different studies conducted in this research project may remain to be improved or 
extended for further investigations. The following points may be considered:  
1. Liquid SNEDDS formulations evaluated in this study may be better developed by 
utilizing the in vitro lipolysis model to elucidate the behavior of the formulation upon 
exposure to conditions similar to those in the real GIT. This is because lipids and 
surfactants may undergo digestion by lipase enzymes in the GIT which may lead to 
loss of solvent capacity and subsequent precipitation of the drug and reduced 
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absorption. Precipitation that occurs during the in vitro lipolysis tests may predict the 
possibility of in vivo precipitation. 
2. Solid SNEDDS powder formulations developed by adsorption methods may need to 
be compressed into tablet dosage forms to obtain high drug load per unit dose. 
Utilization of highly porous adsorbents that possess good flow and high 
compressibility may be useful for this purpose.   
3. HME processing parameters such as the barrel temperature and rotational speed 
may need to be optimized to ensure more extrudability of mixtures of the drug and 
the solid self-emulsifying carrier and at the same time to ensure that the drug is 
completely solubilized in the completely melted carrier.  
4. The characterization methods conducted to investigate physical stability of different 
formulations may need to be extended for thermal analysis techniques such as 
modulated DSC and hot stage microscopy. This would provide information on the 
rate and extent of crystallization of the drug that occur during storage in addition to 
understanding the immediate effects of temperature change on real-time solid state 
of drug formulation.  
5. As the ultimate goal in formulation development of poorly water-soluble drugs is to 
enhance oral absorption, an in vivo evaluation of the oral bioavailability of 
indomethacin from a conventional formulation (tablet or suspension) and from 
selected SNEDDS and S-SNEDDS formulations developed here would be useful.  
The improved solubility of indometacin in the formulations studied here, compared to 
the drug in water alone, and the functionality of the excipients used, gives confidence 
that an improved bioavailability will be observed but this remains to be definitively 
proved. 
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